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Abstract
ADAM15 is a multidomain multifunction transmembrane protein. It participates
in protein ectodomain shedding via the metalloproteinase domain. ADAM15 also
interacts with integrins via the disintegrin domain. ADAM15 mRNA is subject to
complex processing, generating diﬀerent isoforms as a result of alternative splicing.
The splicing aﬀects the intracellular domain (ICD) of the protein, generating dis-
tinct SH3 domain binding regions. The expression of speciﬁc splice forms correlates
with breast cancer prognosis.
We aimed to test if ADAM15 isoforms have distinct functions that may aﬀect mul-
tiple aspects of cell behaviour in isoform-speciﬁc unique ways. We generated an iso-
genic panel expressing each ADAM15 isoform in MDA-MB-231 acells. Comparative
characterisation of the panel demonstrated distinct diﬀerences between isoforms,
such as catalytic function dependant or independent eﬀects on proliferation rate,
changes in cell size, isoform-speciﬁc reorganisation of the actin cytoskeleton.
We discovered ADAM15 isoform-dependant upregulation of tight junction protein
claudin1. Immunoﬂuorescence analysis demonstrated co-localisation of ADAM15
with claudin1 and another tight junction protein ZO1 at cell-cell junctions. Further
immunoprecipitation analysis showed potential complex formation with ADAM15
and ZO1. Pharmacological analysis showed claudin1 upregulation is mediated via
PI3K/mTOR-pathway. Claudin1 upregulation depended on the metalloproteinase
catalytic function of ADAM15, suggesting that ADAM15 isoforms have distinct
substrates. Claudin1 was also found in the nucleus of MDA/ADAM15 A expressing
cells where it could potentially function as a transcription factor.
Focal adhesion (FA) turnover was inﬂuenced by ADAM15 isoform expression. In
MDA/ADAM15 C expressing cells impairment of FA reassembling was observed,
while ADAM15 D expression showed reduced FA disassembly. Comparison of
spreading of ADAM15 isoform expressing cells on ﬁbronectin (FN) and vitronectin
(VN) revealed that most cell lines preferred FN over VN. Expression of ADAM15
E reduced this preference while ADAM15 A altered it in favour of VN over FN.
Changes in subcellular localisation of β3, but not β1-integrin was observed.
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mTORC2 mTOR complex 2
MTS 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium
MUPP1 Multi-PDZ Domain Protein 1
N-cadherin Neural-cadherin
NaOH Sodium hydroxide
NCCN National Comprehensive Cancer Network (NCCN)
NCF1 Neutrophil cytosolic factor 1
NE Nuclear cell extract
NEAA Non-essential amino acids
NGS Next generation sequencing
NISCH Neonatal ichthyosis and sclerosing cholangitis
nM Nanomolar
NPF Nucleation promoting factor
Nrp1 Neuropilin 1
NSCLC non-small cell lung cancer
nt Non target
OB Osteoblast
OSTF1 Osteoclast stimulating factor 1
P/S Penicillin/Streptomycin
PAA Polyacrylamide
PAGE Polyacrylamide gel electrophoresis
PAK Serine/threonine-protein kinase PAK
PAR3 Proteinase-activated receptor 3
PARP1 Poly-ADP-ribose polymerase 1
PBS Phosphate buﬀered saline
PC3 Prostate cancer 3
PCR polymerase chain reaction
PDAC Pancreatic ductal adenocarcinoma
ABBREVIATIONS XIX
PDK1 Phosphoinositide-dependent kinase 1
PDZ Post synaptic density protein (PSD95), Drosophila disc
large tumor suppressor (Dlg1), and zonula occludens-1
protein (ZO1)
pH pH-value
PH domain pleckstrin homology domain
PHLLPP PH domain leucine-rich repeat protein phosphatase
PI Propidium iodide
PI3K Phosphatidylinositol-3-kinase
PIKK PI3K-related kinase
PINCH Particularly interesting cysteine- and histidine-rich pro-
tein
PKC Protein kinase C
PKCζ Protein kinase C ζ
PKL Paxillin-kinase linker
PMA Phorbol myristic acid
PMSF Phenylmethanesulfonyl ﬂuoride
PP2A Protein phosphatase 2A
PR Progesterone receptor
PRAS40 Proline-rich Akt substrate 40 kDa
pRB Retinoblastoma protein
Protor Protein observed with Rictor
PTB domain Phosphotyrosine-binding domain
PTEN Phosphatase and tensin homolog
PTK6 Protein-tyrosine kinase 6
PTP-1B Protein-tyrosine phosphatase 1B
PTP-PEST Protein-tyrosine phosphatase-PEST
PVDF Polyvinylidene ﬂuoride
Pyk2 Proline-rich tyrosine kinase 2
R Arginine
R&D R&D Systems
Rab Ras-related protein
Rac Ras-related C3 botulinum toxin substrate
Raptor Regulatory-associated protein of mTOR
RFS Relapse Free Survival
Rheb Ras homologue enriched in brain
Rho Ras homologue
Rho-GDI Rho-GDP dissociation inhibitors
Rictor Rapamycin-insensitive companion of mTOR
ABBREVIATIONS XX
RIM Regulating synaptic membrane exocytosis protein
RIMBP RIM-binding protein
RIP Regulated intramembrane proteolysis
RIPA Radioimmunoprecipitation assay buﬀer
RNase Ribonuclease
ROCK Rho-associated coiled-coil kinase
ROI Regions of interest
RON Recepteur d’origine nantais (RON)
ROP Retinopathy of prematurity
ROS Reactive oxygen species
RRM RNA-recognition motif
RT-PCR Reverse transcription polymerase chain reaction
RTK Receptor tyrosine kinase
S Serine
S6K Ribosomal protein S6 kinase
sAPPα soluble amyloid precursor protein α
sc Santa Cruz
SDS Sodium dodecyl sulfate
SEA Serine-glutamic acid-alanin
SERM Selective oestrogen receptor modulator
SHIP SH2-containing phosphatases
SHP2 Src homology phosphotyrosyl phosphatase2
siRNA short interference RNA
SNP Single nucleotide polymorphism
SNX Sorting nexin
SR-protein Serine/Arginine-protein
STAT3 Signal transducer and activator of transcription 3
SVMP Snake venom metalloproteinas
T Threonine
T3 Triiodothyronine
TACE TNFα converting enzyme
TAE Tris-acetate-EDTA
TBS Tris buﬀered saline
TBST Tris buﬀered saline Tween
TC Tissue culture
TE Total cell extract
TEER Transepithelial electrical resistance
TEMED N,N,N’,N’-Tetramethylethylendiamine
TGFα Transforming growth factor α
ABBREVIATIONS XXI
TGFβ1 Transforming growth factor-β1
Tis Tumour in situ
TKI Tyrosine kinase inhibitor
TMT-MS-TAILS Tandem Mass Tag R© terminal amino isotopic labelling of
substrates
TNM Tumour node metastasis
TOCA1 Transducer of Cdc42-dependent actin assembly protein 1
Tris Tris(hydroxymethyl)-aminomethan
TSA Trichostatin A
TSC1 Tuberous sclerosis complex 1
TSC2 Tuberous sclerosis complex 2
TSP Thrombospondin
UICC International Union for Cancer Control
UK United Kingdom
UT Untreated
UV Ultraviolet
V Voltage
VCAM1 Vascular cell adhesion molecule-1
VE-cadherin Vascular endothelial-cadherin
VEGF Vascular endothelial growth factor
WASP Wiskott-Aldrich syndrome proteins
WAVE Wiskott-Aldrich syndrome protein-family verprolin ho-
mologous protein
WB Western Blot
WT Wildtype
Y Tyrosine
ZO1 Zona occludens protein 1
ZONAB ZO1-associated nucleic-acid binding
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1.1 Cancer
Cancer is a common name for more than 200 types of diseases. In total this disease
accounts for approximately 20% of deaths in all industrialised countries of the
Western world1. In the UK, over 350,000 new cases of cancer were diagnosed, and
over 160,000 patients died in 20142. Statistically, one in two people born after 1960
will develop some form of cancer during their lifetime2.
Years of research in the ﬁeld of cancer has provided a substantial amount of
knowledge, revealing that this disease and its characteristics are triggered by
genome instability. Mutations that result in the upregulation of oncogenes and also
the loss of function of tumour suppressor genes have been recognised in both human
and animal cancer cells3. There are indications that tumourigenesis is indeed a
complex and multi-step procedure, with every step containing genetic alternations
that drive the transformation of normal cells into tumour cells. The main question
concerning cancer development is what kind and how many regulatory defects
must occur before the transformation of a normal cell into a cancer cell. In year
2000, Robert Weinberg and Douglas Hanaham published an article, proposing
six hallmarks for cancer, which provided a better understanding of the biology
underlying this complex disease4. Over a decade later, two emerging hallmarks
and two enabling characteristics were added. The hallmarks are reprogramming
of energy consumption and evading immune destruction. The characteristics are
tumour-promoting inﬂammation as well as genome instability and mutation3. A
summary of hallmarks is depicted in ﬁgure 1.1.
1. Sustaining proliferative signalling
One of the essential features of cancer cells is their ability to sustain prolif-
eration. While normal cells closely control their growth and division cycle to
insure the normal function of tissues, cancer cells tend to deregulate the cell
cycle and cell growth signals. Enabling cells to become highly proliferative. The
sustained mitogenic signalling in cancer cells is achieved via various methods;
these cells might overexpress growth factor receptors followed by the production
of growth factors by themselves, this results in the stimulation of an autocrine
proliferation. Moreover cancer cells have the ability to send signals to normal
cells located within the stroma, causing production of growth factors by these cells3.
2. Evading growth suppressors
While cancer cells have the ability to sustain proliferative behaviour via the
production of cell cycle and cell growth regulators, it is also necessary for these
cells to be able to evade negative regulators of proliferation. There are numerous
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tumour suppressor genes that act as negative regulators of cell growth and division.
In cancer cells inactivation of such genes results in uncontrolled proliferation.
Retinoblastoma protein (pRB) and p53 are two of the main tumour suppressor
proteins that play an important role in allowing cell proliferation or cell death5.
Figure 1.1: The hallmarks of cancer proposed by Hanahan and Weinberg in 2011. The figure
was adapted and modified from their review3
.
3. Avoiding immune destruction
According to the theory of immune surveillance nascent cancer cells are cleared
from the immune system by early recognition. However, solid tumours evaded this
process either by avoiding detection or survived the immunological killing. The
importance of the immune system is shown in diﬀerent mouse models. Deﬁciencies
in cytotoxic T-lymphocytes, T-helper or natural killer cells led to increased tumour
size. Cancer cells may be able to evade by disabling immune system components.
Natural killer cells and cytotoxic T-cells may be paralysed by transforming growth
factor-β (TGF-β) secretion6. A more subtle way is to recruit immunosuppressive
cells to repress cytotoxic T-cells. These compromises not only regulatory T-cells,
but also myeloid-derived suppressor cells7. Immunoevasion is still an emerging
hallmark and a deeper insight needs to be established.
4. Enabling replicative immortality
Most normal cells can only go through a limited number of cell division cycles, on
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the contrary cancer cells have the ability to multiply indeﬁnitely. This limitation
in normal cells is due to the existence of two main barriers: senescence (non-
proliferative state) and crisis. The state of crisis describes apoptosis, karyotypic
disarray with telomeric end-to-end fusion. Occasionally, a cell can escape crisis
(1:10,000,000). This is described as immortilsation8. These two crucial barriers
against proliferation are used in cells as anticancer defences, resulting in a normal
and healthy cell division. However tumour cells have the potential to become
immortalised by maintaining a suﬃcient telomere length, which can prevent
the activating of the senescence or apoptosis process. This is possible by the
upregulation of telomerase expression in these cells9.
5. Tumour promoting inflammation
Several mechanisms exist in which parts of or the whole cell is degraded. Some
of those functions by inducing an inﬂammatory response, some do not. Usually,
autophagy plays a role in clearing misfolded proteins or damaged organelles. The
ﬁrst step is to surround the target molecule isolating it from the rest of the cell
generating an autophagosome. In the next step it fuses with a lysosome to an
autolysosome in which the inside is broken down by lysosomic enzymes. Another
destructive mechanism is apoptosis. A dying cell contracts and is degraded from
the inside. In a ﬁnal step the cell is engulfed and endocytosed by macrophages.
Together, both process are executed without inﬂammation. In contrast, necrotic
cells enlarge and burst, releasing their contents into the environment triggering an
immune response. Necrosis normally occurs due to bacterial or viral infection. In
context of neoplasia, inﬂammatory cells can be tumour promoting. These cells are
capable of inducing angiogenesis, cell proliferation and invasiveness3. For example,
necrotic cells can release interleukin 1-α, which can stimulate adjacent cells to
proliferate10. This may facilitates neoplastic progression.
6. Activating invasion and metastasis
A main characteristic of malignant tumours is their ability to move through
the extracellular matrix (ECM) and invade other tissues. In order to do so,
tumour cells have the ability to alter their shape and develop changes in their
attachment to adjacent cells and the ECM. This could be achieved by the loss
of Epithelial-cadherin (E-cadherin; a cell-cell adhesion molecule). Furthermore
the down-regulation or mutation inactivation of E-cadherin has been observed in
various tumour cells, suggesting that this adhesion molecule plays an important
role in the invasive and metastatic behaviour of tumour cells. In addition, abnormal
expression of other cell-cell and cell-ECM adhesion molecules has been observed in
more aggressive carcinomas.
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7. Inducing angiogenesis
For tumour cells to survive, just like normal cells, they require nutrients and
oxygen. It is also essential for these cells to discard their metabolic waste and
carbon dioxide. This is achieved by neovascularisation via angiogenesis. In normal
tissues the process of angiogenesis is only activated brieﬂy when required, however
during tumourgenesis, the angiogenic switch is constantly on, resulting in the
formation of new blood vessels that cause expanding neoplastic growth.
8. Genome instability and mutation
The acquisition of hallmarks largely depends on the accumulation of genomic
alterations and maintaining them. Selective advantage of those cells enable them
to outgrow other cells which let them dominate in their environment. Inactivation
of a tumour suppressor can be acquired by epigenetic mechanism like histone
modiﬁcation, DNA methylation, by direct mutation due to UV light or exposure to
chemicals. Each cell has a DNA-maintenance machinery. Defects in genes which
drive these machineries are crucial. They comprise: (1) Detection of DNA damage
and activation of repair mechanisms. (2) Direct repair of damaged DNA. (3)
Interception of mutagenic agents prior to DNA damage. When introduced in mouse
germline, mutant copies of genes involved in these machineries resulted in elevated
cancer incidences11. This supports their role in human cancer development.
Replicative potential induced by telomerase is another hallmark of cancer, this
action also plays a role in genome stability. Loss of telomeric DNA generates
karyotypic instability in tumours. This can lead to deletion or ampliﬁcation of
chromosomal segments. Comparative genomic hybridisation studies revealed the
loss and gains of gene copy numbers during tumour progression. Ampliﬁcations
and deletions at particular genomic sites indicate location of genes which mutations
favour neoplastic progression.
9. Resisting cell death
Apoptosis is a crucial process used by cells to eliminate dysfunctional and dam-
aged cells. One of the hallmarks of malignant tumours is indeed the ability to
evade apoptosis, allowing these tumour cells to grow and divide uncontrollably.
Studies have shown that apoptosis is a natural process which can prevent cancer
development when activated. Research regarding the signalling pathway related to
apoptosis has revealed that the apoptotic program can be activated in response
to numerous physiological stress events seen in many developing cancer cells. As
mentioned earlier DNA damage caused by hyper-proliferation can induce apoptosis
in these cells. However, of interest, studies carried out on diﬀerent types of tumour
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cells have shown that apoptosis is reduced in tumour cells that develop in to
high-grade malignancies and become resistant to therapy.
10. Deregulating cellular energetics
Another emerging hallmark is the altered cellular energetics. Uncontrolled cell pro-
liferation does not only involve deregulated cell growth, but also a higher energy
metabolism to support growth and division. Normal cells generate energy needed
for they metabolism mainly by mitochondrial oxidative phosphorylation, in contrary
to this cancer cells tend to depend on aerobic glycolysis. This was ﬁrst observed by
Otto Warburg, therefore this phenomenon in cancer cells is known as “The Warburg
eﬀect”12. Cancer cells tend to use aerobic glycolysis even in the presents of adequate
oxygen. The underlying mechanisms are not completely understood how a cancer
cells compensate for the approximately 18-fold decreased eﬃciency of adenosine
triphosphate (ATP) production. This is partially achieved by upregulation of glu-
cose transporters which increase the uptake of glucose into the cytoplasm13. Another
interesting process found in some tumours is the presence of two subpopulations.
Glucose-dependent cells secrete lactate which is used by the second subpopulation
as energy source to partially employ the citric acid cycle. Deregulated metabolism
is not part of the core hallmarks yet and needs further investigation. Hypoxic con-
ditions are not necessarily static in tumours. Temporarily normoxic environment
could possibly compensate the lack of oxygen. It is also important to note that
neovascularisation supports tumour progression in many cases.
1.2 Breast Cancer
Breast cancer is the most common type of cancer in the UK. In 2014, over 55,000
cases of cancer were reported. In 2014, over 11,000 patients died from this disease2.
It is estimated that almost 1.7 million women were diagnosed worldwide in 20122.
The majority of cases occur after the menopause, but also many young women
are aﬀected. Known risk factors are ionising radiation, smoking, a high-fat diet,
and prolonged exposure to oestrogens. Genetics also play a role in developing this
disease. In rare occasions men are diagnosed with breast cancer (<1%). Breast
cancer is comprised of several diﬀerent subtypes, this is based on: The location
of the tumour, invasiveness, abnormal expression of hormone receptors, metastatic
rate and the occurrence of inﬂammation.
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1.2.1 Stages of breast cancer
Staging of cancer is important to understand changes in cancer incidence within the
population, the extent of the disease at initial presentation as well as the impact
on cancer treatment. It is an important benchmark for physicians and patients for
deﬁning prognosis and the probability to overcome this disease. Moreover, it is a
crucial base of clinical trials. For breast cancer there are several systems available.
The two most common system, TNM and number/roman staging system, will be
discussed in more detail below. A comparison of both system is depicted in table
1.1.
1.2.1.1 TNM staging system
The “T” stands for tumour and describes the size, the “N” for involvement of the
lymph node and “M” whether the cancer has established far distant metastases.
The TNM system was developed by Pierre Denoix in the 1940s. Since the
1980s the International Union for Cancer Control (UICC) and the American
Joint Committee on Cancer (AJCC) coordinate and reﬁne the guidelines. These
guidelines are published in TNM Classification of Malignant Tumours14 and the
AJCC Cancer Staging Manuel15.
TNM staging has four diﬀerent types. (1) The clinical staging is used based on
information identiﬁed prior to neoadjuvant therapies or surgery. It is based on
imaging tests, biopsies and physical examination. (2) Pathologic staging is deter-
mined individually post surgery. This staging is combined with clinical staging.
(3) Post-therapy or Post-neoadjuvant theraphy staging explains how much cancer
remains after initial systemic and/or radiotherapy treatment prior to surgery (or no
surgery). Either clinical or pathologic staging guidelines are assessed. (4) Restaging
is used to assess recurring disease. It helps to determine the best treatment options.
As a matter of simplicity only the clinical staging system will be explained in detail.
The T stages
The T is followed by a letter, digit or abbreviation to give further details. TX
means that the tumour could not be found or measured. T0 indicated that there is
no proof of a primary tumour. Tis means “tumour in situ” and is used to describe
DCIS. T1-4 are based on the size of the tumour and in which extend the adjacent
tissue is aﬀected. In general T1 means that the tumour is 2 cm in size or less.
However, T1 is sub-grouped, depending on the size of the tumour, into: T1mi, T1a,
T1b and T1c: T1mi indicates a tumour size of 0.1 cm or less. T1a: The tumour
is larger than 0.1 cm, but not more than 0.5 cm. T1b: The size varies between
0.5-1 cm. T1c: The tumour is between 1-2 cm. T2 means the tumour has a size
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between 2-5 cm. T3 means the tumour is larger than 5 cm. T4 is subdivided into
four groups based on the location of metastasis: T4a, T4b, T4c and T4d: T4a
If the tumour has spread to the chest wall. T4b indicates that the cancer has
spread into the skin and the breast might be swollen. T4c means chest wall and
skin are inﬁltrated by tumour cells. T4d is a rare form of breast cancer (1-4%)
and is described as an inﬂammatory cancer with symptoms such as swollen breast.
Cancer cells might be found in both the skin and lymph nodes.
The N stages
The N is followed by a letter, digit or abbreviation to give further details. NX
means that no tumour is found in the lymph nodes or they cannot be assessed.
One reason could be that they were previously removed. N0 indicates that no
cancer cells were found in nearby lymph nodes. There is a threshold for lymph
node scoring: A lymph node can have cancer cells however can be counted as
negative if they only contain isolated tumour cells (ITCs). ITCs are deﬁned either
as single tumour cell, small cluster of cancer cells with less than 0.2 mm in size
or less than 200 cells in one part of the lymph node. N1: Cancer has spread
to the lymph nodes in the armpit, but is not detected in surrounding tissue. A
subtype of N1 is pN1mi which is diagnosed if one or more lymph nodes contain
micrometastasis which are larger than 0.2 mm or contain more than 200 cancer
cells with less than 2 mm in size. N2 is categorised in two groups - N2a and
N2b. N2a: Metastases are found in axillary lymph nodes which are ﬁxed to one
another or to other structures. N2b: Cancer cells are clinically detected in the
internal mammary nodes, but are absent in the axillary nodes. N3 is divided into
three groups: N3a: If metastases are found within lymph nodes below the collar-
bone. N3b: If tumours are detected in the internal mammary and axillary lymph
nodes. N3c: If cancer cells are found in the lymph nodes superior to the collarbone.
The M stages
The M stages indicate if cancer has not spread (M0) or has spread (M1) to other
body parts. In M1 stage tumours are larger than 0.2 mm. However, there is one
exemption within the cMo(i+) stage where neither clinical nor radiographical ev-
idence of distant metastases were found. However, molecularly or microscopically
detected tumour cells are found in circulating blood, bone marrow or other distant
nodal tissue with a size of more than 0.2 mm. Patients in this stage are without
symptoms or signs of metastases.
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1.2.1.2 Number/Roman numeric staging system
The number staging system divides breast cancer in four stages. As the TNM sys-
tem, the number stage system also considers if the cancer is node negative or positive
as well as tumour size and spreading to other body parts. Sometimes, a ﬁfth stage is
included in the system. Stage 0 is the pendant to Tis of the TNM system and refers
to non-invasive breast cancer such as DCIS. Following stages, however, describe all
invasive cancer.
Stage I is further divided into two subcategories IA and IB. Invasion can be ob-
served, but invaded cells measure less than 1 mm in surrounded tissue. Stage IA is
an invasive tumour with up to 2 cm in size, but has not yet spread to the lymph
nodes. Stage IB describes invasive breast cancer with or without a tumour not larger
than 2 cm as well as small groups of breast cancer cells which vary between 0.2 and
2 mm in size and inﬁltrated the lymph nodes.
Stage II is also subcategorised into two groups: IIA and IIB. Three scenarios are
considered in stage IIA cancer: 1) No tumour is found in the breast, but 1 to 3
tumours are seen within the axillary lymph nodes or in the lymph nodes near the
breast bone. These are larger than 2 mm. 2) If the tumour has a maximum size
of 2 cm and has spread to the axillary lymph nodes. 3) If a tumour is between 2-5
cm, but has not yet spread to the axillary lymph nodes. Stage IIB distinguishes
also three scenarios: 1) The tumour is between 2-5 cm in size. Additionally, small
tumours with a size of 0.2-2 mm are found in the lymph nodes. 2) The tumour is
between 2-5 cm in size and the cancer has spread to lymph nodes near the breast-
bone or to 1 to 3 axillary lymph nodes. 3) The tumour is larger than 5 cm, but has
not inﬁltrated the axillary lymph nodes.
Stage III has thee subcategories: IIIA, IIIB and IIIC. IIIA: In this stage diﬀerent
size tumours might be present or in some cases no tumours are found, however 4-9
axillary or breast bone lymph nodes are aﬀected. In some cases tumours grow larger
than 5 cm and small groups of breast cancer cells (0.2 -2 mm) are seen in the lymph
nodes. Alternatively, larger tumours (<5cm) have spread to 1 to 3 axillary or lymph
nodes located near the breastbone. Stage IIIB: In this stage there is no restriction
regarding tumour size. Cancer may or may not have spread to the chest wall. Also
the skin of the breast might be inﬁltrated which causes ulcers and swelling. Alter-
natively, the cancer may have spread to 9 axillary lymph nodes. In the other case
the tumour might have inﬁltrated the lymph nodes near the breastbone. Inﬂamma-
tory cancer, as described in the previous section would be considered as stage IIIB.
IIIC: In this stage it is possible that no tumour is observed or one tumour with no
restricted size is present. Is is also possible that the cancer has metastasised to the
breasts’ chest wall and/or skin. For a type of breast cancer to be grouped in this
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stage the features described above need to be accompanied by one of the following:
Cancer cells have spread to 1) ten or more axillary lymph nodes or 2) lymph nodes
above or below the collarbone or 3) axillary lymph nodes or to lymph nodes near
the breastbone.
Stage IV breast cancer is metastasised and spread to other organs distant from the
primary tumour site such as lung, bones or liver.
Table 1.1: Represenation of how the number and TNM staging system correlate. a Ti includes
T1mi; b Nodal micrometastases of T0 and T1 are classified as stage IB instead of stage IIA. M0
includes M0(i+).
Number staging system TNM staging system
Stage 0 Tis N0 M0
Stage IA T1 N0 M0
Stage IB T0 N1mi M0
T1a N1mi M0
Stage IIA T0 N1b M0
T1 N1b M0
T2 N0 M0
Stage IIB T2 N1 M0
T3 N0 M0
Stage IIIA T0 N2 M0
T1a N2 M0
T2 N2 M0
T3 N1 M0
T3 N2 M0
Stage IIIB T4 N0 M0
T4 N1 M0
T4 N2 M0
Stage IIIC Any T N3 M0
Stage IV Any T Any N M1
1.2.2 Subtypes and treatments of breast cancer
In the past ﬁve years international experts proposed and reﬁned new classiﬁcation
systems for breast cancer. Six subtypes are known: 1) Slow growing Luminal A type,
2) luminal A-like type, 3) fast growing Luminal B type, 4) luminal B-like, 5) basal-
like/triple negative and 6) Her2-positive cancer. It was just recently proposed that
luminal A-like should be added to the subtypes16. Luminal A-like breast cancer
responses much worse to chemotherapy compared to luminal B-like disease. An
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overview of classiﬁcation is shown in table 1.2. The thresholds are not shown.
Table 1.2: Subtype classification system for breast cancer16,17. Her2: Human epidermal growth
factor receptor; ER: Oestrogen receptor; PR: Progesterone receptor.
Subtype Trait
Luminal A ER +ve and/or PR +ve
Her2 -ve
Low Ki-67
Luminal A-like ER +ve
High Ki-67
High PR
Her2 -ve
Luminal B ER +ve
Her2 -ve
Either Ki-67 high or PR low
Luminal B-like ER +ve
High Her2
Any Ki-67
Any PR
Basal-like/Triple-negative ER -ve
PR -ve
Her2 -ve
Her2 positive ER -ve
PR -ve
High Her2
In breast cancer diﬀerent treatment strategies are available as recommended
by the European Society for Medical Oncology (ESMO) and the National Com-
prehensive Cancer Network (NCCN). In this section I will focus on the guidelines
published by ESMO18. Discrepancies between both guidelines were recently debated
by Zagouri et al.19.
In early breast cancer three scenarios post diagnosis are possible. Scenario 1: The
patient has no wish for the breast or conservation (lumpectomy) is not possible due
to e.g. presence of more tumours which formed separately from one another (multi-
centric breast cancer) or a part or the whole breast is removed (mastectomy). This
is followed by diﬀerent options of therapies including chemo-, radio- and endocrine
therapy as illustrated in ﬁgure 1.2. Scenario 2: The tumour is less than 2 cm in
size and/or optimal surgery can be achieved. The patient would undergo a lumpec-
tomy followed by diﬀerent therapies. Scenario 3: The tumour is larger than 2 cm
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or optimal surgery is not feasible and the patient decides against mastectomy. The
prerequisite is that lumpectomy is potentially feasible. The patient needs to start
the systemic induction therapy, normally chemotherapy which can have two out-
comes. If the response is unsatisfactory the patients needs to undergo a mastectomy
followed by the mentioned postoperative therapies. If the repsonse to chemotherapy
is satisfactory a lumpectomy can be performed followed by postoperative therapies.
An overview of this scheme is illustrated in ﬁgure 1.2.
(Neo)adjuvant treatment should start within 2-6 weeks post surgery as eﬃcacy is
decreased if administration is delayed for more than 12 weeks20. In ﬁgure 1.3 treat-
ment choices, according to expression of biomarker and intrinsic phenotype, are
illustrated.
After initial screening, including the hormone receptors ER, Her2 and PR, the treat-
ment pursues following choices: ER-negative tumours with Her2 expression receive
chemotherapy in combination with anti-Her2 medication such as trastuzumab. Duc-
tal triple-negative tumours receive chemotherapy. For special histological types of
triple-negative disease the recommendations of the St. Gallen consensus are en-
dorsed21. They propose endocrine therapy for endocrine responsive histologies.
For high-risk endocrine non-responsive breast cancer chemotherapy is recommended
while for low-risk endocrine non-responsive disease no systemic therapy is endorsed.
In contrast, ER-positive, luminal B and Her2-positive breast cancer a combination
of chemo- and endocrine therapy with trastuzumab is applied. In ER-positive, lumi-
nal B, but Her2-negative cancer a combination of chemo- and endocrine therapy is
applied. For ER-positive, Her2-negative and luminal A-type cancer endocrine ther-
apy only is recommended. However, for high risk cases additional chemotherapy is
proposed18.
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Figure 1.2: Schematic illustration of the early breast cancer treatment algorithm proposed by
ESMO. Adapted and modified from Senkus et al., Primary breast cancer: ESMO Clinical Practice
Guidelines for diagnosis, treatment and follow-up, Annals of Oncology, 201518.
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Figure 1.3: Schematic illustration of (neo)adjuvant systemic treatment options based on instrin-
sic phenotype and biomarker expression proposed by ESMO.
* EMSO endorses the recommendations of St. Gallen consensus for special histological types of
triple-negative disease21. Endocrine therapy is recommended for endocrine responsive histologies
while chemotherapy is proposed for high-risk endocrine non-responsive breast cancer. No systemic
therapy is recommended for low-risk endocrine non-responsive disease.
Adapted and modified from Senkus et al., Primary breast cancer: ESMO Clinical Practice Guide-
lines for diagnosis, treatment and follow-up, Annals of Oncology, 201518.
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A precursor of breast cancer is the ductal carcinoma in situ (DCIS), which is a
non-invasive neoplastic proliferation of epithelial cell and initiates within the lact-
iferous ducts. These cells show a varying degree of cytologic atypia. Around 4,800
women are diagnosed with DCIS in the UK every year2. Metastasis is uncommon
in DCIS, however it could occur if the disease is diagnosed at a late stage or left
untreated. In some cases DCIS can undergo malignant transformation leading to
invasive ductal carcinoma (IDC). Genomic hybridisation studies revealed an almost
identical pattern of genomic alterations in DCIS and IDC22. On the contrary, a lot
of research has shown diﬀerences between non-invasive and invasive breast cancers.
A recent study using gene proﬁling has identiﬁed 74 genes that are involved in the
invasive behaviour of breast cancer23. Gene expression proﬁling revealed a total of
470 genes which are diﬀerently expressed between DCIS and invasive breast cancer.
Especially genes involved in ECM synthesis and organisation were prominent in ep-
ithelium of invasive breast cancer. Lee et al. compared their results to eight similar
studies and found overlap of 74 genes. In silico analysis of these genes correctly
categorised about 90% of breast cancer samples in this and two other studies. An
experimental approach was performed with human DCIS, in which four genes were
knockdown that are elevated in clinical samples of DCIS. These cells were used in a
DCIS xenograft model which resulted in reduced progression to invasive breast can-
cer. In silico and in vivo analysis showed that the identiﬁed set of genes may have
clinical beneﬁts. Detection, diagnosis and therapy of this disease may be improved
by targeting some of the identiﬁed genes.
Oestrogens and progesterones are two important hormones that play a crucial role
in the development of breast cancer. In about 70% of the cases ERα and PR are
present. However, ERβ is often lost. In other breast cancer incidents ERα and
PR are often epigenetically downregulated. Breast cancer which express ERα can
be treated with selective ER modulator (SERM). The action of SERMs is varying
depending on the tissue. In some tissue it can act as agonist in others as antiago-
nist. One of the most common drugs to treat breast cancer is tamoxifen. This is
used in early and advanced ER-positive breast cancer in pre- and postmenopausal
women. In the liver tamoxifen is metabolised to 4-hydroxytamoxifen and acts as low
aﬃnity antagonist for oestrogen. This leads to reduced oestrogen activity such as
transcription of genes which respond to ER activation. Tamoxifen is mostly given in
combination with gonadotropin-releasing hormone analogues (GnRHa). Tamoxifen
and GnRHa are the standard treatment of pre-menopausal patients suﬀering from
breast cancer24 since two-third of patients express ER independent of age25. For
ER-positive breast cancer the mortality is reduced by 31% if treated with tamox-
ifen for a period of ﬁve years26. However, patients respond diﬀerently to tamoxifen
treatment. Some tumours do not respond to treatment despite maintaining ER ex-
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pression27. Aromatase inhibitors have been developed to overcome this problem.
The cytochrome P-450 enzyme aromatase catalyses the synthesis of oestrogens from
androgen precursors28. Its expression occurs in many organs such as ovary, mus-
cles, placenta, hypothalamus, liver, adipose tissue and breast cancer itself. During
puberty the aromatase expression in ovaries is induced by the release of follicle stim-
ulating hormone (FSH). While the ovary contributes most to aromatase expression
the organ loses this ability again after menopause28. Aromatases inhibit the release
of gonadotropin (negative feedback). Blockage of aromatase leads to decrease in
oestrogens which stimulates gonadotropin synthesis which activates the release of
oestrogens and aromatase. As reviewed by Hiscox et al.29, due to the oestrogenic
eﬀects of tamoxifen in other organs such as uterus and vasculature the use of ta-
moxifen is associated with endometrial cancer, stroke and thromboembolic events.
Additionally, after ﬁve years of treatment tamoxifen does not improve survival. In
contrast, aromatase inhibitors do not exert an oestrogenic eﬀect resulting in fewer
side eﬀects. Also for prevention of disease recurrence seem aromatase inhibitors
superior to tamoxifen30. In clinical trials it was found that the aromatase inhibitor
anastrozole was more eﬀective alone than in combination with tamoxifen suggesting
to interfere with each others metabolism29. In combination with signal transduc-
tion inhibitors (e.g. imatinib) a signiﬁcant reduction in tumour growth was found.
However, aromatase inhibitors have a response rate of 50-70% in patients suggesting
limited sensitivity or some level of de novo resistance29. Combinatorial targeting of
other pathways may improve the eﬃciency of aromatase inhibitors. Nevertheless,
the observed superior eﬀect with less side eﬀects, compared to tamoxifen, makes
these inhibitors already clinically relevant.
It has been observed that more aggressive breast cancer often lacks ERs. Predomi-
nantly, proliferation is driven through Her2 familiy receptor tyrosine kinases (RTKs)
via Ras-MAPK pathway. It also inhibits apoptosis via mTOR. To function, Her2
heterodimerises with Her3 and Her4. Thus, gene ampliﬁcation and overexpression
of Her2 correlates with breast cancer progression. In Her2 overexpressing patients
trastuzumab is given as an anti-cancer drug. Trastuzumab is a monoclonal anti-
body targeting the extracellular segment of the receptor. Analysis by the Early
Breast Cancer Trialists’ Collaborative Group (EBCTCG) revealed that 6 month
polychemotherapy using anthracyclines such as FAC (ﬂuorouracil, doxorubicin, cy-
clophosphamide) or FEC (ﬂuorouracil, epirubicin, cyclophosphamide) reduces the
mortality rate by 38% for women when aged 50 years or younger at diagnosis. The
death rate is reduced by 20% when diagnosed with the age of 50-69. The outcome is
largely regardless of tamoxifen treatment, ER as well as nodal status or other tumour
characteristics26. Anthracyclines have a wide spectrum of anti-tumour activity. The
most known mechanisms comprise 1) inhibition of macromolecule synthesis by inter-
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calation with DNA and RNA, 2) induction of lipid peroxidation and DNA damage
by generation of free radicals, 3) alkylation and binding of DNA, 4) crosslinking of
DNA, 5) interfering with DNA unwinding, strand separation and helicase activity,
6) eﬀects on cell membrane and 7) topoisomerase II inhibition resulting in DNA
damage and eventually apoptosis31–33. In ER-positive disease, ﬁve years of tamox-
ifen treatment reduced the mortality rate by 31%, regardless of age, PR status,
chemotherapy or other tumour characteristics26. The same study also showed that
ﬁve years of tamoxifen treatment are more eﬀective than just 1-2 years. ER-positive
women (middle-age) have a approximately 50% reduced mortality rate when sub-
jected to 6 month anthracycline polychemotherapy (e.g. FAC or FEC) followed by
5 years of tamoxifen treatment. The anthracycline-based therapy prior to tamoxifen
further reduced the mortality rate in women aged younger than 50 years (38%) and
50-69 years (20%) to a ﬁnal mortality reduction of 57% and 45%, respectively26.
Results of a 8.4 year long study showed that adding trastuzumab to chemotherapy
of Her2-positive patients the overall survival improved by 37%. After 10 years, the
overall survival increased from 75.2% to 84%. The relapse-free survival (RFS) was
improved by 40% and the 10-year RFS from 62.2% to 73.7%34.
A subtype which is considered to be highly aggressive is basal or triple negative
breast cancer. Patients suﬀering from this disease lack ER, Her2 and PR. Lacking
these receptors make treatment diﬃcult since common drugs, as trastuzumab or
tamoxifen, are inactive without target. In this case conventional therapy such as
chemotherapy is still the preferred treatment option. Good results are shown by
platinum-containing agents like carboplatin oder cisplatin35. Platinum-based durgs
interfere with DNA replication, thus most eﬀective in fast proliferating cells as can-
cer. The chloride ions of e.g cisplatin are displaced by H2O once inside the cell
due to the low cellular ion concentration. The aquated cisplatin favours binding of
DNA by crosslinking covalently purines36. This induces diﬀerence repair pathways
and eventually, when the cell fails to repair the DNA, apoptosis is induced lead-
ing to cell degradation. The platinum-based therapy shows a higher response rate
(88%) in triple-negative breast cancer compared to other subtypes (55%). However
the overall survival after 5 years was worse in triple-negative disease compared to
other breast tumours37. Immunohistochemical analysis investigated the expression
of epidermal growth factor receptor/Her1 (EGFR) in benign lesions and 84 sam-
ples with invasive breast cancer38. The samples were classiﬁed on a molecular level
and stained for EGFR. EGFR was expressed in 41.66% of basal-like cancer, 50% of
luminal B carcinoma and 21.42% of cases with Her2 overexpression38. EGFR is a
potential target for therapy, because it stimulates cell replication similarly to Her2.
Blocking the EGF receptor could cease the stimulating eﬀect resulting in cell cycle
arrest and potential tumour regression39. Targeting of EGFR can be achieved in
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two ways. One is to apply monoclonal antibodies which block ligand binding and
receptor internalisation by binding to the extracellular domain of EGFR. The other
way is to block internal signalling by tyrosine kinase inhibitors (TKIs) which target
the intracellular domain40.
In a clinical phase II trial with hormone resistant tumours the TKI geﬁtinib was
found to be not very eﬀective if applied alone.41. However, in vitro experiments with
triple-negative breast cancer cell lines showed that geﬁtinib enhanced the response
to docetaxel and carboplatin. In combination of all three drugs a syngerstic eﬀect
in these cells was observed42. Docetaxel interferes with microtuble dynamics. It
binds to microtubles thus preventing disassembly/depolymerisation. Accumulation
of these eventually induces apoptosis43. A phase I/II trial with stage IV Her2-
positive breast cancer patients found that a combination therapy with docetaxel,
trastuzumab and geﬁtinib is eﬀective44. Lapatinib, another TKI inhibitor, showed
complete response in Her2-positive disease, but only little eﬀect in other cancer45.
The basal-like subtype of breast cancer (BLBC) is associated with triple-negative
status46 and is known for its aggressive behaviour. However, a study showed that
triple-negative and BLBC are not the same47. They were able to show that only
123 out of 172 triple-negative tumours were BLBC, according to gene expression
proﬁling. From 160 samples, which were tested to be BLBC by gene proﬁling, only
123 were triple-negative based on histological staining. This suggests that not all
BLBC are triple-negative. These ﬁndings were not only conﬁrmed by other stud-
ies48,49, they also showed that triple-negative breast cancer do not form a homoge-
neous subtype in transcriptional terms, unlike BLBC47. This suggests that within
the heterogeneous group of triple-negative breast cancer, a homogeneous subtype
of BLBC forms an entity. Thus the poor prognosis of triple-negative breast cancer
may be a result of the basal-like subtype and is rather a symptom than a subtype39.
A rare and aggressive form is inﬂammatory breast cancer (IBC). It is characterised
by its aggressive behaviour and fast progression. Due to blocked lymph nodes fol-
lowing symptoms can occur in the breast: Swelling, reddening, hot sensation and
ﬁrmer tissue. Other symptoms comprise thickened and/or perforated skin, lumps or
inversion of the nipple. IBC commonly lacks ER/PR and is subjected to ampliﬁca-
tion of Her2 oncogene50. Overexpression of p53 and EGFR can be observed in some
cases and correlate with poor prognosis51,52. In 90% of all tumours RhoC GTPase
is upregulated and its involved in cytoskeletal reorganisation and regulation of an-
giogenic growth factors as well as inﬂammatory cytokines53,54. Evidence suggests
claudin1 is a tumour suppressor involved in invasive breast cancers55.
It has been shown that ER-negative tumours tend to be claudin1 positive compared
to ER positive cancer. In fact ER-positive tumours showed a very weak positivity of
claudin1 or showed complete loss56. In basal-like subtype of breast cancer a signiﬁ-
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cant high association with claudin1 was found, which correlated with poor prognosis
in patients suﬀering from this type of breast cancer56,57. Basal-like breast cancer
(BLBC) is a very aggressive subtype of cancer and is deﬁned by the expression of a
distinct set of genes that encode for proteins such as the EGFR and cytokeratins 5
and 17. These proteins are characteristic in the basal or outer layer of the mammary
gland epithelium. These tumours often occur in young women and cause short re-
lapses58. However, a recent study59 identiﬁed a signiﬁcant correlation between high
levels of claudin1 and BLBC incidents in women aged 55 years or older. A signiﬁcant
association of high claudin1 expression and patient survival was not found. Knock-
down of claudin1 in BLBC cells led to reduced cancer cell migration59. However,
this type of cancer still remains poorly characterised. A recent study also identiﬁed
high levels of claudin1 in a small percentage of luminal and Her2 subtypes57 which
emphasises the heterogeneity of cancer. High levels of claudin1 and 6 were found in
breast cancer 1 (BRCA1) type breast cancer60. Due to the characteristic expression
pattern of claudin1 and 6 it is thought that they can be used to help to distinguish
between sporadic breast cancer incidents and BRCA1 mutation carriers60. BRCA1
is a tumour suppressor gene and the encoded protein plays a role in DNA repair,
more precisely the BRCA1 protein repairs double-strand breaks of the DNA by ho-
mologous recombination. BRCA1 breast cancer is a hereditary cancer and mutation
carriers are also prone to develop ovarian and fallopian tube cancer61. For women
the cumulative risk of beeing diagnosed with breast cancer is about 12% in their
lifetime62,63. The risk of breast cancer at an age of 70 is 3.84%63 while carriers of the
BRAC1 mutation have a likelihood of developing breast cancer of 65%62. In vitro
and in vivo experiments showed that heterozygous inactivation of BRCA1 resulted
in genomic instability in non-cancerous somatic breast cells64. Deletion of AG at po-
sition 185 led to impaired DNA repair and enhanced sensitivity to genotoxic stress.
Thus it is believed that the suﬃciency of BRCA1 may accelerate carcinogenesis in
breast tissue by promoting additional genetic alterations64. Yet it is not known how
this leads to diﬀerential regulation of claudins. It could be that regulatory genes
for claudins lie in areas which are hotspots for double-strand breaks. If BRCA1 is
defective these double-strand breaks then accumulate which may lead to distortion
of claudin expression.
A novel strategy targeting BRCA1 mutation carriers are poly-ADP-ribose poly-
merase 1 (PARP1) inhibitors. PARP1 is involved in the base excision DNA repair
pathway of DNA upon single-strand breaks65. PARP1 binds to exposed ends of
damaged DNA and recruits other repair enzymes to the site of single-strand breaks.
Upon PARP1 inhibition cell replication is arrested at site of single-strand breaks
leading do double-strand breaks. Healthy cells then execute homologous recombi-
nation in which BRCA1 plays an important role. BRCA1-deﬁcient cells cannot be
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repaired this way and activate an alternative pathway called non-homologous end
joining. The latter is much prone for errors compared to error-free homologous
recombination due to its use of intact DNA as a template. Non-homologous end
joining accumulates DNA lesions which ultimately result in genomic instability and
eventually apoptosis39. BRCA2 has similar function working in the same pathway,
thus lack of this protein make the cell susceptible to PARP inhibitors too66. Phase
I and II trials conﬁrmed the anti-tumour activity of PARP inhibitor in BRCA1/2
mutations carriers with little adverse side eﬀects. In a phase I trial with 60 patients
(22 BRCA1/2 carriers) showed the PARP inhibitor olaparib anti-tumour activity
against mutation carriers while mutation-free tumours were unaﬀected67. In a con-
secutive phase II trial with only BRCA1/2 carriers a higher dose of olaparib was
applied which correlated with better response and RFS while the toxicity of the
drug remained low (comparable to mutation-free tumours)68.
Another phase II trial, but solely on triple-negative breast cancer, showed improved
survival when treated with the PARP inhibitor BSI-201 in combination with car-
boplatin and gemcitabine69. The positive eﬀect lies on the fact that triple-negative
breast cancer has often a signiﬁcantly elevated expression of PARP169.
Another subtype of breast cancer is identiﬁed as claudin-low breast cancer, but
remains poorly described. A summary is found in ﬁgure 1.4.
Figure 1.4: Claudin1 expression in subtypes of breast cancer. The image was adapted from
Blanchard et al.56, Zhou et al.70 and Prat et al.71.
Claudin-low tumours can be characterised by cancer stem cell-like features in-
cluding reduced expression of luminal- and proliferative-associated genes such as
aldehyde dehydrogenase isoform 1 (ALDH1), immune response genes such as CD14,
CD79b and vav1, enrichment of EMT markers such as vimentin, twist and snail and
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low expression or absence of luminal diﬀerentiation markers such as ER, PR, ker-
atins 18 and 1971. In contrast to BLBC, claudin-low subtypes have a lower frequency
of being triple negative72. These tumours are the most undiﬀerentiated along the
mammary epithelial type tumours with poor prognosis72.
The expression pattern of claudins, especially claudin1, in diﬀerent cancer subtypes
indicate claudin1 as potential biomarker for breast cancer diagnosis, treatment and
predicting disease progression.
1.3 The ADAM family: A Disintegrin and Met-
alloproteinase
ADAMs are a family of transmembrane glycoproteins that belong to the zinc pro-
tease superfamily - Metzincin. The name Metzincin is derived from the methinoine-
turn sequence within its metalloprotease domain (MP), which is able to bind zinc-
ions. A family tree of endopeptidases is shown in ﬁgure 1.5. They have a vast
spectrum of biological functions such as cytokine and growth factor shedding, a pro-
cess by which biologically active and soluble molecules are released from membrane-
bound precursors. Other functions involve cell migration, control of membrane
fusion, muscle development, fertilisation, cell fate determination in the nervous sys-
tem, axon guidance and intracellular signalling. The ADAM family is comprised
of 40 members of which 22 are found in human. 13 are considered or predicted as
proteolytic active. The existence of ADAM36-40 is only predicted based on genomic
sequences73. A table of all ADAMs discovered is kept up-to-date by White and
Wolfsberg73.
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Figure 1.5: Overview of functional ADAM family members in relation to their MP activity and
site of expression, in comparison with other metzincin superfamily members. Family members
are outlined with rectangles, protease activity with hexagons and site of expression with rounded
rectangles. The tree was adapted and modified from Vandenbroucke & Libert74 and Edwards,
Handsley & Pennington75.
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1.3.1 Structural differences of ADAMs and other metallo-
proteases
ADAMs are multidomain proteins consisting of a signal-sequence, a pro-, a metal-
loproteinase (MP), a disintegrin, cysteine-rich, epidermal growth factor (EGF)-like,
transmembrane and intracellular (ICD) domain (or cytoplasmic tail, respectively).
The functions of each domain will be discussed in more detail in the following sub-
section. An overview of the structure of ADAMs as well as close relatives, which will
be described brieﬂy in this section, are illustrated in ﬁgure 1.6. ADAMs share many
characteristics with other metalloproteinases. Close relatives are the ADAMs with
thrombospondin motifs (ADAMTS), matrix metalloproteases (MMPs), snake venom
metalloproteinases (SVMPs) and the membrane-bound MMPs. These proteins all
share a signal peptide, pro-domain and a zinc-dependent MP domain. However,
they diﬀer in the addition or absence of other motifs.
Kuno et al. named a new family of ADAMs based on the presence of a throm-
bospondin (TSP) homologous domain containing TSP-1 motif. ADAMTS1 for ex-
ample has three TSP-1 motifs. The ﬁrst is ﬂanked by the disintegrin and cysteine-
rich domain whereas the other two are located as a tandem at the C-terminus76.
Compared to ADAMs, ADAMTS proteases lack the transmembrane region hence
they are secreted. All known ADAMTS share the ﬁrst TSP-1 motif. However,
the C-terminal region is highly dynamic and varies within the family. Physiolog-
ical processes include extracellular matrix turnover, ovulation, blood coagulation,
melanoblast development and wound healing. They also play a role in pathological
processes such as cancer, atherosclerosis, arthritis, cancer and angiogenesis77.
SVMPs are the closest to ADAMs. They not only share the signal peptide, pro- and
MP-domain, but also have similar disintegrin- and cysteine-rich domain (ﬁgure 1.6).
Metalloproteinases are very common toxins in snakes and SVMPs are considered as
the primary factors for haemorrhage. Based on the domain organisation SVMPs
are classiﬁed into P-I to P-III. P-I is the simplest protease with just a MP-domain
whereas P-II has an additional disintegrin domain. P-III SVMPs consist of a MP-,
disintegrin- and cysteine-rich domain and are characterised by more biological func-
tions and higher haemorrhagic activity78. Apart from haemorrhage, other activities
include ﬁbrino(geno)lysis79, apoptosis80 and activation of members of the coagula-
tion cascade such as factor x81,82 or prothrombin83,84. It is believed that the RGD
motif within the disintegrin loop (D-loop) plays a role in platelet aggregation and
cell-matrix interactions85. The D-loop will be discussed in subsection 1.3.1.3.
MMPs and membrane-type-MMPs (MT-MMPs) are other relatives of ADAMs.
They diﬀer in the presence or absence of a transmembrane region and a cytoplasmic
tail. One important diﬀerence in the MMP family is that some of them contain a
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haemopexin-like domain (ﬁgure 1.6). The natural function of haemopexin is to bind
free haem in the body and deliver it to the liver, to prevent oxidative stress. However,
there are MMPs which only contain a signal peptide, pro- and MP-domain such as
MMP7 and MMP26. Their major functions are degradation of various connective-
tissue proteins such as laminin86, collagen IV86, ﬁbrin87, elastin88 or growth factors
such as latent transforming growth factor-β1 (TGFβ1)89 or latent vascular endothe-
lial growth factor (VEGF)90. Due to their natural function of ECM degradation
the overexpression of MMPs can lead to various pathological conditions. In various
types of cancers the expression and activity of MMPs is elevated. This is associated
with higher invasion91 and migration92 rate leading to a more advanced tumour
stage93 and reduced survival94. Although MMPs play a big role in disease progres-
sion in some cases they can also be beneﬁcial. Expression of MMP12 in colorectal
carcinoma cells is associated with increased survival95. Another model of human
colorectal cancer suggests that MMP9 expression is associated with smaller metas-
tasis96.
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Figure 1.6: Schematic representation of the ADAM family in comparison with other metalloproteases. Common structures of SVMPs (P-III), ADAMTS
(ADAMTS1), MMPs (MMP11) and MT-MMPs (MT-MMP14) are depicted. Domain addition and organisation varies among the family members. Figure
adapted from Wolfsberg & White97, Tang98 and Parks, Wilson & Lo´pez-Boado99
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1.3.1.1 Signal sequence and pro-domain
Since ADAMs are localised to the membrane they possess an N-terminal signal se-
quence which guides the protein into the secretory pathway followed by fusion with
the cell membrane100. Two forms of these proteins exist, a 110 kDa non-active (con-
taining pro-domain) and an 85 kDa active form (without the pro-domain)100,101.
The pro-domain has two functions: Firstly, it ensures correct folding of the pro-
tein102. Secondly, it keeps the MP-domain inactive through a cysteine switch103.
The cysteine residues interact with the zinc ion of the MP domain causing inacti-
vation97,104,105. ADAMs have consensus sequences RRRR102,106 and RXKR107,108
between the pro- and MP-domain, which are targets for furin proteases. The con-
sensus RRRR sequence is also found in ADAM15.
1.3.1.2 MP-domain
Metzincin family proteins contain an evolutionary conversed Met-turn sequence, lo-
cated within the core of the protein structure. It provides structural integrity, sup-
ports zinc-binding and is indispensable for the function. The Met-turn is inserted
into the core structure and supports zinc-binding109. Depending on the metallo-
protease the catalytic domain contains between 130 and 260 residues which folds
into globular moieties. These are divided in an upper N-terminal and lower C-
terminal subdomain by an active site cleft. The N-terminal subdomain contains the
active-site helix which embeds the HEXGHXXGXXHD zinc binding sequence and
the general base/acid glutamate which acts as catalyst and zinc binding histidines.
The MP domain also contains a binding site for calcium which modulates enzy-
matic activity110 (ﬁgure 1.7). Therefore, calcium chelators can inhibit the protease
reversibly.
Figure 1.7: Three dimensional structure of the catalytic cleft of the MP domain. β-sheets in
cyan, α-helix in orange, Met-turn in green, Zinc binding histidines in blue, zinc ion in magenta and
calcium ion in red. Image taken from Tallant et al, On the relevance of the met-turn methionine
in metzincins, Journal of Biological Chemistry, 2009109.
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1.3.1.3 Disintegrin-domain
The name of the disintegrin-like domain derives from its function. In haemorrhagic
snake venom small proteins are found which block platelet aggregation by binding
platelet integrin αIIbβIIIa111. Within the domain a so called disintegrin loop or
D-loop is found which is necessary for binding to integrins112. The general motif of
this 14 amino acid long sequence is RXXXXXCDXXEXC which is present in most
ADAMs. This sequence is missing in ADAM10 and 17112. Eto at al.113 identiﬁed a
speciﬁc integrin-binding site within the disintegrin loop which is required for binding
α9β1 integrin. The identiﬁed RX6DLPEF-motif is crucial for the binding of α9β1 to
ADAMs, including ADAM15. Due to the lack of the D-loop in ADAM10 and 17 α9β1
is not believed to interact with these ADAMs. ADAM15 is the only known ADAM
within the family with an RGD-motif (at residues 484-486). It has been shown that
ADAM15 interacts via this RGD-motif with α5β1114 and αvβ3113–115. Zhang115
and colleagues were the ﬁrst who found that ADAM15 interacts with integrins in an
RGD dependent manner. They showed that the recombinant ADAM15 disintegrin
domain were found to interact with αvβ3, but not with α2β1, α3β1, α4β1, α5β1, α6β1,
α6β4, αvβ1, αIIbβ3 and αLβ2. Mutation of RGD to SGA completely inhibited the
interaction with αvβ3. Interestingly, upon mutation of the region adjacent to the
RGD-motif (RPTRGD to NWKRGD) the disintegrin domains were recognised not
only by αvβ3, but also αIIbβ3. This suggests that the ﬂanking regions of the RGD-
motif mediate the receptor binding speciﬁcity which is observed for snake venom
disintegrins116,117.
As mentioned before Zhang et al. were not able to visualise the interaction between
ADAM15 and α5β1. However, Nath et al114 were able to deliver evidence years
later. They used a chimeric protein which contain the ECD of ADAM15 fused to
the Fc-portion of IgG. The binding activity was analysed by solid-phase cell-adhesion
assays on haemopoietic cells. Binding was not only observed for α5β1, but also αvβ3
integrin. Furthermore, they found evidence that these interactions depended on the
RGD-motif since blockage by RGD-peptide inhibited cell adhesion.
1.3.1.4 Cysteine-rich domain
Some ADAMs possess a hydrophobic stretch within the cysteine-rich domain which
are believed to play a role in membrane fusion. This hypothesis is based on the
comparison of ADAM1 with viral fusion proteins which share most characteristics
especially a rather hydrophobic region within the cysteine-rich domain118. Today
it is known that ADAMs are involved in cell fusion processes in mammals. Ex-
amples are ADAM1 and 2 in fertilisation97,118, in multinucleated giant cell and
osteoclast formation119, myoblast fusion120 and trophoblast fusion118. A study dis-
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covered that the cysteine-rich domain of recombinant ADAM12 interacts in vitro
with heparan-sulfate proteoglycans in various cell types121. A series of transfections
with syndecans in low level heparan expressing cells enabled cells to adhere to re-
combinant ADAM12122 This shows that the heparan sulfate chains of syndecans
interact with the cystein-rich region of ADAM12. Aﬃnity chromatography showed
interaction of ADAM12 and syndecan-4 which was conﬁrmed with a solid phase
binding assay122. In contrast to the mentioned ADAMs ADAM15 does not contain
a hydrophobic region within the cysteine-rich domain. Therefore, it is unlikely that
it contributes directly to membrane fusion100.
1.3.1.5 EGF-like domain
The cysteine-rich domain is followed by an EGF-like domain. It contains six cys-
teine residues which form three disulﬁde bonds123. It forms a two-stranded β-sheet
followed by a loop to another two-stranded β-sheet124.
In P-selectin, a cell adhesion molecule in endothelial cells and platelets, it is involved
in both ligand recognition and adhesion125. During maturation, dendritic cells seem
to require EGF-like mediated interaction with selectins to mature. Blocking of the
domain attenuates this process126. The cysteine-rich region of ADAM10 is only sep-
arated by 26 residues from the cell membrane which is believed to be disordered127.
Unlike ADAM10 and 17127 all other known ADAMs contain the EGF-like domain.
Surprisingly, it is also reported ADAM17 multimerisation is mediated by its EGF-
like domain128. While Janes et al.127 report that the EGF-like domain is missing
in ADAM10/17 is Lorenzen et al.128 reporting the cysteine-rich domain is missing,
but is compensated by the EGF-like domain. It seems there is confusion about the
less understood structures of ADAMs. An explaination could be due to a misinter-
pretation of the structure. As the cysteine-rich domain, the EGF-like domain is rich
in cysteins too123.
1.3.1.6 Cytoplasmic domain
The ECD and the ICD are linked via a transmembrane domain. While the ECD
is similar throughout the ADAM family, there is great variation within the ICDs.
Three examples of ICDs are illustrated in ﬁgure 1.8. The example comprise very
common members of the ADAM family, ADAM10, ADAM12 and ADAM17. The
cytoplasmic tail among ADAMs is very versatile which explains how they are capable
of fulﬁlling many diﬀerent functions. As illustrated, the length of the ICD is varying.
While the cytoplasmic tail of ADAM10 has a length of 54 amino acids, the ICD of
ADAM17 is over 2-fold and ADAM12 is over 3-fold longer. This statistically leads to
a higher number of interaction and phosphorylation sites. ADAM10 ICD possesses
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various PXXP-motifs serving as SH3 binding site. Additionally it has a threonine
(T) which can be phosphorylated. ADAM12 has two consensus class I (RXXPXXP)
SH3 binding motifs plus an additional class II motif (PXXPXR). A tyrosine serves
as phosphorylation site at the C-terminus. The cytoplasmic tail of ADAM17 only
contains two PXXP motifs, but various phosphorylation sites. Two T and three
serines (S) can be found.
The ICD of ADAM15 and its isoforms is discussed in detail in the following section.
Figure 1.8: Illustration of the cytoplasmic tails of ADM10, 12 and 17. Consensus SH3 class I
(RXXPXXP) and class II (PXXPXR) binding sequences are shown in boldface. The PXXP-motifs
are underlined. The image is based on data from Uniprot129.
1.3.2 ADAMs in normal and disease
1.3.2.1 ADAM functions in normal biological processes
This section will shed light on some functions of better characterised ADAMs in
normal biological processes.
ADAM1 (fertilin-α) and ADAM2 (fertilin-β) were the ﬁrst discovered mammalian
ADAMs130. Their ﬁrst implication was fertilisation since antibody blockage of
ADAM2 inhibited sperm-egg fusion in guinea pigs131. During sperm diﬀerentiation
ADAM1 and 2 are cleaved between their MP- and disintegrin domains resulting in
an N-terminal disintegrin domain of each ADAM subunit in mature sperm132. Due
to the high sequence homology of the disintegrin domain and disintegrin peptides of
snake venom130, and the fact these peptides bind integrins133, it was hypothesised
that the N-terminal domain of ADAM1 and 2 can interact with integrins on the
egg. ADAM3 has also been associated with fertilisation134. Sperm-egg adhesion
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and fusion is inhibited by an eight-residue peptide from the D-loop by almost 90%.
In contrast, equivalent sized peptides from ADAM1,4 and 5 D-loop had either little
or no eﬀect on sperm-egg adhesion and fusion134.
ADAM11 is considered to play a role in pain perception. ADAM11-/- mice showed
only reduced pain response to inﬂammation caused by nociception tests (acetic acid
and formalin injection). In non-inﬂammatory experiments (von Frey hair and hot
plate test) the response remained unaltered135. This suggests that ADAM11 is in-
volved in inﬂammatory mediated pain transmission.
For a limited period of time it was believed that a continuous expression of ADAM12
plays a role in muscle diﬀerentiation. It has been shown that it is required for fu-
sion of mouse myoblasts into myotubes120. Further studies showed that ADAM12
is only transiently upregulated in the beginning of myoblast diﬀerentiation. In un-
diﬀerentiated cells ADAM12 levels remained low136. The interaction of ADAM12
and α-actinin-2 seems to be important for the process of myoblast fusion136.
ADAM22 and 23 were found to be highly expressed in the brain137, alongside
ADAM11138. Since it had been reported that ADAM2 interacts with α6/β1-
subunits139, which is independent of the RGD-motif113, it was hypothesised whether
these ADAMs also interact with cerebral integrins137. This hypothesis has been con-
ﬁrmed since it was shown that ADAM11, 22 and 23 are able to bind the integrin
subunits α6, α9 and β3138. Furthermore, it appears that ADAM22 inhibits cell pro-
liferation in αvβ3 expressing cells138.
A large ﬁeld of ADAM activity is antigen and ectodomain shedding. ADAM10
and ADAM17 are the most well characterised sheddases with more than 25 and 77
known substrates reviewed by Edwards75 and Scheller140. However, substrate shed-
ding is not only restricted to these ADAMs. There are also a number of substrates
known for other ADAM family members. In 1997, ADAM17 was known as MP,
but no physiological function was identiﬁed yet. However, the release of TNFα was
already intensively studied due to its physiological importance. Hydroxamic acid-
based inhibitors suggested the involvement of one or more MPs in TNFα shedding.
By knockdown experiments of ADAM17 a signiﬁcant decrease in soluble TNFα was
found. The enzyme involved in releasing soluble TNFα was given the name TNFα
converting enzyme (TACE). Experiments with expression of recombinant TACE re-
sulted in the production of functional TNFα from its inactive precursor141. ADAM17
cleaves, like other ADAMs, within the stalk sequences which lies N-terminal of the
transmembrane region and is activated by kinases such as PKC or MAPK142. Some
ADAMs seem to work very closely together as published for ADAM9 and ADAM10.
Inhibition of ADAM9 in various cell lines reduced cleavage of cellular prion protein
(PrPc) which releases a small N-terminal fragtment named N1143. Concomitantly,
the release of soluble amyloid precursor protein α (sAPPα) from βAPP via α-secretase
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pathway was reduced143. Since PrPc is a known substrate for ADAM10144, a resuce
experiment was attempted in ADAM10-/- ﬁbroblasts143. Interestingly, release of N1
and sAPPα was not recovered suggesting both ADAMs are necessary. Accordingly,
a ﬂuorimetric substrate for α-secretase activity could not be cleaved in ADAM10
null cells. However, upon co-transfection of both, ADAM9 and ADAM10, the ﬂuo-
rimetric substrate was hydrolysed. This conﬁrms the interplay of both ADAMs in
this process.
This is not the only example were ADAMs have a common substrate. CD23 (de-
scribed in more detail in section 1.3.3.4) can be shed by several ADAMs such as
ADAM8145, ADAM10146, ADAM15145, ADAM28145 and ADAM33147.
A more complex mechanism of proteolytic processing is the regulated intramembrane
proteolysis (RIP) in which ADAMs are involved. As an example, Notch signalling is
a highly conserved and one of the most used intercellular communication pathways.
ADAM10 (ﬁgure 1.9) or ADAM17 are considered as the major sheddase in RIP-
ing of Notch. It is critical for various cellular processes such as homoeostasis, cell
proliferation and diﬀerentiation. However, deregulated signalling is found in many
types of cancer. In mammals, the pathway is activated if one of ﬁve available lig-
ands bind to one of the four existing receptors. The membrane bound receptors are
either cleaved by ADAM10 or ADAM17. Upon cleavage the presenilin dependent γ-
secretase releases the Notch ICD into to the cytosol. From there it translocates into
the nucleuss regulating and activating various processes and pathways as reviewed
by Yuan et al148.
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Figure 1.9: Comparison of catalytically active and inactive ADAMs in RIPing. ADAMs, especially inactive member seem to be important in integrin (blue)
mediated adhesion. Proteolytically active ADAMs are involved in membrane-bound substrate (red) shedding. The ectodomain is released leaving a stub behind.
ADAM10 is a well known example for ligand-induced shedding. Upon interaction of a Notch receptor (red) to a Notch ligand (pink) ectodomain shedding is
induced by ADAM10 leaving a stub with ICD behind. Subsequently, a γ-secretase (cyan) cleaves the ICD from the stub releasing it to the cytosol. This event is
known as regulated intramembrane proteolysis (RIP). Legend: MP = Metalloproteinase domain; Dis = Disintegrin domain; Adapted and modified from Weber
& Saftig, Ectodomain shedding and ADAMs in developments, Development, 2012149.
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1.3.2.2 Involvement in diseases
Since ADAMs possess many functions and are present in almost all tissues and or-
gans throughout the body, dysregulation of these contribute to pathology. ADAMs
have been involved in inﬂammation, infection, asthma, arthritis, cardiovascular and
neurological diseases and several types of cancers. Some implications will be dis-
cussed in more detail in the other chapters.
In multiple sclerosis, expression of ADAM17 was associated with parenchymal astro-
cytes, activated microglia/macrophages and blood vessel endothelium150. Elevated
levels of ADAM17 were found in active lesions with recent breakdown of myelin.
Since ADAM17 is the major sheddase of TNFα it is assumed that this contributes
to the disease progression. TNFα is a major cytokine of proinﬂammation and was
identiﬁed to play a pathogenic role in diseases aﬀecting the central nervous system
including multiple sclerosis150.
TNFα and other proinﬂammatory cytokines play also a role in diabetes type 2. In-
creased concentrations are found, together with soluble adhesion molecules, in the
plasma. Adhesion molecules and cytokines are involved in endothelial-leukocyte in-
teraction. Low density lipoprotein (LDL) from type 2 diabetes patients increased
the expression of ADAM8, 15, 17 and 28, compared to normal LDL151. The LDL
from type 2 diabetes patients diﬀers structurally and biochemically from LDL of
normal people.
Upregulation of ADAM8 correlated with rheumatoid arthritis152. ADAM8 is nat-
urally expressed in intracellular granules and on the cell surface of human neu-
trophils. Activation of the neutrophils induced translocation of ADAM8 to the
plasma membrane where it was released by cleavage. Neutrophils from the synovial
ﬂuid of patients suﬀering from rheumatoid arthritis expressed much higher amounts
of ADAM8 than peripheral blood neutrophils. The degree of joint inﬂammation
directly correlates with the concentrations of soluble ADAM8 found in the synovial
ﬂuid152. ADAM17 was also found to be upregulated in rheumatoid arthritis. Low
concentration of TNFα and oxygen led to hypoxia-inducible factor-1 (HIF-1) medi-
ated increase in mRNA levels of ADAM17153.
ADAM10 contributes to disintegration of adherens junctions during endothelial ac-
tivation and apoptosis154. ADAM10 regulates the release of VE-cadherin in human
umbilical vein endothelial cells (HUVEC) cells. VE-cadherin is important in the
control of endothelial cell permeability, leukocyte transmigration, angiogenesis and
vascular integrity. Increased levels of soluble VE-cadherin are associated with coro-
nary atherosclerosis154.
ADAMs are also associated with asthma on a genetic level155. Asthma is a respira-
tory disorder with recurrently occurring symptoms such as wheezing, breathlessness
CHAPTER 1. GENERAL INTRODUCTION 34
and coughing. A survey of SNPs in a variety of genes identiﬁed ADAM33 as being
signiﬁcantly associated with this disease155.
In prostate cancer nuclear localisation of ADAM10 was found while it was ab-
sent in benign prostate hypertrophy156. Immunocytochemistry experiments showed
ADAM10 translocated from the membrane to the nucleus. Intensity of the staining
directly correlated with diﬀerent prostate cancer staging methods. In breast cancer
ADAM12 was found to contribute to breast cancer progression157. In human breast
cancer, apoptosis of stromal cells is observed, while it is absent in non-malignant
lesions. ADAM12 was found to decrease tumour cell apoptosis, but increased stro-
mal cell apoptosis157. In gliomas elevated expression of ADAM8 and ADAM19 were
found. In these tumours the expression levels and protease activity of both ADAMs
correlated with enhanced invasiveness158. In contrast, ADAM22 is expressed in
normal brain tissue, but is lost in high-grade gliomas138. ADAM10 showed an un-
wanted function in treatment of lymphoma patients159. CD30 is a transmembrane
protein which is often overexpressed in lymphoma cells. Therefore, it is used as
target for immunotherapy. However, upon binding of antibodies to CD30 ADAM10
is activated and cleaves CD30 from the cell surface. Soluble CD30 in turn binds to
the ligand of CD30 that is expressed on non-target cells which are rendered as new
but unwanted target for the therapeutic antibodies159.
These examples emphasised how wide spread and inﬂuential ADAMs are in human
pathology of diseases. It also highlights that the same ADAM can contribute to dif-
ferent diseases as ADAM17 does in rheumatoid arthritis, multiple sclerosis, diabetes
and cancer.
1.3.3 ADAM15
1.3.3.1 ADAM15 splicing
ADAM15 has been implicated in various physiological as well as pathological con-
ditions. These are achieved by processes such as ecotodomain shedding or through
regulation of cell-cell interactions. Altered ADAM15 protein levels have been as-
sociated with arthritis160, cardiac disease161, atherosclerosis162 and cancer163,164.
In breast cancer it was shown that ADAM15 splice variants predict disease stage
and outcome. Not only an aberrant alternative use of exons was found, but also
an increased copy number of ADAM15165. The gene copy number was increased in
cells derived from mammary tumours, but did not correlate with the mRNA lev-
els. Although, in most cancer cell lines the mRNA levels of ADAM15 were slightly
increased, the primary mechanism was alternatively spliced ADAM15. Alternative
spliced ADAM15 isoforms were found in various combinations in cancer cell lines.
Among these cell lines were breast cancer derived cell lines such as BT474, HCC1954,
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SK-BR-3 and T47D and the prostate cancer cell line DU145165. However, mRNA
levels were not increased. In silico analysis of RT-PCR products demonstrated that
the isoform patterns of ADAM15 were non random. In fact sets of various breast
cancer cell lines had preferred splice variants that were expressed.
In order to gain more knowledge about regulation of ADAM15 Kleino et al166
characterised the genomic organisation of regulatory elements and the use of al-
ternative ADAM15 exons in human tissue. The ADAM15 gene is ﬂanked by
FLJ32785/DCST1 and ephrin-A4 genes and spans 11.4 kb from the from point
of translation initiation to the polyadenylation signal. The gene contains 23 exons
and 22 introns and has several transcriptional start sites within a TATAless, CAAT-
less and GC-rich promoter. Four CpG islands are found within the gene. The ﬁrst
and longest extends from the last intron of FLJ32785/DCST1 to the ﬁrst intron of
ADAM15. Two islands are located within intron 1, while the fourth is found in exon
22 and spans past the polyadenylation site166. In all examined ADAM15 transcripts
the exons 18, 22, and 23 were found, suggesting they are used constitutively. In nor-
mal human tissue the majority of variants were found arising from the alternative
use of exons 19, 20a/b and 21a/b. This leads to diﬀerent combinations of regulatory
interaction motifs in the cytoplasmic domain.
Not much is known about the splice factors that are responsible for the alternative
use of exons in the ADAM15 gene. In intron 1 and 2 highly conserved regions with
clusters of regulatory motifs were found, which may contribute to transcriptional reg-
ulation166. Normally, constitutive human exons contain three to seven rescue exonic
splice enhancer (ESE) motifs167. However, exons 19, 20a/b and 21a contain one,
one and three ESE motifs and zero, zero and six putative ESE motifs, respectively.
An overview of this distribution is shown in table 1.3. ESE motifs are sequences
within exons and promote constitutive and regulated splicing. Regulation functions
by networks formed with other ESE motifs, with small nuclear ribonucleoprotein
particles (such as spliceosome subunits) and SR-related proteins168. The conserved
family of SR proteins is involved in constitutive pre-mRNA splicing and are impor-
tant regulators of alternative splicing. They also participate in post-splicing events
such as mRNA nuclear export, mRNA translation and nonsense-mediated mRNA
decay. Its name is composed of the one-letter-codes for the amino acids serine (S)
and arginine (R). Both amino acids are found as long repeats in a part of the protein
which was accordingly named RS domain and is required for protein-protein inter-
actions with other RS domains. Apart from this region, SR-proteins also contain a
RNA-recognition-motif (RRM) domain for sequence-speciﬁc RNA binding169. The
predicted number of SR-protein binding motifs is about 30% lower than the aver-
age in constitutive ADAM15 exons166. Three SR-protein binding motifs were only
found in alternative exons which suggests that the splicing of alternative ADAM15
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exons is less enhanced than the splicing of constitutive exons by ESEs.
Table 1.3: Summary of the presence of exonic splice enhancers (ESE) and putative ESE in the
alternatively used ADAM15 exons 19, 20a/b and 21a. Normally three to six rescue-ESE clusters
are found in constitutive human exons167.
ESE Putative ESE
Exon 19 1 0
Exon 20a/b 1 0
Exon 21a 3 6
Exons 19, 20a/b and 21a also lack exonic splice silencer (ESS)/putative ESS and
heterogeneous nuclear ribonucleoprotein (hnRNP) binding motifs. ESS suppress
splice-site selection and often work alongside ESE. However, ESE sequences are
dominant over ESS168. HnRNPs are complexes consisting of RNA and proteins
binding to pre-mRNA. They prevent the premature export into the cytoplasm.
Also a lower number of exonic splice-regulatory sequences (ESR) are found. Exons
19, 20a/b and 21a only contain seven, eight and three ESRs while constitutive
ADAM15 exons possess approximately 13. The function of ESRs is controversial.
They are believed to function either as ESS or ESE, depending on their relative
exonic location170. In contrast, exon 21b contains several ESRs, ESE, putative
ESE, ESS as well as SR-protein and hnRNP binding motifs.
Contrary to the alternative exons, the alternative introns are rich in ESEs and
ESSs, SR-protein and hnRNP binding motifs. Additionally many intronic splice
enhancers (ISE) are dispersed throughout the introns. Concomitantly, diﬀerent
alternative splice regulation-associated motifs are found in the alternatively spliced
intronic regions of ADAM15. Within these motifs, a recognition sequence for
Fox-family alternative splice regulator proteins was found166,171.
In the intronic region of intron 18, 19 and 20, binding motifs for the neuronal
splice-enhancer Nova1/2 were found166. Nova1 is considered as “master regulator”
in splicing since knockdown of Nova1 altered the splicing of almost 5000 transcripts.
The aﬀected genes are involved in apoptosis, exocytosis, splicing, transcription and
insulin receptor signalling172. Intron 19 contains three while exon 19 possesses only
one binding motif for CELF/BrunoL family proteins166. The CELF/BrunoL family
comprises six members of which a few are involved in post-transcriptional regulatory
processes. These events are alternative splicing and the control of stability and
translation of target mRNAs173. Muscleblind-like protein 1 (MBNL1) binding
motifs were observed in exon 20 as well as in intron 20 and 21166. MBNL1 regulates
alternative splicing by binding speciﬁcally to CUG and CCUG repeats174,175. In
intron 18, 19 and 21 exon skipping-associated C- or G-rich motifs (ESACG-motif)
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are located176. To this day, two patterns of C and G repeats where identiﬁed
causing skipping of an exon. The sequence repeats CTCC or CCTCCC and AGGG
where found adjacent to exons in an intronic region176. It is believed that base
pairing interactions underlie a mechanism which involves the secondary structure
to control exon skipping176. An overview of the alternative splicing-associated
elements are found in table 1.4. Two-third of the motifs are conserved in either
mouse or rat.
ADAM15 contains numerous splice recognition sites, their regulatory role has
not been tested experimentally. So far, only ESRP1 and ESRP2 splice factors
have been validated experimentally to be regulating in ADAM15 splicing. ESRPs
enhance the use of exon 20 and 21. Three splice forms were identiﬁed which enable
the inclusion of on or the other exons or both. Knockdown of the ESRPs led
to decrease of the isoforms177. Based on the results of this study the detected
isoforms were ADAM15 B (inclusion of exon 20a), ADAM15 C (inclusion of exon
20a and 21) and ADAM15 E (inclusion of exon 21). ESPR1 and ESPR2 are highly
conserved paralogs possessing three RRM domains. Both were found by inducing
EMT in a mammary gland epithelial cell line which resulted in downregulation
of both ESPRs. ESPRs not only regulate splicing of ADAM15, but also FGFR2,
CD44, ENAH and p120-catenin splicing178.
Table 1.4: Summary of alternative splicing-associated elements found in exonic and intronc
regions of ADAM15. MBNL: Muscleblind-like protein 1; ESACG: Exon skipping-associated C- or
G-rich motif
Fox Nova1/2
CELF/
BrunoL
MBNL1 ESACG
Exon 19 20
Intron 18, 19, 20, 21 18, 19, 20 19 20, 21 18, 19, 21
The ECD of ADAM15 is conserved, hence it is similar in all isoforms. The ECD
of the variants investigated in this thesis are identical. However, diﬀerences occur in
the ICD. Due to diﬀerential splicing a total of 13 variants have been discovered166.
The present work focuses on ﬁve isoforms: ADAM15 A, B, C, D and E. An overview
of ADAM15 isoforms with its corresponding numbers of amino acid and proline-rich
regions is depicted in table 1.5. Schematic representation of the ADAM15 ICD
organisation in the studied ﬁve isoforms is represented in ﬁgure 1.10.
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Table 1.5: Detailed information about ADAM15 splice variants
ADAM15
isoform
Gene
Bank
variant
AN.1
DNA
sequence
AN.1
Protein
sequence
Amino
acids
Proline-
rich
regions
ADAM15 A 2 NM 003815.4 NP 003806.3 814 3
ADAM15 B 3 NM 207194.2 NP 997077.1 839 4
ADAM15 C 5 NM 207196.2 NP 997079.1 862 5
ADAM15 D 1 NM 207191.2 NP 997074.1 772 0
ADAM15 E 4 NM 207195.2 NP 997078.1 838 4
Figure 1.10: Schematic organisation of proline-rich regions in the ICD of ADAM15 isoforms.
Exon 18, 22 and 23 are the continuous expressed exons which transcribe the transmembrane domain
(TM) and two proline-rich regions (P4 and P5). Exon 19, 20 and 21 are alternatively spliced and
provide one additional proline-rich region (P1, P2 and P3) each. Depending on inclusion of the
exons the affinity towards SH3 domain containing proteins vary.
1.3.3.2 ADAM15 ICD interaction partners.
A diagram illustrating the organisation of the ICD in ADAM15 isoforms is pre-
sented in ﬁgure 1.11. ADAM15 isoforms have common, as well as distinct, interac-
tion partners. Table 1.6 summarises the known interaction partners with ADAM15
isoforms identiﬁed predominantly by in vitro assays. However, characterisation of
1Accession number
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changes in cellular behaviour of these isoforms are still elusive. In MDA-MB-435,
we have previously shown that expression of ADAM15 A, B and C had diﬀerential
eﬀects on morphology, adhesion, migration and invasion179. However, further work
is necessary to characterise potential isoform-speciﬁc, as well as catalytic function
dependent eﬀects of ADAM15 on cancer cell behaviour. Thus in this project we
aimed to generate a set of isogenic ADAM15 A-E WT and catalytically inactive iso-
form expressing MDA-MB-231 cells to enable us to carry out detailed comparative
analysis of ADAM15 isoform-speciﬁc eﬀects.
Figure 1.11: Organisation of the ICD and its translational sequence differences. (A) Schematic
view of the cytoplasmic exon organisation depicted as black rectangles. Exon 20a and 20b have a
size difference of one amino acid166. Exon 21a and 21b are two different splice regulatory sites166.
(B) Representation of the ADAM15 splice variant ICDs. PXXP motifs are underlined. The
two Src family RTK binding consensus class I (RXXPXXP) and class II (PXXPXR) sequences
are showed in boldface. ADAM15 A represents the first identified, widely expressed and most
commonly researched ADAM15. ADAM15 B contains an additional 75 bp insert adding another
proline-rich region (italic). ADAM15 C does have the same 75 bp insert plus another 72 bp
sequence (underlined italic) increasing the proline rich region to five. ADAM15 D introduces a
frameshift mutation leading to a premature stop codon. ADAM15 E is lacking the 75 bp insert,
but possesses the 72 bp sequence. The figure is adapted and modified from Zhong et al.179
In order to generate a table (table 1.6) combining all known interactions between
ADAM15 and other proteins several approaches were combined. Interactions were
categorised into four groups: - = no or very weak; + = weak; ++ = medium; +++ =
strong interaction. If no data to a particular isoform was not available the interaction
was stated as N/A. Pull-downs and IPs were judged according to the intensity of the
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Western blot band. No bands were categorised as no interaction while weak bands
were grouped into weak interaction. Strongly over-saturated bands were indicated as
strong interaction while everything in between was judged as medium interaction.
Since Klein et al.?? displayed their results as heat map the diﬀerent shades of
grey was grouped into the same categories as Pull-downs and IPs. White indicates
no/weak interaction, while black shows very strong interaction. Approximately
14 diﬀerent shades could be visually identiﬁed. White, followed by two darker
shades, are considered as no/weak interaction. Black is shown as strong interaction.
The remaining 10 shades were separated: The weaker half was considered as weak
interaction while the more intense half was treated as medium interaction.
Table 1.6: Interaction of different proteins with the ICD of ADAM15 isoforms. Association
is done via SH3 domain if not stated otherwise. The table is based on work of Kleino180,181,
Poghosyan182 and Zhong179. - = no or very weak; + = weak; ++ = medium; +++ = strong
interaction. N/A = Data not available.
AHI1: Abelson helper integration site 1; Btk: Bruton’s tyrosine kinase; CIP4: Cdc42 interact-
ing protein 4; Eps8L: Epidermal growth factor receptor kinase substrate 8-like protein; FBP17:
Formin-binding protein 17; Grb2: Growth factor receptor-bound protein 2; Itk: Interleukin-2-
inducible T-cell kinase; MAD2: Mitotic arrest deficient 2; NFC1: Neutrophil cytosolic factor 1;
OSTF1: Osteoclast stimulating factor 1; PTK6: Protein-tyrosine kinase 6; RIMBP: Regulating
synaptic membrane exocytosis protein (RIM)-binding protein Src: sarcoma; SNX: Sorting nexin;
TOCA1: Transducer of Cdc42-dependent actin assembly protein 1;
A15 A A15 B A15 C A15 D A15 E
AHI1 + ++ ++ - +
Btk +++ +++ +++ - +++
CIP4 ++ ++ ++ - ++
FBP17 ++ ++ ++ - ++
Fyn ++ ++ ++ - ++
Grb2 (I) ++ +++ +++ - ++
Grb2 (II) ++ +++ +++ - ++
Hck2 ++ ++ ++ - ++
Intersectin 1 (III) + ++ ++ - +
Intersectin 2 (III) ++ ++ ++ - ++
Itk +++ +++ +++ - +++
Lck ++ +++ +++ - ++
Lyn ++ ++ ++ - ++
MAD23 ++ ++ ++ - ++
NCF1/p47phox ++ +++ +++ - ++
Nck1 (I) - ++ ++ - +
Nephrocystin ++ +++ +++ - ++
2Binding also via SH2 domain182
3Binding not via proline-rich regions due to absence of SH3 domain
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Table 1.6 Continued: Interaction of different proteins with the ICD of ADAM15 isoform.
A15 A A15 B A15 C A15 D A15 E
OSTF1 ++ +++ +++ - ++
p85α ++ ++ ++ - ++
pErk1/22 + + + - N/A
PTK6/Brk ++ ++ - - N/A
RIMBP1 ++ ++ ++ - ++
RIMBP2 + + ++ - ++
RIMBP3 +++ +++ +++ - +++
Src ++ ++ ++ - ++
SNX9 +++ +++ +++ - +++
SNX18 ++ ++ ++ - ++
SNX33 +++ +++ +++ - +++
Tec ++ +++ +++ - ++
Tks5 (I) ++ +++ +++ - ++
Tks5 (V) ++ +++ +++ - ++
TOCA1 ++ ++ ++ - ++
1.3.3.3 ADAM15 in pathological conditions
A common way to elucidate the function of genes is to inactivate them in research
animals. The resulting changes in either phenotype or physiology oﬀer insights into
their natural function(s). ADAM15 double knockout mice (ADAM15-/-) have been
generated in the lab of Carl Blobel183. They could not observe any morphological
changes in examined tissues compared to age-matched wildtype (WT) adult ani-
mals. This suggests either functional redundancy with other ADAMs or ADAM15
does not play an essential role in tissue development. However, in vascular cells an
extraordinary high level of ADAM15 was found which indicates a role in patholog-
ical neovascularisation. To investigate the role of ADAM15 in neovascularisation
ADAM15-/- and WT mice were subjected to the retinopathy of prematurity (ROP)
model in which young mice are exposed to high oxygen levels (75%) for 5 days,
and then returned to normoxic air. The decline in oxygen concentration induces
a strong angiogenic stimulus, which leads to pathological neovascularisation in the
retina. The result was ADAM15-/- mice showed 64% less angiogenesis compared to
their WT controls. In western blot analysis they observed an increase in ADAM15
expression from WT ROP treated animals in the retina. Therefore, they concluded
that ADAM15 plays a role in pathological neovascularisation, but is not required
for normal angiogenic development.
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Bo¨hm and colleagues hypothesised that ADAM15 promotes pathological extracellu-
lar matrix (ECM) remodelling, based on the ﬁnding of increased ADAM15 expres-
sion in human neoplastic cartilage and osteoarthritic spicimens184. In ADAM15-/-
mice histopathological examination of knee joints revealed accelerated development
of osteoarthritic lesions185. They found mild hyperplasia of synovial membrane and
proteoglycan loss from cartilage matrix. However, more pronounced changes were
found as well. Severe cartilage erosions in various degrees could be observed last-
ing from superﬁcial changes, deep ﬁssures, necrotic or complete loss of cartilage185.
Cartilage derived detritus was found incorporated into synovial membrane resulting
in inﬂammation. This irreversible damage was only observed in ADAM15-/- mice
(7 of 12), but not in WT controls185. Based on these ﬁndings they concluded that
ADAM15 does not have a destructive, rather a homoeostatic role in joint integrity
and cartilage remodelling.
Another area in which ADAM15 has been implicated is the regulation of permeabil-
ity in epithelial and endothelial cells. In endothelial cells semi-permeable barriers
regulate the transport of ﬂuids, solutes as well as cells across the wall of blood vessels.
Barrier dysfunction, due to hyperpermeability, is a key event in the development of
vascular diseases associated with inﬂammation. This includes atherosclerosis162, di-
abetic complications186, sepsis187 as well as cancer inﬂammation and metastases188.
In human umbilical vein endothelial cells (HUVECs) depletion of ADAM15 at-
tenuated thrombin-induced barrier dysfunction189. Thrombin is a common used
stimuli to induce barrier dysfunction due to redistribution of vascular endothelial-
cadherin (VE-cadherin) and associated catenins190. Concomitantly, it was observed
that ADAM15 knockdown also decreased endothelial permeability and overexpres-
sion led to hyperpermeability independent of its catalytic function189. Neutrophil
transendothelial migration was also observed being dependent on ADAM15 expres-
sion since knockdown led to inhibition while overexpression increased migration189.
These events are mediated via Src/Erk1/2-pathway and are independent of VE-
cadherin shedding189. Later the same group was able to show in mouse model, that
ADAM15 contributes to atherosclerosis by regulation of endothelial barrier dysfunc-
tion involving c-Src and c-Yes162. In a mouse model with lipopolysaccharide (LPS)
induced acute lung injury, upregulation of ADAM15 was observed in association
with neutrophil inﬁltration and pulmonary oedema191. In ADAM15–/– mice LPS
induced inﬂammatory injury was attenuated and reduced neutrophil inﬁltration191.
This data suggests that increased ADAM15 expression promotes inﬂammatory lung
injury by increasing endothelial cell permeability and neutrophil transmigration. To
further add evidence of ADAM15 beeing involved in regulating endothelial perme-
ability a micro RNA (miRNA), miR-147b, was identiﬁed which decreased total and
surface expression of ADAM15 in endothelial cells. In the same cells LPS induced
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barrier dysfunction was attenuated when treated with miR-147b. An antagomir to
miR-147b induced hyperpermeability of the endothelial cells with a similar eﬀect as
LPS192.
According to literature ADAM15 has a high impact in cancer. Within the last
decade scientists found elevated expression of ADAM15 in a variety of cancers, such
as lung193,194, aggressive breast164, prostate164 and pancreatic cancer195.
In 2005, the ﬁrst paper was published demonstrating the expression of ADAM15
in lung carcinomas193. ADAM15 is also upregulated in the lungs upon inﬂam-
mation. LPS induced inﬂammation promotes ADAM15 overexpression facilitating
neutrophil inﬁltration and plasma leakage which leads to pulmonary oedema191.
In ADAM15-/- mice the inﬂammatory injury was greatly attenuated. To support
this ﬁnding in vitro experiments demonstrated that ADAM15 deﬁciency diminished
permeability and neutrophil transmigration within endothelium191. These obser-
vations provide evidence that ADAM15 contributes to acute lung inﬂammation by
disrupting endothelial barrier integrity promoting hyperpermeability response. The
function of ADAM15 in non-small cell lung cancer (NSCLC) is still not known. A
recent publication by Dong et al. attempts to shed light on this194. They found
that overall and relapse free survival (RFS) of NSCLC patients correlate with high
expression of ADAM15. Upon shRNA-mediated knockdown of ADAM15, invasive-
ness and cell migration were reduced. In the epithelial lung carcinoma cell line
A549 ADAM15 overexpression led to increased invasion. They also demonstrated
ADAM15 upregulated the matrix metalloproteinase 9 (MMP9) via the MAPK path-
way.
1.3.3.4 ADAM15 as a sheddase
In section 1.3.2.1 the shedding activity of ADAMs in general was desribed. This sec-
tion focuses on ADAM15 and its proteolytic activity. Due to its clinical importance
research for ADAM15 is increasing. So far only ten substrates have been identiﬁed:
Collagen IV196, CD23145, pro-amphiregulin197, pro-transforming growth factor α
(pro-TGFα)197, pro-heparin-binding EGF-like growth factor (pro-HB-EGF)198, E-
cadherin199, Fibroblast growth factor receptor-2IIIb (FGFR2IIIb)200, ADAM10201,
pro-MMP9194 and major histocompatibility complex (MHC) class I polypeptide-
related sequence B (MICB)195. These substrates are summarised in table 1.7.
The ﬁrst substrate for ADAM15 was identiﬁed by Martin et al. in 2002. They hy-
pothesised that ADAM15 MP is actively involved in human mesangial cell (HMC)
migration. Gelatinolytic activity of ADAM15 was conﬁrmed by zymography. To fur-
ther substantiate the observation collagen IV was incubated with puriﬁed ADAM15
from HMCs. The result was that ADAM15 degraded collagen IV in a dose-dependent
manner. To conﬁrm that ADAM15 was actively involved, the epxeriment was re-
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peated with either the addition of ethylenediaminetetraacetic acid (EDTA), leu-
peptin or phenylmethanesulfonyl ﬂuoride (PMSF) to HMC puriﬁed ADAM15. The
samples were subjected to western blotting and probed for collagen IV. Only EDTA
reduced the degradation of collagen IV while ADAM15 was not inhibited by leu-
peptin or PMSF.
The ﬁrst signalling related substrate for ADAM15, CD23, was identiﬁed by Fourie
et al. and published 2003145. Earlier, Bonnefoy and et al. discovered that CD23
(FcεRII), a low aﬃnity receptor for IgE, is proteolytically released by an unknown
metalloprotease. CD23 upregulates IgE production and induction of inﬂammatory
cytokines202. Together with ADAM15, ADAM8 and ADAM28 were also identiﬁed
as CD23 sheddase.
A year later Scha¨fer et al. demonstrated that cleavage of pro-TGFα is dependent on
ADAM15 in the human urinary bladder cancer cell line TCCSUP197. In the same
publication they also showed the dependency of ADAM15 in proteolytic processing
of pro-amphiregulin in another human urinary bladder cancer cell line 5637C197.
Dominant-negative mutants of ADAM15, lacking pro-and MP-domain were stably
transfected. Those mutants blocked the EGFR transactivation signal induced by
lysophosphatidic acid (LPA), which induces EGFR tyrosine phosphorylation.
Hart and co-workers discovered ADAM15 as pro-HB-EGF sheddase. When endoge-
nous ADAM15 was inhibited by short interference RNA (siRNA) the thrombin-
induced EGFR tyrosine phosphorylation was reduced. To conﬁrm this ﬁnding, they
chose the same approach as Scha¨fer et al. Dominant-negative ADAM15 mutants
were transfected into MDA-MB-231 and MCF-7 cells, in which thrombin-induced
EGFR tyrosine phosphorylation was again reduced198.
In 2008, Najy and colleagues revealed E-cadherin as substrate for ADAM15199. The
ﬁrst observation was that the overexpression of ADAM15 in MCF-7 cells correlated
with elevated amounts of soluble E-cadherin in conditioned media. On the other
hand, stable downregulation of ADAM15 by shRNA in these cells led to less sol-
uble E-cadherin in the media. To further conﬁrm, in vitro cleavage analysis was
performed in which isolated E-cadherin and ADAM15 were co-incubated in equal
ratios. A dose-dependent increase in soluble E-cadherin was observed. To ascertain
that E-cadherin is an ADAM15 substrate, they added the broad spectrum MMP in-
hibitor 1,10-phenanthroline which reduced ADAM15 mediated E-cadherin cleavage
in vitro.
Duan et al. demonstated that ADAM15 is involved in shedding of MICB195. MICB
is a polymorphic, glycosylated, non-classical MHC class I protein anchored in the
cell membrane. It is stress-induced and upregulated in lung, kidney, prostate, breast
and colon cancer, although is it considered to be restricted to the gastrointestinal
tract195. A study showed that soluble MICB, released by shedding, correlates with
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high tumour stage and poor diﬀerentiation in pancreatic cancer203. Cleaving MICB
from the tumour cell reduces immunogenicity204 while shedding of MICB induces
internalisation and degredation of one of its ligands (NKG2D) which is normally ex-
pressed under stress by infected or transformed cells to initiate cytotoxic response205.
They found a correlation between ADAM15 and MICB in pancreatic ductal adeno-
carcinoma (PDAC) patients. Thus they suggest ADAM15 as therapeutic target for
MICB shedding.
ADAM15 substrates exist also within the same family. ADAM10 is subjected to
RIPing201. Tousseyn et al. could detect four bands in western blot experiments. A
85 kDa (pro-protein), a 65 kDa (mature form), a 10 kDa band which can only be
detected with a C-terminus speciﬁc antibody, and 55 kDa fragment from the super-
natant, that is only immunoreactive with N-terminal antibodies. The last fragment
is considered as soluble ADAM10. From this they concluded ADAM10 must be
processed by an unknown protein. To identify potential sheddases of ADAM10
a panel of inhibitors was screened. Those inhibiting ADAMs and MMPs showed
accumulation of the soluble form while the C-terminal fragment (CTF) was re-
duced. This suggested the candidate belongs to the family of metalloproteinases. In
ADAM9/15/19 null and ADAM9/15 null cells reduction of the CTF was observed
suggesting those three ADAMs are involved. However, ADAM19-/- MEFs did not
conﬁrm the assumption. To further substantiate that ADAM9 and 15 are involved
in ADAM10 shedding, COS cells, which express low levels of ADAM10, were tran-
siently transfected with ADMA10. In contrast to WT COS cells, a strong double
band and soluble ADAM10 were detected. Co-overexpression of increasing amounts
of WT, but not catalytically inactive ADAM15, resulted in stronger bands of the
CTF and soluble ADAM10. The same was observed with ADAM9. This conﬁrms
the hypothesis that ADAM15 and ADAM9 are involved in shedding ADAM10.
Maretzky et al. revealed FGFR2IIIb as substrate for ADAM15. So far the cleav-
age of ADAM15 substrates was based on research with isoform A. However, they
were the ﬁrst group to show that shedding activity can be splice form-dependent in
ADAM15200. They were able to show that ADAM15 B, with an additional proline-
rich region (ﬁgure 1.10), has increased shedding activity compared to ADAM15 A
overexpressing cells. An additional proline-rich insert adds a binding site for Src.
No diﬀerence in in the catalytic activity of ADAN15 A or B could be observed in
Src-/- mouse embryonic ﬁbroblasts (MEFs). However, stable transfection of wild-
type Src rescued the singiﬁcantly higher activity in ADAM15 B, but not in ADAM15
A overexpressing cells. This emphasises that research needs to target also the other
splice variants of ADAM15. In 2015, a study announced another substrate for
ADAM15194. In vivo experiments showed interaction of ADAM15 with MMP9. In
vitro they could demonstrate that ADAM15 was able to cleave pro-MMP9 and ac-
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tivates it. This suggests that pro-MMP9 is bearing a target sequence for ADAM15
MP, but it remains to be elucidated if this happens in vivo as well.
Table 1.7: Overview of substrates shed by ADAM15
Substrate Category Reference
Collagen IV ECM Martin et al196
E-cadherin Transmembrane protein Najy et al199
Pro-Amphiregulin Growth factor Scha¨fer et al206
Pro-HB-EGF Growth factor Hart et al198
Pro-TGFα Growth factor Scha¨fer et al206
CD23 Receptor Fourie et al145
FGFR2IIIb Receptor Maretzky et al207
ADAM10 Metalloproteinase Tousseyn et al201
Pro-MMP9
Matrix
metalloproteinase
Dong et al194
MICB
Stress-induced ligand
for NKG2D
Duan et al195
1.4 Cell proliferation
Cell proliferation describes the increase in cell number due to cellular growth and
division. It is not only essential for physiological events such as cell growth and
normal tissue function but also for pathological mechanism such as tumourigenesis.
Deregulation of proliferation is caused by the perturbation of various mechanisms
and signalling pathways within the cell. A series of events in which various pathways
are involved is the cell cycle in which the DNA is replicated and the cell mass in-
creases. Two major phases during cell cycles occur: S-phase in which chromosomes
duplicate and M-phase in which chromosomes are segregated and the cell divides
(cytokinesis). Since cells need more time to increase there mass than doubling the
chromosome, the cell cycle has also gap-phases. G1-phase between M- and S-phase,
and a G2-phase between S-phase and mitosis (ﬁgure 1.12 a). The gap phases provide
not only time for cell growth, but also time to monitor the environment. This en-
sures to have appropriate conditions and preparations completed prior to cell cycle
progression. If conditions appear unfavourable such as G1-delays the cell can enter
a specialised resting phase named G0.
To avoid malfunction of cell cycle events, such as partial initiation of chromosome
condensation or breakdown of the nuclear envelope, the cells have a cell cycle con-
trol system consisting of various biochemical switches. A central component are the
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cyclin-dependent kinases (CDKs). The activity of CDKs is alternating throughout
the cell cycle. This leads to changes in phosphorylation states of intracellular pro-
teins controlling diﬀerent events. As the name CDK implies the most important
protein regulating their activity belongs to the group of cyclins. The kinase activity
of CDKs is only activated if bound tightly to cyclins. CDKs have preferred inter-
action partners, some exclusively interact with only one cyclin (ﬁgure 1.12 b). For
example CDK1 preferably binds to cyclin B, but is also able to bind to cyclin A,
D and E. Contrary, CDK4 can only interact with cyclin D. Complex formation of
both proteins triggers cell cycle events.
Figure 1.12: Model of cell cycle with active cyclins and CDKs. (a) Three major transition
phases have to be passed by dividing cells: G1/S-phase transition in which is the beginnning
of DNA replication, G2/M-phase transition which is marked by the onset of nuclear envelope
breakdown and chromosome condensation. The third phase is the meta-to-anaphase transition
in which the segregation of sister chromatids occurs. (b) Interaction of CDKs can be separated
into two groups. CDK1 and 2 bind cyclin A, B, C and D whereas CDK 4 and 6 only interact
with cyclin D. Thick red lines indicate the preferred interaction partners. (c) Early G1-phase is
regulated by D-type cyclins and CDK4 or CDK6 (not shown) whereas cyclin E/CDK2 induces
S-phase transition. Late S-phase is regulated by cyclin A-CDK1/CDK2 wheras cyclin B-CDK1
drive mitosis. (d) Next to the classical cell-cycle control model, a minimal threshold model has
emerged based on CDK-knockout studies. This suggests it is sufficient to control the interphase if
either CDK1 or CDK2 is bound to cyclin A. In contrast, cyclin B-CDK1 is important for mitosis.
The differences are likely to be based on localisation of the molecules. The image was taken from
Hochegger, Takeda & Hunt in Cyclin-dependent kinases and cell-cycle transitions: does one fit
all?, Nature reviews. Molecular cell biology, 2008208
In general, cyclins are grouped in four classes as illustrated in ﬁgure 1.12 c. In
vertebrates, G1/S-cyclins (type E cyclins) activate CDK2 in late G1-phase and in-
duce entry into cell cycle. Cyclin E levels decrease in S-phase. S-cyclins (type A
cyclins) interact with either CDK1 or CDK2 and induce chromosome duplication.
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Cyclin A levels remain high until mitosis is triggered. M-cyclins (type B cyclins)
stimulate entry into mitosis by interacting with CDK1. The last group belongs to
G1-cyclins (type D cyclins) which assist cyclin E in controlling entry into S-phase.
This type D cyclins are able to interact with CDK4 and CDK6. The cellular events
which happen during cell cycle progression are versatile. Cyclins do not only ac-
tivate its partner CDK, but direct it to and activate a diﬀerent set of substrate
proteins. Full activation of the cyclin-CDK complex is achieved by phosphoryla-
tion of an amino acid close to the active site of a CDK. This is mediated by the
group of CDK-activating kinases (CAK). Phosphorylation causes a conformational
change enhancing in turn phosphorylation of their target proteins. This processes
are tightly regulated. CDKs possess also another phosphorylation site which leads
to inactivation upon phosphorylation of Wee1. In contrast, dephosphorylation by
Cdc25 causes increased CDK activity. Other regulatory mechanisms are known, but
not further described. One are the group of CDK inhibitor proteins (CKIs). The
mode of action lies on a conformational change of the CDKs active site rendering
inactive.
1.5 Cell migration
Cell migration, as illustrated in ﬁgure 1.13, is crucial for the development of multi-
cellular organisms. In mammals during embryogenesis a proportion of cells migrate
over long distances. Neural crest cells, a highly migratory multipotent cell popu-
lation migrates throughout the embryo to eventually diﬀerentiate into multiple cell
types such as neurons, smooth muscle cells and adipocytes209. However, migration
is not only restricted to physiological events, it also contributes to disease progres-
sion. In solid cancer types, cells enter blood vessel or lymph nodes to form distant
metastases210.
The way how cells migrate can be changed rapidly. They are highly ﬂexible and the
mode of migration can be altered between single cell and collective cell migration211.
Motility also depends on the composition and stiﬀness of the environment including
surrounding cells and the ECM212. The interaction with other cells aﬀect and reg-
ulate the migration too. Upon cell-cell interaction cells undergo contact inhibition
in which the migrating cell stalls. Consecutively, it leads to cell-cell adhesion or a
change of direction. In many cancer cells this contact inhibition is defective213.
Migration of the cell requires several molecular mechanisms. The initial step is to
adhere to a cell surface such as other cells or ECM. Adhesion thereby serves two
functions: One is to generate traction via interaction of the actin ﬁlaments to the
extracellular substratum. The second function is to organise migration regulating
signalling networks which also control gene expression, cell proliferation and sur-
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vival214.
Activated integrins bind to ECM components such as ﬁbronectin or vitronectin.
This can lead to clutering of the integrin receptors and/or a conformation change
which leads to recruitment of intracellular signalling components such as FAK or
vinculin. A more detailed introduction in focal adhesion dynamics is presented in
chapter 5. Nascent adhesions, the precursor of focal adhesions are formed in the
lamellipodium of migrating cells. Its formation depends on the rate of actin poly-
merisation as well as its inhibition. Within the lamellipodium FAK and vinculin
bind to Arp2/3215,216 regulating lamellipodia dynamics.
The morphological changes a cell needs to undergo in order to migrate is a highly
dynamic process. This process is driven by actin polymerisation which begins with
the formation of new actin ﬁlaments. It is regulated by three classes of nucleating
proteins including the Arp2/3 complex, tandem-monomer-binding nucleators and
formins217. The Arp2/3 complex is unique since it branches oﬀ new actin ﬁlaments
from an exisiting strands at an angle of 70 ± 7◦218 It consists of seven members
including Arp2 and Arp3 which have similar structure to monomeric actin. In order
to function, the complex needs also nucleation promoting factors (NPF). Arp2/3
mediated nucleation is regulated by many proteins, the most promiment family of
NPFs are the family of Wiskott-Aldrich syndrome proteins (WASP) such as WAVE
and WASH. Nucleation occurs at the pointed end and does not aﬀect the assembly
rate at the barbed end217.
The two other existing families of nucleation factors produce linear ﬁlaments.
The family of tandem-monomer-binding nucleators includes proteins such as spire,
leiomodin and cordon-bleu. They bind at least three actin monomers forming a
stable trimer. Tandem-monomer-binding nucleators bind to the pointed end of the
actin ﬁlament and leave the barbed end free, similar to the Arp2/3 complex219.
Formins represent the other family of linear nucleating factors which stabilise spon-
taneously formed actin trimer. Members of the formin family comprise proteins
such as mDia1 and 2 which associated with the rapid growing barbed end of an
actin ﬁlament and regulate its elongation220. Formins have conserved actin poly-
merisation domains of which one binds to actin monomers while the other interacts
with proﬁlin-actin complexes and promotes the addition of the monomeric actin217.
Actin polymerisation leads to stress ﬁbre formation which are mediated by Rho GT-
Pases. This mechanism is crucial in moving cells forward. This induces contractile
forces which, together with retrogade actin movement, build up tension to pull the
trailing edge forward.
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Figure 1.13: The four stages of 2D cell migration upon attachment. Focal adhesions are formed
(green). 1. Extension: Actin rapidly polymerises (red) and pushes the leading edge to the
front resulting in lamellipodium formation. 2. Adhesion: The lamelipodium adheres to the
substratum forming a focal contact/new adhesion (neon green). 3. Translocation: Actin stress
fibre formation induces contractile forces. Together with retrogade actin movement tension is build
up which pulls the trailing edge forward. 4: De-adhesion: Focal adhesion disassembly occurs
in the back removing cell attachment (dark green). Image was adapted from Fibroblasts and the
Ground They Walk On by Tschumperlin, D. J., Physiology, 2013221.
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This tension, together with other factors, lead to disassembly of adhesions on
both ends likely to be regulated in diﬀerent ways. While the disassembly of the
adhesion at the leading edge is mediated by FAK-Src signalling through paxillin,
Erk and myosin light-chain kinase occurs222, is the release of the trailing edge less
well understood. However it seems it involves a weakening or separation of the
integrin-ECM linkages or integrin-cytoskeletal interaction. This is at least partially
driven by contractile forces. This results in severing of the integrins form the actin
cytoskeleton which remain on the substratum. Components associated with the
cytoskeleton translocate towards the direction of the cell body214. However, integrin
recycling as well as endocytosis seem to be involved as well223.
1.5.1 ADAM15 in migration
Various lines of evidence suggest that ADAM15 plays a role in cell migration. First
experiments were performed by overexpressing ADAM15 in NIH3T3 cells224. Over-
expression led to reduced migration on ﬁbronectin due to increased cell-adhesion.
The inihbitory eﬀect of ADAM15 in cell migration on ﬁbronectin was conﬁrmed in
CHO cells. Furthermore, it was shown that adhesion is enhanced by increase of α5-
integrin expression at the cell surface mediated via Erk1/2 inactivation225. Further
evidence that ADAM15 negatively inﬂuences cell migration was demonstrated by
experiments overexpressing the disintegrin domain of ADAM15 in a hepatoma cell
line. Overexpression led to decreased migration accompanied by reduced prolifera-
tion226. Contrary, in prostate cancer 3 (PC3) cells inhibition of ADAM15 reduced
cell migration as well as adhesion to laminin, ﬁbronectin and vitronectin227. That
ADAM15 can also have the opposite eﬀect in cell migration was further conﬁrmed.
In a rat model of rheumatoid arthritis knockdown of ADAM15 decreased migration
of ﬁbroblast-like synoviocytes228.
These examples show that ADAM15 can either promote or inhibit cell migration
depending on the cellular context. How individual ADAM15 isoforms will aﬀect
migration has not been investigated yet.
1.6 Epithelial-mesenchymal transition
Epithelial to mesenchymal transition (EMT) describes the process in which cells lose
their cell polarity and cell-cell junctions which are necessary to keep contact with
neighbouring cells. Cells which undergo EMT gain mesenchymal properties, such
as ﬁbroblastoid morphology, changes in gene expression (an overview of epithelial
and mesenchymal expression markers is listed in ﬁgure 1.14), increased motility,
ability to invade the basal membrane, enhanced migration, loss of polarity, el-
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evated resistance to apoptosis and increased production of ECM components229–231.
Figure 1.14: Illustration of cells undergoing EMT with corresponding specific markers. Epithelial
cells lose their polarity and cobblestone-like morphology. Mesenchymal cells are non polarised and
appear fibroblastoid. Commonly used markers are listed next to the characteristic phenotype.
Coexpression of markers from epithelial and mesenchymal cells define an intermediate state of
EMT. Image was adapted from Kalluri & Weinberg in Review series The basics of epithelial-
mesenchymal transition, Journal of Clinical Investigation, 2009230.
An important transitional process is the loss of epithelial-cadherin (E-cadherin).
During EMT the expression of E-cadherin is switched to neural cadherin (N-
cadherin). N-cadherin is mostly expressed among mesenchymal cells, whereas
E-cadherin is a marker for epithelium. E-cadherin is crucial for the cell shape
since it connects the α- and β-catenin to the actin cytoskeleton. This helps to
sustain cell shape and polarity. EMT initiation and execution is caused by several
transcription factors and miRNAs. Transcription factors involved in inhibiting
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E-cadherin directly comprises zinc ﬁnger proteins of the SNAIL superfamily, such
as snail or slug, zinc ﬁnger and E-box binding proteins of the ZEB family, such
as ZEB1 or ZEB2 or TWIST proteins. Examples for indirect inhibition are the
homeobox proteins goosecoid and SIX1 or the forkhead-box protein FOXC2232.
1.7 Cell junctions
Epithelial and endothelial cells have the important role to assemble barriers to sep-
arate tissue. Their function is to regulate the exchange of ions and diﬀerent sized
molecules. The two main players in junctional organisation are adherens junctions
(AJ) and tight junctions (TJ). Junctional proteins are classiﬁed in three groups:
The ﬁrst are structural transmembrane proteins, which facilitate contact between
membranes of adjacent cells. The second group comprises plaque proteins which
associate with the cytoskeleton. The last group are signalling proteins which enable
cell-cell communication. Apart from AJs and TJs, cell-cell junctions also contain
desmosomes and gap junctions. Desmosomes are adhesive spot-like junctions which
connect the intermediate ﬁlaments of adjacent cells via desmosomal cadherins. Be-
side stabilisation of tissue architecture desmosomes also contribute to cellular sig-
nalling of neighbouring cells233. Unlike AJ’s,TJs’ and desmosomes, gap junctions
do not contribute to the structural integrity of cell-cell junctions. They form inter-
cellular channels which facilitates the exchange of ions and other larger cytoplasmic
solutes234. Therefore, they are important in cell-cell communications.
Since AJs and TJs contribute most to cell-cell contacts the following subsections
focus on those only.
1.7.1 Adherens junctions
AJs are located immediately below tight junctions. AJs are composed of two com-
plexes, the cadherin-catenin and nectin-afadin complex. An illustration of both is
shown in ﬁgure 1.15. The name cadherins is originated from their requirement of
calcium ions (calcium-adhering).
The classical cadherin-catenin complex consists of α–, β– and p120-catenin. E-, P-
and N-cadherins contain ﬁve N-terminal cadherin repeats which are necessary for
the Ca2+-interaction as well as the cadherin-mediated adhesion. It is followed by
a transmembrane domain and a C-terminal ICD. The cadherin ICDs bind to the
armadillo repeats (not shown) of p120- and β-catenins. α-catenin associates with
either β-catenin or its close relative γ-catenin. Cells are opposed with a distance of
about 10-20 nm between their plasma membranes235.
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Figure 1.15: Illustration of an adherens junction. The nectin-afadin complex (left) consists of a
homodimeric receptor of either nectin-1, 2, 3 or 4 which associate with the actin binding protein
afadin. Nectins possess an ECD which has three IgG-like loops, a transmembrane region and
an ICD with a C-terminal PDZ binding motif (not shown). Afadin serves as adapter protein
and establishes the connection between the nectins and actin. The classical cadherin-catenin
complex (right) consists of α, –β– and p120 catenin. E-, P- and N-cadherins contain five N-terminal
cadherin repeats which can bind Ca2+. It is followed by a transmembrane domain and a C-terminal
ICD. The cadherin ICDs bind to the armadillo repeats (not shown) of p120- and β-catenins. α-
catenin associate with either β-catenin or its close relative γ-catenin. Depending on its constitution
α-catenin binds either to cadherin/catenin or actin. The figure was adapted from Niessen in
Tight junctions/adherens junctions: basic structure and function, The Journal of investigative
dermatology, 2007236.
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The calcium binding sequences of the ECD of the cadherins are crucial to es-
tablish the connection among neighbouring cells. In fact, the interaction of calcium
ions with the sequences dictate the conformation of the ECD237. Upon association
with calcium the ECD of cadherins bind to opposing cadherins via a homophillic
interaction235.
It has been shown that the cadherin-p120 catenin interaction is important to main-
tain cell-surface stability238. Also, p120-catenin is a major regulator of Rho GTPase
signalling239. For a long time it was believed that α-catenin connects β-catenin to
the actin cytoskeleton. However, it seems that α-catenin binds either to cadherin
or actin ﬁlaments. It is reported that α-catenin is a monomer or homodimer. De-
pending on its form its aﬃnity is stronger toward cadherin/catenin (monomer) or
to actin (homodimer)240. The nectin-afadin complex consists of a homodimeric re-
ceptor of either nectin-1, 2, 3 or 4 which associate with the actin binding protein
afadin (AF6). The nectins enable the complex to employ a homophilic as well as
heterophilic adhesion with either other nectins or nectin-like receptor molecules.
Nectins possess an ECD which has three IgG-like loops, a transmembrane region
and an ICD with a C-terminal PDZ binding motif241. Afadin serves as adapter
protein and establishes the connection between the nectins and actin. Afadin con-
sists of a PDZ-, a dilute-, a forkhead associated (FHA)- and two Ras-associating
domains129. The PDZ domain of afadin associates with the nectins and is thus
responsible for the interaction. Within the nectin-afadin complex it seems that the
dilute domain is involved in stress ﬁbre formation242. The role of the FHA domain
is to bind phosphopeptide and thus has a regulatory function. At least one of the
Ras associated domains is able to bind to Rap1A, a small GTPase and member of
the Ras superfamily243.
Studies with CHO cells showed that co-expression of ADAM15 and vascular
endothelial-cadherin (VE-cadherin) led to translocation of ADAM15 to the cell pe-
riphery244. Cell-cell contacts in these cells are established by VE-cadherin mediated
AJ formation. Co-expression of ADAM15 not only resulted in translocation, but
also to co-localisation with VE-cadherin. This proposed that ADAM15 may be a
component of AJ in endothelial cells. Experiments in HUVEC cells demonstrated
that VE-cadherin is not a substrate for ADAM15189.
1.7.2 Tight junctions
TJs are the most apical structure of cell-cell junctions forming the border between
basolateral and apical membrane (ﬁgure 1.16). Their function is not only to provide
structural integrity, they are also a site for signalling, polarity cues and binding site
for intracellular vesicles. Three major TJ protein families mediate cell-cell adhesion.
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Figure 1.16: Illustration of a tight junction. TJs are the most apical structure of cell-cell junctions
forming the border between basolateral and apical membrane. Their function is to provide struc-
tural integrity, they are a site for signalling, polarity cues and binding site for intracellular vesicles.
The three major TJ proteins mediating cell adhesion are claudins, occludins and JAMs. Tricellulin
is found in tricellular TJ. Cingulin forms a complex with JAM-A and interacts with actin filaments
as well as myosin II and several TJ proteins including paracingulin, occludin, ZO1, ZO2 and ZO3.
ZO proteins function as scaffold proteins and provide structural integrity supporting the assem-
bly of multiprotein complexes. The figure was adapted from Niessen in Tight junctions/adherens
junctions: basic structure and function, The Journal of investigative dermatology, 2007236.
These structural transmembrane proteins are claudins, occludins and junctional
adhesion molecules (JAMs). Occludins are transmembrane proteins. They contain
three extracellular loops which are ﬂanked by four transmembrane domains. Hence
Occludin passes the plasma membrane four times with the N- and C-terminus lo-
calised in the cytoplasm. In cancer occludin plays an important role, due to its role
in barrier formation. An important step in cancer progression is the formation of
metastases by gaining the ability to invade vascular endothelium. Therefore, TJs
need to be overcome ﬁrst and loss would facilitate invasion. Thus the loss of occludin
correlates with increased invasion. A protein which has structural similarities with
occludin is tricellulin. It is predominantly localised in tricellular junctions of epithe-
lia. Its function is to contribute to barrier formation245. Cingulin interacts with
actin ﬁlaments as well as myosin II and several TJ proteins including paracingulin,
occludin, ZO1, ZO2 and ZO3. It was also found to be in a complex with JAM-A246.
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A schematic representation of occludin, claudin1, JAM-A, ZO1, ZO2 and ZO3 is
shown in ﬁgure 1.17. Unlike occludins JAMs have only one transmembrane do-
main. The cytoplasmic tails bind to PDZ domain-containing proteins such as ZO1
or afadin247. Within their ECD two Ig-like domains can be found248. Those are
not only important for tight junction assembly, but are also involved in reovirus
binding, platelet aggregation and leukocyte migration. Blocking the IgG-like do-
mains results in reduced barrier function. This is caused by the inhibition of JAM
homodimer formation249. ZO proteins function as scaﬀolding molecules and provide
structural integrity supporting the assembly of multiprotein complexes in intercel-
lular junctions. They link the ﬁlamentous cytoskeleton to the integral proteins.
ZO proteins also appear to participate in cell growth and proliferation250. Due to
the possession of a guanylate kinase (GuK ) domain they belong to the family of
membrane-associated guanylate kinase (MAGUK)-like proteins. Molecular studies
demonstrated that ZO proteins contain conserved nuclear export and localisation
motifs251,252. Tight junction are also the target and site of several diseases such as
infectious diseases, vitamin D mediated malabsorption of Ca2+ ions and cancer.
Often microorganisms target tight junction such as Clostridium perfringens. Its
enterotoxin is a common cause of food poisoning which uses claudin3 and 4 as re-
ceptors253,254. Upon binding of C.perfringens enterotoxin to claudin3 or 4 the new
complex is internalised causing distortions in the functions of TJs255. The bacterium
Vibrio cholerae causes severe diarrhoea by digesting occludin via a combination of
several toxins256. It was also found that reorganisation of the actin cytoskeleton
occured by targeting ZO1256.
Calcium plays an essential role in several physiological functions, such as blood coag-
ulation, neuromuscular transmission, bone mineralisation, cell-cell adhesion, muscle
contraction and intracellular signalling. Since claudins have a major role in cell
permeability they are also involved in uptake of calcium. Mice, deﬁcient for vitamin
D receptor showed decreased expression of claudin2 and 12257.
Cancer cells also undergo changes in their composition of TJ. They lose their po-
larity and speciﬁc functions with reduced development of TJ. It was observed that
well diﬀerentiated colorectal and endometrial adenocarcinomas expressed occludin.
Further de-diﬀerentiation led to loss of occludin and tight junctions258,259.
These were just a few examples how diverse the TJ mediated cause of dieases can
be. More detailed information about pathological implications involving claudins
are dicussed below.
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Figure 1.17: Illustration of the structure of tight junction proteins. A1: Occludin, drawn as
linear structure. WW-motif (Itch binding domain); TM1-4 (transmembrane domains); EC1-2
(Extracellular loops 1 & 2) are rich in Glycine (G) and Tyrosine (Y); IL (Intracellular loop); PY
(Nedd4-2-binding domain); Occludin can be phosphorylated at indicated positions: Y (Tyrosine),
C (Cysteine), S (Serine), T (Threonine), A2: Depiction of occludins natural organisation. B
Illustration of claudin1 in its natural organisation. KDYV -motif serves as PDZ-interaction motif.
C: Picture of the natural organisation of JAM-A. D: Illustration of ZO-proteins. PDZ (PSD95-
Dlg1-ZO1-domain), SH3 (Src homology 3 domain), GuK (guanylate kinase domain). The figure
was adapted from Cummins260, Krause et al.261, Ebnet et al.262 and Bazzoni & Dejana263.
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1.7.3 Claudins
The claudin family consists of 24 members which are distributed diﬀerently within
tissues and organs. Localised on 12 diﬀerent chromosomes they are encoded by at
least 17 human genes and their size varies from 22 to 27 kDa depending on the
type of expressed claudin264. One of the major functions of claudins is to regulate
intercellular permeability of ions265. This depends on the type of claudin present,
as the amino acid charge of the extracellular loops varies. It was demonstrated that
altering the charges lead to changes in ion speciﬁcity of the barriers266. Claudins
can be separated into two groups: Pore-forming or barrier-forming proteins. Typical
member of tight epithelia are claudin 1, 3 and 4. These are commonly found in
organs in which a tight epithelium is crucial for its natural function such as the gall
bladder267 or prostate268. On the other hand, claudins can increase the permeability.
This is in particular important for organs or tissues, which require diﬀusion of ions.
Diﬀusion of ions is an important prerequisite of homoeostasis. Claudin2 and 16
are examples of the claudin family which increase the ion permeability. Claudin2
is typically found in the crypts of small and large intestine269. Intestinal crypts
are known to be responible for resorption of digested nutrients. Another organ
which requires the exchange of ions is the kidney. Claudin16 is found in the thick
ascending limb of the henle’s loop, which is known for its high paracellular cation
permeability270. It was found that especially the ﬁrst extracellular loop is important
for the regulation of paracellular ion permability271.
1.7.3.1 Claudin1
Claudin1 is normally found in tissues and organs which rely on functional bar-
riers to keep compartments separated. For example, claudin1 is found in brain
endothelial cells which are characterised by a high, TJ induced, transepithelial elec-
trical resistance and decreased paracellular permeability272. Another common loca-
tion is in mammalian breast duct cells, where it is normally distributed across the
membrane273. In contrast, claudin1 is normally absent in mesenchymal tissues and
haematopoietic cells since these do not take part in separating tissue compartments
or in forming cellular layers274.
First experiments which demonstrated the importance of claudin1 in barrier forma-
tion were conducted by Furuse et al.275 They generated knockout mice which lack
claudin1 expression. The mice were born normally, but died within a day. The
animals failed to generate TJs in the epidermis which resulted in a loss of water
by evaporation. Although, the organisation of keratinocytes appeared normal, they
were not able to prevent the dehydration. In control wildtype mice close examina-
tion of healthy epidermis revealed continues TJs in the stratum granulosum in which
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claudin1 is concentrated. Experiments with subcutaneously applied tracer demon-
strated that the dye is not able to pass through the epidermis in healthy animals.
In contrast, claudin1 deﬁcient epidermis was not able to hold the tracer back and
diﬀused through the skin275.
Mutations in the gene of claudin1 have been found. Aﬀected people suﬀer from
neonatal ichthyosis and sclerosing cholangitis (NISCH) syndrome276. Other symp-
toms include oligodontia, sclerosing cholangitis, enamel dysplasia, scaling alopecia
and leukocyte vacuolisation. Only four patients with this disease have been dis-
cribed which were two inbred kindreds of Moroccan origin277. The aﬀected gene was
mapped to chromosome 3q27-28 which encodes claudin1. A homozygous deletion in
exon 1 (position 200-201) of two nucleotides (TT) resulted in a frameshift mutation
leading to a premature stop codon at amino acid 67276. Later a diﬀerent mutation in
a Swiss family was found also leading to a premature stop codon, but at a diﬀerence
amino acid (on position 120)278. No claudin1 expression was found in the liver of
these patients276. It appears that the predominant syndromes, ichthyosis and scle-
rosing cholangitis, occur due to lack of claudin1 in skin and liver275,279. Claudin1
is expressed in the bile canaliculi of the liver. The function of it is to transport the
bile acid into the bile duct279. The syndrome of ichthyosis is likely due to the same
reasons as in the claudin1-/- mice. Due to the lack of proper functioning TJs, water
cannot be retained which leads to the phenotype of this disease. This highlights
once more how crucial claudin1 is for barrier formation.
Scientiﬁc evidence is available to highlight that claudin1 is a key player in cell clus-
tering. In vitro experiments show that claudin null cells establish cell-cell contact
upon introduction of claudin1. Fibroblasts transfected with claudin1 formed strands
of TJ in which claudin1 is localised280.
Several signalling pathways have been implicated in regulating claudin1 expression.
It has been demonstrated that claudin1 expression is regulated by PKC in rat choroid
plexus cells281. Leotlela et al.281 demonstrated in melanoma cells a direct correla-
tion of PKC activity and claudin1 expression. They also showed that in endogenous
cells lacking claudin1, phorbol myristic acid (PMA) treatment induced PKC me-
diated upregulation of claudin1 expression. Concomitantly, inhibition of PKC led
to reduced claudin1 expression. In intestinal epithelial cells, stimulation by TNFα
increased claudin1 expression282. It was also found that HIF1β mediates intestinal
epithelial TJ integrity by regulation of claudin1283.
For a long time it was believed that the C-terminal PDZ-binding motif of claudin1 is
responsible for membrane localisation. However, Ru¨ﬀer and Gerke284 demonstrated
that C-terminal deletion mutants (ΔKDYV) continued to localise at the apical TJs.
Removal of the entire C-terminal domain led to mislocalisation in the cytoplasm.
This suggests that the residues C-terminal to the last transmembrane domain are
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Figure 1.18: Illustration of the interaction between claudin1 and ZO1. Claudin1 is a transmem-
brane protein with two extracellular loops. The C-terminal KDYV-domain of claudin1 interacts
with the N-terminal PDZ (PDZ1) domain of the ZO1/ZO2/ZO3291. The latter are obligate in-
tracellular proteins and connect the TJ proteins to the actin cytoskeleton. EL1-2 (Extracellular
loops 1 & 2) are rich in Glycine (G) and Tyrosine (Y); TM1-4 (Transmembrane domain 1-4); PDZ
(PSD95-Dlg1-ZO1-domain); KDYV (Lysine-Aspartic acid-Tyrosine-Valine, binds to PDZ domain).
crucial for membrane homing. Besides, the C-terminal tail contains Ser/Thr/Tyr
phosphorylation sites285. Phosphorylation of claudin1 by MAPK286 or PKC287 pro-
motes barrier function in TJs.
All interaction partners of claudin1 bind via their PDZ-domains to the KDYV-motif.
An illustration of three proteins, ZO1, ZO2 and ZO3 is shown in ﬁgure 1.18. The
ZO proteins possess three PDZ domains, but the interaction with claudin1 is medi-
ated by the N-terminal PDZ1 domain262. The ZO proteins connect claudin1, and
other TJ proteins, to the actin cytoskeleton. Another claudin1 binding partner is
the multi-PDZ domain protein 1 (MUPP1)262, it is involved in opioid tolerance and
opioid-induced hyperalgesia288 and the regulation of olfactory sensory neurons289.
It has also been reported that claudin1 forms a complex with CD81, a member of
the tetraspanin family, so serve as a co-receptor for HCV entry290.
As previously mentioned the ﬁrst extracellular loop of claudin1 has a particular
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importance regulating ion permeability. However, it is not only important for ho-
moeostasis, but it also serves as viral receptor for Dengue292 and Hepatitis C virus
(HCV)293. Since claudin1 appears to be essential for many physiological processes,
dysregulation has drastic eﬀects in pathology.
Dysregulation of claudin1 is observed in many diseases. It is one of the few claudins
which are expressed continuously throughout the intestine294. Thus it was found
that several diseases aﬀecting the intestine show abnormal expression of claudin1.
In ulcerative colitis the expression of claudin1 is elevated282,295. The rate of in-
ﬂammation plays a role in rate of expression. Severely inﬂamed tissues obtained
at biopsy showed higher claudin1 expression compared to slightly inﬂamed sam-
ples295. On the other hand, in irritable bowel syndrome (IBS) claudin1 expression
is decreased296. In correlation with reduced claudin1 expression, the intestinal per-
meability was increased. Compared to healthy biopsies, claudin1 localisation shifted
towards the cytoplasm in colonic mucosa tissue in IBS296. This emphasises that not
only the expression, but also localisation of claudin1 is important in disease pro-
gression. The most dysregulation of claudin1 has been observed in cancer. Loss and
gain has been associated with several types of cancer. Claudin1 upregulation was
observed in thyroid297, pancreatic298, colorectal299 and gastric cancer300. Contrary,
downregulation has been observed in liver301,302, lung303 and breast cancer304.
It has been hypothesised that claudin1 acts as a tumour suppressor in invasive hu-
man breast cancer. First evidence was demonstrated by the reexpression of claudin1
in breast cancer spheroids, which induces apoptosis305. MDA-MB-361 cells were
transduced with claudin1 leading to to prominent membrane localisation correlated
with the rate of apoptosis. In parallel, it was observed that the paracellular diﬀusion
rate was reduced306. Together this suggests that loss of claudin1 membrane locali-
sation contributes to tumour progression. The importance of claudin1 seems to be
the limitation of the inﬂux of nutrients and growth factors in breast cancer cells. In
normal epithelial breast cells loss of claudin1 led to neoplastic transformation307.
Interestingly, this was found by deletion of the mitochondrial DNA (mtDNA) which
suggest claudin1 regulation is downstream of the oxidative phosphorylation chain.
A study with patients observed a correlation of decreased claudin1 expression and
recurrent disease308. The immunohistochemical expression of claudin1 in 83 patients
was observed. 26 patients with recurring breast cancer showed signiﬁcantly lower
expression of claudin1 compared to the group of non-recurrent disease. Decreased
expression correlated with short RFS. The expression pattern was also signiﬁcantly
lower in node positive patients. Therefore claudin1 expression correlates with the
status of recurrence and the malignant potential of breast cancer308. Later, a larger
study using tissue microarray found diﬀerential claudin1 expression in ER+ve and
-ve samples. Signiﬁcantly more ER+ve tumours express claudin1 compared to ER-
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ve ones56. Considering ER-ve cancer is more aggressive than ER+ve, it supports
the hypothesis of claudin1 beeing a tumour suppressor. Although less common, loss
in ER+ve occurs. Experiments about the mechanisms have been conducted. One
study was searching for mutations in the promoter and coding regions of CLDN1,
but none were found304. Recent work suggests that methylation of CpG islands in
the promoter region of claudin1 is associated with low expression of claudin1309.
Another mechanism regulating claudin1 expression involves miRNAs. In ovarian
cancer cells miR-155 was found to decrease claudin1 levels at mRNA and protein
level310. Concomitantly, miR-155 mediated suppression of claudin1 reduced prolif-
eration and invasion of these cells310. On the other hand, elevated levels of miR-155
were found in blood samples of breast cancer patients were it is associated with
cancer progression311,312. Thus, in breast cancer miR-155 might play a role in
downregulating claudin1.
Apart from the previously discussed subtypes of breast cancer a novel subset was
proposed which is characterised by the high levels of claudin1 and reviewed by Myal
et al.264. Over- and underexpression of claudin1 in breast cancer has been reported
which emphasises how complex its role in cancer pathology is. Despite supporting
evidence that claudin1 functions as a tumour suppressor there is also proof for other-
wise. It was found that ER-ve breast cancers had frequently more claudin1 positive
tumours than ER+ve cancers56. The same group could also show that claudin1
positivity is associated with BLBC56. Myal et al. have proposed that during tu-
mourigenesis claudin1 expression is not lost in all tumour cells. Furthermore they
suggest that cells retaining claudin1 expression are predetermined to become ER-ve
BLBC. In these cells claudin1 would not take the role of a tumour suppressor, but
a tumour promoter. In order to explain the evolution of breast cancer two hypo-
thetical models were proposed: A linear model in which diﬀerent subtypes originate
from the same cell which means these subtypes are acquired by genetic and epigen-
tics. The non linear model suggests the diﬀerent subtypes originate from diﬀerent
cells such as stem or progenitor cells313. Believing in the linear model would ques-
tion whether the increased frequency of claudin1 in ER-ve cancer56 occurred due
to re-expression of claudin1. This turns the tumour suppressor properties into tu-
mour enhancing. The causes of re-expression would be caused by genetic mutation
or epigenetic modiﬁcation of the claudin1 gene. In hereditary and sporadic breast
cancer sequence analysis of of the CLDN1 coding region did not identify any sig-
niﬁcant changes304. Myal et al. suggest that accumulation of claudin1 may be due
to a defective interaction with claudin1 binding partners. It may accumulate in the
cytoplasm if the transportation to the membrane is distorted where it may escape
downregulation by other molecules. In addition, it is thought that the strength of
tight junctions is determined by the exact combination of expressed claudins314.
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Therefore, a consequence of accumulation of claudin1 in ER-ve breast cancer could
be due to an altered composition of TJ proteins. Taken together claudin1 is a fas-
cinating protein and the evidence on both functioning as tumour suppressor and
enhancer makes it even more interesting.
It has been demonstrated the claudin1 is also involved in EMT. Claudin1 induced
MAPK/Erk-pathway mediated EMT in human liver cells through activation of Slug
and ZEB1315. In colon cancer, claudin1 upregulates ZEB1 via PI3K/Akt-pathway
which results in reduced E-cadherin expression316. In breast cancer, claudin1 up-317
and downregulation59 have also been shown to modulate the expression of several
EMT related genes317. In contrast to colon cancer, overexpression of claudin1 down-
regulates ZEB1 in MCF7 cells317. This shows that claudin1 has an eﬀect on EMT,
but is cancer type dependent. It has also been demonstrated that claudin1 is reg-
ulated by EMT markers. Slug and snail, which are able to repress transcription of
claudin1 by binding to the E boxes within the promoter318.
In cancer it was observed that claudin1 deregulates certain MMPs which results in
increased motility and invasiveness319,320. In breast cancer, direct interaction of
claudin1 and MMPs have been shown. The interaction is crucial for MMP1 and
proMMP2 activation319. This suggests that claudin1 may play a role in matrix
degradation during cell invasion.
Due to the natural functions of claudin1 it is believed that it also plays a role in
collective cell migration. Cancer cell migration is generally distinguished by two
characteristics: Single cell or collective cell migration. During single cell migration
one cell detaches from the tumour and re-localises to distant tissue or organs where
it starts to metastasise. Gain of mesenchymal characteristics and/or loss of polarity
facilitate this progress321. Contrary, collective cell migration is characterised by the
movement of whole cell clusters. They maintain cell-cell junctions, form protru-
sions, use cell-matrix adhesion receptors, form focal adhesions, utilise proteolytic
breakdown of ECM components and use the actin-myosin machinery for cell move-
ment321.
There is scientiﬁc evidence that claudin1 is involved in collective cell migration.
It has been demonstrated that loss of keratin 8 and 18 leads to EMT marker in-
dependent upregulation of claudin1. Concomitantly, cells increase collective cell
migration and invasiveness322. Keratin 8 and 18 are proteins of epithelial cell-
speciﬁc intermediate ﬁlaments. Their loss during EMT is associated with tumour
chemoresistance and metastasis. Keratin depleted cells showed hyperactivation of
the PI3K/Akt/NFκB signalling pathway as well as increased MMP2 and 9 expres-
sion322.
Immunohistochemical analysis of ductal carcinoma cells showed either complete loss
of claudin1 or a scattered distribution among these cells273. Contrary, in apocrine
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metaplasia, a benign cystic breast disorder, claudin1 membrane localisation was fre-
quently observed273. In colon cancer, particularly in metastatic lesions, claudin1 is
upregulated and frequently mislocalised from the cell membrane to the cytoplasm
and nucleus301. Majority of human colorectal carcinomas possess a mutation in
the gene of adenomatous polyposis coli (APC), a negative regulator controlling β-
catenin expression323. Interestingly, those cell lines with APC mutations upregulate
claudin1 expression. This conﬁrms the fact that claudin1 is a probably target of β-
catein/Tcf signalling299. However, it was found that some cell lines with wildtype
APC do not have detecable levels of claudin1, even with a mutation which sta-
bilises β-catenin301. This suggests the involvement of other mechanisms underlying
claudin1 modulation. Active β-catein/Tcf is not suﬃcient to activate claudin1 ex-
pression. Due to the clinical implications of claudin1 it is suggested as tumour
marker and potential therapeutic target. Treatment of anti-claudin antibodies in-
hibited cell growth of metastatic colorectal cancer xenograft in mice324. Increased
levels in MCF7 breast cancer cells decreased survival and rendered these cells more
susceptible to several anti cancer drugs317. Soini274 proposed to use claudins as
marker for tumours. The expression proﬁle of claudin1, together with claudin2, 3,
4, 5 and 7 can be used to distinguish melanocytic lesions, as well as lymphoid and
soft tissue tumours. Apart from cancer, claudin1 is involved in viral diseases, espe-
cially in the uptake of HCV. Also for viral diseases claudin1 should be considered to
be a therapeutic target, because the uptake of HCV can be blocked by a monoclonal
antibody against the EL1 of claudin1325.
1.8 The PI3K/Akt/mTOR pathway
The phosphatidylinositol-3-kinase (PI3K)/Akt/Mechanistic target of rapamycin
(mTOR) pathway is involved in various processes such as cellular metabolism,
growth, proliferation, metastasis and cytoskeletal reorganisation326.
PI3K is a heterodimeric kinase consisting of a regulatory p85 and a catalytic p110
subunit. An illustration of the two subunits is depicted in ﬁgure 1.19. The cat-
alytic subunit consists of an N-terminal p85-binding motif, a Ras-binding motif, a
C2 domain, a helical domain followed by the catalytical domain327. The function
of C2 domains are to target the protein to the cell membrane328. The helical do-
main acts as scaﬀold329. p85 contains an SH3 domain, a BH (B-cell lymphoma 2
(Bcl2) homology) domain which is ﬂanked by proline-rich regions at each end, and
a p110-binding domain ﬂanked by two SH2 domains. The SH3 domain interacts
with PXXP-motifs330 while the SH2 domains bind to phosphotyrosines within the
YXXM-motif331. The BH domain interacts with the Rho family proteins Cdc42 and
Rac1332,333. Two of the major kinases in this pathway are Akt and the Ser/Thr
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kinase phosphoinositide-dependent kinase 1 (PDK1). The schematic representation
is also shown in ﬁgure 1.19. The pleckstrin homology (PH) domains of PDK1 and
Akt are the binding motifs for PIP2/3. interaction
334.
Figure 1.19: Illustration of PI3K and its activator Akt. A1: Schematic of p110 - the catalytic
subunit. It consists of a p85-binding- , a Ras-binding-, a C2-, a helical- and catalytic domain. A2:
The regulator subunit p85 contains an SH3 motif, a BH-domain flanked by proline-rich regions
(PR) and a p110-binding domain flanked by SH2 motifs. B: Scheme of Akt which comprises a
pleckstrin homology (PH)-. followed by a catalytic-, and regulatory domain. C: PDK1 consists
of a kinase- and PH-domain. The image is adapted from Vanhaesebroeck et al. in The emerging
mechanisms of isoform-specific PI3K signalling, Nature reviews: Molecular cell biology, 2010335
mTOR is a multidomain Serine/Threonine kinase which belongs to the PI3K-
related kinase (PIKK) family336. It is highly conserved in various species336,337.
The mTOR was identiﬁed after the drug rapamycin had been discovered. Section
2.8.2 describes rapamycin and other drugs in more detail. mTOR is the catalytic
subunit of two distinct protein complexes: mTORC1 and mTORC2. A simpliﬁed
scheme is shown in ﬁgure 1.20. The mTOR complexes are deﬁned by their
association with the scaﬀold proteins regulatory-associated protein of mTOR
(Raptor) and rapamycin-insensitive companion of mTOR (Rictor). Raptor only
associates with mTORC1 whereas Rictor associates with mTORC2. There are
also additional components which are exclusive to individual complexes. mTORC1
associates with proline-rich Akt substrate 40 kDa (PRAS40) whereas mTORC2
contains mammalian stress-activated protein kinase-interacting protein 1 (mSIN1)
and protein observed with Rictor (Protor). Both complexes also share common
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regulatory components such as mammalian lethal with SEC13 protein 8 (mLST8)
and DEP domain-containing mTOR-interacting protein (DEPTOR)338.
Raptor is a 150 kDa adaptor protein for mTOR and constitutively bound to
mTORC1. It is crucial for its activity and essential in regulating mTORC1. Upon
stimulation of insulin or other upstream activators mTOR phosphorylates Raptor
at Ser863339. PRAS40 is a 40 kDa substrate of Akt. It has proline-rich regions
and is a negative regulator of mTORC1. In unphosphorylated state it binds to
mTORC1 and blocks the interaction of Rheb GTPase. Upon insulin stimulation
Akt phosphorylates PRAS40 which disassociates from mTORC1 allowing its
activation339.
Deptor is an 48 kDa endogenous inhibitor of mTOR. mTOR can directly in-
teract with Deptor which expression is negatively regulated by mTORC1 and
mTORC2340. Suppression of Deptor leads to reduced mTORC activity. In multiple
myeloma disease Deptor is overexpressed and crucial for the survival of the myeloma
cells, because downregulations induces apoptosis. In vitro activity of 4E-BP1 and
S6K1 is reduced upon depletion of Deptor340.
mLST8 is a 36 kDa regulator protein. It can directly interact with mTOR. The
full kinase activity of mTOR is only achieved by binding mLST8. However, the
interaction is only essential for mTORC2 since the knockdown of mLST8 caused
disruption of the mTOR/Rictor complex, but did not aﬀect the mTOR/Raptor
interaction341.
mSIN1 acts as scaﬀolding protein since ablation of SIN1 disrupts mTOR-Rictor
interaction in yeast342. It is also required for mTORC2 mediated Akt phosphory-
lation at Ser473342,343. The FRB binding site of mTOR is a speciﬁc binding site
for FKBP12, a protein which belongs to the family of peptidylprolyl isomerases344.
Beside the function as isomerase FKBP12 also functions as chaperone345.
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Figure 1.20: Schematic representation of the PI3K/mTOR pathway. Pharmacologcial inhibitors
are displayed as a red squared box. Arrows indicate the activation or phosphorylation (P) of a
downstream molecule. Lines with horizontal bar indicated inhibition of downstream target.
The PI3K/mTOR pathway is activated downstream of RTKs such as Erb fam-
ily receptors, FGFR and IGF-1R346,347. PI3K is also stimulated by the catalytic
domain of the small GTPase RAS348. An illustration of the pathway is depicted
in ﬁgure 1.20. Activated PI3K translocates to the plasma membrane and phospho-
rylates phosphatidylinositol 4,5-bisphosphate (PIP2) to phosphatidylinositol 3,4,5-
triphosphate (PIP3)329. PIP3 activates PDK1
334 as well as Akt. Partial activation
of Akt is also done by PDK1 on Thr308349, but full activation of Akt is medi-
ated by mTORC2 at Ser473350. Activated Akt phosphorylates tuberous sclerosis
complex 2 (TSC2) which causes the disruption of the TSC1/TSC2 complex. This
complex serves as GAP for Ras homologue enriched in brain (RHEB) GTPase,
because TSC1/TSC2 interaction causes hydrolysis of Rheb which remains in its in-
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active GDP bound state351. Upon inactivation of TSC1/TSC2 complex GTP-Rheb
phosphorylates mTORC1 which leads to its activation. Active mTORC1 leads to
elevated protein synthesis by eukaryotic initiation factor 4E (EIF4E)-binding pro-
teins (4E-BP1) and ribosomal protein S6 kinase.
Termination of PI3K signalling is achieved by diﬀerent mechanisms. The most com-
mon mechanism is interference with PIP2/PIP3 conversion or the dephosphorylation
of Akt. The SH2-containing phosphatases (SHIP1 and SHIP2) can bind to the 5th
position of the inositol ring of PIP3. Dephosphorylation leads to PIP2 which renders
it inactive again349. Also the conversion of PIP2 to PIP3 can be antagonised by the
phosphatase and tensin homolog (PTEN) which dephosphorylates PIP3 to PIP2
352.
Therefore, the loss of PTEN activates both mTORC1 an 2340. The other mecha-
nism comprises direct interaction with Akt. Dephosphorylation of Akt at Thr308
by PP2A353 and at Ser473 by PH domain leucine-rich repeat protein phosphatase 1
and 2 (PHLPP1/2). A schematic representation of mTOR is depicted below (ﬁgure
1.21).
Figure 1.21: Schematic overview of mTOR. Several HEAT repeats cand be found followed by
a FAT domain. The FRB is the specific binding site for FKBP12. FKBP12 is the target of
Rapamycin. The kinase domain lies adjacent priot to the c-terminal FAT domain (FATC). The
illustration is adapted from Cargnello et al., The expanding role of mTOR in cancer cell growth
and proliferation, Mutagenesis, 2015338.
In intestinal porcine epithelial cells (IPEC) L-Tryptophan induced mRNA
upregulation of tight junction proteins via mTOR activation354. Upregulation of
occludin, claudin1, ZO1 and ZO2 were observed, but expression of claudin1 and
ZO3 were unaﬀected. A new paper from 2016 demonstrated that in IPEC cells
glucagon-like peptide-2 (GLP-2) promotes claudin1, ZO1 and occludin expression
via the PI3K/mTOR pathway355. GLP-2 is an intestinotrophic growth hormone
that facilitates the biological function of the intestines.
1.9 Integrins - cellular bridges
Integrins are heterodimeric transmembrane receptors mediating cell attachment to
the ECM. They consist of non-covalently bound α- and β-subunits. To date, 18 α-
and 8 β-subunits are known. In mammals 24 diﬀerent integrin heterodimers exist.
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Both subunits are single transmembrane glycoproteins with a short C-terminal ICD
(about 50 amino acids) and large N-terminal ECD (over 700 amino acids). The
familiy of integrins comprises many cell surface receptors which interact with sev-
eral ECM components such as collagens, ﬁbronectin (FN), laminins and vitronectin
(VN) via their extracellular portion356. Almost all integrin heterodimers associate
via their β-chain with the cytosolic talin. The ICD binds to diﬀerent cytoplasmic
proteins which establish interaction to the actin cytoskeleton. Unlike kinases, which
are activated via phosphorylation, integrin activation is mediated via a conforma-
tional change. Integrins can be in a folded (inactive) or unfolded (active) state.
During the inactive state, both α- and β-chains are in close proximity and adhere to
each other. Upon unfolding of the ECD the contact is abolished and the transmem-
brane domain and ICD move apart. This exposes the binding site for talin. Binding
of talin induces actin assembly at the ICD complex of the integrin as well as a se-
quence of intracellular signalling events such as Src and focal adhesion kinase (FAK)
phosphorylation. The process when integrins activate intracellular signalling events,
induced by extracellular matrix ligation, are referred to as “outside-in signalling”.
Talin competes with the α-subunit for β-chain interaction. When talin binds to the
β-subunit the heterodimer separates. The extracellular portion extends and goes
into active conﬁrmation which allows ligand interaction. This process is referred
to as “inside-out signalling”. However, “inside-out signalling” can also be induced
via external regulators. One example is the signalling molecule phosphatidylinositol
4,5-bisphosphate (PIP2) which is expressed in response to receptor activation. PIP2
activation can be induced by G-protein coupled receptors (GPCRs) or RTKs357.
The aﬃnity and ligand speciﬁcity of integrins can be inﬂuenced by the divalent-
cation-binding domain, present in both α– and β-chain. Therefore, extracellular
concentration of Mg2+ and Ca2+ aﬀect integrin activity. Integrin-induced adhesion
signalling pathways can activate cytoskeletal reorganisation and alter gene expres-
sion by outside-in or inside-out activation358.
Since its is known that ADAM15 interacts via its RGD motif with α5β1114 and
αvβ3114,115 as well as RGD-independently to α9β1359, I will focus on the functions
of the subunits involved in this interaction.
1.9.1 Integrin subunits
1.9.1.1 α5
Loss of function mutations that occur in the murine α5 gene caused embryonic death
if present on both alleles. This was observed after interbreeding of mice which were
heterozygous for the α5 mutation. From 120 liveborn progenies none were homozy-
gous for α5 mutation. Embryos homozygous for the mutation were identiﬁed by
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southern blot analysis. All of them showed deformations from day 8.5 to 10.5. At
day 10.5 the number of homozygous mutated embryos was reduced and displayed de-
terioration. At day 11.5 to 12.5 no homozygous mutated embryos were found which
suggested that they die around day 11.360. Examination of histological specimens
revealed that posterior trunk regions have defects in neural tube and the mesoderm.
Also defects of vascularisation were observed since the formation of blood vessels
was impaired.
The only known integrin heterodimer containing an α5 subunit is α5β1 that specif-
ically interacts with the RGD motif in FN. The fact that the mutant embryos die
that early in development points out how important α5β1 is for embryogenesis, even
when there are several other integrins mediating adhesion to FN. This suggests α5β1
has unique functions other than FN binding. Indeed, tissue sections from α5-null
embryos showed expression of FN and the FN-matrix pattern was indistinguishable.
Additionally, no diﬀerences were observed in FA formation when analysed by vin-
culin and talin analysis. It seems the function of α5 is essential in some processes
such as embryogenesis in which other integrins fail to compensate the loss. Contrary,
in other events as assembly of FN matrices or formation of focal adhesions (FA) the
lack of α5 can be compensated.
1.9.1.2 α9
The α9 subunit only associates with β1 to form the α9β1 integrin receptor. This
heterodimer interacts with the ECM proteins osteopontin and tenacsin C as well
as vascular cell adhesion molecule-1 (VCAM1). Expression of the receptor was
observed in hepatocytes, smooth muscle cells and some epithelia.
Mice which are deﬁcient in α9 were born alive, but showed signs of respiratory
distress between 6 and 12 days of age. Within 2 days after onset of this symptom
the mice died. The reason of death was found to be chylothorax, an obstruction of
the thoracic duct. This causes the space between chest wall and lung to be ﬁlled
with milky ﬂuid high in triglycerides. In addition a high concentration of cholesterol
and a high number of lymphocytes were found. Histological analysis of the chest
wall revealed accumulation of inﬂammatory cells accompanied with oedema.
These results suggest that α9 integrin is crucial for development of the lymphatic
system including the thoracic duct.361
1.9.1.3 αv
αv-subunits are widely expressed. They are expressed in neural crest cells, glia cells,
muscle cells, osteoclasts, epithelia, blood vessels during development and in angio-
genic tumours362.
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In 80% of the mice αv ablation is lethal. However, all embryos develop normally to
stage E9.5, and only 20% were born alive, but died at the day of birth. By E10.5 the
majority of embryos exhibited pericardial oedema and deteriorated at E11.5. While
the vascularisation of the yolk sac was normal, abnormalities of the placenta were
observed. Speciﬁcally, αv-null placenta had reduced labyrinthine zones. The pro-
portion of born progenies suﬀered from intestinal and intracerebral haemorrhages.
This condition became more serious with increasing age. No other organs showed
haemorrhage and were well vascularised. Additionally, postnatal mice exhibit cleft
palates362.
1.9.1.4 β1
The β1 subunit associates with at least ten diﬀerent α-chains and is the largest in-
tegrin subfamily. β1 family integrins are considered as particularly important in
embryogenesis where they mediate adhesion and provide positional information for
morphogenesis.
This is conﬁrmed by the generation of β1-null mice since deﬁciency caused lethality
shortly after implantation of the embryo363. In order to determine whether the
β1 gene is essential for early embryonic development (until E3.5) blastocysts of het-
erozygous females, which were mated with heterozygous males, were isolated. About
a ﬁfth of the blastocysts were homozygous for β1 mutation. This suggests that the
β1 gene is not crucial in the very early stage of embryogenesis363. In another ex-
periment chimeric β1-deﬁcient mice were generated from two independent β1-null
embryonic stem cells (ES cells). Histological examination of E8.5 embryos found
labeled ES cells in all germ layers suggesting that cells diﬀerentiate and migrate
normally363. β1-deﬁcient cells were found in all analysed regions, suggesting that
migration of neuronal cells can occur in the absence of β1 containing integrins.
Separately, Stephens et al. demonstrated that absence of β1 is lethal during early
postimplantation development364. In vitro, β1-null embryos were able to form blas-
tocysts which outgrew normal trophoblasts. They were indistinguishable to the
wildtype and heterozygous embryos. However, during the experiment the inner cell
mass of the blastocyst was smaller and disorganised compared to the control em-
bryos. These experiments further conﬁrmed the importance of β1-chains in normal
embryogenic development.
1.9.1.5 β3
The β3-subfamily comprises αvβ3 and αIIbβ3 which have been implicated in a variety
of functions. This includes thrombosis and platelet aggregation for αIIbβ3 integrin.
For αvβ3 integrin it includes implantation, placentation, bone remodeling, angiogen-
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esis and tumour progression.
β3-deﬁcient mice are viable and fertile. However, they show all symptoms of the
Glanzmann thrombasthenia - the human bleeding disorder. Their symptoms com-
prise clot retraction and platelet aggregation, prolonged bleeding as well as cuta-
neous and gastrointestinal bleeding365. Implantation of the embryo appears inde-
pendent of β3, but placental defects occurred which lead to foetal mortality. As
a consequence of the haemorrhaging anaemia lead to reduced postnatal survival.
It has been reported that retinal neovascularisation of newborn mice is inhibited
by peptides which block αvβ3 function366. However, this observation could not be
conﬁrmed since the pattern of the neovascularised vessel of the β3-null mice did not
show diﬀerences to the control mice. This suggests that this mechanism is indepen-
dent of the β3-chains. β3-integrins are involved in locomotion, shape, cell signalling
and cell cycle regulation.
1.9.2 Integrin endocytosis
The presence of integrins on the membrane is crucial for various cell functions.
Thus the control of availability at this compartment is important. Internalisation
is a crucial mechanism in which integrins are withdrawn from the membrane. In
general endocytosis is separated into two groups: Clathrin-dependent and clathrin-
independent endocytosis. Both will be discussed in detail below. Clathrin-coated
vesicles (CCV) are crucial for membrane traﬃcking in cells and do not only transport
integrins. Clathrin forms a triskelion shape which is composed of three 190 kDa
heavy and three 25 kDa light chains as illustrated in ﬁgure 1.22 a. The heavy
chains provide a structural backbone whereas the light chains regulate assembly
and disassembly of the lattice. Each arm consists of the following parts, starting
from the centre: Proximal segment, knee, distal segment, ankle, linker and terminal
domain. Interaction of triskelia leads to formation of a polyhedral lattice which
surrounds the vesicle. The triskelia can form diﬀerent structures as illustrated in
1.22 b. The mini-coat is made up of 28 triskelia and has a tetrahedral symmetry. The
hexagonal barrel structures contain 36 triskelia with D6 (six-sided dice) symmetry.
The soccer ball structure comprises 60 triskelia with icosahedral symmetry367.
CHAPTER 1. GENERAL INTRODUCTION 74
Figure 1.22: Illustration of the clathrin triskelion including examples of different lattices. a)
Triskelion with labeled segements of the heavy chain (blue). Order from N- to C-terminus towards
the vertex: Terminal domain, linker, ankle, distal segment, knee, proximal segment. The schematic
positions of the light chains is indicated in yellow. b) Assembled structures of clathrin formed in
vitro. Mini-coats show a tetrahedral symmetry; Hexagonal barrel show a D6 symmetry; Soccer
ball show a icosahedral symmetry. A triskelion is highlighted in blue in the hexagonal barrel. the
image was taken from Fotin et al, Molecular model for a complete clathrin lattice from electron
cryomicroscopy, Nature, 2004367.
1.9.2.1 Clathrin-dependent endocytosis
In general, the clathrin-dependant integrin internalisation mechanism is better un-
derstood and characterised when compared with the clathrin-independent mech-
anism. The ICD of integrin β-chains contain NXXY-motifs. This motif recruits
transmembrane receptors to CCV through interaction with adaptor proteins such
as AP2 adaptor complex368. Other adaptor proteins such as disabled (Dab) and
protein numb homologue contain phosphotyrosine-binding (PTB) domains which
can bind to to NPXY-motifs369. Both contribute to the endocytosis of integrins.
Numb can associate directly with β1- and β3-integrins. Knockdown of numb in-
hibits internalisation of α5β1 and αvβ3 by modulation of proteinase-activated recep-
tor 3 (PAR3)-protein kinase C ζ (PKCζ) signalling. Studies found another adaptor
protein, disabled homologue 2 (Dab2), involved in clathrin-dependent β1 endocyto-
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sis370. Quantitative proteomic analysis showed that β1-integrins are the preferred
cargo of Dab2-mediated endocytosis since these were the main proteins depleted
from the cell membrane371. β1-integrins are recruited to Dab2-rich clathrin-coated
structures (CCS) were they get internalised. Clathrin, Dab2 and AP2 are recruited
to the adhesion sites, followed by integrin endocytosis into CCS370. Experiments
with conformation-speciﬁc antibodies showed that only active β1-integrins are en-
docytosed during FA disassembly370. Neuropilin 1 (Nrp1) directly associates and
protmotes α5β1-mediated endothelial cell adhesion to FN at adhesion sites. Nrp1 is
a transmembrane glycoprotein that is expressed on endothelial cells, neurons, diﬀer-
ent types of tumours and tumour-derived cell lines. In Ras-related protein (Rab) 5-
positive early endosomes, the serine-glutamic acid-alanin (SEA)-motif of Nrp1 binds
to the homomultimeric endocytic adaptor Gα interacting protein (GAIP)-interacting
C terminus, member 1 (GIPC1) which selectively stimulates the internalisation of
active α5β1372. Nrp1 dependent internalisation of integrins occur along ﬁbrillar ad-
hesions. Fibrillar adhesions are highly matured and not generally seen in migrating
cells. They are characterised by large stress ﬁbers and underlying ﬁbrillar FN. In-
ternalisation of α5β1-NRP1 complexes also require the recruitment of myosinVI. It
links GIPC1 to the SEA-motif of Nrp1. This bridges the myosin motor to the in-
tegrin and assists in the formation and transportation of endocytic vesicles across
actin ﬁlaments372.
It was believed that the integrin levels on the membrane dictate the speed of
migration. However it was found that the internal pool of integrins is responsible
and not the cell surface level371. A reason could be that the internal pool might get
recycled and contribute to new focal contacts at the leading edge. It still needs to
be investigated at which cellular location clathrin-dependent endocytosis occurs. It
has been reported that it occurs only near FA373, at the apical surface374 or at the
entire cell surface371.
1.9.2.2 Clathrin-independent endocytosis
Both, α5β1 and αvβ3 are endocytosed via CCS, but internalisation can also occur via
diﬀerent routes. It has been shown that α5β1 can be endocytosed independently of
the NXXY-motif and clathrin by upregulating Rab21375. Clathrin and NXXY-motif
independent endocytosis seems to occur via cholesterol-sensitive caveolar routes
which can be activated by Rab21376. In myoﬁbroblasts and endothelial cells, α5β1
and αvβ3 localise to caveolae, cholesterol-containing membrane structures. Despite
the fact that these integrins have been shown to be internalised by CCV it has
also been demosntrated that β1-integrin is endocytosed via a clathrin-independent,
but caveolin1 mediated route377. Another route which has long been known to
regulate integrin endocytosis is via the direct interaction of PKCα and the ICD of
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β1-integrin378. Prior to internalisation, the β1-chain is traﬃcked to an endosomal
compartment via a Ca2+/PI3K/dynamin1-dependent route. It is assumed that
this happens through prolonged clustering of integrins, demonstrated with α2β1.
Antibody-induced clustering of this integrin induced a lateral movement along
actin ﬁlaments on the cell surface. Small clusters are fused together during
this lateral movement and were subsequently internalised into caveosome-like
perinuclear structures mediated via PKCα activity379. In primary neutrophils, it
has been shown that αLβ2-integrin is internalised via a clathrin-independent and
cholesterol-sensitive pathway380.
1.9.3 ADAM15 and integrins
ADAM15 contains a disintegrin domain which has been shown to interact with in-
tegrins. Experiments with a recombinant disintegrin domain or ECD of ADAM15
were used to reveal its function. The ﬁrst experiments with recombinant disintegrin
domain of ADAM15 were carried out by Zhang et al. They expressed the disintegrin
domain as a fusion protein with GST and used the pull-down approach to identify
binding partners. They were the ﬁrst who discovered that αvβ3 binds to the disinte-
grin domain in an RGD-dependent manner115. One year later Nath et al.114 demon-
strated the interaction between ADAM15 and αvβ3 and also α5β1 in haemopoietic
cells using the recombinant ADAM15 ECD. The interaction of ADAM15 with αvβ3
was further conﬁrmed with recombinant human ADAM15 disintegrin domain using
a phage display381. The recombinant ADAM15 disintegrin domain inhibited the
binding of αvβ3 to vitronectin in a dose-dependent manner. Subsequently, similar
results were observed for αIIbβ3 on ﬁbrinogen382. Jeon et al. showed that altering
the amino acid residues proximal to the RGD sequence (RPTRGD and NWKRGD)
increase the aﬃnity of αIIbβ3 towards the disintegrin domain of ADAM15.
Hou et al. demonstrated that the recombinant human disintegrin domain of
ADAM15 reduces migration and proliferation of Bel-7402 cells in a liver cancer
model. This was as a result of a partial G2/S arrest with concomitant increase in
activity of the initiation caspases 8 and 9 as well as the executioner caspase 3226. In
the same study they used a zebraﬁsh as a model for tumour xenografts of Bel-7402
cells and as model for apoptosis induction. They demonstrated that 1 pM recombi-
nant disintegrin domain led to reduced growth of metastasis while a ten times lower
dose induced severe cell death in somatic cells of the zebraﬁsh226.
Eto et al.113 conﬁrmed that αvβ3 binds ADAM15 via its RGD-motif. They also
showed that α9β1 interacts with ADAM15 independently of the RGD motif. The
interaction required Arg481 and the Asp-Leu-Pro-Glu-Phe residues (488-492).
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Chen et al. demonstrated that overexpression of ADAM15 in CHO cells, expressing
endogenous α5β1, led to decreased migration and enhanced adhesion on FN, which
was the consequence of ADAM15-driven cell surface expression of α5β1. Using IP
and immunoﬂuorescence analysis they conﬁrmed no interaction between ADAM15
and α5β1-integrin. Instead, overexpression of ADAM15 decreased Erk1/2 phos-
phorylation. Pharmacological inhibition of Erk1/2 phosphorylation enhanced α5
expression on the cell surface225. This experiments revealed a novel mechanism in
which ADAM15 regulated migration and adhesion via Erk1/2.
ADAM15 is also found in exosomes which are released by PMA stimulation383.
ADAM15-positive exosomes show enhanced binding to αvβ3-integrin in an RGD-
dependent manner. ADAM15 containing exosomes suppressed FN- and VN-induced
growth, cell adhesion, migration and in vivo tumour growth. This experiments sug-
gest that ADAM15 may function as a tumour suppressor in an exosome-mediated
way by interacting with integrins.
It has been demonstrated that ADAM15 isoforms interact with Nck, but with vary-
ing aﬃnity179. Under genotoxic stress ADAM15 enhanced FAK and Src phospho-
rylation384,385. Crosstalk between ADAM15 and integrins was also found in inﬂam-
matory diseases as well as in diﬀerent types of cancers. In the crypt abcesses of in-
ﬂammatory bowel disease α5β1 positive leukocytes were found in close contact with
ADAM15 positive epithelial cells. In regenerative areas, α5β1- and αvβ3-positive
pericryptic myoﬁbroblasts were in close contact with ADAM15-positive epithelial
cells386. Histological analysis of primary colon tumour samples showed downreg-
ulation of ADAM15 in poorly diﬀerentiated carcinomas. This downregulation was
statistically signiﬁcant with increased localisation of α5β1-integrin at the cell mem-
brane. In immunoﬂuorescence stainings it was observed that normal epithelial colon
cells express ADAM15 at their basolateral membrane, but do not express α5β1. Con-
trary, in carcinoma cells with downregulated ADAM15 expression, α5β1 was found
at the basolateral membrane387. This suggests an ADAM15-to-α5β1 switch. An-
other observation which was made by the same group was that downregulation of
ADAM15 in the tissue sample correlated with downregulation of α3β1. Regulation
of α3β1 by ADAM15 has not been shown before. More studies need to be carried
out to address this novel ﬁnding. Direct correlation of ADAM15 expression and αv
membrane localisation has been observed in prostate cancer 3 (PC3) cells. Knock-
down of ADAM15 resulted in a decreased localisation of αv at the cell surface227.
In ovarian cancer cells overexpressed ADAM15 signiﬁcantly reduced αvβ3-mediated
adhesion to vitronectin388 which could be due to higher aﬃnity of the integrin to
the RGD motif of ADAM15. Co-localisation of ADAM15 and αvβ3 is often observed
in lung cancer cell lines193.
While there is substantial evidence on integrin and ADAM15 interactions, and po-
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tential implications for normal cell biology as well as pathological conditions, the
work carried out to date reﬂects only what happens between speciﬁc integrins and
ADAM15 A isoform. Whether the other ADAM15 isoforms aﬀect integrin biology
diﬀerently is currently unknown and requires further research.
1.9.4 Ras homologue (Rho) GTPases are key players in cy-
toskeleton rearrangement
Migration is a process which requires the communication between two opposing
ends of the cell. Not only coordination of protrusions in the leading front and
retraction at the rear are important, also shape, organisation and polarity that are
driven by the cytoskeleton. In respect of locomotion three distinct activities are
involved to move a cell forward: 1) Protrusions in the front of cell structures, rich
in actin, are pushed out. 2) Attachment, in which the cell membrane is connected
to the substratum by the actin cytoskeleton. 3) Traction in the rear. The trailing
cytoplasm is drawn forward. These cytoskeletal rearrangements are governed by the
Rho protein family: Rho, Ras-related C3 botulinum toxin substrate (Rac) and cell
division control protein 42 homologue (Cdc42). The function of Rho is to regulate
actin stress ﬁbre assembly, whereas Rac regulates membrane ruﬄes and lamellipodia
formation at the cell periphery, while Cdc42 is responsible for ﬁlopodia formation389.
Figure 1.23: Illustration of Rho-GTPase activation. Rho-GDIs release inactive Rho-GTPases in
the cytoplasm. Sequestered Rho-GTPases are targeted to the cell membrane. GEFs mediate their
activation by binding to GTP. GAPs promote their inactivation by binding to GDP. The image
is adapted from Huveneers and Danen, Adhesion signaling - crosstalk between integrins, Src and
Rho, Journal of Cell Science, 2009390.
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Within the cytoplasm GTPases are bound by Rho-GDP dissociation inhibitors
(Rho-GDI) as shown in ﬁgure 1.23. Sequestered Rho-GTPase from Rho-GDIs are
targeted to the plasma membrane. GTPase switches between an active GTP-bound
and an inactive GDP-bound state. Guanine nucleotide exchange factors (GEFs)
promote activation of GTPase through the catalytic removal of GDP and enabling
GTP binding whereas GTPase-activating proteins (GAPs) show the opposite eﬀect,
causing down regulation of GTPase activity.
The initiation of cell adhesion and spreading occurs in parallel with inhibition of
RhoA and activation of Rac1 and Cdc42. This increases actin-mediated protrusion
formation and suppresses actomyosin contractility. Later, the activities of Rac1 and
Cdc42 decline while RhoA activity increases which leads to FA and stress ﬁbre for-
mation. The reason of this mutually exclusive behaviour is that RhoA suppresses
the activity of Rac1 and vice versa. Rac1 inhibits low-molecular-weight protein tyro-
sine phosphatases by induction of reactive oxygen species (ROS) production. This
leads to an increase in tyrosine phosphorylation and activation of p190RhoGAP
which inhibits RhoA activity391. In contrast, RhoA inactivates Rac1 by promoting
Rho-associated coiled-coil containing kinases (ROCK)-mediated phosphorylation of
FilGAP392. FilGAP is a ﬁlamin A-binding RhoGTPase-activating protein. It func-
tions as a GAP for Rac1, localising to sites of membrane protrusions.
Integrins are the major regulators of RhoGTPases largely via the FAK-Src com-
plex. A simpliﬁed illustration of integrin-mediated RhoGTPse activation is shown
in ﬁgure 1.24. Upon binding of an integrin to a ligand the cytoplasmic domain un-
folds and various FA initiation proteins are recruited to the the membrane such as
talin and FAK. Recruitment of FAK causes its autophosphorylation at Y397 which
serves as binding site for the SH2 domain of Src. This leads to transphosphoryla-
tion of FAK within the kinase domain activation loop at Y576 and Y577 as well as
C-terminal domain at Y861 and Y925393. This phosphorylation events serve two
purposes: They maximise the kinase activity of FAK and generate new binding
sites for other proteins. The active FAK/Src complex recruits and phosphorylates
the scaﬀolding protein p130Cas394. Active p130Cas associates with the adaptor
protein v-crk sarcoma virus CT10 oncogene homologue (Crk) thereby recruiting en-
gulfment and motility 1 (ELMO1) and dedicator of cytokinesis-180 kDa (Dock180).
The Dock180-ELMO1 complex promotes the formation of membrane protrusions by
functioning as an unconventional GEF for Rac1395. Apart from activating p130Cas
the FAK/Src complex also phosphorylates paxillin that subsequently recruits the Ar-
fGAP paxillin-kinase linker (PKL) as well as the mutual GEF for Rac1 and Cdc42,
Pak-interacting exchange factor-β (β-PIX). Rac1 is recruited and activated by β-PIX
via direct interaction396. A proline-rich region of Rac1 binds to the SH3 domain of
β-PIX396.
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Figure 1.24: Simplified illustration of integrin induced regulation of Rho-GTPases. At the site
of integrin activation Src and FAK are recruited and form a complex. This complex modulates
Cdc42, Rac1 and RhoA activity via several pathways. The image is adapted from Huveneers and
Danen390 and Dra´ber, Sulimenko and Dra´berova´397.
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It has been demonstrated that PKL can be directly phosphorylated by Src and/or
FAK398 while β-PIX is activated by Src399. Furthermore, Src mediates the transient
inhibition of RhoA through regulation of p190RhoGAP400.
There are multiple downstream targets of RhoGTPases with direct eﬀects on actin
cytoskeleton rearrangements. This includes formins, kinases and members of the
Wiskott-Aldrich syndrome protein (WASP) family and other scaﬀolding proteins.
The most prominent contributors are the mammalian Diaphanous formin (mDia),
proteins of WASP and Wiskott-Aldrich syndrome protein-family verprolin homol-
ogous protein (WAVE), ROCK and p21-activated kinase (PAK). Cdc42 and Rac1
activate PAK which promotes LIM-motif containing kinase (LIMK) activity. Both,
Cdc42 and Rac1, activate the Arp2/3 complex, Cdc42 through WASP while Rac1
stimulates it via WAVE401. Cdc42-mediated Arp2/3 activation leads to ﬁlopodia
formation while Rac1-regulated Arp2/3 stimulation leads to membrane ruﬄing and
lamelipodia formation. Interestingly, the ADAM15 adaptor protein Grb2 is an al-
ternative activator of WASP, stimulating actin polymerisation. Cdc42 and Grb2
elicit a synergistic eﬀect by simultaneous binding to N-WASP which increases its
activity402.
RhoA promotes stress ﬁbre formation via activation of mDia and ROCK. Besides,
ROCK also mediates actomyosin contractility via phosphorylation of myosin II light
chain (MLC) and myosin light chain phosphatase (MLCP). Activation of LIMK by
ROCK leads to phosphorylation of coﬁlin. This leads to inhibition of coﬁlin which
is associated with actin-ﬁlament turnover403.
RhoGTPase-mediated mDia activation has a promoting eﬀect on cytoskeleton rear-
rangement by stabilising microtubules404.
In addition to integrins, GPCRs and RTKs have the ability to activate RhoGT-
Pases405,406. Furthermore, GPCRs can also activate G-protein subunits such as G
12/13 regulating RhoGEFs407. These subunits modulate the turnover of membrane
ruﬄes upon growth factor induction408. The Swiss 3T3 cell line has shown stress
ﬁbre formation and FA assembly prior to G 12/13 stimulation via the RhoGTPase
pathway. Overexpression of β1-integrin enhances Rac activity and lamellipodia
formation whereas the overexpression of β3-integrins showed an increase in Rho
activity and stress ﬁbre formation409. More than half of the 58 known RTKs
activate at least one Rho family member. Several RTKs are able to activate the
same Rho GEFs, but it is also possible that a single RTK activates diﬀerent Rho
GEFs (16 in total) which increases the complexity of RTK signalling.
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1.9.5 Focal adhesions and their turnover
Migration is dependent on the generation of short-term self-assembling complexe
named focal adhesions (FA). FA assemble around the cytoplasmic domains of inte-
grins that connect the ECM to the cytoskeleton and other intracellular molecules.
FA are made of from a variety of proteins with wide ranging functions. They
comprise not only integrins as ECM adhesion receptors, but also kinases like Src
and FAK, and adaptor proteins such as paxillin which contributes to intracellular
complex formation. Together they orchestrate the rearrangement of the actin
cytokeleton with eﬀects on cellular behaviour such as migration and locomotion. A
simpliﬁed illustration of a FA complex is shown in ﬁgure 1.25. FA dynamics are
mainly regulated by phosphorylation events and changes in actomyosin-generated
tension410.
The assembly of FA is mostly introduced by outside activation mediated by inte-
grins. A key molecule regulating integrin activation is talin. The function of it is
to provide a link between the cytoplasmic tail of integrins and actin411. Moreover,
upon binding of talin to the cytoplasmic tail of the β-subunit talin triggers a
conformational rearrangement of the integrin ECD enhancing their aﬃnity412. In
a specialised domain of talin a phosphotyrosine-binding motif was found which
was able to activate αIIbβ3 integrin412. This phosphotyrosine-binding motif is also
found in other proteins which interact with integrins. However, this is not suﬃcient
for integrin activation highlighting the crucial role for talin. The talin-binding
site in β-integrin tails overlap with a ﬁlamin-binding site413. Filmanins are actin
cross-linking proteins connecting the cytoskeleton to cell membrane receptors (not
shown in ﬁgure 1.25).
Another interacting protein found to bind the ICD of β1-integrin is the integrin-
linked kinase (ILK)414. It is found in a multiprotein complex and functions as a
scaﬀolding-protein. The localisation of ILK to FAs is regulated by particularly
interesting cysteine- and histidine-rich protein (PINCH)415. ILK also interacts
with the actin-binding proteins α-parvin (aﬃxin)416, β-parvin (CH-ILKBP)417
and the adaptor protein paxillin418. The interaction with paxillin regulates the
localisation of ILK to FAs418. The kinase activity of ILK is negatively controlled
by the Ser/Thr phosphatase ILK-associated phosphatase (ILKAP)419. ILK is
positively regulated in a PI3K dependent manner since it was bound and activated
by PIP3
420. Activated ILK in turn phosphorylates the downstream targets of PI3K
Akt and glycogen synthase kinase-3 (GSK3). In contrast, PIP3 inhibition by PTEN
decreased the activity of ILK421. Biochemical experiments demonstrated that ILK
is able to form a PINCH mediated complex with Nck-2 which co-localised with
α5β1-integrin in periperhal ruﬄes415.
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FAK is a cytosolic protein kinase and a key regulator of FA that functions as
signalling molecule and adaptor protein. FAK binds to HDRK-motifs in β1- and
β5-subunits and to adjacent sequences422. Autophosphorylation of FAK at Y397
leads to recruitment of Src, which in turn phosphorylates Y576/577 and Y925
residues in FAK. FAK is then able to recruit various signalling molecules regulating
FA assembly and disassembly222,423. It can also recruit talin to nascent adhesions
independently of talin-β1-interaction424. FAK signalling also stimulates the
association with talin and promotes PIP2 production at FA
425. Another member of
the FAK family is the proline-rich tyrosine kinase 2 (Pyk2). Its activation is similar
to FAK since it is phosphorylated at a tyrosine (Y402). Upon phosphorylation a
binding site for the SH2 domain of Src is exposed426. Despite their common way of
activation the response to α5β1 mediated ﬁbronectin binding is diﬀerent. Pyk2 is
only activated weakly while FAK is stimulated strongly426.
Src is a non-receptor tyrosine kinase. It is an important signalling molecule since
FAK phosphorylation by Src is essential for FA turnover423. In Src-deﬁcient
ﬁbroblasts cell-spreading on VN, but not on FN is inhibited427. Co-localisation of
Src with the αv-subunit was found, but not with the β1-chain427. The C-terminal
Src kinase (Csk) (not shown in ﬁgure 1.25) is a cytosolic tyrosine kinase which
negatively regulates Src activity by phosphorylating the regulatory tyrosine residue
Y527, which is conserved in all Src family kinases428–430. Csk translocates to FAs
when Src kinases are activated431. Fibroblasts expressing FA-targeted Csk lost
integrin-mediated adhesion due to reduced Src activity430.
The deleted in liver cancer 1 (DLC1) is a potential tumour suppressor gene encoding
a RhoGAP which co-localises with vinculin and tensin2 at FA432. It negatively
controls the Rho/ROCK/MLC pathway and its presence in FA was demonstrated
in many cell types433.
Tensins belong to the family of FA proteins and are able to bind to the ICD of
the integrin β-chains via its PTB domain434. It also contains a SH2 domain at the
C-terminus and share sequence homology with PTEN. Tensins contribute not only
to FA assembly and to actin cytoskeleon organisation435,436, but also play a role in
signal transduction, for example by activating the JNK and p38 pathway437.
Paxillin is a multi-domain scaﬀolding protein playing an essential role in FA
dynamics. Upon growth factor response or adhesion stimuli, paxillin becomes
phosphorylated by several kinases. This generates further bindings sites for other
FA proteins. Thus it controls, together with other structural and regulatory
proteins, gene expression, cytoskeletal reorganisation and cell adhesion438.
Caveolins are the primary structural proteins of caveolae. Caveolae are invaginations
in the cell membrane participating in signal transduction and cellular transport439.
The caveolin family comprises three members Caveolin1 (Cav1), Cav2 and Cav3
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whereas Cav1 was found in FAs where it serves as scaﬀolding protein. Rac1 drives
the accumulation of Cav1 to FAs while its translocation requires phosphorylation
at Y14 by Src440,441.
Figure 1.25: Illustration of a focal adhesion complex. FA complexes are formed in which het-
erodimerc integrins link the ECM to cytoplasmic proteins. Cascades of phosphorylation and de-
phosphorylation events regulate cellular processes. Adapted from Yam et al., Role and significance
of focal adhesion proteins in hepatocellular carcinoma, Journal of Gastroenterology and Hepatology,
2009.
FA are generally short lived, and their continuous assembly and disassem-
bly is necessary to assure cell movement. Nocodazole-induced microtubule-
depolimerisation is a common way to address FA turnover. It is an anti-mitotic
drug inhibiting microtuble assembly by binding to the heterodimer tubulin. The
CHAPTER 1. GENERAL INTRODUCTION 85
aﬃnity of nocodazole to interact with tubulin varies, depending to which isotype of
tubulin it binds to373. Serum-starved cells possess only few focal adhesions. Noco-
dazole treatment induces stress ﬁbre formation and FA assembly via activation of
Rho GTPase442. The regrowth of microtubles after washing out nocodazole lead
to disassembly of FA which is independent of Rho and Rac, but depending on dy-
namin and FAK443. This shows that FA disassembly is not just the reversal of FA
formation, but an independent complex mechanism. Later it was found that this
mechanism is also dependent on clathrin.
1.10 Rationale, hypothesis and aims of the
project
Previous research on ADAM15 has predominantly focused on the most abundant
and ubiquitously expressed isoform, ADAM15 A, demonstrating the importance of
ADAM15 in a variety of processes that regulate cell behaviour in normal, as well as
pathological conditions. However, recent ﬁndings show that ADAM15 is subjected
to alternative splicing that regulates the presence of speciﬁc protein-protein interac-
tion motifs within the ADAM15 ICD. The expression of speciﬁc ADAM15 isoforms
correlates with diﬀerential prognosis in breast cancer survival, suggesting that these
isoform-speciﬁc intracellular interactions regulate ADAM15 functions. This was
illustrated by the interplay of ADAM15 B and Src tyrosine kinase, where Src as-
sociates with ADAM15 B ICD, phosphorylates a critical tyrosine within the ICD,
leading to enhanced shedding of transmembrane receptor FGFR2IIIb by ADAM15
B. Hence, the principal hypothesis we wanted to test was the following: ADAM15
isoforms have similar, as well as distinct functions that may aﬀect multiple aspects
of cell behaviour in isoform-speciﬁc unique ways. To test the hypothesis, the project
consisted of the following major aims:
1. To generate and characterise an isogenic cell panel expressing individual wild
type and corresponding catalytically inactive ADAM15 isoforms.
2. To compare and contrast the role of individual ADAM15 isoforms in regulating
cell-cell adhesion.
3. To compare and contrast the role of individual ADAM15 isoforms in regulating
cell-ECM interactions.
Chapter 2
General Methodology
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2.1 Statistical analysis
Throughout this thesis the signiﬁcance for various experiments is calculated with
GraphPad Prism 6.01. If not stated otherwise one- or two-way analysis of variance
(ANOVA) were performed. Conﬁdence intervals are as follows: ∗ = p ≦ 0.05; ∗∗ =
p ≦ 0.01; ∗ ∗ ∗ = p ≦ 0.001; ∗ ∗ ∗∗ = p ≦ 0.0001. The error bars in bar charts
indicate the standard deviation.
2.2 Cell Culture
2.2.1 Cancer cell lines
The work in this project is based on cancer cell lines, primarily on MDA-MB-231.
Throughout the thesis other cell lines appear which were used as controls. In the
following subsections they are brieﬂy described.
2.2.1.1 MDA-MB-231
MDA-MB-231 is a breast cancer cell line derived from a 51 year old Caucasian
woman suﬀering from an adenocarcinoma. MDA-MB-231 are of epithelial origin
and were derived from pleural eﬀusion (metastatic site). Although they are derived
from epithelial tissue they demonstrate mesenchymal morphology which is due to
epithelial-mesenchymal-transition (EMT) . The tumour origin was the mammary
gland. Karyotyping shows aneuploidity with 52 to 68 chromosomes (modal number
= 64), but lack chromosome 8 and 15444,445. MDA-MB-231 cells are triple-negative,
which means they are lacking the expression of ER, PR and Her2/Neu. MDA-MB-
231 cells are highly invasive446 and tumourigenic447.
2.2.1.2 T47D
T47D were used as a control cell line in some experiments due to their naturally
high expression of ADAM15 and claudin1 and their propensity to form tight junc-
tions. They were removed from a metastatic site, the pleural eﬀusion. They have
been derived from a 54 year old Caucasian female suﬀering from ductal carcinoma.
T47D are true epithelial cells expressing high amounts of E-cadherin. They have a
modal chromosome number of 65 while lacking chromosome 7,9 and 10. Contrary,
chromosome 11 is generally present in 4 copies444. T47D cells express ER and PR,
but lack HER2/Neu446.
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2.2.1.3 A431
A431 were also used as a control cell line due to its high expression of epithelial
markers. These cells were derived from a 85 year old female suﬀering from epider-
moid carcinoma. The cell line was extracted from the skin and shows clear epithelial
morphology. They have a modal chromosome number of 74444.
2.2.2 Generation of an isogenic cell panel expressing
ADAM15 WT and E349A isoforms in MDA-MB-231
cells
The construction of pcDNA5/FRT/ADAM15 isoform plasmids and the generation
of all cell lines were performed by Dr Zaruhi Poghosyan.
The generation of a isogenic cell panel expressing ADAM15 isoforms, as described
in table 1.5 and ﬁgure 1.10, was achieved by using the Invitrogen Flp-In
TM
sys-
tem. An adapted scheme of the transfection strategy is depicted in ﬁgure 2.1. The
ScaI linearised pFRT/lacZeo plasmid was introduced ﬁrst into original MDA-MB-
231 cells, according to manufcaturer’s protocol, using Lipofectamine 2000. The
pFRT/lacZeo vector introduces the Flp recombination target (FRT) site and a
Zeocin resistance gene. Zeocin-resistant clones were isolated and expanded followed
by screening for single integration sites (see section 3.2 for detailed validation). A
validated clone was used to co-transfect pOG44, expressing Flp recombinase, and
pcDNA5/FRT/ADAM15 constructs. Clones were picked, selected and expanded in
Hygromycin B (450 μg/mL) containing growth medium.
In order to generate proteolytic inactive variants the zinc-binding sequence
HEXGHXXGXXHD-sequence was mutated as shown by Maretzky et al.200. Mu-
tations are introduced to change the acidic glutamic acid (E), which is negatively
charged, to an aliphatic alanine of neutral charge. The conversion of the amino acids
prevents zinc-binding leading to a non-functioning MP-domain.
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Figure 2.1: Generation of isogenic constitutive ADAM15 isoform expressing MDA-MB-231 breast
cancer cells using the Invitrogen Flp-In
TM
system as described in table 1.5 and figure 1.10. Image
was taken and modified from Invitrogen.
2.2.3 Maintaining cell lines in culture
All cell lines were kept in Dulbecco’s modiﬁed eagle medium (DMEM) supple-
mented with 10% (v/v) fetal bovine serum (FBS), 100 units/mL Penicillin, 100
μg/mL Streptomycin and 2 mM L-Glutamine (L-Glu). In other sections the term
“normal or complete growth medium” is used to refer to this media composition.
Cells were maintained in a humidiﬁed incubator at 37◦C with 5% CO2. MDA-MB-
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231/FRT cells were cultured with additionally 100 μg/mL Zeocin, MDA-MB-231
with expressing ADAM15 WT or E349A constructs were grown with 450 μg/mL
Hygromycin. Short hairpin RNA (shRNA) expressing cell lines were maintained
in 1 μg/mL Puromycin which is added to their normal media composition. Cells
were passaged regularly, usually twice a week. Depending on the cell line, conﬂuent
dishes were split with ratios between 1 : 10 and 1 : 4.
2.2.4 Freezing and thawing of human cell lines
Cells were expanded in either T75 (75cm2 surface area) or T175 (175cm2 surface
ﬂasks). As soon as they were conﬂuent cells were trypsinised and spun down. Af-
terwards they were resuspended in medium and mixed 1:1 with freezing medium.
The suspension was then immediately distributed to cryo vials with 1 mL of total
volume. A conﬂuent T75 ﬂask was split between four cryo vials whereas a T175
was split into ten vials. Subsequently the vials were cooled down in a Mr. Frosty
freezing container at -80◦C. The freezing container is the preferred method since it
allows optimal cool down rate of -1◦C/min. For long term storage the cryo vials
were kept in liquid nitrogen.
Frozen cells were thawed by immersing them halfway in 37◦C warm water bath to
assure rapid thawing. As soon as the suspension was liqueﬁed cells were transferred
into a falcon tube with 10 mL of medium to dilute the DMSO, reducing the toxicity
to the cells. The cells were centrifuged for 5 minutes (500 x g) and resuspended in
fresh medium (including selection antibiotic if required) and cultured in a T25 ﬂask.
2.3 MTS proliferation assay
Cell lines were seeded into 96-well plates with 3x103 cells per well in 100 μL volume.
They were plated as triplicates into four plates, one for each time point (24h, 48h,
72h and 96h). After each time point 20 μL of CellTiter 96 R©AQueous One Solu-
tion was added to each well and incubated for 4h at 37◦C. After incubation the
absorbance was immediately measured at 450 nm.
For analysis the blank was subtracted from the reading of the samples. The mea-
surement after 24h was considered as 1.
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2.4 Determination of cell size
2.4.1 Microscopic determination of cell size
In order to quantify the area which is covered by the cell, phase-contrast images
were taken at 200 x magniﬁcation and quantiﬁed with ImageJ. An image of a corner
square of the Neubauer counting chamber was used to set the scale since the dimen-
sion are known (250 μm2). For each cell line ﬁve images, during exponential growth
phase, of random positions were taken using an EVOS XL core imaging system
(ThermoScientiﬁc). This was done for three diﬀerent passages to achieve 15 images.
For each picture ten representative cells were chosen and the cell area was outlined
and measured. This led to 150 measured cells for each cell line. For statistical
analysis Bartlett’s test for equal variances was used to determine the signiﬁcance.
As follow-up test Dunnett’s multiple comparison test was used. The results are
presented as a box-and-whiskers plot.
2.4.2 Flow cytometric analysis of cell size
The forward scatter (FSC) of ﬂow cytometrical analysis gives an indication about
the size of cells. Analysis was performed using an Accuri C6 ﬂow cytometre.
A fraction of trypsinised and resuspended cells was stained with propidium iodide
(PI) at a ﬁnal concentration of 10 μg/mL, to exclude dead cells, and measured
subsequently.
For analysis FlowJo 10.0.7 R2 was used. The FSC-A (Area) was plotted against
the FSC-H (Height) to discriminate doublets. The subpopulation was then used in
a histogram with PI to distinguish live and dead cells. The ﬂuorescence intensity of
dead cells is usually 50-fold greater compared to living cells, thus the peak of the
living population is gated. The new gate was then used in another histogram with
FSC-A to determine the cell size. An example of the gating strategy is shown in
ﬁgure 2.2.
The median was automatically calculated by FlowJo. For comparison, a scatter plot
was generated and one-way ANOVA was performed.
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Figure 2.2: Gating strategy for determination of the cell size using flow cyotmetry. (a) The
SSC area was plotted against the FSC area to exclude cell debris. (b) To discriminate doublets
the subpopulation was used. The FSC height was plotted against the FSC area (c) The resulting
subpopulation was then displayed as a histogram showing PI staining on the x-axis. Autofluorescent
cells show up around 103 whereas dead cells display at 106. (d) The live population is than plotted
as FSC-A-Histogram in which FlowJo can automatically determine the median value.
2.5 Demethylation assay
4 x 106 cells were seeded into 35 mm dishes using medium supplemented with FBS,
P/S and L-Glu. On the following day two dishes per cell line were treated with
33.3 μM Decitabine (5-aza-2’-deoxycytidine). After 24h Decitabine was replaced
with a higher concentration of 50 μM. On the following morning the treatment was
repeated with 50 μM Decitabine. In the evening, one dish containing Decitabine was
replaced with fresh Decitabine in combination with 500 nM Trichostatin A (TSA) .
After overnight incubation the cells were processed as described in section 2.7. The
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western blot was probed with V5 to visualise ADAM15 isoform expression.
2.6 Wound healing assay
Cells were seeded into 6 cm dishes in normal growth medium and grown until con-
ﬂuence. Seven parallel wounds were introduced with a white tip (0.5 μL - 10 μL).
Detached cells were removed by swirling followed by aspiration. The medium was
temporarily replaced by OptiMEM during the acquisition of the images at time
point 0h. The pictures were taken with 100 x magniﬁcation. Afterwards the cells
were fed with normal growth medium and consecutive images were acquired after 8,
24, 32 and 48h using an EVOS XL core cell imaging system (ThermoScientiﬁc).
Analyis was carried out with a modiﬁed version of the MRI wound healing tool in
ImageJ. The tool only works with 8-bit images which need to be manually converted.
The modiﬁcation was done by adding the appropriate command line to automatise
this step. Three wounds with 640,000 ± 75,000 μm2 were used for further analysis.
The 0h time points were normalised to 100% and the wound closure was calculated
using Microsoft Excel. Statistical analysis was carried out with 2-way ANOVA and
Bonferroni post-test in GraphPad Prism 5.01. ADAM15 isoform expressing cells
were compared to to the parental cell line MDA-MB-231/FRT.
2.7 Protein analysis
2.7.1 Subcellular fractionation
Cells were grown until conﬂuence and harvested by trypsinisation, followed by inac-
tivation with complete growth medium. The cells were counted using the Neubauer
counting chamber and adjusted to 2.5 x 106 (which equals a packed volume of 20 μL
in a 1.5 mL tube). Cells were centrifuged and resuspended in ice cold PBS. One vial
with 2.5 x 106 cells was lysed with radioimmunoprecipitation assay (RIPA) buﬀer
as described in section 2.7.2. The vial for subcellular fractionation was processed
according to the manufacturer’s protocol. However, following changes were made
to achieve cleaner separation: Incubation times were doubled and the pellets were
washed twice with ice cold PBS after transferring the extract, before adding the
consecutive compartment lysis buﬀer.
Fractions were subsequently stored in -80◦C until further processing. Prior to west-
ern blot analysis samples were quantiﬁed according to the manufacturer’s protocol
of the GLISA kit to balance deviation in protein concentration during extraction.
For western blot analysis 10 μg of total lysate as well as cytoplasmic and membrane
extract were loaded. The amount of used nuclear fraction was 5 μg. Samples were
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diluted with RIPA buﬀer prior to the addition of 6 x loading dye. As controls,
antibodies against heat shock protein 90 (HSP90) were used as cytoplasmic con-
trol. Antibodies against R-cadherin were used as membrane control and antibodies
against Lamin A/C were used as nuclear control.
2.7.2 Lysate preparation
Cells were grown in various sized petri-dishes and harvested at diﬀerent stages of
conﬂuences depending on the experiment. After seeding cells were cultured for at
least 48h prior to collection. Dishes were placed on ice and washed twice with PBS.
Snippets of ﬁlter paper were used to drain surplus washing buﬀer. An appropriate
volume of RIPA lysis buﬀer (table 2.1) was applied to the dish and incubated for 5
min on ice. A rubber policeman was used to scrape the cells from the surface. The
cell suspension was transferred to a new pre-chilled tube and incubated another
10 min on ice. Subsequently, the lysate was sonicated three times for 10 sec each
with 30 sec of cooling-down phase between pulses. Sonicated samples were store at
-80◦C until further processing.
200 mM Phenanthroline
– 901.05 mg 1,10-Phenanthroline
Adjust to 2 mL with Methanol
Store aliquots of 1 mL at -20◦C
20x Phosphatase inhibitor
– 2 tablets PhosSTOP per
1 mL MilliQ water
Store aliquots of 200 μL at -20◦C
25x Proteinase inhibitor
– 1 tablet cOmplete
proteinase inhibitor
per 2 mL MilliQ water
Store aliquots of 200 μL at -20◦C
Lysis buffer
– RIPA buﬀer (purchased)
– 1:20 Phosphotase inhibitor
– 1:20 Phenanthroline (10 mM)
– 1:25 Proteinase inhibitor
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Table 2.1: Volumes of lysis buffer in different dishes and confluence
Confluence 35 mm 60 mm 100 mm 150 mm
50% 50 μL 150 μL 200 μL 500 μL
70% 100 μL 200 μL 300 μL 750 μL
100% 150 μL 250 μL 350 μL 1000 μL
150% 200 μL 300 μL 400 μL 1200 μL
2.7.3 Protein quantification
To enable comparison of protein samples, it is crucial to determine the protein
concentration. For this purpose the bicinchoninic acid (BCA) protein assay kit
was used (Pierce). Lysates were thawed on ice and spun down for 15 minutes at
full speed (21,100 x g) at 4◦C to remove cell debris. The supernatant was then
transferred into pre-chilled 1.5 mL tubes. The quantiﬁcation was carried out in a
96-well plate according to the manufacturer’s manual. The bovine serum albumine
(BSA) standards were diluted 1 : 10 in the lysis buﬀer. In total nine standards (0-2
mg/mL) were used in duplicates. Samples were used in triplicates to minimise minor
deviation through pipetting. The plate was incubated for 2 h in the incubator. The
ideal wavelength to measure the absorbance of the BCA assay is at 562 nm.
Figure 2.3: Almost ideal result of a standard curve for the determination of protein concentrations
However, the plate reader did not have the correct ﬁlter thus it was measured
at 595 nm. According to the manufacturer this does not cause a problem if the
incubation time is increased to 2h (compared to 30 min normally). A standard curve
was plotted using cubic regression (ax3 + bx2 + cx + d). The sample concentration
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was calculated accordingly. Using a polynomial of degree three the formula can give
a very precise standard curve as seen in ﬁgure 2.3 which results in a more accurate
determination of protein concentration. This should contribute to the quality of
further processed experiments such as sodium dodecyl suldate polyacrylamid gel
electrophoresis (SDS-PAGE) which is described in section 2.7.6.
2.7.4 Immunoprecipitation (IP)
Cells were seeded in either 10 cm or 15 cm dishes using complete growth medium and
grown until they were conﬂuent. Lysis and quantiﬁcation were done as described
in sections 2.7.2 and 2.7.3. Depending on the IP either Sepharose G beads or α-V5
aﬃnity gel was used. For Sepharose G 20 μL of slurry per IP was transferred into
a new tube and washed thrice with PBS followed by 1 min centrifugation with 500
x g. Between 500-1,000 μg protein was diluted to a volume of 500 μL. 10 μL of
the washed slurry was added to the diluted protein and incubated for 1h at 4◦C on
a rotary wheel to pre-clear the lysate. The remaining beads were resuspended in
3% (w/v) BSA/PBS to block unspeciﬁc binding. After incubation the vials were
spun down for 1 min at 500 x g. The pre-cleared supernatant was transferred into
a new tube. The BSA/PBS was aspirated from the remaining beads, resuspended
in RIPA buﬀer and shared between the supernatants (equivalent of 10 μL slurry per
IP). The antibody of interest was then added. All tubes were sealed with paraﬁlm
and incubated overnight on the rotary wheel at 4◦C. After incubation, the IPs were
centrifuged for 1 min at 500 x g and the supernatant was aspirated. The beads were
washed thrice with RIPA lysis buﬀer. After the last washing step approximately 25
μL of bed volume was left behind and 5 μL 6x loading dye was added. All IPs were
boiled at 95◦C for 5 min followed by SDS-PAGE as described in subsection 2.7.6.
For V5 IPs α-V5 aﬃnity gel was used which is directly conjugted to V5 antibodies.
Therefore, pre-clearing and blocking steps are omitted. Due to the smaller size of
the beads centrifugation steps were carried out at full speed (21,100 x g). All other
steps remained constant.
2.7.5 Preparation of Polyacrylamide (PAA) gels
PAA gels were prepared with buﬀers described in section 2.7.5.1 and reagents listed
in section 9.3.2. First, a running gel was prepared from the recipe in table 2.2 and
topped up with isopropanol. After 30 min the isopropanol was removed and the
stacking gel solution was applied (table 2.3). PAA gels were prepared one day in
advance and stored for up to a week, wrapped in moist tissue and cling ﬁlm, at 4◦C.
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Table 2.2: Recipe for polyacrylamide running gels
7% 8% 10% 12% 17%
H2O 5.75 mL 5.5 mL 5.0 mL 4.5 mL 3.2 mL
1.5 M Tris pH 8.8 2.5 mL 2.5 mL 2.5 mL 2.5 mL 2.5 mL
40% Acryl:Bis 29:1 1.75 mL 2.0 mL 2.5 mL 3.0 mL 4.3 mL
10% SDS 100 μL 100 μL 100 μL 100 μL 100 μL
10% APS 100 μL 100 μL 100 μL 100 μL 100 μL
TEMED 10 μL 10 μL 10 μL 10 μL 10 μL
Table 2.3: Recipe for polyacrylamide stacking gel
4%
H2O 6.5 mL
0.5 M Tris pH 6.8 2.5 mL
40% Acryl:Bis 29:1 1.0 mL
10% SDS 100 μL
10% APS 100 μL
TEMED 10 μL
2.7.5.1 Reagents for Polyacrylamide gels
This subsection lists all reagents used to make PAA gels.
0.5 M Tris pH 6.8
– 30.29 g Tris-base
Adjust pH to 6.8 with HCl
Adjust to 500 mL with MilliQ water
Store aliquots of 50 mL at -20◦C
10% (w/v) APS
– 5 g Ammonium persulfate
Adjust to 50 mL with MilliQ water
Store aliquots of 1 mL at -20◦C
1.5 M Tris pH 8.8
– 90.86 g Tris-base
Adjust pH to 8.8 with HCl
Adjust to 500 mL with MilliQ water
Store aliquots of 50 mL at -20◦C
10% (v/v) SDS solution
– 50 mL of 20% SDS solution
Add 50 mL of MilliQ water
Store at room temperature
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2.7.6 SDS-PAGE
Quantiﬁed protein lysates were adjusted to 2 μg/μL with lysis buﬀer and 6 x loading
dye and boiled at 95◦C for 5 min. Samples were then mixed by ﬂicking and cen-
trifuged with full speed (21,100 x g) at RT for 1 min. 10 μL of the protein mixture
(20 μg) was loaded onto a PAA gel ﬁlled with 1 x SDS running buﬀer and run at 90
volts (V) until the separation within the running gels started. The voltage was then
increased to 130 V and stopped as soon as the running front reached the bottom of
the gel. The gel was subsequently transferred onto polyvinylidene ﬂuoride (PVDF)
membrane as described in section 2.7.7.
2.7.6.1 SDS-PAGE buffers and solutions
This subsection lists all buﬀers and solution which were used for SDS-PAGE.
6x Protein loading dye
– 300 mM of 0.5 M Tris pH 6.8
(6 mL)
– 0.05% (v/v) of 1% (w/v)
Bromophenol blue solution
(500 μL)
– 20% (v/v) of 99% Glycerol
(2 mL)
– 1.5% (v/v) of 10% (v/v) SDS
solution (1.5 mL)
– 625 μL β-Mercaptoethanol
Store aliquots of 300 μL at -20◦C
10x SDS-PAGE Running buffer
– 250 mM Tris-Base (30.28 g)
– 1.92 M Glycine (144.13 g)
– 1% (v/v) of 20% (v/v) SDS
solution (50 mL)
Adjust to 1 L with MilliQ water
1x SDS-PAGE Running buffer
– 100 mL 10x SDS-PAGE
running buﬀer
– 900 mL MilliQ water
2.7.7 Western blot
PVDF membranes were activated in methanol, rinsed with MilliQ water and equi-
librated in anode I buﬀer for at least 20 min. PAA gels were rinsed in cathode
buﬀer. The blotting sandwich was assembled as follows (from bottom to top): three
sheets of ﬁlter paper soaked with anode II buﬀer, three sheets of ﬁlter paper soaked
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with anode I buﬀer, equilibrated membrane, PAA gel and six sheets of ﬁlter pa-
per soaked with cathode buﬀer. The lid of the Turboblot bay was closed carefully
and run at 25 V and 1 A for 30 min. The membrane was blocked in either 5%
(w/v) semi-skimmed milk or 5% BSA (w/v), if phospho-antibodies were used, in
tris buﬀered saline with 0.1% (v/v) Tween-20 (TBST) at RT for 1h. Since primary
antibodies were always diluted in 5% BSA (w/v) in TBST, milk blocked membranes
were rinsed several times in TBST, whereas BSA blocked membranes were not prior
to primary antibody incubation.
A list of all antibodies used for western blots in this project are shown in table 2.4.
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2.7.7.1 Western blot buffers and solutions
This subsection lists all buﬀers and solution which were used for western blotting.
Anode I buffer
– 25 mM Tris-Base (3.03 g)
– 20% (v/v) Methanol
(200 mL)
Adjust to 1 L with MilliQ water
Anode II buffer
– 300 mM Tris-Base (36.34 g)
– 20% Methanol (200 mL)
Adjust to 1 L with MilliQ water
Cathode buffer
– 25 mM Tris-Base (3.03 g)
– 25 mM 6-Aminohexanoic
acid (5.24 g)
– 5% Methanol (50 mL)
– 0.05% SDS (2.5 mL of 10%
SDS solution)
Adjust to 1 L with MilliQ water
10x TBS
– 200 mM Tris-Base (24.2 g)
– 150 mM NaCl (88.0 g)
Adjust pH to 7.6 with HCl and
ﬁll up to 1 L with MilliQ water
1x TBST
– 10% (v/v) 10x TBS (100 mL)
– 90% (v/v) MilliQ water
(900 mL)
– 0.1% (v/v) Tween-20 (1 mL)
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2.7.7.2 Antibodies for western blot
Table 2.4: Detailed information about antibodies used for western blotting
Antibody Supplier
Catalogue
number
Source
Detected
band(s)
Primary
antibody
dilution
Secondary
antibody
dilution
Actin Sigma A2066 Rabbit 42 kDa 1:4,000 1:5,000
ADAM15 (ICD) Abcam ab39159 Rabbit 115 kDa 1:2,000 1:8,000
β1-Integrin Abcam ab52971 Rabbit 140 kDa 1:10,000 1:10,000
β3-Integrin Santa Cruz sc-14009 Rabbit 125 kDa 1:1,000 1:4,000
Claudin1 Invitrogen 37-4900 Mouse 22 kDa 1:1,000 1:5,000
E-cadherin CST #3195 Rabbit 135 kDa 1:1.000 1:4.000
FAM190A Santa Cruz sc-246676 Goat
100 kDa
74 kDa
1:500 1:2,000
Lamin A/C CST #4777 Mouse
74 kDa
63 kDa
1:10,000 1:10,000
HSP90 CST #4874 Rabbit 90 kDa 1:1,000 1:4,000
V5 Sigma 46-0705 Mouse 115 kDa 1:10,000 1:10,000
OB-cadherin CST #4442 Rabbit 120 kDa 1:1,000 1:4,000
Occludin Invitrogen 71-1500 Rabbit
79 kDa
65 kDa
1:3,000 1:8,000
pS6 (S235/236) CST #2211 Rabbit 32 kDa 1:1,000 1:2,000
R-cadherin GeneTex GTX62825 Rabbit 100 kDa 1:50,000 1:10,000
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Table 2.4 Continued: Detailed information about antibodies used for western blotting
Antibody Supplier
Catalogue
number
Source
Detected
band(s)
Primary
antibody
dilution
Secondary
antibody
dilution
Slug CST #9585 Rabbit 30 kDa 1:1,000 1:5,000
V5 Invitrogen 46-0705 Mouse
115 kDa
(ADAM15
isoforms)
1:10,000 1:10,000
Vimentin CST #5741 Rabbit 57 kDa 1:5,000 1:15,000
ZO1 CST #8193 Rabbit 220 kDa 1:1,000 1:4,000
ZO2 CST #2847 Rabbit 150 kDa 1:1,000 1:5,000
Goat Santa Cruz sc-2020 Donkey - - -
Mouse GE Healthcare NA-931 Sheep - - -
Rabbit GE Healthcare NA-934 Donkey - - -
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2.7.7.3 Densitometry for western blot analysis
The ﬁlms of developed membranes were scanned at 600 dpi. ImageJ was used to
carry out densitometrical analysis. Each band was outlined with the rectangular
selection tool. The ﬁrst band was set as ﬁrst lane (Analyze → Gels → Select First
Lane). The rectangular selection box is then dragged over the second band and
set as next lane (Analyze → Gels → Select Next Lane). As soon as all bands are
marked with boxes the peaks could be plotted (Analyze → Gels → Plot Lanes).
The baseline under the peak was then continued with the straight line tool to close
the peak area. The wand (tracing) tool is used to select the inside of the peak which
displays the area in the regions of interest (ROI) manager in square pixel. The bands
of the protein of interest was then normalised to the actin control and compared.
2.8 Inhibitor treatments
2.8.1 Treatments
Cells were seeded into 6 cm dishes in duplicates. After 72h, at approximately 50%
conﬂuence, cells were treated with the corresponding inhibitors. Dilutions were
made in OptiMEM if not stated otherwise. Total volume of the medium was 2 mL
for incubation overnight. The application volume of the inhibitors was equalised to
2 μL per dish. If not stated otherwise, the reconstitution reagent was DMSO. An
untreated and vehicle control were included.
2.8.2 Inhibitors of various pathway
In this section a variety of inhibitors (table 2.5) were used targeting several pathways.
The aim was to perturb the expression of claudin1 to identify which pathway(s) are
involved in ADAM15-mediated upregulation. The origin and mode of action will be
explained for those inhibitors which helped identifying the underlying pathway of
claudin1 regulation.
Table 2.5: Inhibitors used in this project.
Inhibitor
Com-
pany
Cat.
no.
Stock
conc.
Final
conc.
Target
Bim1 Millipore 203290 1 mM 1 μM
Novel and
classical PKC
FLLL31 Sigma F9057 5 mM 5 μM STAT3
Geﬁtinib see footnote1 500 μM 500 nM EGFR
1Kind gift from Stephen Hiscox
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Table 2.5 Continued: Inhibitors used in this project.
Inhibitor
Com-
pany
Cat.
no.
Stock
conc.
Final
conc.
Target
Go¨6976
Merck/
Millipore
365250 1 mM 1 μM
Ca2+ – dependent
PKCα and β
Ku0063794 Sigma SML0382 1 mM 1 μM mTOR
LY294002 CST #9901 50 mM 50 μM PI3K
PD98059 Sigma P215 10 mM 10 μM MAPK
PI-103
Selleck-
chem
S1038 1 mM 1 μM PI3K
PP2 Sigma P0042 100 μM 100 nM Src family kinase
Rapamycin
Merck/
Millipore
553210 100 μM 100 nM mTOR
Rottlerin
Merck/
Millipore
557370 5 mM 5 μM PKCδ
SB203580 Sigma S8307 10 mM 10 μM p38MAPK
In the following section I am going to elaborate on the inhibitors which were of
particular interest.
2.8.2.1 PI3K inhibitors
In this chapter two inhibitors were used to target the PI3K pathway - LY294002
and PI-103.
LY294002 was, along wortmannin, one of the ﬁrst PI3K inhibitors. Since it binds
to all class I variants it belongs to the category of “pan-inhibitors”. It is a synthetic
compound based on the ﬂavonoid quercetin448. LY294002 is widely used, due to its
higher speciﬁcity and stability in solution, compared to wortmannin448. Although,
both mode of action is to target the ATP binding pocket within the catalytic domain
of PI3K, LY294002 is a reversible inhibitor while wortmannin is not.
LY294002 and wortmannin cannot be used in therapeutics, since they do not dis-
tinguish between isoforms. Studies show that PI3K isoforms possess non redundant
functions downstream of diﬀerent receptors449. Therefore, there is still ongoing need
for inhibitors which speciﬁcally inhibit each isoform.
One of the newer and more selective inhibitors is the synthetic pyridinylfuranopy-
rimidine based inhibitor PI-103. It selectively inhibits the p110/α/β/γ/δ subunits
in varying concentrations450. As LY294002 and wortmannin, PI-103 also competes
for ATP and interacts with the ATP binding pocket of the p110 subunit451.
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2.8.2.2 Mammalian target of Rapamycin (mTOR) inhibitors
In this chapter two inhibitors were used to target the mTOR pathway - Rapamycin
and Ku0063794.
Rapamycin was the ﬁrst drug identiﬁed which targets mTOR. That is the reason why
mTOR is named the mammalian target of rapamycin. Rapamycin was discovered in
soil samples from the island of Rapa Nui452 (Easter Islands) and is produced by the
bacterium Streptomyces hygroscopicus. It belongs to the group of macrolides and
has a immunosuppressant mode of action. Its inhibitory behaviour results from the
ability to bind FK506-binding protein 12 (FKBP12), a small protein which specif-
ically associates with mTOR close to the kinase domain. Upon binding a complex
is formed thus ceasing its activity337,453,454.
Another and rather recent inhibitor against mTOR is Ku0063794. It is small
molecule which inhibits both mTORC1 and mTOR2455. The half maximal in-
hibitory concentration (IC50) is approximately 10 nM. It is highly speciﬁc, since
the activity of 76 other kinases as well as 7 lipid kinases is not aﬀected even with
103-fold higher concentration455. Importantly, class 1 PI3Ks are not aﬀected ei-
ther. Ku0063794 can permeate the cell membrane and suppresses phosphorylation
of Akt and S6K. Experiments show that Ku0063794 induces G1-cell-cycle arrest and
suppress cell growth.
2.9 Immunofluorescence
2.9.1 Pretreating of coverslips
If not stated otherwise, 3 x 16 mm glass cover slips were transferred into a 35 mm
plastic dish and covered with growth medium without any antibiotic. The cover
slips were incubated for at least 24h at 37◦C and 5% CO2.
2.9.2 Plating of cells
Before cells were seeded onto the coated cover slips the medium was changed cor-
responding to the cell line described in subsection 2.2. Depending on the cell line
between approximately 5 x 104 and 1.5 x 105 were seeded and grown at least 72h
to assure a natural growth pattern.
2.9.3 Staining of IF slides
Cover slips were ﬁxed in 4% (v/v) formaldehyde (FAH) for 20 min at RT, then
washed once in PBS. After that the cells were permeabilised with 0.1% (w/v) saponin
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in PBS at RT for 2 min. The cover slips were washed in PBS and blocked in 1%
(w/v) BSA at RT for 30 min. The primary antibody probing was done in blocking
buﬀer overnight at 4◦C. A list of used antibodies is shown in table 2.6. Following
overnight incubation the cover slips were washed three times in blocking buﬀer and
then incubated with AlexaFluor (AF) secondary antibody at RT for 1h in the dark.
Coverslips were then washed three times with PBS and mounted on a microscope
slide using Prolong mounting media (with DAPI). The slides were dried in the dark
overnight at RT.
Table 2.6: Detailed information about antibodies used for Immunofluoerescence
Antibody Supplier
Catalogue
number
Source Dilution
ADAM15 (ECD) R&D MAB935 Mouse 1:100
AF488 (α-mouse) Invitrogen A11001 Goat 1:1,000
AF488 (α-rabbit) Invitrogen A11008 Goat 1:1,000
AF568 (α-mouse) Invitrogen A11031 Goat 1:1,000
AF568 (α-rabbit) Invitrogen A11011 Goat 1:1,000
Claudin1 Invitrogen 37-4900 Mouse 1:100
Claudin1 Invitrogen 51-9000 Rabbit 1:100
Paxillin Abcam ab32084 Rabbit 1:250
Phalloidin1 Invitrogen A12379
Amanita
phalloides
1:40
V5 Invitrogen 46-0705 Mouse 1:500
Vinculin
Santa
Cruz
sc-73614 Mouse 1:100
ZO1 CST #8193 Rabbit 1:200
2.9.4 Examination of IF slides
Coverslips were examined using a Leica SP5 confocal microscope. For AlexaFluor-
488 ﬂuorescent dyes an argon laser with 488 nm excitation wavelength was used.
For AlexaFluor-568 ﬂuorescent dyes a helium-neon laser with 543 nm excitation
wavelength was used. DAPI was examined with a 405 nm diode laser. If not stated
otherwise acquisition of the images was performed at 400 Hertz scan speed with a
resolution of 1024 x 1024 pixel.
1Toxin; directly conjugated to AlexaFluor-488
CHAPTER 2. GENERAL METHODOLOGY 107
2.10 shRNA knockdowns
The production of lentiviral particles and generation of the knockdown cell lines
were performed by Dr Zaruhi Poghosyan.
2.10.1 Production of lentiviral particles
293FT cells were cultured in DMEM medium supplemented with 10% FBS, 100
units/mL Penicillin, 100 μg/mL Streptomycin, 4 mM L-Glu, 1 mM MEM sodium
pyruvate, 0.1 mM MEM non-essential amino acids (NEAA) and 500 μg/mL Ge-
neticin. Cells were maintained in a humidiﬁed incubator at 37◦C with 5% CO2. A
day prior to transfection 293FT cells were seeded into 10 cm dishes with 5 x 106
cells using growth medium without antibiotics which will be referred to as trans-
fection medium. On the day of transfection the medium was replaced with Opti-
MEM. Transfection was done according to manufucaturer’s protocol using Lipofec-
tamine 2000 and ViralPower
TM
packaging mix containing plP1, plP2, plP/VSVG
and pLKO.1 expression constructs. An overview of the used plasmids is shown
in table 2.7. A day after transfection the medium was replaced with transfection
medium. After 48h the supernatants were collected and snap frozen in aliquots.
Lentiviral particles were stored at -80◦C until transduction.
Table 2.7: shRNAs used for stable knock down cell lines
Supplier Catalogue number Target Description
Sigma NM 003815.3-1890s21c15 ADAM15 Mission shRNA
Sigma NM 003815.3-1361s21c1 ADAM15 Mission shRNA
Sigma NM 003815.3-1736s21c1 ADAM15 Mission shRNA
Sigma NM 003815.2-497s1c1 ADAM15 Mission shRNA
Sigma NM 003815.2-1076s1c1 ADAM15 Mission shRNA
Sigma NM 021101.3-902 CLDN1 Mission shRNA
Sigma NM 021101.3-402 CLDN1 Mission shRNA
Sigma NM 021101.3-305 CLDN1 Mission shRNA
Sigma NM 021101.3-626 CLDN1 Mission shRNA
Sigma NM 021101.3-627 CLDN1 Mission shRNA
2.10.2 Generation of stable knock down cells using shRNA
T47D or MDA-MB-231/ADAM15 A expressing cells were seeded into 35 mm dish
with 2.5 x 105 cells each in complete growth medium without antibiotics. The fol-
lowing day, shClaudin1 or shADAM15 containing lentiviral particles were added to
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the cells. 8 μg/mL of Polybrene R© (hexadimethrine bromide) was added to enhance
transduction. A day after infection the medium was replaced with fresh transfec-
tion medium. On the following day the medium was replaced with complete growth
medium containing 1 μg/mL Puromycin for selection. Cells got expanded and knock-
down eﬃciency determined by western blot analysis as described in section 2.7.
2.11 mRNA analysis
2.11.1 RNA extraction
RNA extraction was done according to the manufacturer’s protocol using Qiagen
QIAshredder and RNeasy Kit. The elution step was done twice with 25 μL water.
2.11.2 RNA quantification
RNA was quantiﬁed using a NanoDrop R© ND-1000. The measurement was done in
duplicate and the averaged concentration was used for further analysis.
2.11.3 Reverse transcription
1 μg RNA was mixed with 500 nM random hexamers, 400 nM dNTP mix and
RNase/DNase free water to achieve a total volume of 12 μL. All upcoming incu-
bation steps were done in a thermo cycler. The mix was heated up to 65◦C for 5
min and quickly chilled on ice. 4 μL of 5 x ﬁrst-strand buﬀer and 400 μM Dithio-
threitol (DTT) were added and incubated at 25◦C for 2 min. After that 200 units
of Superscript II reverse trascriptase were added and following temperature proﬁle
was applied: 25◦C for 10 min, 42◦C for 50 min, 70◦C for 15 min and then cooled at
4◦C inﬁnitely. The ready products were then either stored temporarily at 4◦C until
further processing or at -80◦C for long term storage.
2.11.4 PCR
Following the reverse transcription claudin1 and glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH) were ampliﬁed from the complementary DNA (cDNA) with
primers displayed in table 2.8. The master mix was prepared according to the man-
ufacturer’s protocol. Ingredients, volumes and concentrations are shown in table
2.9. The settings for the thermal cycler are displayed in table 2.10.
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Table 2.8: PCR primer sequences
Gene Direction Sequence
Claudin1 Forward 5’-ccaacgcggggctgcagctgttg-3’
Claudin1 Reverse 5’-ggatagggccttggtgttgggtaag-3’
GAPDH Forward 5’-cgtcaaggctgagaacgggaagcttgtcatcaatgg-3’
GAPDH Reverse 5’-catgccagtgagcttcccgttcagctcagggatg-3’
Table 2.9: Protocol for KAPA PCR master mix. Final volume per reaction was 12.5 μL
Component Volume
Final
concentration
PCR-grade water 3 μL -
2x KAPA Taq ReadyMix 6.25 μL 1x
10 μL forward primer 0.625 μL 0.5 μM
10 μL reverse primer 0.625 μL 0.5 μM
cDNA 2 μL -
Table 2.10: PCR cycle protocol. a) Claudin1; b) GAPDH
Temperature Duration Cycles
Initial denaturation 95◦C 3 min 1
Denaturation 95◦C 30 sec
25Annealing a) 60◦C / b) 66◦C 30 sec
Extension 72◦C 1 min
Final extension 72◦C 10 min 1
Hold 4◦C ∞ 1
2.11.5 Agarose gel electrophoresis
Samples were separated on 1% agarose gels (in 1 x Tris-acetate-EDTA (TAE) buﬀer,
purchased). The total volume for a midi-gel was 120 mL and mini-gel 50 mL. The
gels were run at 100 V. GelRed was used as non toxic alternative for ethidium
bromide.
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2.12 Focal adhesion dissassembly assay
2.12.1 Treatment with nocodazole
Cells were plated on glass coverslips as described in section 2.9 and grown for 72h in
complete media, then serum starved overnight. Afterwards the medium was replaced
with 10 μM nocodazole (in serum free DMEM) and incubated for 4h at 37◦C. The
nocodazole was then washed oﬀ twice with serum free DMEM and incubated for 15,
30, 45, 60 and 120 min to allow FA disassembly. Cells were ﬁxed as described in
section 2.9.3.
2.12.2 Immunofluorescence staining
IF staining was performed as described in section 2.9.3.
2.12.3 Exmaination of slides
The examination of slides was described in section 2.9.4. For this experiments a
digital zoom factor of 3 was applied to acquire all the images.
2.12.4 Semi-automated image analysis
The images retrieved from the confocal microscope are packed as Leica image ﬁle
(.lif) and need to be extracted using the software LAS AF Lite. Exported pictures
are potentially cropped to achieve single cell images, which are analysed by ImageJ.
For total cell area the phalloidin staining was used (green channel). Example im-
ages of each processing step are shown in ﬁgure 2.4. The picture was loaded into
ImageJ and converted into a 16 bit image to allow further conversion. It is then
subjected to mean dark threshold in black & white (B&W) mode. This makes
the stained cells uniformly black coloured. The binary colour values were set to 4
(black) and 255 (white) followed by analysing the particles with size=1000-Infinity
and circularity=0.05-1.00 to avoid noise and artefacts. The area was exported in
a tab-separated values ﬁle (.tsv) to allow to transfer the measurement into Excel.
Separately, a joint photographic experts group (.jpeg) ﬁle was generated with the
image seen in ﬁgure 2.4 c to allow manual examination of the analysed cell. This
eliminates wrongly measured cells from the evaluation. The macro code written for
this analysis is displayed in listing 2.1.
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Figure 2.4: Measurement of total cell area. (a) The green channel with phalloidin was taken and
(b) converted into an 16 bit image. (c) The mean dark threshold is applied to convert the cell
into a filled binary image. (d) The area of the cell is measured using Analyze particles option.
Listing 2.1: Macro code used to determine cell area of phalloidin stained cells during focal
adhesion analysis
macro ” Ce l l area an a l y s i s ” {
d i r = ge tD i r e c to ry (”Choose a Di rec to ry ” ) ;
l i s t = g e tF i l e L i s t ( d i r ) ;
setBatchMode ( t rue ) ;
f o r ( i =0; i< l i s t . l ength ; i++) {
path = d i r+l i s t [ i ] ;
open ( path ) ;
run (”16 – b i t ” ) ;
setAutoThreshold (”Mean dark ” ) ;
// run (” Threshold . . . ” ) ;
// setThresho ld (4 , 255 ) ;
run (” Convert to Mask ” ) ;
run (” Analyze P a r t i c l e s . . . ” , ” s i z e =1000– I n f i n i t y
c i r c u l a r i t y =0.05 –1.00 c l e a r add ” ) ;
path2 = d i r+F i l e . nameWithoutExtension ;
saveAs (”JPEG” , path2+”–bin . jpeg ” ) ; c l o s e ( ) ;
saveAs (” r e s u l t s ” , path2+”– r e s u l t s . t sv ” ) ;
roiManager (” r e s e t ” ) ;
}
}
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For analysis of FA the vinculin staining (red channel) was used. Example im-
ages of each processing step are shown in ﬁgure 2.5. The picture was opened in
ImageJ and converted into a 16 bit image. The background was subtracted using
a rolling ball radius of 10 pixels and the sliding paraboloid algorithm to decrease
the likelihood of artefacts being ampliﬁed later. Next the contrast was increased us-
ing the Contrast Limited Adaptive Histogram Equalization (CLAHE)456,457 plugin
with following settings: blocksize=50 histogram=256 maximum slope=6 to include
weaker FA staining. To further enhance FA structures, especially with noisy back-
ground, the Laplacian of Gaussian 3D (LoG3D)458 ﬁlter was applied. The LoG ﬁlter
size was deﬁned as σx=5 and σy=5 followed by Yen
459,460 thresholding in B&W
mode. The binary areas were quantiﬁed by analyze particles with following settings:
size=1-Infinity and circularity=0.05-1.00.
Figure 2.5: Analysis of FA. (a) The red channel with vinculin staining was taken and (b)
converted into an 16 bit image. (c) Background was subtracted and (d) contrast increased using
the CLAHE plugin (e) The LoG3D is applied to further enhance the focal adhesions. (f) To achieve
a binary image a threshold is applied using the Yen method. (g) The particles are analysed to
obtain the borders of the focal adhesions.
The macro code (listing 2.2) for the quantiﬁcation of FA is similar to the one
used for measuring the cell area. The function to select the folder, batch mode and
the output is the same.
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Listing 2.2: Macro code used to analyse area and intensity of focal adhesions
macro ”Focal adhes ion an a l y s i s ” {
d i r = ge tD i r e c to ry (”Choose a Di rec to ry ” ) ;
l i s t = g e tF i l e L i s t ( d i r ) ;
setBatchMode ( t rue ) ;
f o r ( i =0; i< l i s t . l ength ; i++) {
path = d i r+l i s t [ i ] ;
open ( path ) ;
run (”16 – b i t ” ) ;
run (” Subtract Background . . . ” , ” r o l l i n g=10 s l i d i n g ” ) ;
run (”CLAHE ” , ” b l o c k s i z e=50 histogram=256 maximum=6”);
t i t l e = g e tT i t l e ;
run (”LoG 3D” , ” sigmax=5 sigmay=5”);
selectWindow (”LoG of ”+ t i t l e ) ;
setAutoThreshold (”Yen ” ) ;
run (” Analyze P a r t i c l e s . . . ” , ” s i z e=1– I n f i n i t y
c i r c u l a r i t y =0.05 –1.00 c l e a r summarize add ” ) ;
path2 = d i r+F i l e . nameWithoutExtension ;
saveAs (”JPEG” , path2+”–bin . jpeg ” ) ;
selectWindow ( t i t l e ) ;
run (” Revert ” ) ;
roiManager (”Measure ” ) ;
saveAs (” r e s u l t s ” , path2+”– r e s u l t s . t sv ” ) ;
selectWindow (”Summary ” ) ;
saveAs (” r e s u l t s ” , path2+”Summary . t sv ” ) ;
roiManager (” r e s e t ” ) ;
c l o s e ( ) ;
}
}
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2.13 Quantification of cell spreading plated on
ECM components
Adhesion and motility of cells highly depend on interaction between ECM substrates
and the cell. Furthermore, adhesion is a key event in generating cell shape and
tissue organisation. Determine whether ADAM15 isoforms adhere diﬀerently to
ECM substrates could give indication if integrin traﬃcking is aﬀected by ADAM15.
Quantiﬁcation of cell spreading is done by measuring the area a cell spans on the
surface. This gives an impression about the degree of cell spreading.
2.13.1 Cell plated on ECM components
Glass cover slips were coated with either complete growth medium or an ECM
substrate (table 2.11) for 1h at 37◦C. After a wash with PBS cells were plated in
OptiMEM 1:12.5 from a conﬂuent T25 ﬂask. After 45 min and 105 min a cover
slip of each coating was ﬁxed in 4% FAH for 15 min and stained according to the
procedure described in section 2.9.3.
Table 2.11: Detailed information about antibodies used for focal adhesion disassembly assay
Coating Supplier Cat. No. Stock Final Dilution
Medium Gibco 11960-085 - - -
Fibronectin Sigma F1141 1 mg/mL 10 μg/mL 1:100
Vitronectin Invitrogen Phe0011 1 mg/mL 10 μg/mL 1:100
2.13.2 Analysis of cell spreading
Cells were examined at 630x magniﬁcation. In total, ten images of random positions
were acquired. Analysis was performed by ImageJ.
In ImageJ the scale was adjusted by using the scale set by the Leica AS AF Lite
software. The analyze particles-function was set to exclude on edges to omit any
cells touching the image margin. This avoids the inclusion of incomplete captured
cells. Potential gaps within the cells, due to the used algorithm, were compensated
with the include holes-function to avoid falsiﬁed measurements.
The picture was loaded into ImageJ and converted into a 16 bit image to allow
further conversion. It is then subjected to triangle dark threshold in B&W mode.
This makes the stained cells uniformly black coloured. The binary colour values
were set to 12 (black) and 255 (white) followed by analysing the particles with
size=50-Infinity and circularity=0.05-1.00 to avoid noise and artefacts. The
area was exported in a tsv-ﬁle to allow to transfer the measurement into Excel.
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Separately, a jpeg ﬁle was generated with the image seen in ﬁgure 2.6 b to allow
manual examination of the quantiﬁed cell. This eliminates wrongly measured cells
from the evaluation. The macro code written for this analysis is displayed in listing
2.3.
Listing 2.3: Macro code used to analyse cell spreading
macro ”ECM spread ing ” {
d i r = ge tD i r e c to ry (”Choose a Di rec to ry ” ) ;
l i s t = g e tF i l e L i s t ( d i r ) ;
setBatchMode ( t rue ) ;
f o r ( i =0; i< l i s t . l ength ; i++) {
path = d i r+l i s t [ i ] ;
open ( path ) ;
run (”16 – b i t ” ) ;
setAutoThreshold (” Tr iang l e dark ” ) ;
// run (” Threshold . . . ” ) ;
// setThresho ld (12 , 255 ) ;
run (” Convert to Mask ” ) ;
run (” Analyze P a r t i c l e s . . . ” , ” s i z e =50– I n f i n i t y
c i r c u l a r i t y =0.05 –1.00
d i sp l ay exc lude c l e a r i n c lude add ” ) ;
path2 = d i r+F i l e . nameWithoutExtension ;
saveAs (”JPEG” , path2+”–bin . jpeg ” ) ;
c l o s e ( ) ;
saveAs (” r e s u l t s ” , path2+”– r e s u l t s . t sv ” ) ;
roiManager (” r e s e t ” ) ;
}
}
After analysis the outcome was manually checked for errors such as cells which
could not be told apart by ImageJ. An example image is shown in ﬁgure 2.6. In order
to count the number of cells the corrected table of measurements was subjected to
cell count by Excel using the count-function (=COUNT(xy:xz)). Cells at the edge
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of the images are excluded as well as clusters.
Figure 2.6: Example image of cell spread on ECM components. The image shows an example
of MDA/ADAM15 A expressing cells plated on VN for 105 min. a) Image as it was acquired by
confocal microscopy. b) Jpeg of analysed image from the ImageJ automated script for manual
verification. c) The same jpeg image, but with highlighted events. The red arrows indicate cells
on edge which are automatically excluded by the script. The blue arrow indicates a cluster of
cells which could not be told apart by ImageJ. Since the right cell of the cluster is touching the
frame of the image ImageJ excluded it as cell on edge. Cluster in the centre of the image were
not automatically removed for the measurement, but manually afterwards. Cells within the green
circle were valid to measure the cell area. Scale bar = 25 μm
2.14 GTPase-linked Immunosorbent Assay
(GLISA)
Cells were seeded with a ratio of 1:5 from conﬂuent T25 ﬂasks in 10 cm dishes and
grown for 72h. Dishes were then placed on ice, the medium was aspirated and the
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plate was washed once with PBS. PBS was aspirated and the plate tilted, whatman
paper was used to remove surplus liquid. 250 μL GLISA lysis buﬀer was added,
scraped, transferred to a pre-chilled tube and incubated for 5 mins on ice. The sam-
ples were centrifuged for 1 min at full speed (14,800 x g). 30 μL cell suspension was
transferred into a new pre-chilled screw cap tube for quantiﬁcation. The remain-
ing lysate was shared between two tubes. All were snap frozen in liquid nitrogen.
Sample preparation did not exceed 10 min. Quantiﬁcation was done according to
manufacturer’s protocol. The samples were equalised to the one with the lowest con-
centration within an experiment. In three independent experiments the range was
between 970 and 1000 ng/μL detecting active Rho and Rac GTPase. The assay was
performed in duplicates according to manufacturer’s protocol. Incubations using the
orbital shaker were done at 300 rpm. The incubation time for HRP detection was
15 min. Absorbance was measured at 492 nm. The average of both readings was
taken and the blank subtracted from the samples including positive control. The
parental cell line was normalised to 1 and the fold diﬀerence calculated by dividing
ADAM15 A-E WT expressing cells by the parental cell line. The results are plotted
as bar chart.
Chapter 3
Characterisation of ADAM15
isoform expressing cells
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3.1 Introduction
3.1.1 Aims of the chapter
1. Generation of a cell panel which can be used to observe changes to cell be-
haviour induced by ADAM15-isoforms
2. Characterisation of changes in morphology
3. Characterisation of changes in proliferation
4. Characterisation of changes in migration
3.2 Results
The main aim of this chapter was to create isogenic cell lines overexpressing prote-
olytically active and inactive ADAM15 splice variants in order to determine their
role in breast cancer. Our group had previously linked ADAM15 splice variant ex-
pression to diﬀerential outcome in breast cancer179. Therefore, these cells provide
an excellent in vitro model to investigate if and how ADAM15 isoforms may aﬀect
various aspects of cell biology diﬀerently, to be able to elucidate potential func-
tions of these isoforms in breast cancer. MDA-MB-231 cells express predominantly
ADAM15 A and very little ADAM15 B or E (unpublished data). Analysis with
isoform-speciﬁc primers needs to be conducted as both spliceforms diﬀer only by
one amino acid in size (table 1.5).
3.2.1 Validation of parental MDA-MB-231/FRT cell line
The Invitrogen Flp-InTMsystem allows the integration of a gene of interest at a
speciﬁc genomic location in mammalian cells. A recombination site is inserted into
the genome of cells, which allows the insertion of the genes of interest in a speciﬁc
recombination site.
An MDA-MB-231/FRT cell line had previously been created by Dr. Zaruhi
Poghosyan by transfecting linearised pFRT/lacZeo vector into MDA-MB-231 cells.
Using southern blotting a single integration site had been identiﬁed for a clone lack-
ing obvious cellular phenotype changes (ﬁgure 3.1 a). This cell line showed identical
growth rate when compared to unstransfected MDA-MB-231 cell (ﬁgure 3.1 b).
Therefore we selected these cells for further validation and subjected them to next
generation sequencing (NGS) .
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Figure 3.1: Characterisation of MDA-MB-231 and MDA-MB-231/FRT. (a) Phase-contrast im-
ages of MDA-MB-231 and MDA-MB-231/FRT cells. Scale bar = 100 μm (b) MTS assay of
MDA-MB-231 and MDA-MB-231/FRT. Cells were seeded in 96-well format with 3 x 103 cells
per well. After 24, 48, 72 and 96h MTS solution was applied and incubated for 4h at 37◦C.
Plates were measured at 450 nm. Values got normalised to 1 at 24h. Statistical significance
was assessed with two-way ANOVA and Bonferroni post-test. MDA-MB-231/FRT (grey) were
compared to MDA-MB-231 (white) at each time point. Confidence intervals are as follows:
∗ = p ≤ 0.05, ∗∗ = p ≤ 0.01, ∗ ∗ ∗ = p ≤ 0.001. n=3
Low-coverage whole genome sequencing (LCWGS) was performed and the
pFRT/lacZeo vector integration site mapped in the human genome. Bioinformatic
analysis of the sequencing was done by Dr Kevin Ashelford, Cardiﬀ University.
The results showed that the vector was integrated on chromosome 4 at position
91,481,550 - 91,481,600 which can be seen in ﬁgure 3.2. Alignment of the sequence
to the human genome with Basic Local Alignment Search Tool (BLAST) conﬁrmed
that the vector was integrated in an intronic region (between exon 5 and 6) of the
gene for FAM190A.
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Figure 3.2: A screenshot of the software Integrative Genomics Viewer (IGV) visualising the integration site of the pFRT/lacZeo vector in the genome of
MDA-MB-231 cells. Based on analysis of the low-coverage sequencing the vector is integrated at position 91,481,550 - 91,481,600 on chromosome 4. n=1
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A cell panel was generated by co-transfecting ADAM15 splice variant expres-
sion plasmid with pOG-44 recombinase expression plasmid into MDA/FRT cells
and subsequent selection with hygromycin to generate stable cell lines. ADAM15
variant expression was veriﬁed by western blot analysis using the V5-epitope tag en-
coded by each respective expression plasmid (ﬁgure 3.3). The molecular mass of the
ADAM15 variants corresponds to about 115 kDa with variant D being considerably
smaller, due to its shorter cytoplasmic tail. ADAM15 A and B showed the highest
expression, while ADAM15 C and D were expressed the least. ADAM15 E expres-
sion was lower than the one of ADAM15 A and B, but more than ADAM15 C and
D expression. The protein levels of the ADAM15 E349A variants were comparable
to ADAM15 E WT and similar for all inactive mutants. To conﬁrm that phenotypic
changes in our cell panel were due to ADAM15 expression and not due to changes
in FAM190A expression we tested whether FAM190A expression was aﬀected by
over expression of the ADAM15 transgenes by western blotting. Figure 3.4 shows
identical expression of FAM190A across the whole ADAM15 splice variant cell panel
which were comparable to levels in parental MDA-MB-231 cells.
Figure 3.3: Western blot analysis of cell lysates for ADAM15 isoform expression detected via its
V5-tag in MDA-MB-231 cells. n=14
Figure 3.4: Protein expression analysis of FAM190A in MDA/ADAM15 WT and E349A express-
ing cells. The recombination site is integrated within an intronic region of FAM190A gene. Equal
expression suggests the translation is not negatively influenced by integration. n=2
In order to understand whether ADAM15 C and D expression levels were due to
epigenetic silencing cells were treated with decitabine (5-aza-2’-deoxycytidine) or in
combination with TSA (ﬁgure 3.5). Decitabine hypomethylates DNA by inhibition
of DNA methyltransferase and TSA inhibits deacetylation. The blot shows, that
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expression of variant C and D is upregulated by decitabine/TSA treatment. How-
ever, decitabine is more eﬀective in MDA/ADAM15 C than D expressing cells. We
conclude that hypermetyhlation is a cause of downregulating ADAM15, but other
mechanism regulating gene transcription may be involved as well.
Figure 3.5: MDA/ADAM15 C and D expressing cells treated either with medium, decitabine
(33.3 μM & 50 μM) and decitabine in combination with TSA (500 nM). n=2
3.2.2 ADAM15 isoform expression differentially affects cell
morphology
Upon successful expansion of the cell lines it was noticeable that cell morphology
was changed dependent on the splice variant expressed. Figure 3.6 shows that cells
are more prone to cluster formation, especially in ADAM15 A, C and D expressing
cells. They possess a cobblestone-like appearance compared to normal MDA-MB-
231 cells, which grow scattered and are more elongated. Additionally, I compared
the cell morphology of the WT ADAM15 expressing cells with cells expressing the
inactive E349A mutants (see A E349A for the ADAM15 A splice variant). The
cellular cluster formation was not as prominent as in WT cells, but can be noticed
in A E349A, D E349A and E E349A expressing cells.
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Figure 3.6: Representative phase-contrast images of MDA/FRT, MDA/ADAM15WT and E349A
isoform expressing cells. Scale bar = 100 μm.
To address whether the morphological changes depend directly on ADAM15
we generated stable knockdown cell lines targeting the coding region of ADAM15.
Lentiviral particles were made as described in section 2.10. MDA/ADAM15 A ex-
pressing cells were seeded into 35 mm dishes with cell number of 5 x 105 and grown
overnight. Polybrene was added to the supernatant containing lentiviral particles
with either incorporated shRNA targeting ADAM15 or non-target (nt) shRNA. The
medium on the seeded cells was replaced with the lentiviral supernatant and incu-
bated overnight at 37◦C. One day after infection the supernatant was replaced by
fresh transfection medium. The next day, the medium was replaced by complete
growth medium containing puromycin for selection. Surviving cells were expanded
and cell lysates analysed for ADAM15 expression by western blotting (ﬁgure 3.7 a).
Analysis of ADAM15 expression showed, that MDA/FRT contain little ADAM15.
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MDA cells overexpressing ADAM15 A have a much higher protein level of ADAM15.
Knockdown by shRNA decreased ADAM15 expression to a level which is below the
level of ADAM15 in MDA/FRT cells.
As shown in phase-contrast images MDA/FRT cells grow as single cells with spindle-
like morphology (ﬁgure 3.7 b). MDA cells overexpressing ADAM15 A grew in
cobblestone-like structures (ﬁgure 3.7 c). MDA/ADAM15 A shADAM15 expressing
cells reversed to the original phenotype of MDA-MB-231 cells (3.7 d). This indicates
that the changes in morphology depend on the overexpression of ADAM15 A.
Figure 3.7: Epithelial morphology is directly dependent on ADAM15 A overexpression. a) West-
ern blot analysis of MDA/FRT, MDA/ADAM15 A and MDA/ADAM15 A shADAM15 expressing
cells. b) Phase-contrast images of the parental MDA/FRT cell line, MDA/ADAM15 A expressing
and MDA/ADAM15 A shADAM15 cells. Scale bar = 100 μm
3.2.3 ADAM15 isoform expression affect cell size
Analysis of phase-contrast microscopy images indicated that cell size may be aﬀected
by ADAM15 overexpression. Five random images were acquired from MDA-MB-
231 and ADAM15 WT expressing cells at 200x magniﬁcation. In each image ten
representative cells were measured. This was repeated twice more (with one week in
between) making a total of 150 cells per cell line. Surface area of the cells growing
on TC plastic area was determined for each cell line and compared to the parental
MDA/FRT cells. The results are displayed in ﬁgure 3.8 and statistical analysis
performed to evaluate changes in comparison to the parental cell line. ADAM15
C and E expressing cells were signiﬁcantly larger than MDA-MB-231. ADAM15 D
cells were larger as well, but to a lesser degree. In contrast, cells overexpressing the
ADAM15 B variant were signiﬁcantly smaller. The ADAM15 A spliceform did not
change the cell size.
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Figure 3.8: Measurement of cell spreading of MDA/ADAM15 isoform expressing cells. Five
images of exponential growing cells were randomly taken and ten representative cells per pic-
ture were measured. Statistical significance was assessed with Dunnet’s multiple comparison test.
MDA/ADAM15 WT expressing cells were compared to the 231/FRT control. MDA/ADAM15 A-
E WT expressing cells were compared to the MDA/FRT control cell line. Confidence intervals are
as follows: ∗ = p ≤ 0.05, ∗∗ = p ≤ 0.01, ∗ ∗ ∗ = p ≤ 0.001, ∗ ∗ ∗∗ = p ≤ 0.0001. The measurement
was repeated in three independent biological experiments. n=150
To conﬁrm change in cell size an additional experiment was performed using
forward scatter (FSC) analysis. An indication of cell size or volume is given by the
FSC measured in ﬂow cytometry461–463.
Scattering of light occurs when a cell or particle deﬂects or refracts light of the
laser beam. This depends on the physical properties of the passing object, the size
and its internal complexity. A ﬂow cytometre contains several detectors, one is in
the front of the light beam (FSC) while several other detectors are at the site of it
measuring the side scatter (SSC). The FSC is proportional to the cell-surface area or
size of the particle or cell. It measures primarily the diﬀracted light close to the axis
of the incoming light of the photo diode. The SSC is proportional to the internal
complexity or cell granularity and measures primarily reﬂected and refracted light.
It is collected at approximately 90◦ to the leaser beam. Since only the FSC is a
measure of cell size the SSC was not used.
Cells were trypsinised, washed and stained with propidium iodide (PI) and analysed
with a ﬂow cytometre. After discriminating debris, doublets and dead cells the FSC-
Area (FSC-A) was measured. The median of three independent experiments was
plotted as box-and-whiskers plot as shown in ﬁgure 3.9. FSC-A analysis conﬁrms
that MDA/ADAM15 C and E expressing cells are signiﬁcantly larger than their
parental cell line, while MDA/ADAM15 C expressing cells increase cell size the
most. Interestingly, FSC-A analyses showed that MDA/ADAM15 A expressing
cells were signiﬁcantly larger as well, but smaller than MDA/ADAM15 C and E
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expressing cells.
Figure 3.9: Measurement of cell size of MDA/ADAM15 isoform expressing cells. 20,000 events
were counted and the median of three independent experiments compared. (a) Number of events
plotted against the FSC-A: black = MDA/FRT; blue = ADAM15 A; orange = ADAM15 B;
green = ADAM15 C; pink = ADAM15 D; red = ADAM15 E. (b) Scatter plot comparing the
median of all experiments. Statistical significance was assessed with Dunnet’s multiple comparison
test. MDA/ADAM15 A-E WT expressing cells were compared to the MDA/FRT control cell line.
Confidence intervals are as follows: ∗ = p ≤ 0.05, ∗∗ = p ≤ 0.01, ∗ ∗ ∗ = p ≤ 0.001, ∗ ∗ ∗∗ = p ≤
0.0001. n=3
As mentioned earlier, the expression of ADAM15 isoforms led to cell rounding
and clustering to varying degree, with particularly ADAM15 A isoform expressing
cells having cobblestone-like appearance, while the host cell line is elongated and
mesenchymal. To quantify this the circularity was calculated from the cell outlines
used to determine cell area of ﬁgure 3.8. All ADAM15 isoform expressing cells
were more circular compared to the host cell line (ﬁgure 3.10). A perfect circle is
represented by the value of 1.
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Figure 3.10: Circularity measurement of MDA/ADAM15 isoform expressing cells. five im-
ages of exponential growing cells were randomly taken and ten representative cells per picture
were measured. Statistical significance was assessed with Dunnet’s multiple comparison test.
MDA/ADAM15 A-E WT expressing cells were compared to the MDA/FRT control cell line. Con-
fidence intervals are as follows: ∗ = p ≤ 0.05, ∗∗ = p ≤ 0.01, ∗ ∗ ∗ = p ≤ 0.001, ∗ ∗ ∗∗ = p ≤ 0.0001.
This was repeated in three independent biological experiments. n=150
3.2.4 The expression of ADAM15 isoforms affects prolifer-
ation rate in MDA-MB-231 cells
Next we asked whether the growth rate is aﬀected by ADAM15. Therefore the
proliferation assay MTS was performed. Cells were seeded into 96-well plate which
was measured every 24h. The 24h time point was normalised to 1 and the fold
diﬀerence calculated. Apart from ADAM15 B expressing cells the expression of all
other ADAM15 WT isoforms reduced growth rates to varying degree (ﬁgure 3.11).
In MDA/ADAM15 A, D and E expressing cells the change in growth rate was inde-
pendent of the catalytic function. Cells expressing the corresponding catalytically
inactive mutants behaved in a similar fashion. However, the expression of ADAM15
C isoform reduced the growth rate of MDA cells the most, and this required its
catalytic function, as the expression of ADAM15 C E349A did not aﬀect growth
rate.
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Figure 3.11: Cell proliferation assay with MDA/FRT, ADAM15 WT and E349A expressing
cells. MDA-MB-231/FRT compared to ADAM15 A-E WT and E349A expressing cells. 96-well
plates were seeded with 3 x 103 cells per well and measured every 24h for 96h in total. Results were
equalised to 24h and converted to fold difference. Statistical significance was assessed with post-hoc
Bonferroni’s multiple comparison test after performing two-way ANOVA analysis. The individual
ADAM15 WT and E349A isoform was compared to the MDA/FRT control cell line. Confidence
intervals are as follows: ∗ = p ≤ 0.05, ∗∗ = p ≤ 0.01, ∗ ∗ ∗ = p ≤ 0.001, ∗ ∗ ∗∗ = p ≤ 0.0001. n=3
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3.2.5 ADAM15 splice variants alter cytoskeleton rearrange-
ment
We have previously shown that overexpression of ADAM15 splice variants A and B
alter actin rearrangement in MDA-MB-435 cells179. Here we compared cytoskeletal
architecture of ADAM15 A-E WT in MDA-MB-231.
The host cell line and MDA/ADAM15 isoform expressing cells were seeded onto glass
coverslips and grown for 72h. Afterwards they were ﬁxed with FAH and stained with
phalloidin-488 as described in section 2.9. The slides were examined with a confocal
microscope. Representative images are shown in ﬁgure 3.12 and a summary of the
results displayed in table 3.1
MDA/ADAM15 B expressing cells looked similar to the host cell line. Straight
and curved actin bundles were found in the periphery. Some stress ﬁbres,
invadopodia-like structures and loose actin meshwork was observed within the cell.
MDA/ADAM15 A expressing cells formed membrane ruﬄes. Some stress ﬁbres
and a large number of invadopodia-like structures were found within the cell. Only
MDA/ADAM15 D expressing cells showed more invadopodia-like structures, but
not ruﬄe formation and less stress ﬁbres. They also showed curved and straight
actin bundles at the periphery. MDA/ADAM15 C expressing cells showed primarily
thick curved bundles of actin ﬁlaments at the cell periphery with reduced numbers
of invadopodia-like structures and stress ﬁbres. Finally, MDA/ADAM15 E express-
ing cells showed prominent stress ﬁbres, with a reduced number of invadopodia-like
structures.
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Figure 3.12: Immunofluorescence staining of the actin cytoskeleton in MDA/FRT and
MDA/ADAM15 A-E WT expressing cells. Green: Actin cytoskeleton stained with phalloidin-
488; Blue: Nucleus stained with DAPI. Scale bar = 10 μm. Actin structures summarised in
table 3.1 are labelled with arrows in the image in which they are most abundant. Five examples
of each are shown. Magenta arrow: Ruﬄes; Cyan arrow: Curved actin bundles; Yellow arrow:
Invadopodia-like structures; White arrow: Stress fibres. n=6
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Table 3.1: Subjective categorisation of observed actin structures and their abundance. “-” = not
present, “o” present, “+” = prominent, “++” = abundant.
Cell line Ruﬄes
Curved
actin
bundles
Invado-
podia-like
Stress
fibres
MDA/FRT - o + +
MDA/15 A ++ o + +
MDA/15 B - o + +
MDA/15 C - ++ + +
MDA/15 D - o ++ +
MDA/15 E - o + ++
During examination of the actin cytoskeleton Invadopodia-like structures were
observed. Co-staining with V5 revealed that ADAM15 is localised in the centre of
these structures (ﬁgure 3.13). This was seen in MDA/ADAM15 B, C, D and E ex-
pressing cells. Despite possession of Invadopodia-like structures in MDA/ADAM15
A expressing cells, localisation of ADAM15 in this structures was not observed.
Figure 3.13 a shows that the majority of ADAM15 is found in the intermediate
Z-position. ADAM15 intensity was fading towards the basal and apical position.
Figure 3.13 b shows the intermediate Z-position of MDA/ADAM15 C, D and E
expressing cells. ADAM15-positive Invadopodia-like structures are marked with ar-
rows.
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Figure 3.13: Immunofluorescence analysis detected ADAM15 in invadopodia-like structures in
MDA/ADAM15 B, C, D and E expressing cells. Yet, we failed to detect co-localisation of ADAM15
A in invadopodia. Green = phalloidin; Red = V5-ADAM15; Blue = Dapi. Arrows indicate
co-localisation of invadopodia and ADAM15. a) ADAM15 B expressing cells from different Z-
positions. Top panel shows the apical position of acquisition. The middle panel shows the in-
termediate position while the lower panel shows the basal Z-position. b) ADAM15 C, D and E
expressing cells showing invadopodia with co-localised ADAM15 indicated by arrows. ADAM15 D
expressing cells demonstrate and increase number of invadopodia compared to the other cell lines.
Scale bar = 10 μm. n=2
GTPases are major mediators of actin rearrangement. Since Rho activity corre-
lates with stress ﬁbre formation and Rac drives cortical actin production, we sought
to determine whether their overall activities varied across our cell panel. Based on
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the diﬀerent actin structures present within each cell population, we would expect
to see higher Rho activity in MDA/ADAM15 E expressing cells, and higher Rac
activity in MDA/ADAM15 A and C expressing cells.
Cells were seeded into 10 cm dishes and lysed after 72h in GLISA kit lysis buﬀer.
The harvesting was done within 10 min. The samples were aliquoted, snapfrozen
and stored at -80◦C until further processing.
The GTPase activity was analysed with the RhoA and Rac1 G-LISA activation
assay kits according to the manufacturer. GTPase activity of MDA/ADAM15 ex-
pressing cells was compared to the parent control and the fold diﬀerence shown as
bar graphs in ﬁgure 3.14. No signiﬁcant changes in total Rho and Rac activity
between cell lines were observed.
Figure 3.14: Determination of RhoA and Rac1 GTPase activity. (a) RhoA GLISA with MDA-
MB-231/FRT and ADAM15 isoform expressing cells. (b)Matching Rac1 GLISA. Statistical signif-
icance was assessed with the post-hoc Dunnet’s multiple comparison test after performing one-way
ANOVA analysis. MDA/FRT was used as reference and the fold difference was set to 1. The
MDA/ADAM15 A-E WT expressing cells were then compared to the MDA/FRT control cell line.
Confidence intervals are as follows: ∗ = p ≤ 0.05, ∗∗ = p ≤ 0.01, ∗ ∗ ∗ = p ≤ 0.001, ∗ ∗ ∗∗ = p ≤
0.0001. n=3
3.2.6 ADAM15 isoforms differentially regulate cell migra-
tion
The vast majority of ADAM15-related research so far was carried out focusing on
the most abundant isoform, ADAM15 A. Based on the literature the disintegrin do-
main of human ADAM15 is known to inhibit migration in human hepatoma cells226.
Monolayers of Bel-7402 cells were wounded and diﬀerent concentrations of recombi-
nant human disintegrin of ADAM15 was administered resulting in a dose-dependent
decrease of wound closure. The potential eﬀect of individual ADAM15 isoforms on
migration of MDA cells was analysed by using a 2D scratch-wound assay.
Cells were seeded and grown until conﬂuent, scratch wounds were introduced and
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analysed using phase-contrast microscopy at 8, 24, 32 and 48h intervals. The wound
area at 0h timepoint was set to 100% and wound closure was analysed over time. The
results are shown in ﬁgure 3.15. Parental cells showed complete wound closure after
48h. Decreased migration was observed in all cell lines apart from MDA/ADAM15
E expressing cells. MDA/ADAM15 A and B expressing cells close the wound to ap-
proximately 15% and 25%. while MDA/ADAM15 C and D expressing cells showed
the slowest wound closure (about 50%.). The latter one did not close the wound
after 96h (data not shown), whereas ADAM15 C expressing cells did.
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Figure 3.15: Wound healing assay of MDA/ADAM15 isoform expressing cells a) Example im-
ages of MDA-MB-231/FRT and ADAM15 WT isoform expressing cells right after wounding (0h),
24h and 48h. (b) Column charts comparing the parental cell lines against each ADAM15 WT
expressing isoform. Images were analysed with ImageJ. Wound at 0h was considered as 100% and
closure correspondingly calculated. Statistical significance was assessed with post-hoc Bonferroni’s
multiple comparison test after performing two-way ANOVA analysis. The individual ADAM15
WT isoform was compared to the MDA/FRT control cell line. Confidence intervals are as follows:
∗ = p ≤ 0.05, ∗∗ = p ≤ 0.01, ∗ ∗ ∗ = p ≤ 0.001, ∗ ∗ ∗∗ = p ≤ 0.0001. n=3
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3.3 Discussion
In this chapter I have characterised the isogenic cell panel expressing ADAM15 A-E
WT and E349A expressing cells in MDA-MB-231 cell line. LCWGS revealed a single
insertion of the FRT site within an intronic region of the gene FAM190A. Western
blot analysis conﬁrmed that insertion or recombination did not negatively inﬂuence
the expression of FAM190A. I showed that the insertion of the recombination site
did not change morphology or growth rate of the cells. Western blot analysis of the
generated MDA/ADAM15 isoform expressing panel showed that ADAM15 A and B
is slightly over- and C and D little underexpressed compared to ADAM15 E and their
corresponding catalytically inactive mutants. Decitabine and TSA treatment indi-
cated that the reduced expression of ADAM15 C and D is due to hypermethylation.
Phase-contrast analysis showed that the cell morphology changed depending on the
expressed ADAM15 isoform and catalytic activity. MDA/ADAM15 A WT express-
ing isoforms showed dense cobblestone-like appearance compared to MDA/ADAM15
A E349A. Downregulation of the induced ADAM15 A isoform rescued the original
morphology. MDA/ADAM15 C and D expressing cells were signiﬁcantly larger than
parental or other isoform expressing cells. All cell lines expressing ADAM15 isoforms
were less elongated and rounder. MDA/ADAM15 A, D and E expressing cells grew
slower than MDA/FRT independent of their catalytic function. MDA/ADAM15 C
expressing cells had the slowest proliferation rate which depended on the catalytic
function. MDA/ADAM15 B expressing cells did not change the growth rate.
We have shown that the actin rearrangement is diﬀerent in all MDA/ADAM15 WT
isoform expressing cells. MDA/ADAM15 A expressing cells have a high number of
invadopodia-like structures and membrane ruﬄes while MDA/ADAM15 B express-
ing cells are similar to MDA/FRT. MDA/ADAM15 C expressing cells have much
more cortical actin while MDA/ADAM15 D expressing cells are rich in invadopodia-
like structures too. MDA/ADAM15 E has very high number of stress ﬁbres. To ad-
dress whether this is caused by RhoA and Rac1 GTPase, major contributor to actin
rearrangement, the cell panel was tested for RhoA and Rac1 activity using G-LISA.
However, no signiﬁcant changes compared to the parental cell line were observed.
Migration was also aﬀected by ADAM15 expression. Expression of ADAM15 A and
B slowed the migration rate down by approximately 20% while ADAM15 C and D
reduced it by 50%. ADAM15 E showed no changes.
The FRT integration site in MDA-MB-231 cells was validated by LCWGS. As the
name implies, the coverage of this methods is rather low. The 1000 Genomes Project
had an average coverage of 3.6x in 179 analysed samples and let to the identiﬁcation
of approximately 15 million single nucleotide polymorphisms (SNPs)464 . Since the
aim was to identify the locus of a sequence with more than 8 kilobase pairs (kbp)
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LGWGS seemed to be appropriate. However, there could be a possibility to get no
coverage where the vector is integrated. This would only provide information on
the copy number and not on the location. Mapping demonstrated that a coverage
of 1x-5x was achieved. The adjacent sequences were identiﬁed as intronic region of
FAM190A.
The WB analysis revealed that FAM190A expression is equal suggesting that no
negative eﬀects were induced since the insertion happened in a non-coding area.
Equal levels could have also been achieved by rescuing the expression of FAM190A
on the other chromosome, since insertion happened only once and genes are nor-
mally in doublets. Another indication of an integration without side eﬀects is that
no phenotypical changes were induced. According to its function, FAM190A is still
uncharacterised, but evolutionary conserved in vertebrates465. Patel et al. showed
that knock down of FAM190A by shRNA caused multinuclearity, cytokinesis defects
and multipolar mitosis466 suggesting it is involved in those events. Occasionally,
multinuclear and giant cells were found which could suggest cytokinesis defects.
However, multinuclear94,467 and giant cells are also sometimes found in MDA-MB-
23194. Thus, the host cell line was considered suitable to use for recombining in the
ADAM15 sequences.
The recombination step into the same parental MDA/FRT clone was repeated twice
more with ADAM15 isoforms, and in each case the expression levels of ADAM15
C and D were lower than the rest. Treatment with decitabine or in combination
with TSA increased the levels of ADAM15 C and D. Decitabine is an inhibitor of
DNA methyltransferase while TSA inhibits histone deacetylase (HDAC) class I and
II468. DNA methylation, histone acetylation and deacetylation play a crucial role in
regulating gene expression. Active transcriptional chromatin is linked to hyperacety-
lation via histone acetyltransferases (HATs), whereas silenced genes are associated
with hypoacetylation induced by HDACs. Interestingly, the MDA/ADAM15 E349A
splice variants show equal expression throughout. A reason could be that the ac-
tive MP domain in WT cells is involved in signalling pathways that regulate factors
which are harmful to the cell, thus gene silencing is used as means of cell protection.
Alternatively, it might directly regulate HDACs and HATs by processing transcrip-
tions factors. So far this was only observed in MDA-MB-231 cells since MCF-7,
PC3 and LNCaP cells (unpublished data) allow equal expression.
We observed that, depending on expressed ADAM15 isoform, cell shape changed
dramatically. Naturally, MDA-MB-231 cells grow spindle-shaped like ﬁbroblasts.
However, ADAM15 A isoform expressing cells grow as more epithelial-like cells which
could indicate re-activated mechanism which leads to transformation into epithelial
cells. This matter will be discussed in chapter 4 in which I will focus on identifying
the reason for epithelial-like cell clustering.
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Upon ADAM15 overexpression the spindle-like appearance switched to a rather
round phenotype. Since cytoskeletal rearrangement is the major mechanism dic-
tating cell shape469 it is highly likely that ADAM15 introduces changes in assem-
bly/disassembly of either actin, tubulin or microﬁlament dynamics.
Initial characterisation of the morphology of the cell panel revealed that
MDA/ADAM15 C and E expressing cells are signiﬁcantly larger than the other
isoform expressing cells. One reason could be a that ADAM15 induces changes in
key players of G1/S-phase transition. During G1-phase the cell acquires mass neces-
sary for the transition to S-phase in which the DNA is replicated. During G1-phase
Retinoblastoma protein (pRB) is bound to E2F transcription factor and the release
is induced by phosphorylation of pRB by the dimer cyclin-D/CDK4/6 as reviewed
ﬁrst by Weinberg470. One potential reason could be a reduced amount of pRB,
other upstream signalling molecules or restricted phosphorylation. This would sug-
gest that only the mass increases, but the nucleus/DNA amount is comparable to
the non-enlarged isoforms. Defects in cytokinesis seem unlikely, because the major-
ity of cells should be binucleated, which was not observed in immunoﬂuorescence
stainings. Additionally, it is possible that ADAM15 C and D upregulate speciﬁc
signalling pathways, such as PI3K, that increase cell size. I will discuss the PI3K
pathway in detail in chapter 4.
The results of the proliferation assay suggests that more than one mechanism is
involved. Cells showing reduced growth mostly showed it is independent of the cat-
alytic function (ADAM15 A, D and E). However, in MDA/ADAM15 C expressing
cells it depends on an active MP domain. In MDA/ADAM15 B cells the pro-
liferation rate was not aﬀected unlike the others. This points out that the speciﬁc
protein-protein interactions with individual ICDs have a role in regulating ADAM15
functions necessary for cell proliferation. There are several ways ADAM15 could
contribute to proliferation such as shedding of cell surface receptors necessary for
proliferative signals such as EGFR or IGFR. Also the interaction with integrins
with the disintegrin domain or kinase/adaptor protein interactions with the ICD
are likely do modulate cell growth.
Previously, we showed that overexpression of ADAM15 B in MDA-MB-435 cells in-
troduced prominent changes to the actin cytoskeleton compared to the introduction
of ADAM15 A. ADAM15 B expressing cells were less well spread, smaller, fewer and
short actin stress ﬁbres and stronger cortical actin staining179. This was not seen in
the MDA-MB-231 cells which may suggest it depends on the cell type. This raised
the question whether the activity of Rho family GTPases is altered by ADAM15
expression since these GTPases play an essential role in the reorganisation of the
actin cytoskeleton471. ADAM15 may also mediate GTPase activity via activation
of receptor tyrosine kinases such as EGFR. ADAM15 is able to activate HB-EGF
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by shedding198, which in turn is known to induce strong RhoA activation472.
ADAM15 has also the potential to inﬂuence RhoGTPases via adaptor proteins or Src
family kinases due to its binding motifs for SH2 and SH3 domains as well as phospho-
rylation site of the ICD. Assembly of protein complexes might induce downstream
signalling resulting actin rearrangement. As described earlier, Src has essential func-
tions in integrin-mediated Rho GTPase activation. ADAM15 isoforms with diﬀerent
aﬃnities towards Src could aﬀect this mechanism. ADAM15 isoform speciﬁc changes
in actin rearrangement were found, but no diﬀerences in total RhoA and Rac1 activ-
ity was observed. During the experiment the lysates were prepared from exponential
growing cells. The aim was to determine the GTPase activity in their natural growth
phase. However, since they do not grow identically, it could have happened that the
GTPase activity was balanced and thus no signiﬁcant changes were observed. To
overcome this issue cell lines could be serum starved and synchronised by addition of
FBS. Alternatively, pull-down assays can be performed. Usually a fusion protein of
a Rho GTPase binding domain and glutathione-S-transferase (GST) is made which
binds to the active form of the speciﬁc Rho GTPase in a lysate. Several probes for
monitoring GTPase activity are in use. They are all high-aﬃnity domains of Rho-
GTPase eﬀectors. To pull down active RhoA commonly the RhoA binding domain
of Rhotekin is used. For active Rac and Cdc42 the PAK-CRIB motifs of PAK1 is
used. To investigate only active Cdc42 the CRIB domain of WASP is taken473. A
pull-down is achieved by use of glutathione coated beads which have a high aﬃnity
to GST. Pulled down proteins are then analysed by western blotting.
Pull downs, or the used G-LISA kits, analyse the total GTPase activity in a cell
population. However, the GTPase activity can diﬀer within a cell, depending on its
localisation. To overcome this problem, single cell based assays need to performed
to speciﬁcally determine GTPase activity across the whole cell. The simplest ap-
proach would be to use IF anlysis, in which antibodies are used that speciﬁcally
target active GTPases. A more quantitative approach can be done using ﬂuores-
cence resonance energy transfer (FRET) which measures the energy transfer between
to chromophores474. A similar approach is ﬂuorescence-lifetime imaging microscopy
(FLIM). While conventional confocal microscopy makes use of the ﬂuorescence inten-
sity, is FRET based on energy transfer and FLIM makes use of the exponential decay
of ﬂuorescent samples475. These approaches would help to reveal the distribution
of Rho and Rac GTPases which are potentially aﬀected by ADAM15. Beside the
direct examination of Rho and Rac their downstream eﬀectors ROCK (for RhoA)
and PAK1 (for Rac) can be analysed for the activation. Apart from RhoA and
Rac1 there are many other members of the GTPase family which are also known
to regulate the actin cytoskeleton: For example Rac2 and 3476, RhoB-G476–478 and
Cdc42476. Therefore, it is important to include other members of the GTPase fam-
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ily into future experiments. Interestingly, RhoE is a unique GTPase since it lacks
GTPase activity, but is able to bind GTP479. Thus it is believed that RhoE is
constantly active. Nevertheless, it was demonstrated that RhoE controls the actin
organisation under mechanical stress in human periodontal ligament cells478. This
emphasises the need of including non classical Rho GTPases.
In MDA/ADAM15 B expressing cells the least amount stress ﬁbres were observed.
This could be due to increased activity of RhoE since it is demonstrated that it
inhibits stress ﬁbre formation477. MDA/ADAM15 C expressing cells could poten-
tially have increased Cdc42 GTPase activity, since together with Rac GTPases,
Cdc42 regulates the formation of cortical actin-associated structures mediated via
Arp2/3 complex480. Stress ﬁbres, as predominantly enriched in MDA/ADAM15 E
expressing cells, are normally the result of high RhoA activity. Active RhoA acti-
vates ROCK kinase which nucleates and polymerises actin ﬁlaments. Concomitantly,
ROCK phosphorylates LIM-kinase which in turn inactivates coﬁlin by phosphory-
lation. Inactivation of coﬁlin prevents degradation of the stress ﬁbres481. Several
scenarios may be theoretically possible without increase of RhoA activity. Firstly,
ROCK is activated independently of RhoA. Second, LIM kinase is activated inde-
pendently of Rho-ROCK or coﬁlin may be degraded/inactive independently of the
classical upstream activation. It has been demonstrated that Src is able to bind
and phosphorylate RhoGDI which decreases the ability to interact with Rho GT-
Pases482. The release of RhoGTPases from RhoGDI complexes in the cytoplasm is
a key event for RhoGTPase activity.
In order to investigate changes in the actin cytoskeleton, potentially aﬀected by
ADAM15, we stained our cell panel with phalloidin to visualise the actin cytoskele-
ton. We found an enhanced number of invadopodia-like structures483 in ADAM15
A and D expressing cells. Invadopodia are actin-based dynamic protrusions of
the cell membrane which are sites of attachment and degradation of the ECM.
Indeed, ADAM15 has been aﬃliated with degradation of the ECM. ADAM15, ex-
tracted from renal glomerulus cells (mesangial cells), was found to degrade colla-
gen IV and gelatin196. Additionally, we observed ADAM15 localised in the centre
of these invadopodia-like structures (appendix, ﬁgure 3.13). ADAM15 localisation
in invadopodia-like structures is somewhat expected, as ADAM15 ICD associates
with TKS5, an adaptor protein that acts as a scaﬀold in invadopodia. In order
to evaluate if ADAM15 isoforms, that localise to invadopodia, have speciﬁc ECM
degrading capacity, a gelatin invadopodia assay is required. Cells are plated on a
ﬂuorescent-labeled gelatin matrix which can be ﬁxed and co-stained for IF analysis.
Invadopodia activity would be visualised by decreasing ﬂuorescent signal at sites of
degradation484.
According to literature ADAM15 is involved in cell migration. In a rat model
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of rheumatoid arthritis the knockout of ADAM15 caused reduced migration of
ﬁbroblast-like synoviocytes. It was observed that the expression of pro-inﬂammatory
chemokines and cytokines was suppresed by ADAM15228. A previous study showed
that the recombinant human disintegrin domain of ADAM15 slows down migra-
tion in hepatocellular carcinoma cells by inducing G2/S arrest
226. However, the
mechanism must be more complex since the disintegrin domain remain constant
throughout the isoforms and no diﬀerence in migration was observed in ADAM15 E
expressing cells. This indicates that the ICD has an important role in migration. Ex-
periments with HUVEC cells and peripheral blood cells showed that overexpression
of ADAM15 promoted whereas inhibition reduced neutrophil transendothelial mi-
gration189. They identiﬁed the Src/Erk1/2-axis as pathway regulated by ADAM15
activity. In CHO cells, which express endogenous α5β1-integrin, overexpression
of ADAM15 enhanced cell adhesion and reduced migration on ﬁbronectin225. It
was observed that the surface expression of α5 increased with ADAM15 expression
while Erk1/2 phosphorylation was decreased. Experiments with ovarian cancer cells
demonstrated that ADAM15 impairs motility via its ability to bind αvβ3-integrin
via its RGD motif388. Vitronectin is the major ECM ligand for αvβ3. Rendering the
RGD sequence inactive (RGD to SGA) increased the migration on vitronectin. This
suggests that migration is impaired by the competition of ADAM15 and vitronectin
for αvβ3. There is a lot of evidence in literature indicating the role of ADAM15
in cell migration. However, the proliferation rate might have inﬂuenced the wound
closure of MDA/ADAM15 C expressing cells, as they are the slowest growing iso-
form. This however does not aﬀect MDA/ADAM15 D expressing cells, as they have
comparable growth rate with the other isoforms. Nevertheless, inﬂuence of prolifer-
ation cannot be ruled out. To overcome this issue the experiment can be repeated
with pretreatment of Mitomycin C485. Mitomycin C prevents cell proliferation by
crosslinking the DNA486.
Charrier et al. carried out migration experiments, speciﬁcally with the shortest
known isoform of ADAM15 most likely ADAM15 D101. Wound healing assays
showed that overexpression of the shortest ADAM15 variant led to decreased wound
closure. Especially the last examples identifying a close relationship with integrins
and ADAM15 show that crosstalk between ADAM15 and integrins seems very im-
portant for adhesion and migration and may explain whether these interaction play
a role in our used breast cancer model. Another key mediator of adhesion and mi-
gration in cells are focal adhesions which need to be closer investigated. Chapter 5
will focus on this.
Chapter 4
ADAM15 mediated upregulation
of claudin1 expression
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4.1 Introduction
4.1.1 Aim of this chapter
In the previous chapter I described the morphological changes inﬂuenced by the
expression of speciﬁc ADAM15 isoforms. One of the prominent features was cell
clustering, and cell-cell junction formation in some isoform expressing cells.
1. Identify the cause of cell clustering
2. Identify potential pathways involved in ADAM15-mediated cell clustering
3. Identify potential implications of ADAM15-mediated cell clustering
The main aim in this chapter was to investigate if and how ADAM15 isoforms
are involved in regulating cell-cell junctions.
4.2 Results
4.2.1 MDA/ADAM15 isoform expressing cells do not un-
dergo mesenchymal-epithelial transition (MET)
Original MDA-MB-231 cells grew as single cells with elongated spindle-like ap-
pearance indicating a mesenchymal phenotype. Stable expression of ADAM15
isoforms led to morphological changes of MDA-MB-231 cells. With exception of
MDA/ADAM15 B expressing cells, the other cell lines formed clusters to varying
degree. Especially ADAM15 A and C expressings cells showed cobblestone-like
morphology (chapter 3 ﬁgure 3.6). We suspected that MDA cells underwent MET
which is the reverse mechanism of EMT. EMT describes the phenomenon when
epithelial cells lose their cell polarity and cell-cell adhesion property. This process
can be reversed and described as reversal of EMT or MET. MDA-MB-231 cells lost
their epithelial characteristics and are true mesenchymal cells. To evaluate whether
the expression of ADAM15 isoforms triggered MET, the expression levels of ep-
ithelial and mesenchymal markers were analysed by western blotting (ﬁgure 4.1).
E-cadherin, which is expressed in many epithelial, but not mesenchymal cells487,
was only detected in the control cell line A431. No changes in the expression levels
of the mesenchymal markers slug487 and vimentin488 were observed in the ADAM15
variant expressing MDA panel. This suggests that the introduction of ADAM15 did
not induce MET.
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Figure 4.1: Expression of EMT/MET markers in the host cell line and MDA/ADAM15 isoform
expressing cells. n=2
Another group of proteins responsible for cell-cell adhesion are tight junction pro-
teins487. Diﬀerent members of this group were screened for changes in expression
(ﬁgure 4.2 a). ZO1 and ZO2 levels were unaltered across the cell line panel investi-
gated. In contrast, occludin levels were variable across the cell panel as seen in ﬁgure
4.2 a. However, expression changes were not statistically signiﬁcant. Occludin and
ZO1 were found to be slightly diﬀerent within independent samples. However, den-
sitometry of MDA/ADAM15 isoform expressing cells showed no signiﬁcantly altered
expression (ﬁgure 4.2 b).
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Figure 4.2: Unchanged expression of various tight junction proteins. a) The expression of ZO1
(n=3), ZO2 (n=1) and occludin (n=5) were not altered in MDA/FRT and MDA/ADAM15 isoform
expressing cells. Occludin expression highly varied within experiments. b) Densitometry analysis
of Occludin/Actin and c) ZO1/Actin expression. No significant changes were observed compared
to the parental cell line. Kruskal-Wallis test was performed with Dunn’s multiple comparison test.
MDA/ADAM15 A-E WT and E349A expressing cells were compared to the MDA/FRT control
cell line. Confidence intervals are as follows: ∗ = p ≤ 0.05, ∗∗ = p ≤ 0.01, ∗ ∗ ∗ = p ≤ 0.001. n=5
4.2.2 ADAM15 overexpression leads to claudin1 upregula-
tion
Next we investigated whether claudin expression levels were aﬀected by ADAM15
expression. Together with occludins, claudins are a family of TJ proteins which
directly connect adjacent cells. The cell panel was seeded and harvested as soon the
dishes were conﬂuent. Western blot analysis was performed to analyse the expres-
sion of claudin1. Signiﬁcant upregulation of claudin1 was found in MDA/ADAM15
A, C and E expressing cells (ﬁgure 4.3). Compared to the parental cell line, the
claudin1 expression in MDA/ADAM15 A expressing cells was almost 7 fold higher.
On average, the level of claudin1 was 3 fold higher in MDA/ADAM15 C and E than
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in parental cells. In MDA/ADAM15 B and D expressing cells claudin1 was not
upregulated. By western blot analysis weak bands of claudin1 in the catalytically
inactive MDA/ADAM15 A, C and E E349A expressing cells could be observed.
However, expression was not signiﬁcantly increased. These results indicated that
upregulation of claudin1 expression in response to ADAM15 A, C and E requires
the proteolytic activity of ADAM15.
RNA analysis demonstrated that claudin1 expression is 3 fold higher in
MDA/ADAM15 A expressing cells compared to MDA/FRT cells. MDA/ADAM15
C and E expressing cells showed 2.5 and 2 fold higher amounts of claudin1 RNA.
The RNA levels of claudin1 in MDA/ADAM15 B and D, as well as in E349A
expressing cells, were either equal or less compared to MDA/FRT cells.
Figure 4.3: ADAM15 upregulates claudin1 in an isoform specific manner.(a) Representative
western blot of claudin1 expression (b) Claudin expression at protein level. Densitometry was
performed using ImageJ. Claudin1 expression was normalised to the actin control and displayed
as arbitrary unit (au). Statistical significance was assessed with one way ANOVA and Dunnet’s
multiple comparison test. MDA/ADAM15 A-E WT and E349A expressing cells were compared
to the MDA/FRT control cell line. Confidence intervals are as follows: ∗ = p ≤ 0.05, ∗∗ = p ≤
0.01, ∗ ∗ ∗ = p ≤ 0.001. n=4 (c) Claudin1 expression at RNA level. n=1
Slightly elevated expression of claudin1 was also found in the E349A variant of
MDA/ADAM15 A, C and E expressing cells, but the increase was insigniﬁcant. This
ﬁnding was conﬁrmed on both protein (ﬁgure 4.3 a and b) and RNA level (ﬁgure
4.3 c). MDA/ADAM15 isoform expressing cells were harvested from 10 cm dishes
and RNA was extracted. The TaqMan analysis was carried out by the lab of Dylan
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Edwards (University of East Anglia, Norwich, UK) in one experiment. In summary,
claudin1 upregulation was signiﬁcantly increased in MDA/ADAM15 A, C and E
expressing cells.
As cells grow more conﬂuent, tight junctions stabilise. This leads to accumula-
tion of tight junction proteins. To conﬁrm whether the newly expressed claudin1
behaves like a classical tight junction protein, identical numbers of MDA cells ex-
pressing ADAM15 isoforms were seeded in duplicates. The ﬁrst set was harvested
for protein analysis during exponential growth (50%), while the second set was har-
vested two days after the cells became conﬂuent (>100%) (ﬁgure 4.4). Western
blot analysis was performed for claudin1. In the parental cell line (MDA/FRT)
weak bands for each density were observed. This indicates that MDA-MB-231 cells
do express claudin1, but in an amount which is close to the detection threshold
(ﬁgure 4.4). Claudin1 expression was detected in parental and MDA/ADAM15
D expressing cells, but no diﬀerence could be observed between both densities. In
MDA/ADAM15 A, C and E expressing cells claudin1 expression increased at >100%
conﬂuence compared to 50%. In constrast, MDA/ADAM15 B expressing cells lacked
the expression of claudin1 and a higher density did not change its level. In order
to tell if the accumulation of claudin1 is signiﬁcant in MDA/ADAM15 C and E
expressing cells, a further repeat is necessary. Concomitantly, the membrane was
also probed for V5-ADAM15. The protein levels of ADAM15 were independent of
cell density.
Figure 4.4: Claudin1 expression is dependent on cell density in MDA/ADAM15 A expressing
cells. a)Western blot analysis of MDA/FRT and MDA/ADAM15 A-E WT expressing cells probed
for claudin1 and V5-ADAM15. Actin was used as loading control. b) Results of densitometric
analysis of claudin1 expression shown as column diagram. Densitometry was performed using
ImageJ. Claudin1 expression was normalised to the actin control and displayed as arbitrary unit
(au). Statistical significance was assessed with students T-test. The increase in claudin1 expression
between 50 and >100% density was addressed. Statistical analysis was performed where applicable.
MDA/ADAM15 WT was compared to the MDA/FRT control cell line. Confidence intervals are
as follows: ∗ = p ≤ 0.05, ∗∗ = p ≤ 0.01, ∗ ∗ ∗ = p ≤ 0.001. The number of repeats is shown above
the individuals bars.
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4.2.3 ADAM15 co-localises with claudin1 in MDA-MB-231
cells
Aberrant expression and mislocalisation of claudin1 correlates with very aggressive
basal-like beast cancer59. We identiﬁed that ADAM15 A cells did not undergo
MET (section 4.2.1). We hypothesised that claudin1 might not necessarily be
restricted to cell-cell junctions in these cells. It was sought to determine the
localisation of claudin1 in MDA/ADAM15 A cells. These cells were chosen for
subsequent experiments as they had the highest expression of claudin1.
Glass coverslips were coated with growth medium for at least 24h. Cells were
seeded and incubated for 72h to reach a conﬂuence of about 30% and to allow
cell-cell junctions to form. Subsequently, IF staining was performed as described in
section 2.9.
In MDA/ADAM15 A expressing cells co-localisation of both claudin1 and ADAM15
was observed in cell-cell junctions and in the periphery (ﬁgure 4.5). Some claudin1
was detected in the cytoplasm, but much more of ADAM15 was localised there.
In the parental MDA/FRT cell line some claudin1 was detected across the cell,
but neither in the membrane nor cell-cell junctions. The expressed amount was
localised to the cytoplasm, but seemed close to the detection threshold. A431 cells
showed a very strong localisation of claudin1 in cell-cell junctions and partially at
the membrane and the cytoplasm. Since ADAM15 was detected with an anitbody
against the V5-tag endogenous ADAM15 in MDA/FRT and A431 was not picked up.
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Figure 4.5: Co-localisation of overexpressed ADAM15 and claudin1 in MDA/ADAM15 A ex-
pressing cells. The left column shows expression and localisation of claudin1 in MDA/ADAM15 A,
MDA/FRT and A431 cell lines. The middle column displays ADAM15 expression and localisation
visualised with an antibody against its V5 tag. The right column shows the merged image. Arrows
indicate the localisation of claudin1 and ADAM15 in cell-cell junctions and at the periphery. Scale
bar = 10 μm. n=6
4.2.4 ZO1 and ZO2 - new ADAM15 interaction partners
The immunolocalisation analysis of claudin1 and ADAM15 raised the possibility
that these proteins might form a complex. It is known that the only protein-protein
interaction motifs in ADAM15 ICD are the tyrosines and proline-rich regions, that
allow direct interactions with SH2 and SH3 domains of various proteins, respec-
tively. However, claudin1 does not contain SH2 or SH3 domains, hence it is unlikely
to interact with ADAM15 directly. Contrary, ZO1, a protein that directly binds to
claudin1, has an SH3 domain129 which could potentially link claudin1 and ADAM15.
To address the hypothesis that ZO1 forms a complex with ADAM15 and claudin1
IFs were performed with MDA/ADAM15 A expressing cells (ﬁgure 4.6). In
MDA/ADAM15 A, the analysis shows that ZO1 is primarily found in the mem-
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brane and cell-cell junctions with a moderate expression in the cytoplasm. This
also applies to ADAM15. The merged image demonstrated ADAM15 and ZO1
co-localisation along cell-cell junctions, as well as the cell periphery.
Figure 4.6: Co-localisation of overexpressed ADAM15 and ZO1 in MDA/ADAM15 A expressing
cells. The left column shows expression and localisation of ZO1 in MDA/ADAM15 A, MDA/FRT
and A431. The middle column displays ADAM15 expression and localisation visualised with an
antibody against its V5 tag. The right column shows the merged image. MDA/FRT and A431
cells do not contain V5 tagged ADAM15 and serve as negative control. Scale bar = 10 μm. n=3
In the parental MDA cell line and A431 cells ZO1 was primarily found in cell-
cell junctions. A moderate localisation was also observed in the membrane and
cytoplasm. MDA/FRT and A431 cells do not express V5-tagged ADAM15. They
serve as negative control for V5. However, some unspeciﬁc signal was observed.
A431 were used as control since ZO1 is expressed in large quantities.
Additionally, to investigate whether endogenous ADAM15 co-localises with claudin1
and ZO1, I carried out IF analysis of T47D cells (ﬁgure 4.7). T47D are epithelial
cells expressing high levels of claudin1 and ADAM15. IFs were performed with T47D
cells and stained for claudin1 or ZO1 and co-stained for ADAM15 using an antibody
against the ADAM15 ECD. Claudin1 and ADAM15 were primarily localised in cell-
cell junctions and periphery. A moderate expression was also found in the cytoplasm.
CHAPTER 4. ADAM15 MEDIATED UPREGULATION OF CLAUDIN1
EXPRESSION 152
Co-localisation of ZO1 and ADAM15 was also observed predominantly in cell-cell
junctions and periphery.
Figure 4.7: Co-localisation of ADAM15 and claudin1 in T47D cells. Areas of co-localisation are
highlighted with an arrow. The top row shows T47D cell stained with claudin1 (left column, red)
and ADAM15 (middle column, green). The right column presents the merged image of claudin1
and ADAM15. The bottom row shows T47D stained with ZO1 (left column, red) and ADAM15
(middle column, green). The right column presents the merged image of ZO1 and ADAM15. Scale
bar = 10 μm. n=3
These results suggest that these proteins are likely to be in a complex. To
conﬁrm whether ZO1 and ADAM15 are indeed in a complex, immunoprecipitation
analysis was performed. Parental MDA/FRT and MDA/ADAM15 A-E expressing
cells were seeded into 10 cm dishes and grown until conﬂuent. IPs were performed
with 1 mg of total protein lysates from each cell line. ADAM15 isoforms were
immunoprecipitated from MDA/ADAM15 isoform expressing cells with an anti-V5
antibody. Western blot analysis (ﬁgure 4.8) showed diﬀerent levels of ADAM15
isoforms with the highest deviation in ADAM15 D isoform. This is likely to aﬀect
the IP results. In ﬁgure 4.8 a ZO1 was co-IPed with ADAM15 A, B, and C isoforms,
but was not observed in ADAM15 D and E expressing cells. To conﬁrm complex
formation between ADAM15 isoforms and ZO1 reverse IPs were also performed.
ZO1 was immunoprecipitated from lysates of MDA/FRT and MDA/ADAM15 A-E
expressing cells. The western blots were probed with ZO1 to conﬁrm successful
precipitation. Antibodies against V5 were used to detect the coIPed ADAM15
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isoforms (ﬁgure 4.8 b). ADAM15 was detected in ZO1 in MDA/ADAM15 A, B, C
and E expressing isoform.
We questioned whether ZO2 would be in a complex with ADAM15, since it also
contains an SH3 domain. ZO2 was immunoprecipitated from lysates of MDA/FRT
and MDA/ADAM15 A-E expressing cells. The western blots were probed with ZO2
to conﬁrm successful precipitation. Antibodies against V5 epitope were used to
detect co-IPed ADAM15 isoforms. ADAM15 A, B, C and E isoforms precipitated
equally with ZO2. We also detected some ADAM15 D in ZO2 IPs.
Figure 4.8: Co-IPs of ADAM15, ZO1 and ZO2 in MDA/FRT and MDA/ADAM15 A-E exoressing
cells. (a) V5 IP probed with V5, Grb2 and ZO1. (b) ZO1 IP probed with ZO1 and V5. (c) ZO2
IP probed with ZO2 and V5. n=2
These data suggest that ADAM15 A, B, C and E isoforms are in a complex
with ZO1 and ZO2 and that ZO1 and ZO2 are potential new ADAM15 interaction
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partners.
To validate that we are able to detect co-IPed proteins, I performed IPs with α-V5
and probed for Grb2, a known interaction partner of ADAM15179,181,182. As ex-
pected, Grb2 co-IPed with all ADAM15 isoforms except D, which does not contain
the Grb2 interaction motif.
To conﬁrm the IP results, we carried out IF analysis for ADAM15 and ZO1 in
ADAM15 isoform expressing cell lines. As we can see in ﬁgure 4.9, exogenously
expressed ADAM15 localises to cell-cell junctions in ADAM15 A, B, C, and E ex-
pressing cells, where it co-localises with ZO1.
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Figure 4.9: Co-staining of V5-ADAM15 and ZO1 in MDA/FRT as well as MDA/ADAM15
isoform expressing cells. The left columns shows ZO1 staining (red) while the middle column
shows ADAM15, visualised via its V5 tag (green). The right columns shows the merged image.
The nucleus is visualised with DAPI (blue). Scale bar = 10 μm. n=3
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4.2.5 Claudin1 is localised in the nucleus of ADAM15 A
expressing cells
In the course of claudin1 IF analysis a small proportion of MDA/ADAM15 A ex-
pressing cells showed positive staining for claudin1 in the nuclei as shown in ﬁgure
4.10.
Figure 4.10: Co-localisation of ADAM15 and claudin1 in MDA/FRT and MDA/ADAM15 A
expressing cells. MDA/FRT serve as negative control. The used ADAM15 antibody targets the
ECD. Scale bar = 10 μm. n=3
To address whether this ﬁnding is speciﬁc claudin1 targeting shRNA was pack-
aged into lentiviral particles and transduced into MDA/ADAM15 A expressing
cells. Clones were selected in puromycin and expanded. The western blot method
was used to identify successful downregulation (ﬁgure 4.11 b). MDA/ADAM15
A, MDA/ADAM15 A non-target, MDA/ADAM15 A shClaudin1 expressing cells
were grown on medium coated glass coverslips until 50% conﬂuent and subsequently
stained as described in section 2.9. ADAM15 was stained with antibodies against
the ECD. Both, MDA/ADAM15 A and MDA/ADAM15 non-target cells showed
cytoplasmic and peripheral staining of ADAM15. Claudin1 was detected at the
periphery, in the cytoplasm and in the nucleus of a small proportion of examined
cells. As previously shown (ﬁgure 4.5) the IF analysis demonstrated ADAM15 and
claudin1 co-localisation at the cell-cell junctions and cell periphery. MDA/ADAM15
A shClaudin1 expressing cells show much less staining throughout and considerably
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less in the nuclei. ADAM15 staining remained unaltered in MDA/ADAM15 A
shClaudin1 expressing cells.
Figure 4.11: Immunofluorescence stainings and western blot validation of ADAM15 and claudin1
in MDA/ADAM15 A, MDA/ADAM15 A non-target and MDA/ADAM15 A shClaudin1 expressing
cells. a) Representative IF images. Antibodies against the ECD of ADAM15 (red) were used and
co-stained with claudin1 (green). DAPI was used to visualise the nucleus (blue). Scale bar = 10
μm. b) Western blot validation of used cells showing the expression of claudin1, ADAM15 and
actin. n=2
Claudin1 nuclear staining was conﬁrmed further by another claudin1 anti-
body. The primary anti-mouse (Invitrogen 37-4900) and anti-rabbit (Invitrogen
51-9000) antibodies were used to stain claudin1 in MDA/ADAM15 A non-target
and MDA/ADAM15 A shClaudin1 expressing cells.
Cells were seeded on medium coated glass coverslips. These cells were grown for
72h and stained as described. The mounting was done with Prolong mounting me-
dia which is supplemented with DAPI. In ﬁgure 4.12 a summary of the examined
slides is shown. The ﬁrst two rows show MDA/ADAM15 A non-target express-
ing cells stained with 37-4900 and 51-9000. In both images claudin1 is stained in
bright green. Staining can be found throughout the cytoplasm, some accumulation
in cell-cell junctions and membrane as well as in the nucleus. There was not much
diﬀerence in the ﬂuorescence intensity between the antibodies.
To address whether the claudin1 signal is speciﬁc the staining was also done in
MDA/ADAM15 A shClaudin1 expressing cells. Figure 4.11 b shows that the shRNA
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knockdown was successful therefore expected to see less claudin1 expression in these
cells. The central column shows that the lower panel, compared to the upper panel,
had reduced expression of claudin1. However, weak expression was still observed in
the cytoplasm, cell-cell junctions, membrane and nucleus.
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Figure 4.12: Validation of claudin1 antibodies for immunofluorescence staining. Both antibodies
were purchased from Invitrogen. 37-4900 is a monoclonal mouse antibody and 51-9000 is a poly-
clonal rabbit antibody. The upper panel shows MDA/ADAM15 A non-target shRNA expressing
cells. The lower panel shows MDA/ADAM15 A shClaudin1 expressing cells. The left column
shows the DAPI staining of the tested cell lines. The middle panel shows the same cells stained
with each of the claudin1 antibodies. The right panel shows a merged images of both. Scale bar
= 10 μm
. n=1
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Based on the results we could not see any changes between the antibodies. Ac-
cording to western blot analysis (ﬁgure4.11) b knockdown of claudin1 was highly
eﬃcient. However, in ﬁgure 4.12 b nuclear background staining was observed sug-
gesting a degree of unspeciﬁc binding. To conﬁrm that the nuclear localisation
further fractionation experiments were performed from MDA/ADAM15 A express-
ing cells.
Cells were seeded into 10 cm dishes and grown until conﬂuent. Conﬂuent dishes
were trypsinised and counted. 2.5 x 106 cells were lysed as described in section
2.7.2. The same cell number was subjected to fractionation as described in section
2.7.1. Following quantiﬁcation, 10 μg of total cell extract (TE), cytoplasmic (CE)
and membrane extract (ME) was used as well as 5 μg of nuclear extract (NE) to
perform a protein analysis via western blot (ﬁgure 4.13).
HSP90 serves as cytoplasmic control while R-cadherin is used as membrane control.
Lamin A/C was chosen as nuclear control. As detection control TE was used which
was detected in all probings. Within the CE we detected claudin1 and ADAM15, but
less compared to the TE. In the ME a prominent amount of claudin1 and ADAM15
was detected, comparable to the TE. This shows that this is the primary site of
localisation. In the NE a weak band of claudin1 as well as ADAM15 was found.
This data indicates that the membrane is the primary site of expression for claudin1
and ADAM15. However, both proteins also localise to the cytoplasm and nucleus.
Figure 4.13: Localisation experiment of claudin1 in MDA/ADAM15 A expressing cells. Total
cell lysate (TE) serves as control. Fractions of cytoplasm (CE), membrane (ME) and nucleus (NE)
with corresponding compartment controls: HSP90, R-cadherin and Lamin A/C, respectively. n=3
4.2.6 ADAM15 ablation leads to downregulation of claudin1
Next, we asked whether claudin1 expression depends on continuous ADAM15 ex-
pression. We used the MDA/ADAM15 A shADAM15 expressing cells, described
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in chapter 3, to investigate whether ADAM15 expression is necessary for claudin1
upregulation. ShRNA was introduced into lentiviral particles and transduced into
MDA/ADAM15 A expressing cells. Emerging clones, during puromycin selection,
were expanded and screened for successful knockdown. These knockdown cell lines
were kept in puromycin selection to retain the stable knockdown and prevent out-
growth of clones without insert. Figure 4.14 shows a comparison of the generated
cell lines. ADAM15 expression was analysed by western blot and detected with an
antibody against ADAM15. Parental MDA/FRT cells served as control cell line
with only moderate amounts of endogenous ADAM15 and no detectable claudin1.
Non-target shRNA was introduced into MDA/ADAM15 A to ensure the infection
did not alter ADAM15 expression. These cells express high levels of ADAM15
and detectable claudin1. The shRNA against ADAM15 in clones #22 and #71
showed successful suppression of expression of ADAM15. Interestingly, downregula-
tion of ADAM15 expression led to a decrease in claudin1 levels. This suggests that
ADAM15 expression is necessary for claudin1 upregulation.
To conﬁrm this, the cell line T47D was used which has high endogenous levels of
ADAM15 and claudin1. ShRNA against the 3’ untranslated region (3’UTR) of
ADAM15 was transduced into these cells. As before, the protein expression was
analysed by western blot (ﬁgure 4.14 b). In both, T47D (WT) and T47D non-
target shRNA, a high expression of endogenous ADAM15 as well as claudin1 was
observed.
Figure 4.14: Knockdown of ADAM15 with shRNA in MDA/ADAM15 A expressing cells and
T47D breast cancer cells analysed by western blot. (a) As shown in figure 4.3 a overexpression
of ADAM15 A in MDA-MB-231 cells led to upregulation of claudin1. Upon downregulation of
ADAM15 with shRNA claudin1 expression is concomitantly reduced. (b) Western blot analysis of
T47D cells which have high endogenous levels of ADAM15 and claudin1. ShRNA against ADAM15
led to successful reduction in ADAM15 protein levels. Concomitantly, claudin1 expression is low-
ered as well.
As seen with MDA/ADAM15 expressing cells, downregulation of endogenous
ADAM15 expression led to a signiﬁcant decrease in claudin1 expression. This con-
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ﬁrms that ADAM15 expression is necessary for claudin1 upregulation.. The pheno-
type of those cells did not change (ﬁgure 4.15).
In summary, shRNA targeting ADAM15 led to concomitant reduction in claudin1
levels in cells overexpressing ADAM15 and cells showing naturally high levels of
ADAM15 and claudin1. Thus claudin1 expression depends on ADAM15 expression
at least in breast cancer cells. In T47D cells ADAM15-mediated downregulation of
claudin1 did not aﬀect cell morphology (ﬁgure 4.15).
Figure 4.15: Phase-contrast images of T47D non-target and T47D shADAM15 expressing cells.
a) T47D cells stably transfected with non-target shRNA. b) T47D cells stably transfected with
shRNA targeting ADAM15. Scale bar = 100 μm.
4.2.7 Claudin1 upregulation is regulated via PI3K/mTOR
pathway
In order to understand how claudin1 is upregulated various signalling pathways
were analysed. The initial experiment screened a selected panel of inhibitors target-
ing several major pathways. This panel comprised p38MAPK (SB203580), MAPK
(PD98059), PI3K (LY294002), EGFR (Geftinib), Signal transducer and activator of
transcription 3 (STAT3) (FLLL31), novel and classical protein kinase C bisindolyl-
maleimide inhbitor 1 (Bim1), Ca2+-dependent PKCα and β (Go¨6976) and PKCδ in-
hibitor (Rottlerin). The p38MAPK, PI3K and PKC inhibitors were chosen, because
claudin1 expression is regulated via these pathways in adult rat hepatocytes489.
Geﬁtinib was chosen, because it was reported that EGF-induced EGFR activation
increased claudin1 expression in Madin-Darby canine kidney (MDCK) II cells490.
STAT3 inhibitor was used since it is reported that STAT3 regulates barrier function
in intestinal epithelial cells491. The reason of choosing a MAPK inhibitor was that
ADAM15 interacts with pErk1/2179 and that claudin1 regulates intestinal epithelial
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homoeostasis via Erk/Notch signalling492. Cells were seeded into 10 cm dishes and
grown for 48h to establish potential tight junction formation. Cells were treated
with recommended pharmacological doses for 24h, lysates taken and analysed by
western blot and RNA for claudin1 expression.
Validation (only by western blot) of the used inhibitors Geﬁtinib, LY294002,
PD98059 and PP2 is shown in ﬁgure 4.16. Additionally, the PKC inhibitors were
provided and validated by Wanger et al.493. FLLL31 was provided and validated by
Dodd et al.494. SB203580 was provided and validated by Davis et al.495. Rottlerin
was validated by Stephens et al.496.
Figure 4.16: Validation of inhibitors used to determine the pathway involved in claudin1 up-
regulation. Gefitinib (EGFR inhibitor, 0.2/1/2 μM); LY294002 (PI3K inhibitor, 1 μM); PD98059
(MAPK inhibitor, 2.5 μM); PP2 (Src family kinase inihbitor, 100 nM). n=1
Only the inhibition of PI3K by LY294002 led to reduced claudin1 expression
(ﬁgure 4.17 d). None of the other inhibitors changed claudin1 expression suggesting
claudin1 upregulation is mediated by PI3K pathway. (ﬁgure 4.17 a-c)
CHAPTER 4. ADAM15 MEDIATED UPREGULATION OF CLAUDIN1
EXPRESSION 164
Figure 4.17: Screening for signalling pathways potentially involved in claudin1 upregulation in
MDA/ADAM15 A expressing cells. Duration of treatment was 24h with following inhibitors:
SB203580 (10 μM; n=1), PD98059 (10 μM; n=4), Gefitinib (0.5 μM; n=2), FLLL31 (5 μM;
n=1), Bim (1 μM; n=3), Go¨6976 (1 μM; n=3), Rottlerin (5 μM; n=3), PP2 (100 nM; n=3)
and LY294002 (50 μM; n=5). Densitometry and analysis of the mRNA was performed using Im-
ageJ. Claudin1/GAPDH ratio was normalised to the DMSO control. The result is shown as fold
difference in bar graphs. To address statistical significance one-way ANOVA was performed. The
inhibitor treated samples were compared to the vehicle control. Confidence intervals are as fol-
lows: ∗ = p ≦ 0.05; ∗∗ = p ≦ 0.01; ∗ ∗ ∗ = p ≦ 0.001. a) Representative images and quantification
of analysed mRNA and protein. GAPDH was used as control for mRNA analysis whereas actin
was used as control for protein. The RNA was reverse transcribed to cDNA and amplified with
claudin1 and GAPDH-specific primers followed by separation on a agarose gel. b) mRNA and
protein analysis of Src family kinase inhibitor PP2 (100 nM). Claudin1/Actin ratio was normalised
to the DMSO control. c) mRNA analysis of the PI3K inhibitor LY294002 (50 μM).
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In order to conﬁrm the role of PI3K pathway in ADAM15-dependent claudin1
upregulation, we used another PI3K inhibitor, PI-103 to conﬁrm the ﬁndings. Ad-
ditionally, mTOR is another major signalling pathway downstream of PI3K. Thus
we also employed inhibitors to mTOR: Rapamycin, that inhibits mTORC1, and
Ku0063794, which inhibits mTORC1 and mTORC2. Phase-contrast images of the
cells were taken after 24h inhibitor treatment to observe morphological changes of
MDA/ADAM15 A, C and E expressing cells. The phenotype of DMSO treated
cells was unchanged compared to to untreated cells conﬁrming that the solvent had
no adverse eﬀect on cell morphology. LY294002 treatment of the cells resulted in
spindle-like morphology, which was mostly seen in MDA/ADAM15 A expressing
cells (ﬁgure 4.18). This phenotype was mostly prominent in MDA/ADAM15 A ex-
pressing cells, to a lesser extent in MDA/ADAM15 C and least in MDA/ADAM15
E expressing cells. Objectively, PI-103, Rapamycin and Ku0063794 treatment did
not aﬀect the phenotype of all tested cells.
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Figure 4.18: Representative phase-contrast images of MDA/ADAM15 A, C and E expressing
cells after 24h of inhibitor treatment. The first column shows images of MDA/ADAM15 A, the
second column MDA/ADAM15 C and third column MDA/ADAM15 E expressing cells. From top
to bottom: UT, DMSO, LY294002 (50 μM), PI-103 (1 μM), Rapamycin (100 nM) and Ku0063794
(1 μM). Scale bar = 100 μm.
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Western blot analysis (ﬁgure 4.19 a and b) demonstrated moderate, but
signiﬁcant claudin1 downregulation when cells were treated with LY294002. In
contrast, PI-103 treatment did not reduce the expression of claudin1 in any of the
tested cells (ﬁgure 4.19 a and c). Rapamycin treatment reduced the claudin1 levels
signiﬁcantly in MDA/ADAM15 A and C, but not in E expressing cells (ﬁgure 4.19
a and d). However, this inhibitor was less eﬃcient then LY294002 when claudin1
levels were quantiﬁed using ImageJ (ﬁgure 4.19 b and d). Neither of these cells
responded to Ku0063794 treatment (ﬁgure 4.19 a and d). To conﬁrm that the
inhibitors were eﬀectively blocking the mTOR pathway, the western blots were
probed with an antibody detecting phosphorylated S6, which is downstream of
PI3K/mTOR pathway. All treatments resulted in reduction of pS6 phosphorylation.
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Figure 4.19: ADAM15 A, C and E expressing cells treated with PI3K and mTOR inhibitors. Den-
sitometry on the bands was carried out using ImageJ. Claudin1 expression values were normalised
to actin and then to the DMSO control of each isoform. The result is shown as fold difference us-
ing bar graphs. To address statistical significance two-way ANOVA was performed. The inhibitor
treatment was compared to the vehicle control for MDA/ADAM15 A, C and E expressing isoform
individually. Confidence intervals are as follows: ∗ = p ≦ 0.05; ∗∗ = p ≦ 0.01; ∗ ∗ ∗ = p ≦ 0.001.
n=3
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The moderate decrease in claudin1 protein levels in response to PI3K/mTOR
inhibitors led us to hypothesise that claudin1 might be very stable over the time pe-
riod that inhibitor treatment was performed. To address that I treated ADAM15 A
expressing cells with cycloheximide (CHX), a protein biosynthesis inhibitor. West-
ern blot analysis demonstrated that claudin1 protein is stable over 24h period, and
that claudin1 levels reduced after prolonged (48h) treatment with a high (10 μg/mL)
dose of CHX (ﬁgure 4.20). Figure 4.20 c shows the total protein concentration of
the used samples which served as positive control for protein synthesis inhibition.
After 48h of growth the total protein concentration increased by approximately 50%
in UT and DMSO treated samples. CHX treatment successfully inhibited protein
synthesis since the protein concentrations were similar to the starting concentration
prior to incubation/treatment.
Figure 4.20: Claudin1 expression is stable for up to 48h in MDA/ADAM15 A expressing cells.
MDA/ADAM15 A expressing cells were treated with either DMSO, 5 or 10 μg/mL CHX at 70%
confluence. One dish was lysed immediately without treatment. Protein lysates were harvested
after 24 or 48h of CHX treatment. (a) Protein analysis of claudin1 and actin. (b) The bands
were quantified with ImageJ and the ratio of claudin1:actin normalised to the UT control at 0h.
The result is shown in fold difference. (c) Absorbance of total protein concentration which serves
as control of protein synthesis inhibition. n=1
As the CHX treatment conﬁrmed that claudin1 protein is stable for at least 24h,
we analysed claudin1 mRNA levels in response to PI3K/mTOR inhibition. The
inhibitor treatments were repeated as described earlier, followed by RNA extrac-
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tion. RT-PCR was performed with extracted RNA. The cDNA was in turn used for
PCR, and products ampliﬁed with claudin1- and GAPDH-specﬁc primers. Upon
treatment with LY294002 claudin1 mRNA was signiﬁcantly reduced by over 70% in
MDA/ADAM15 A, C and E expressing cells (ﬁgure 4.21). When cells are treated
with PI-103 a reduction of claudin1 mRNA is observed in all tested cell lines. How-
ever, the reduction was only statistically signiﬁcant in MDA/ADAM15 C expressing
cells. Claudin1 mRNA levels were signiﬁcantly downregulated in all cell lines in re-
sponse to rapamycin. While Ku0063794 treatment reduced claudin1 mRNA levels
in all cell lines, the reduction was statistically signiﬁcant only in MDA/ADAM15
C expressing cells. To conclude, LY294002 and Rapmycin treatment suppressed
claudin1 mRNA signiﬁcantly in all cell lines tested. PI-103 and Ku0063794 treat-
ment achieved statistically signiﬁcant reduction of claudin1 mRNA levels only in
MDA/ADAM15 C expressing cells.
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Figure 4.21: Amplified cDNA from extracted RNA of MDA/ADAM15 A, C and E expressing
cells treated with PI3K and mTOR inhibitors for 24h. Extracted RNA was reverse transcribed
to cDNA and amplified with claudin1 and GAPDH-specific primers followed by separation on a
agarose gel. Bands were quantified using ImageJ. The ratio of claudin1:GAPDH was normalised
to the DMSO control. a) Visualised cDNA bands of claudin1 and GAPDH on a 1.2% agarose
gel with inverted colours. The results are depicted as line graphs for b) LY294002 (50 μM), c)
PI-103 (1 μM), d) Rapamycin (100 nM) and e) Ku0063794 (1 μM). Statistical significance was
addressed by two-way ANOVA. The inhibitor treatment was compared to the vehicle control for
MDA/ADAM15 A, C and E expressing isoform individually. Confidence intervals are as follows:
∗ = p ≦ 0.05; ∗∗ = p ≦ 0.01; ∗ ∗ ∗ = p ≦ 0.001. n=3
CHAPTER 4. ADAM15 MEDIATED UPREGULATION OF CLAUDIN1
EXPRESSION 172
4.2.8 Claudin1 expression does not affect cell migration
In section 3.2.6 I demonstrated that overexpression of ADAM15 isoforms diﬀeren-
tially aﬀected scratch wound healing. As aberrant expression of claudin1 has been
implicated in modulating cell motility, I determined whether claudin1 plays a role
in mediating the defects in wound closure seen previously.
For this purpose MDA/ADAM15 A expressing cells with shRNA downregulation of
claudin1 expression were generated and used in scratch wound assays (ﬁgure 4.22).
Successful downregulation of claudin1 in MDA/ADAM15 A expressing cells is shown
in ﬁgure 4.11 b. As previously shown MDA/ADAM15 A expressing cells were not
closing the wound after 48h. MDA/ADAM15 A non-target sh expressing cells were
not signiﬁcantly diﬀerent either. MDA/ADAM15 A shClaudin1 expressing cells did
not change the rate of wound closure compared to both control cells. Therefore mi-
gration rates are independent of claudin1 expression level in ADAM15 A expressing
MDA-MB-231 cells.
CHAPTER 4. ADAM15 MEDIATED UPREGULATION OF CLAUDIN1
EXPRESSION 173
Figure 4.22: Wound healing assay of MDA/ADAM15 A, MDA/ADAM15 A non-target shRNA
and MDA/ADAM15 A shClaudin1 expressing cells. a) Example images after wounding, 24h and
48h. Scale bar = 200 μm. b) Bar chart comparing the wound closure of the cell lines. Statistical
significance was assessed with post-hoc Bonferroni’s multiple comparison test after performing two-
way ANOVA analysis. MDA/ADAM15 A non-target shRNA and MDA/ADAM15 A shClaudin1
expressing cells were compared to the MDA/ADAM15 A expressing control. Confidence intervals
are as follows: ∗ = p ≦ 0.05; ∗∗ = p ≦ 0.01; ∗ ∗ ∗ = p ≦ 0.001.n=3
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4.3 Discussion
The most important ﬁnding in this chapter is ADAM15 isoform-dependent and
catalytic function dependent upregulation of claudin1, as well as the identiﬁcation
of ZO1 and ZO2 as potential new interaction partners of ADAM15. Upregulation of
claudin1 is not signiﬁcantly increased in their E349A mutants. In MDA/ADAM15
A expressing cells claudin1 expression depends on cell density. Claudin1 co-localises
with ADAM15 at cell-cell junctions and periphery in MDA/ADAM15 A expressing
cells and in T47D. In a proportion of cells claudin1 is also localised in the nucleus.
ZO1 co-localises with ADAM15 in MDA/ADAM15 isoform expressing cells and
in T47D. ZO1 and ZO2 are found to be novel interactions partners of ADAM15.
ADAM15 ablation leads to downregulation of claudin1. Claudin1 upregulation is
regulated via the PI3K/mTOR pathway. In MDA/ADAM15 A expressing cells
claudin1 does not mediate migration.
Screening of several EMT markers conﬁrmed that ADAM15 expression did not cause
MET. One of the most dominant markers of epithelial cells is E-cadherin497,498.
Snail and slug, among other proteins, are able to bind to the E-cadherin promoter
suppressing its transcription499. Slug has been detected in the whole cell panel and
was only absent in the epithelial control whereas E-cadherin could only be detected
in A431 cells. To further disprove MET the samples were analysed for vimentin
which is only expressed in mesenchymal cells500 and was detected, unchanged, in
the host cell line as well as the ADAM15 isoform expressing cells. These observations
conﬁrmed that ADAM15 expression did not cause MET in this breast cancer cells.
Since epithelial growth relies on cell-cell junction formation and MDA/ADAM15
A expressing cells show dense epithelial-like morphology we hypothesised whether
diﬀerential regulation of tight junctions proteins are involved.
Tight junctions are important contributors in dense epithelial cells growth. The
major protein families in cell-cell interaction are occludins and claudins. Both are
integral proteins which are linked by ZO proteins to the actin cytoskeleton. Neither
ZO1 nor ZO2 nor occludin showed altered expression, but claudin1 was signiﬁcantly
upregulated in ADAM15 A, C and E expressing cells.
Next it was observed that claudin1 is dependent on cell density. With advanced
cell density claudin1 levels increased. It has been reported that the half-life and
level of ZO1 expression increases with cell density501 and overexpression of ZO1 in-
hibits proliferation in low-density cells502. Matter and Balda503 proposed a working
model in which accumulation of a TJ protein sensor for cell density. In non conﬂuent
cells the expression of TJ proteins is low and the inhibition of pathways reducing
proliferation is weak. By increasing cell density expression levels of TJ increase and
proteins stabilise at the forming TJs. This leads to recruitment of signalling pro-
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teins such as ZO-1-associated nucleic-acid binding protein (ZONAB) and PTEN and
therby inhibit proliferation. This may indicate that MDA/ADAM15 A expressing
cells form tight junctions. Additionally, previously ADAM15 has been implicated
in regulating epithelial and endothelial cell permeability162,189,191,192,224, although
this ADAM15 function has never been linked to claudin1 or any other tight junction
related gene expression. Two classical and well established methods of addressing
TJ permeability are transepithelial electrical resistance (TEER) measurement504,505
and paracellular permeability assay504,506. TEER measures voltages which passes
through a conﬂuent layer of cells. This gives an indication about the resistance.
The paracellular permeability assay makes use of diﬀerently sized dextran which is
conjugated with a ﬂuorescent dye. Smaller and larger sized conjugates are applied
onto a conﬂuent layer of cells grown on a porous membrane. Depending on the
tightness of the TJ, varying amounts of the labelled dextran passes through. These
experiments were performed by a colleague in the lab, and the results showed no
diﬀerence in TEER and paracellular permeability between MDA/ADAM15 A non-
target shRNA, MDA/ADAM15 A shADAM15 and MDA/ADAM15 A shClaudin1
expressing cells. This results suggest that claudin1 upregulation alone is not suﬃ-
cient to form functional tight junctions. Claudin1 is a crucial component of TJs.
Interference with the EL1 of claudin1 increased permeability271. However, it seems
that more contributors are required to establish functional tight junctions. We have
not investigated the expression and localisation of JAM proteins or the localisation
of occludins or other claudin family members. It is likely that one or more are lack-
ing in the cell-cell junctions of MDA/ADAM15 A expressing cells and thus cannot
form functional TJ. RNA and protein analysis followed by confocal microscopy could
answer this question. Claudin1 is a small transmembrane protein which function is
to maintain the barrier function among epithelial cells. It regulates the paracellular
diﬀusion of small ions across adjacent cells. Other functions comprise maintenance
of cell polarity and epithelial cell homoeostasis. It has also been considered to be a
tumour suppressor in human breast cancer. In TJs claudin1 binds ZO proteins via
its C-terminal PDZ-binding motif. The interaction is established via the N-terminal
PDZ domain of ZO1/ZO/ZO3. In MDA/ADAM15 A expressing cells claudin1 was
primarily found in the cytoplasm, but also in the cell-cell junctions and periphery.
A proportion of cells showed localised claudin1 in the nucleus. Co-localisation of
claudin1 and ADAM15 was primarily observed in cell-cell junctions and periphery,
but not in the nucleus. Concomitantly, ZO1 also co-localised with ADAM15 in
cell-cell junctions and periphery. CoIP experiments revealed direct interaction of
ADAM15 A, B, C and E expressing cells with ZO1. IPs with ZO2 showed coIP of
V5 in MDA/ADAM15 A-E expressing cells. In ZO2 IPs we observed a ADAM15
D speciﬁc band. However, ADAM15 D is the truncated isoform which lacks the
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proline-rich regions which interact with the SH3 domains as the ones in ZO2. Recent
ﬁndings in our lab showed that ADAM15 D forms a dimer with ADAM15 A (unpub-
lished data). Therefore we assume the anti-V5 antibody binds to V5-ADAM15 D in
ADAM15 D expressing cells which dimerised with untagged endogenous ADAM15 A
that in turn is bound by ZO2. Detection with anti-V5 antibody picks up ADAM15
D in western blot experiments but not the untagged ADAM15 A.
According to Uniprot129 Claudin1 and ADAM15 are not able to interact due to
the lack of interaction motifs. However, complex formation would be possible via
ZO1. It has been shown that ZO1 (also ZO2 and ZO3) can interact with its PDZ
domain and claudin1-8 via their COOH-terminal KDYV sequence291. ZO1 also has
an SH3 domain129 which is known to bind to proline-rich regions. ZO1 and ZO2 as
interaction partners of ADAM15 raises the question about the beneﬁt for the cell.
It is known that ZO1 proteins link claudins and occludins to the actin cytoskele-
ton262,507. Complex formation of ADAM15 with ZO1 would assure localisation of
ADAM15 to the tight junctions. A potential role for ADAM15 could be to increase
microvascular permeability which is considered as a central hallmark of inﬂamma-
tion. It has been demonstrated that occludin is degraded by an unknown MMP
to increase TJ permeability508. Recently, occludin was identiﬁed as substrate for
MMP2509. Since ADAM15 is closely related to MMPs and possess catalytic activity
there could be potential role as regulator of tight junctions.
Claudin1 was not only found in cell-cell junctions and plasma membrane, but also
in the nuclear fractions of MDA/ADAM15 A expressing cells. Nuclear claudin1 has
been found in benign nevi and early stage melanoma510. Nuclear localisation was
also found in metastatic osteosarcoma KRIB cells511, but the function remains un-
known.
The major question is how ADAM15 upregulates claudin1. Inhibitor treatments
showed that the PI3K/mTOR pathway is involved in upregulating claudin1 expres-
sion. Inhibition of both, PI3K and mTOR, led to reduced claudin1 expression.
Western blot analysis showed that inhibition of PKCs upregulated claudin1. How-
ever, densitometry analysis of the western blot resulted in insigniﬁcant upregulation.
It may still be that this method is not sensitive enough and should be repeated with
a quantitative approach such as PKC activity assays. An explanation would involve
the crosstalk of those pathways. LY294002 and PI-103 prevent indirectly phospho-
rylation of Akt since it is downstream of PI3K. Phosphorylation of Akt at S473 is
necessary for its activation. It seems if this mechanism is inhibited claudin1 expres-
sion is reduced. In contrast, phosphorylation of Akt could lead to upregulation of
claudin1. As this was observed upon treatment with diﬀerent PKC inhibitors. In
keratinocytes it was shown that inhibition of PKC increased insulin-like growth fac-
tor 1 (IGF-1)-incuded phosphorylation at S473 in Akt512. In contrast, stimulation
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of PKC by an activator reduced Akt phosphorylation at S473512. Both observations
suggest that PKC activation inhibits Akt activity. To conﬁrm this hypothesis the
treatments need to be repeated and claudin1 mRNA levels analysed.
It is not known how ADAM15 exactly drives claudin1 upregulation via PI3K/mTOR
pathway. One possibility could be via Src kinase which interacts directly with the
proline-rich regions of ADAM15 ICD via its SH3 domains166,179. The most plausible
scenario would be that distinct intracellular protein-protein interactions with alter-
native ADAM15 ICDs modulate the extracellular MP function of ADAM15, leading
to the shedding of speciﬁc substrates as illustrated in ﬁgure 4.23. These would
then activate the corresponding receptors, followed by downstream PI3K/mTOR
activation. This would be in line with our previous collaborative work showing
ADAM15 B mediated shedding of FGFR2IIIb as a result of interacting with and
being activated by Src tyrosine kinase207. It has been shown that Src is in a com-
plex with PI3K513 and also acts as a regulator514. In adult rat alveolar cells,
Src is important in the activation of sodium-potassium adenosine triphosphatase
(Na+/K+ – ATPase). Treatment of the thyroid hormone triiodothyronine (T3) in-
duces expression of Na+/K+–ATPase via PI3K/Akt and MAPK/Erk1/2 pathways.
Inhibition of Src blocked the activity of the Na+/K+–ATPase. Furthermore, T3 in-
duced phosphorylation of both Erk1/2 and Akt was blocked. These ﬁndings suggest
that Src regulates Na+/K+ – ATPase activity by both pathways. However, treat-
ment of MDA/ADAM15 A expressing cells by PP2 (Src family kinase inhibitor) did
not reduce claudin1 protein levels. This could be due to long half life of claudin1
which was shown in this chapter. Another reason could be that Src kinase functions
alongside other mediators and inhibition upstream of PI3K can be rescued. On
the contrary, Src and ADAM15 interaction might have no role in claudin1 upreg-
ulation. Considering that ADAM15 B has strong interaction with Src181 and no
upregulation of claudin1 was observed. It is known that p85α and ADAM15 ICD
interact181, but it can be excluded as a reason for claudin1 upregulation. Kleino
et al. presented strong interaction of the SH3 domain of p85α and the proline-rich
regions of ADAM15 isoforms. Especially ADAM15 B showed a strong interaction in
the peptide array, together with ADAM15 C and E. However, our MDA/ADAM15
B expressing cells do not upregulate claudin1. Thus direct interaction of PI3K to
ADAM15 may not activate the PI3K/mTOR signalling pathway.
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Figure 4.23: Schematic representation of the hypothesised ADAM15/PI3k/mTOR pathway.
Pharmacological inhibitors are displayed as a red squared box. Arrows indicate the activation
or phosphorylation (P) of a downstream molecule. Lines with horizontal bar indicated inhibition
of downstream target.
Taken together, upregulation of claudin1 seems to be isoform speciﬁc and MP
domain dependent. The ECD of ADAM15 isoforms are identical therefore some-
thing else dictates its function. The only diﬀerence between the cell lines are the
length and number of proline-rich regions.
A hypothesis is that diﬀerent intracellular interaction partners mediate claudin1
upregulation. The gain or loss of proline-rich regions could dictate the interac-
tion with adaptor proteins or kinases. It is known that the cytoplasmic tail of
ADAM15 spliceforms diﬀerentially associate with proteins179,180,182. As an exam-
ple, In MDA/ADAM15 A expressing cells a protein could interact with one of the
three available proline-rich regions which is necessary for claudin1 regulation. The
fourth proline-rich region in MDA/ADAM15 B expressing cells might have a higher
aﬃnity to another adaptor which blocks the association of other proteins.
In order to address the pathways mediating claudin1 upregulation, LY294002 a
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PI3K inhibitor was preferred over wortmannin due to its stability in vitro. The
tested half life of wortmannin is between 8-13 min515 which makes 24h treatments
impossible. The prolonged incubation period was necessary due to the stability of
the expressed claudin1. To conﬁrm the ﬁndings with LY294002, the newer and more
speciﬁc PI-103 inhibitor was used. However, the inhibition was not as striking as
with LY294002. A reason could be the stability of the compound or the used con-
centration. Compared to LY294002, PI-103 already showed therapeutic potential
in vivo, but it suﬀered from extensive metabolism450. Thus, it cannot be excluded
that the cells in vitro also metabolise the inhibitor rapidly, since it is also used
at a much lower concentration. In summary, it was demonstrated that ADAM15
upregulates the TJ protein claudin1 in an isoform speciﬁc and catalytically depen-
dent manner. Upregulation is mediated via the PI3K/mTOR pathway. Claudin1
is directly regulated by ADAM15 in MDA-MB-231 and T47D cells, but it has no
eﬀect on cell migration. Claudin1 is localised primarily in the cell-cell junctions
of MDA/ADAM15 A isoform expressing cells. However, claudin1 was also found
in membrane, cytoplasm and, most interestingly, in the nucleus. This suggests a
potential function as regulator of transcription. ADAM15 was found in a complex
with ZO1 and ZO2 which suggests it is a potential regulator in tight junctions.
Several papers have been published describing the correlation of claudin1 expres-
sion and cell migration. One study showed that a stable knockdown of keratins 8
and 18 upregulated claudin1 via PI3K/Akt/NFκB pathway which led to increased
collective cell migration and invasiveness of epithelial cancer322. Concomitantly,
in mammary gland carcinoma cells (BT-20), claudin1 knockdown reduced cell mi-
gration59. In colorectal cancer tissue miR-155 was signiﬁcantly upregulated516. It
was observed that upregulation of miR-155 increased claudin1 expression which
in turn enhanced cell migration and invasion. Many other studies conﬁrm that
claudin1 promotes migration in healthy cells as well as several types of cancer. The
promotion of migration by claudin1 was observed in healthy liver cells315, breast
cancer317, melanoma281,510,517, hepatocellular carcinoma315, gastric cancer300,518
and lung cancer519 (both mediated by TNFα). However, the opposite has also been
reported. In MDCK and T47D cells, active Recepteur d’origine nantais (RON) re-
duced claudin1 expression and promoted cell migration520. RON belongs to the
family of RTKs and regulates survival, growth, diﬀerentiation and migration. It is
often overexpressed in several types of primary cancers520. Based on literature I was
curious to see if claudin1 is also involved in the process of migration in MDA-MB-231
cells. In chapter 3 it was shown that MDA/ADAM15 A expressing cells signiﬁcantly
reduces cell migration compared to its parental control. Thus, I was interested to
see whether claudin1 upregulation aﬀects wound healing. Next, I performed scratch
wound experiments on MDA/ADAM15 A expressing cells, MDA/ADAM15 with
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non-target shRNA and also cells with shClaudin1 knockdown. The results showed
that there is no signiﬁcant diﬀerence between MDA/ADAM15 A non-target shRNA
and shClaudin1. This means that in MDA-MB-231 cells the migration is indepen-
dent of claudin1 expression. However, claudin1 can still contribute to collective cell
migration as reported in diﬀerent papers322,519. Collective cell migration has sev-
eral implications which makes it crucial to understand the underlying mechanisms.
One is that invasion is described as a similar collective behaviour of which cells
established the development of protrusions, shape generation and interaction with
the ECM521. On the ﬁrst glance, it is paradox to have cells performing collective
cell migration since the scientiﬁc dogma states that mesenchymal cells move single-
celled while epithelial cells perform collective cell migration522. In this chapter it
was conﬁrmed that our cells did not undergo MET and remain mesenchymal. How-
ever, ADAM15 A overexpression makes them grow epithelial-like. In general, the
beneﬁt of collective migration is to retain a structure or tissue while remodelling
it. Second, mobile cells drag immobile ones along. Third, movement as a collective
ensures correct distribution of the cells and cell shaping. Fourth, it adds robustness
to the collective. As an example, core cells are more protected from the immune
system. Claudin1 could contribute to all mentioned beneﬁts as a key player in main-
taining the integrity of the motile cells. There are several experiments to perform to
prove if MDA/ADAM15 A expressing cells migrate as a collective. Data from the
wound healing assays suggest that cells perform sheet migration, which is a charac-
teristic of epithelium. However, to investigate this process a better resolution and
live imaging would be beneﬁcial. A highly sophisticated approach to determine the
kind of migration is force mapping523. The theory is that this experiment measures
the dynamic traction forces which are exerted by epithelial cells which are combined
with a multiple particle tracking. The sensors for measurement are a high-density
array of microfabricated elastomeric pillars below the cells. Bending of the pillars
give an estimate of the mechanical activity. This assay is a powerful tool to proﬁle
cell types. Diﬀerent information such as degree of scattered cells, tractions force,
the orientation of migration front can be measured. Another powerful tool is to ob-
serve the migration of cells embedded in matrigel. This 3D environment represents
a more physiological system in which more complex movements such as sprouting
or branching can be observed.
I conclude that claudin1 expression is mediated by catalytic active ADAM15 A, C
and E isoform which shed an unknown substrate that in turn activates an unknown
receptor. The activated receptor promotes claudin1 expression via the PI3K/mTOR
pathway. Knockdown by shRNA targeting ADAM15 (shADAM15) as well as phar-
macological inhibition of PI3K and mTOR inhibited claudin1 upregulation. An
illustration of the hypothesised mechanism is displayed in ﬁgure 4.24.
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Figure 4.24: Regulation of claudin1 expression by catalytic active ADAM15 A, C and E re-
quires PI3K and mTOR signalling. Catalytic active, but not inactive, ADAM15 A, C and E
isoforms shed an unknown substrate which activates an unknown receptor. The activated receptor
stimulates claudin1 expression via the PI3K/mTOR pathway. Knockdown by shRNA targeting
ADAM15 (shADAM15) as well as pharmacological inhibition of PI3K (LY294002, PI-103) and
mTOR (Rapamycin, Ku0036794) inhibited claudin1 upregulation.
Chapter 5
ADAM15 mediated changes in
breast cancer cell adhesion
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5.1 Introduction
5.1.1 Aim of the chapter
1. Investigate whether FA turnover may cause changes in cell migration
2. Investigate whether ECM spreading caused changes in cell migration
5.2 Results
5.2.1 Focal adhesion dynamics are differentially regulated
by ADAM15 isoforms
FA are specialised cellular structures responsible for adhesion to a substrate which
occurs in many cell types. Within these structures integrins on the plasma membrane
interact with ECM components thereby establishing a link between the cell and its
environment.
The wound healing assay (section 3.2.6) revealed that the expression of ADAM15
isoforms aﬀects the migration rate of MDA-MB-231 cells. While the expression
of ADAM15 E had no eﬀect on the motility of these cells, the expression of all
the other isoforms reduced the wound closure rate with ADAM15 D expression
decreasing cell motility the most. This raised the question whether FA turnover is
altered in ADAM15 expressing cells, since cell movement requires the assembling
and disassembling of these structures. To assess the presence and distribution of FA
in our cell panel I conducted a pilot IF analysis of paxillin/vinculin in resting cells.
ADAM15 isoform expressing cells were seeded onto glass coverslips, allowed to grow
for 72h, ﬁxed and subjected to IF analysis. Figure 5.1 a shows representative images
of immunostaining for paxillin and vinculin. As these cells were not synchronised, we
would expect balanced and comparable FA distribution. However, the abundance
as well as orientation of vinculin positive FA were strikingly diﬀerent within the cell
panel. In an attempt to quantify these diﬀerences 100 cells from each cell line in
random ﬁelds were assessed and ordered in four groups based on the strength of
vinculin staining (ﬁgure 5.1 b).
Cells which did not show any visible FA were categorised in one group (non). Cells
with only a few FA were considered as “low”. In case FA cover the majority of
the periphery or are “uncountable” due to their abundance FA were categorised
as “high”. Cells which did not ﬁt in the group “low” or “high” are considered as
“medium”.
There were no major diﬀerences observed in the distribution and abundance of FA
between ADAM15 A and E isoform expressing cells. Both contained similar cell
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numbers with FAs of low (nascent adhesions), moderate (focal complexes), and
high (FA) vinculin intensity. When compared with the parental cell line, they both
contained more cells with high intensity vinculin staining. On the other hand,
ADAM15 B and C isoform expressing cells were similar to each other, most of them
possessed FAs of low vinculin intensity. In contrast to all the other cell lines, the
vast majority of the analysed ADAM15 D expressing cells contained FAs with high
vinculin intensity. The described diﬀerences indicated that the FA turnover may
be aﬀected by ADAM15 expression, where the expression of ADAM15 B and C
isoforms prevented the formation of strong FA, and on the contrary, the expression
of ADAM15 D isoform prevented the disassembly of mature FA.
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Figure 5.1: Continued on the next page
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Figure 5.1: Assessment of FA in MDA/FRT and MDA/ADAM15 WT isoform expressing cells.
a) IF analysis of the cell panel stained with the FA markers paxillin (green) and vinculin (red).
The nucleus was visualised with DAPI (blue). Left column: Paxillin staining; Central column:
Vinculin staining; Right column: Merged images. Scale bar = 10 μm. b) Quantification of the
assessed FA by examining the vinculin staining. The slides were examined by a meander-shaped
course while the first 100 cells were classified into one of four groups: No-, low-, moderate- or high
vinculin. n=1
To address whether FA turnover is aﬀected by the expression of ADAM15 iso-
forms, we conducted a FA disassembly assay using nocodazole as described by
Ezratty et al443 and Villari et al524. Nocodazole disrupts microtubule assembly by
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binding to β-tubulin373. As microtubules are necessary for FA disassembly, noco-
dazole treatment stabilises FAs, allowing to evaluate if a cell is able to form FA,
as well as the maximum potential coverage of FA in a cell. Once the nocodazole is
washed out, microtubules begin to form, allowing FA to disassemble. The rate of the
FA disassembly followed by recovery and formation can be monitored over time. In
order to synchronise the FA turnover, cells were serum-starved overnight, followed
by nocodazole treatment for 4h hours. Coverslips were ﬁxed prior to nocodazole
treatment, at the end of nocodazole treament, and after 15, 30, 45, 60 and 120 min
post washout. Cells were stained with phalloidin and vinculin to visualise FAs. Ten
representative images were acquired and analysed for the coverage of FA on the
cell surface as a percentage of total cell area as well as the average feret diameter
of FA as described in section 2.12. The number of analysed cells per cell line and
timepoints are shown in table 6.1.
Table 5.1: Cell numbers analysed in focal adhesion disassembly assay.
MDA/
FRT
A15 A A15 B A15 C A15 D A15 E
Nocodazole 50 48 62 30 56 52
Washout 15 min 27 35 37 33 29 38
Washout 30 min 43 45 39 34 41 48
Washout 45 min 36 39 47 38 34 33
Washout 60 min 44 48 53 35 37 45
Washout 120 min 31 48 41 25 34 36
Nocodazole treatment demonstrated (ﬁgure 5.2) that all cell lines have the ca-
pacity to form mature FA irrespective of the expressed ADAM15 isoform. There
were no obvious diﬀerences between the cell lines: The FAs covered 8-10% of the
total cell area, with an average feret diameter of 19-22 μm. Once the nocodazole
was washed out, within 15 min in all cell lines, with the exception of ADAM15 D
expressing cells, the FA successfully disassembled, as measured by the reduction of
FA coverage down to below 1% of the total cell area, and the feret diameter down
to 9 μm. The most pronounced reduction occurred in ADAM15 E expressing cells,
where the total coverage of FA dropped to 0.8% compared with the parental control
cell line. The FA disassembly continued for the following 15 min with the FA area
reduced down to 0.7%. ADAM15 D expressing cells stood out during this ﬁrst phase
of the experiment. They failed to disassemble their FA to the level comparable with
the other cell lines, with the FA coverage being reduced down to only 5% of the to-
tal cell area, and the average feret diameter reducing down to 14 μm. These values
did not change during the following 15 min of the nocodazole washout. By 45-60
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min post nocodazole washout FAs begin to regrow slowly in all cell lines with the
exception of ADAM15 B, C and E expressing cells. FA coverage area in these cells
remains at approximately 1% of the total cell area, as opposed to 2% in parental
and ADAM15 A expressing cells and nearly 6% in ADAM15 D expressing cells. At
this time point, while the average FA feret diameter in most cell lines reached 9-12
μm, it remained at 10 μm in ADAM15 C expressing cells, and strikingly, nearly 15
μm in ADAM15 D expressing cells. These observed diﬀerences were more striking
at the end of the assay period of 120 min post nocodazole washout. FA coverage
area was comparable in parental, as well as ADAM15 A, B and E isoform express-
ing cells, reaching up to 3%, with an average feret diameter of 13 μm. However, in
ADAM15 C expressing cells FA coverage remained below 1%, and, on the contrary,
in ADAM15 D expressing cells at 6% of the total cell area, with an average feret
diamter of 17 μm.
In summary, all cell lines have the ability to form FA irrespective of the expressed
ADAM15 isoform. However, the disassembly and re-assembly showed diﬀerences.
Parental and ADAM15 A, B and E expressing cells showed similar FA turnover while
ADAM15 C expressing cells displayed reduced re-assembly. ADAM15 D expressing
cells failed to disassemble the FA to a comparable level with the other cell lines, but
re-assembled them in a higher rate. Of all the cell lines, only ADAM15 D expressing
cells assembled their FA to a degree comparable with the pre-nocodazole stage.
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Figure 5.2: Continued on the next page
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Figure 5.2: Continued on the next page
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Figure 5.2: Continued on the next page
CHAPTER 5. ADAM15 MEDIATED CHANGES IN BREAST CANCER CELL
ADHESION 194
Figure 5.2: Continued on the next page
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Figure 5.2: Continued on the next page
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Figure 5.2: Focal adhesion disassembly assay of MDA/FRT and MDA/ADAM15 WT isoform
expressing cells. Cells were grown for 72h and serum starved overnight, followed by 4h Noc (10
μM) treatment. Noc was removed and cells were washed twice with serum free medium. Cells were
fixed directly before (pre-noc), after 4h of Noc treatment and after 15, 30, 45, 60 and 120 min of
washout. The cells were stained for phalloidin (green) and vinculin (red). the nuclei were visualised
with DAPI (blue). Images were acquired at a confocal microscope with 630 x magnification and
3 x digital zoom. The cell lines were compared to each other for every time point and shown
as box-and-whisker plot. Analysis was performed using the semi-automated script for ImageJ
described in section 2.12. The results appear in following order: Pre-noc (n=1); Noc 4h (n=3);
15 min washout (n=2), 30 min washout (n=3), 45 min washout (n=2), 60 min washout (n=3),
120 min washout (n=2). a) Representative images of the experiment Left column: Phalloidin
staining; Central column: Vinculin staining; Right column: Merged images. Scale bar = 10 μm.
b) The total area of FA per cell. c) Average feret diameter of all FAs combined. Statistical
significance was assessed with the post-hoc Dunnet’s multiple comparison test after performing
one-way ANOVA analysis. MDA/ADAM15 A-E expressing cells were compared to the MDA/FRT
control cell lines. Confidence intervals are as follows: ∗ = p ≤ 0.05, ∗∗ = p ≤ 0.01, ∗ ∗ ∗ = p ≤
0.001, ∗ ∗ ∗∗ = p ≤ 0.0001. Scale bar = 10 μm. The experiment was repeated in three independent
experiments for 4h nocodazole, 30 and 60 min washout. The time point for 15, 45 and 120 min
washout was repeated twice. Analysed images were checked manually to exclude false positive
cells which result from the used algorithm. d) Summarised total area of FA per cell shown as
line graph e) Summarised average feret diameter of all FA combined. Red: MDA/FRT; Blue:
MDA/ADAM15 A; Grey: MDA/ADAM15 B; Yellow: MDA/ADAM15 C; Green: MDA/ADAM15
D; Purple: MDA/ADAM15 E, Noc: nocodazole.
5.2.2 ADAM15 isoforms affect cell spreading on different
ECM substrates
In the previous section we identiﬁed that the dynamic turnover of FA is aﬀected by
the expression of individual ADAM15 isoforms, whereas the expression of ADAM15
C delays or reduces the FA maturation rate, while the expression of ADAM15 D
compromises the disassembly of FA. The dynamic turnover of FA depends on the
internalisation and recycling of integrins. Integrins are key proteins in mediating
the assembly of FAs linking the ECM to the actin cytoskeleton. On the other
hand, integrin endocytosis is one of the events necessary for FA disassembly. Cells
use speciﬁc integrins receptors to recognise ECM components and bind to them,
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facilitating cell adhesion. It is known that ADAM15 disintegrin domain interacts
with α5β1 and αvβ3 integrins. We hypothesised that ADAM15 isoform-dependent
eﬀects on FA turnover might be due their diﬀerential eﬀects on integrin cell surface
presentation, or integrin endocytosis and recycling. Thus we decided to investigate
which of these integrins might be diﬀerentially expressed on the cell surface. The
level of cell adhesion and spreading on a speciﬁc ECM component can inform us
which integrin is mediating the cell attachment. We decided to carry out a pilot
experiment to test if ADAM15 isoform expressing cells show diﬀerences in their
attachment and spreading on FN (α5β1 and αvβ3 ligand), and on VN (αvβ3 ligand).
Glass cover slips were coated with either complete medium, FN or VN for 1h at
37◦C. Afterwards cells were seeded onto the cover slips and incubated for 60 min.
Images were taken at 0, 15, 30, 45 and 60 min. The earliest diﬀerences in cell
spreading on these substrates were observed at 45 min as demonstrated in ﬁgure
5.3.
In this assay the parental, as well as ADAM15 A and B expressing cells behaved
similar to each other, and showed better attachment and spreading on FN,
although parental cells spread more on FN than ADAM15 A and B expressing
cells. ADAM15 E expressing cells adhered and spread equally well on FN and VN
compared to medium coated surface. The degree of spreading on FN was more in
ADAM15 E expressing cells than ADAM15 A or B expressing cells. ADAM15 C
and D isoform expressing cells behaved similar to each other, and, unlike all the
other cells, adhered and spread on all surfaces equally eﬃcient, and the degree of
spreading on all surfaces was higher compared to the other cell lines.
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Figure 5.3: Phase-contrast images of MDA/FRT and MDA/ADAM15 WT expressing cells plated
on medium, FN (10 μg/mL) or VN (10 μg/mL) coated coverslips. Coverslips were coated with the
corresponding substrate for 1h at 37◦C. Afterwards MDA/FRT or MDA/ADAM15 WT express-
ing cells were plated for 45 min and subsequently phase-contrast images were acquired at 100 x
magnification. Scale bar = 100 μm
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In summary (table 5.2), all cell lines showed best attachment and adherens on FN
followed by VN and medium. However, expression of ADAM15 A and B seemed to
decrease attachment and spreading while ADAM15 C and D promoted it. ADAM15
E behaved similar to the parental cell line. Thus we conclude expression of ADAM15
isoforms aﬀect substrate dependent cell adhesion and spreading.
Table 5.2: Summary of the adhesion and spreading experiment. Coverslips were coated with
medium, FN (10 μg/mL) or VN (10 μg/mL) for 1h at 37◦C. Parental and ADAM15 isoform
expressing cells were seeded and phase-contrast images were acquired after 0, 15, 30, 45 and 60
min. This table shows the analysed degree of spreading after 45 min as the first differences were
observed at this time point.
Cell line Result
MDA/FRT FN >VN >Medium
MDA/A15 A FN = VN >Medium
MDA/A15 B FN >VN >Medium
MDA/A15 C FN >Medium = VN
MDA/A15 D Medium = FN = VN
MDA/A15 E FN = VN >Medium
Our pilot experiment indicated that there are diﬀerences in cell attachment and
spreading on FN and VN between the cell lines depending on the expression of
ADAM15 isoforms. To be able to quantify these diﬀerences, we conducted another
experiment. Glass coverslips were coated with either complete medium, FN (10
μg/mL) or VN (10 μg/mL) for 1h at 37◦C. Cells were trypsinised and plated onto
the coverslips for 45 and 105 min. Subsequently, the cells were ﬁxed and stained
with phalloidin followed by confocal microscopic examination. Acquired pictures
were analysed with ImageJ. The number of cells analysed for each cell line, time
point and ECM substrate is shown in table 5.3 below.
Table 5.3: Number of cells analysed on ECM coated substrates after 45 and 105 min.
Medium Fibronectin Vitronectin
45’ 105’ 45’ 105’ 45’ 105’
MDA/FRT 61 77 70 53 86 79
ADAM15 A 36 67 73 68 75 69
ADAM15 B 40 89 83 72 86 81
ADAM15 C 43 55 48 49 66 62
ADAM15 D 35 56 64 59 79 79
ADAM15 E 41 50 77 64 77 73
Plating of cells on complete growth medium, FN and VN are shown in ﬁgure 5.4,
5.5 and 5.6, respectively. MDA/ADAM15 isoform expressing cells were compared
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to MDA/FRT. On medium coating, after 45 min of plating MDA/ADAM15 A, B
and E expressing cells showed similar cell surface area and spread, when compared
to MDA/FRT (Figure 5.4 a). In contrast, MDA/ADAM15 C and D expressing
cells showed increased spreading. One hour later we observed that the MDA/FRT
cells reached the same degree of spreading as MDA/ADAM15 C, D, E expressing
cells, while the MDA/ADAM15 A and B isoform expressing cells did not increase
the spread area to the same extent. Additionally, quantiﬁcation of cell numbers
revealed that the expression of ADAM15 isoforms impaired cell attachment, as sig-
niﬁcantly more MDA/FRT cells had adhered after 45 min than ADAM15 expressing
cells. After the prolonged incubation, at 105 min, comparable numbers of parental
and ADAM15 B expressing cells had adhered, while signiﬁcantly less numbers of
ADAM15 A, C, D and E expressing cells adhered on this surface.
To quantify α5β1-dependent cell adhesion and spreading, cells were plated on FN
coated coverslips. Analysis of cell surface area revealed signiﬁcant diﬀerences in
ADAM15 A and B expressing cells, whose spread area was nearly 50% less at
both analysed time points than of all the other cell lines (ﬁgure 5.5 b and c).
MDA/ADAM15 C and D expressing cells spread somewhat more than the other
cell lines. Overall far less ADAM15 isoform expressing cells adhered to FN when
compared with the parental cells within the ﬁrst 45 min. After another hour, how-
ever, some of these diﬀerences were reduced, with only ADAM15 A and C isoform
expressing cells having adhered less then all the other cell lines.
To quantify αvβ3-dependent cell adhesion and spreading cells were plated on VN
coated coverslips. Analysis of the cell surface area showed signiﬁcant diﬀerences be-
tween ADAM15 B expressing cells compared with all the other cell lines. Throughout
the duration of the assay they remained at least 25% smaller then the rest. Addi-
tionally, while parental, as well as ADAM15 C, D and E expressing cells continued
to spread by 105 min, ADAM15 A and B expressing cells failed to spread to similar
levels. Quantiﬁcation of cell numbers revealed that by 45 min comparable numbers
of parental, as well as ADAM15 A, B and D cells adhered to VN, while there were
signiﬁcantly less ADAM15 C and D expressing cells adhered to this surface. By
105 min however, only MDA/FRT and ADAM15 D expressing cells had comparable
numbers adhered to VN, and much reduced numbers of the other cell lines adhered,
with ADAM15 C expressing cells showing the least number of cells adhered on VN.
Comparison of cell spreading on these substrates (ﬁgure 5.7) revealed that most
preferred FN over VN, but ADAM15 E reduced this preference, and the expression
of ADAM15 A altered it in favour of VN over FN. FN is the major ligand for α5β1
and αvβ3 and VN for αvβ3. This results suggest that ADAM15 aﬀects integrin inter-
action. This may occur due to diﬀerential cell surface localisation, general changes
in integrin expression or altered ADAM15-integrin interaction.
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Figure 5.4: Immunofluorescence analysis of MDA/FRT and MDA/ADAM15 isoform expressing
cells plated on medium coated surface. Glass cover slips were coated with complete medium for
1h at 37◦C. Afterwards MDA/FRT or ADAM15 isoform expressing cells were plated for 45 or 105
min and subsequently fixed and stained with phalloidin-488 (green). Nucleus is stained with DAPI
(blue). Images were acquired by a confocal microscopy. Cell area and number were analysed by
ImageJ. a) Representative images of the acquired images. b) Degree of cell spreading shown as bar
chart. c) The average of counted cells per image shown as box plot. Statistical significance was
assessed with the post-hoc Dunnet’s multiple comparison test after performing one-way ANOVA
analysis. MDA/ADAM15 A-E expressing cells were compared to the MDA/FRT control cell lines.
Confidence intervals are as follows: ∗ = p ≤ 0.05, ∗∗ = p ≤ 0.01, ∗ ∗ ∗ = p ≤ 0.001, ∗ ∗ ∗∗ = p ≤
0.0001. The number of analysed cells is shown in table 5.3.
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Figure 5.5: Immunofluorescence analysis of MDA/FRT and MDA/ADAM15 isoform expressing
cells plated on FN coated surface. Glass cover slips were coated with FN (10 μg/mL) for 1h at
37◦C. Afterwards MDA/FRT or ADAM15 isoform expressing cells were plated for 45 or 105 min
and subsequently fixed and stained with phalloidin-488 (green). Nucleus is stained with DAPI
(blue). Images were acquired by a confocal microscopy. Cell area and number were analysed by
ImageJ. a) Representative images of the acquired images. b) Degree of cell spreading shown as bar
chart. c) The average of counted cells per image shown as box plot. Statistical significance was
assessed with the post-hoc Dunnet’s multiple comparison test after performing one-way ANOVA
analysis. MDA/ADAM15 A-E expressing cells were compared to the MDA/FRT control cell lines.
Confidence intervals are as follows: ∗ = p ≤ 0.05, ∗∗ = p ≤ 0.01, ∗ ∗ ∗ = p ≤ 0.001, ∗ ∗ ∗∗ = p ≤
0.0001. The number of analysed cells is shown in table 5.3.
CHAPTER 5. ADAM15 MEDIATED CHANGES IN BREAST CANCER CELL
ADHESION 203
Figure 5.6: [Immunofluorescence analysis of MDA/FRT and MDA/ADAM15 isoform expressing
cells plated on medium, FN and VN coated surfaces. Glass cover slips were coated with complete
growth medium, FN (10 μg/mL) or VN (10 μg/mL) for 1h at 37◦C. Afterwards MDA/FRT and
ADAM15 isoform expressing cells were plated for 45 or 105 min and subsequently fixed and stained
with phalloidin-488 (green). The nucleus was visualised with DAPI (blue). Images were acquired
by a confocal microscopy. Cell area and number were analysed by ImageJ using a semi-automated
script descried in section 2.13.2. a) Representative images of the acquired images of either medium,
FN or VN coated glass cover slips b) The corresponding degree of cell spreading shown as bar
charts. c) The average of counted cells per image shown as box plots. Statistical significance was
assessed with the post-hoc Dunnet’s multiple comparison test after performing one-way ANOVA
analysis. MDA/ADAM15 A-E expressing cells were compared to the MDA/FRT control cell lines.
Confidence intervals are as follows: ∗ = p ≤ 0.05, ∗∗ = p ≤ 0.01, ∗ ∗ ∗ = p ≤ 0.001, ∗ ∗ ∗∗ = p ≤
0.0001. The number of analysed cells is shown in table 5.3.
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Figure 5.7: Summary of IF analysis of MDA/FRT and MDA/ADAM15 isoform expressing cells plated on medium, FN and VN coated surfaces. Cell area
is shown as bar chart while the cell number is displayed as box-and-whiskers plot. Statistical significance was assessed with the post-hoc Dunnet’s multiple
comparison test after performing one-way ANOVA analysis. All three samples were compared to each other. Confidence intervals are as follows: ∗ = p ≤
0.05, ∗∗ = p ≤ 0.01, ∗ ∗ ∗ = p ≤ 0.001, ∗ ∗ ∗∗ = p ≤ 0.0001. The number of analysed cells is shown in table 5.3.
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5.2.3 ADAM15 isoforms may affect integrin cell-surface lo-
calisation
Our analysis of FA turnover, as well as of cell spreading on FN and VN suggests
that either the cell surface presence, ability to associate with their preferred ECM
component, or overall expression of integrins α5β1 and αvβ3 is altered depending
on ADAM15 isoform expression. If the expression of speciﬁc ADAM15 isoforms
aﬀected the internalisation and recycling of these integrins, that would result in
diﬀerential accumulation of the integrins in the cytoplasm and membrane.
To get better understanding if integrin traﬃcking is altered, subcellular fraction-
ation experiments were performed from exponential growing cells and subjected
to protein analysis by western blot. The membranes were probed with speciﬁc
antibodies to the β1 and β3 subunits (ﬁgure 5.8).
This analysis revealed that the β1 subunit is exclusively localised to the cell
membrane. Interestingly, the size of β1 in MDA/ADAM15 D expressing cells
is smaller while β1 is larger in MDA/ADAM15 E expressing cells compared to
MDA/FRT, MDA/ADAM15 A, B and C expressing cells. On the other hand,
diﬀerences in subcellular localisation of the β3 subunit were observed, that depended
on the expression of speciﬁc ADAM15 isoforms. The relative distribution of β3
was comparable in the parental, as well as ADAM15 B, C, and D expressing cells,
where it was present in both compartments. However, in ADAM15 D expressing
cells there was more β3 in the cytoplasmic than in the membrane fraction. In
ADAM15 A and E expressing cells β3 was exclusively in the membrane fraction. As
cytoplasmic control HSP90 was used which was primarily located in the cytoplasm.
As membrane control, the western blot was probed for R-cadherin which was
primarily detected in the membrane.
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Figure 5.8: Distribution of β1- and β3-integrin in MDA/FRT and ADAM15 isoform express-
ing cells. The experiment was performed by fractionation and analysis by western blot. a)
Representative images of the fractionation experiment of the cell panel. Lane 1 shows to-
tal cell lysate (TE). Lane 2 shows cytoplasmic extract (CE) with HSP90 as control. Lane
3 shows membrane extract (ME) with R-cadherin as control. b) Densitometry of the frac-
tionation experiment where applicable. Statistical analysis was performed by Mann-Whitney
t-test by comparing ADAM15 A and D expressing cells. Confidence intervals are as follows:
∗ = p ≤ 0.05, ∗∗ = p ≤ 0.01, ∗ ∗ ∗ = p ≤ 0.001, ∗ ∗ ∗∗ = p ≤ 0.0001. Cell panel for β3: n=2;
MDA/FRT, MDA/ADAM15 B, C and E for β1: n=2; MDA/ADAM15 A and D: n=3
During the fractionation experiments we observed that the molecular weights of
both β1 and β3 varied within the panel. Also, β3 immunobloting revealed multiple
bands of diﬀerent molecular weights which are approximately at 110, 100 and 80
kDa. To conﬁrm whether the observed changes in the size of these integrin subunits
were not an artefact of trypsinisation, and, additionally, to investigate if there are
changes in the overall expression levels of β1 and β3, I performed WB analysis of the
total protein lysates (ﬁgure 5.9). We did not observe the same pattern of diﬀerent
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molecular weights for β3, as seen during the fractionation experiment, conﬁrming
our suspicion. However, the changes in the molecular weight of β1 were observed
using this approach as well. The β1-subunit in MDA/ADAM15 D expressing cells
appeared smaller, while the one in MDA/ADAM15 E expressing cells was larger,
compared to the other cell lines. There was no diﬀerence in the molecular weight
of β1 in MDA/FRT, MDA/ADAM15 A-C as well as MDA/ADAM15 A-E E349A
expressing cells. Analysis of β3-chain showed that the molecular weights are slightly
larger in MDA/15 E WT and cells expressing the catalytic inactive variants of
ADAM15.
Figure 5.9: Expression of β1- and β3-integrins in MDA/FRT, MDA/ADAM15 WT and
MDA/ADAM15 E349A expressing cells. a) Representative western blot images of β1 and β3
expression. Actin serves as loading control. b) Densitometry analysis of β1 expression presented
as bar graphs. Statistical significance was assessed with the post-hoc Dunnet’s multiple compar-
ison test after performing one-way ANOVA analysis. MDA/ADAM15 WT and E349A express-
ing cells were compared to the MDA/FRT control cell line. Confidence intervals are as follows:
∗ = p ≤ 0.05, ∗∗ = p ≤ 0.01, ∗ ∗ ∗ = p ≤ 0.001, ∗ ∗ ∗∗ = p ≤ 0.0001. β1: n=5; β3: n=1
5.3 Discussion
In chapter 3 section 3.2.6 we observed that expression of ADAM15 isoforms led to
impaired cell migration, especially in ADAM15 C and D expressing cells. In this
chapter we sought to get closer understanding of how ADAM15 isoforms might af-
fect cell motility. ADAM15 has the potential to regulate cell motility via several
of its functions, such as MP-mediated ECM degradation, disintegrin-mediated in-
tegrin and FA regulation, or aﬀecting the activity and localisation of intracellular
signalling molecules via ICD-mediated direct protein-protein interactions. Here we
focused on elucidating the likely regulation of integrins and integrin-mediated dy-
namic FA turnover by ADAM15 isoforms. The pilot experiment, looking at general
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distribution of FA in cells grown on coverslips for 72h, revealed striking diﬀerences in
the abundance and intensity of FA between ADAM15 isoform expressing cell lines.
ADAM15 B and C expressing cells had fewer, weaker and smaller FA compared to
MDA-MB-231 cells while on the other hand, ADAM15 D expressing cells had many
large FA. This gave the impression that ADAM15 isoforms have distinct eﬀects on
FA maturation and disassembly. More quantitative experiments, using nocodazole
as a mean to stabilise FA, conﬁrmed these ﬁndings. Nocodazole treatment demon-
strated that all the cell lines have the capacity to form mature, large FA. However,
we found that MDA/ADAM15 C expressing cells have a much slower rate of re-
assembly of FA compared to the parental cell lines whereas ADAM15 D expression
signiﬁcantly reduces disassembly and enhances assembly of FA. One reason for this
ﬁnding could be due to eﬀects on microtuble re-growth. FA disassembly relies on
microtuble re-growth post nocodazole washout. If re-growth is impaired cells fail
to disassemble FAs443. Alterations in microtuble dynamics in our cell panel were
not investigated, but may explain our ﬁndings. Repeating the FA disassembly as-
say with vinculin/tubulin co-staining could answer whether microtuble formation is
aﬀected in these cells.
In ADAM15 D expressing cells the FA stay larger throughout the time course as
judged by the average feret diameter. These impairments in FA turnover might
explain why the expression of ADAM15 C and D reduce cell migration. The re-
duced ability of ADAM15 C expressing cells to form mature FA would compromise
the ability of cells to pull the cell body forward. On the other hand, the reduced
disassembly of FA in ADAM15 D expressing cells would not allow the cell to retract
the trailing edge.
There are many factors that inﬂuence the dynamic turnover of FA. One such factor
is FAK. While phosphorylation of FAK is necessary for FA assembly, the dephos-
phorylation of FAK is essential for FA disassembly. Reduced migration due to high
numbers of FAs was demonstrated by You et al525. Knockdown of the Src homology
phosphotyrosyl phosphatase 2 (SHP2) led to increased numbers of FA while reducing
the migration rate. Biochemical analysis demonstrated that FAK dephosphoryla-
tion was signiﬁcantly decreased. Hartman et al. conﬁrmed that upon knockdown of
SHP2 migration is reduced in MDA-MB-231 and MDA-MB-468 cells526. SHP2 is re-
cruited to FAs where it dephosphorylates FAK at Y397526. SHP2 possesses two SH2
domains525,526 which could potentially interact with phosphorylated tyrosines in the
cytoplasmic domain of ADAM15. Thus ADAM15 may recruit a phosphatase to FA
to modulate FAK activity. Other phosphatases involved in FAK-Y397 dephosphory-
lation are the protein-tyrosine phosphatase 1B (PTP-1B)527 and the PEST-sequence
containing protein-tyrosine phosphatase-PEST528. Both phosphatases contain mul-
tiple proline-rich regions which could form a ternary complex with ADAM15 via
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Grb2. Indeed we have observed that ADAM15 D expressing cells contain hyperacti-
vated FAK by persistent phosphorylation of Y397, Y576/577 and Y925 (Appendix:
ﬁgure 9.4). Due to the truncated ICD of ADAM15 D no potential interaction with
phosphatases or adaptor proteins is possible. Therefore, ADAM15 D may fail to
recruit these to the FA complex to dephoshphorylate FAK, which would lead to
stabilisation and reduced disassembly of FA in this cell line.
ADAM15 is known to interact with integrins and their endocytosis is crucial for
focal adhesion disassembly. Therefore, it may be possible that ADAM15 isoforms
have diﬀerential aﬃnity towards integrins which maybe regulated by the ICD. The
lack of the ICD of ADAM15 D could enhance extracellular binding to the integrins
and thus impair the endocytosis.
Integrins are endocytosed via a clathrin-dependent route which leads to the disas-
sembly of FA. It was shown that this mechanism relies on the clathrin adaptors AP2
and DAB2 as well as dynamin-2370. An interesting link between clathrin-mediated
endocytosis and ADAM15 is provided by SNX9. SNX9 and dynamin-2 assemble in
the cytoplasm as a resting complex. In the presence of ATP this complex is acti-
vated. RNAi experiments showed that SNX9 is an essential mediator of dynamin-2
traﬃcking to the membrane529. As shown in table 1.6 SNX9 is a known interaction
partner of ADAM15 with very high aﬃnity towards ADAM15 A, B, C and E, but
does not interact with ADAM15 D. One hypothesis could be that this resting com-
plex consists of several molecules with distict function including ADAM15. That
the resting complex is composed of more than dynamin-2 and SNX9 is known529.
An additional molecule within this complex was identiﬁed as aldolase. Aldolase
binds to an acidic sequence of SNX9 blocking the binding activity of SNX9. SNX9
phosphorylation releases aldolase and turns SNX9 competent for membrane binding.
ADAM15 as potential member of the resting complex could bring an SH3 domain
containing kinase close which does the phosphorylation of SNX9. Since dynamin-2
is crucial for integrin endocytosis and SNX9 essential for dynamin-2 recruitment en-
docytosis would be impaired with ADAM15 D since it lacks the interaction motifs
to participate in the resting complex. Since we still saw disassembly of FA it may
have been rescued by endogenous full length ADAM15 or other adaptor proteins.
Another hypothesis involves Intersectin 1/2. Intersectins are molecular scaﬀolds
that play essential roles at the early stage of clathrin-mediated endocytosis (CME)
by clustering the membrane sculpting FCHo1/2 proteins which mark the assem-
bly sites of clathrin-coated pits. Intersectin 1/2 are known binding partner for
ADAM15180,181. Continuous interaction with ADAM15 could reduce the rate of
endocytosis. As integrins are mainly dependent on CME, reduced endocytosis may
have a negative inﬂuence on cell motility and migration, but may enhance cell ad-
hesion. On the other site, ADAM15 could recruit intersectins to the membrane
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marking integrins for endocytosis. Since ADAM15 D is unable to bind Intersectins,
the endocytosis of those integrins might be impaired. In order to recycle α5β1 and
αvβ3 it follows a Rab11 dependent-route which requires inactivation of GSK3β by
Akt530. Akt activity is also required to phosphorylate a protein which recruits β1
into a recycling coat complex containing clathrin531,532. In chapter 4 we identiﬁed
that the PI3K signalling pathway is modulated by ADAM15. Since Akt is down-
stream of PI3K it may be inﬂuenced by ADAM15 isoforms indirectly. ADAM15 C
may inﬂuence the localisation of Akt in way to prevent β1 to be recruited to the
recycling coat complex.
Another potential mechanism could involve PKCε mediated integrin recycling.
PKCε phosphorylates the intermediate ﬁlament protein vimentin (expressed in mes-
enchymal cells) which releases the β1-subunit to allow recycling533,534. A way this
mechanism could be inﬂuenced is via substrate competition. PKCε phosphorylates
ADAM17 which induces release of amphiregulin from the cell membrane535. Am-
phiregulin is also a known substrate of ADAM15197, but the underlying mechanism
of how ADAM15 is activated to release amphiregulin is not well understood yet.
Therefore, ADAM15 isoforms may be a potential substrate for PKCε phosphoryla-
tion too, which could be even isoform dependent. As described in the introduction,
ILK is a kinase which is recruited to the plasma membrane during FA formation.
ILK was identiﬁed as a binding partner for ADAM12536, thus ADAM15 could po-
tentially interact with ILK as well. In ruﬄes, ILK was found in a complex with
Nck and co-localised with α5β1-integrin415. Nck is also an adptor protein known to
interact with ADAM15179.
Adhesion of cells to a substrate is mediated by integrins. The more eﬃcient a cell is
able to bind the substrate the quicker cells spread. Our pilot cell spreading experi-
ment suggested that MDA/ADAM15 A and B expressing cells spread less compared
to the control (MDA/FRT) on all surfaces. In contrast, MDA/ADAM15 C and D
expressing cells spread much more compared to the control.
The more detailed and quantiﬁed analysis conﬁrmed the ﬁndings of the pilot exper-
iment. In parental cells we observed that cells adhere and spread quicker on FN
over VN. This is likely to happen because FN interacts with both α5β1 and αvβ3
integrins537 while VN binds only to αvβ3538,539. In these cells there are theoretical
twice as many receptors for FN compared to VN (assuming the quantities are even).
Expression of ADAM15 A and B leads to reduced adhesion and spreading on FN
as well as VN when compared with the parental cells. This could potentially be as
a result of these isoforms interacting with α5β1 and αvβ3 with much higher aﬃnity,
thus reducing the availability of these integrins to interact with their substrates.
Interestingly, while all the cell lines prefer spreading onto FN rather than VN, the
expression of ADAM15 A changes this preference in favour of VN. This suggests
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that perhaps ADAM15 A interacts more with α5β1 than with αvβ3, leaving more of
this integrin to bind to VN. To address this question ligand binding assays could be
used to determine the aﬃnity of integrins to the individual ADAM15 isoforms.
On the other hand, the expression of ADAM15 C and D isoforms led to more
spreading on FN as well as VN, when compared with the parental cell line. This
increased spread area could be either because these cells are generally larger (as dis-
cussed in chapter 3) or because there are more of these integrins free and available
to bind to the ECM components facilitating adhesion.
We did not observe any changes in the total expression levels of β1- and β3-integrin
subunits. However, the molecular weight of β1 diﬀered in our cell lines, smaller in
ADAM15 D expressing cells and larger in ADAM15 E expressing cells compared
with the rest of the cell panel. No diﬀerences were observed in subcellular localisa-
tion of β1. In contrast, subcellular fractionation demonstrated that there is more β3
in the cytoplasmic fraction of ADAM15 D expressing cells than in the membrane
fraction when compared with the rest of the cell panel. In cardiac rat myocytes and
ﬁbroblasts a 55 kDa fragment of β1-integrin was found540. This fragment stimu-
lated the size and shape of these cells and altered ECM interaction. In myocytes
the adhesion to collagen was enhanced. Interestingly, the MMP inhibitor GM6001
decreased the β1 shedding in myocytes, but not in ﬁbroblasts. This suggests that
other proteinases, such as ADAMs, might be involved. Also integrin shedding seems
highly dependent on the cell type. Up to date no ADAM is known to shed inte-
grins. Beside β1, it was also demonstrated that β2 is cleaved as well541,542. In
a model for synovial inﬂammation it has been demonstrated that β2 is shed from
the surface of leukocytes in a TNFα-dependent manner541. Another study demon-
strated that β2 integrin is cleaved in mouse macrophages in a MMP-dependent
manner. However, we do not think that part of β1 is shed in our ADAM15 D ex-
pressing cells, as the same short molecular weight β1 is recognised by an antibody
speciﬁc to the amino-terminus of the protein (data not shown). A potential reason
for altered molecular weight of β1-integrin in ADAM15 expressing cells could be
post-translational modiﬁcation such as diﬀerential glycosylation. In keratinocytes
it was demonstrated that N-glycosylation of β4-integrin was essential to control ad-
hesion and locomotion543. Posttranslational modiﬁcations involve many enzymes
including kinases, phosphatases, transferases and ligases. Src was found to regulate
O-glycosylation by redistributing N-acetylgalactosaminyl transferases from the golgi
complex to the endoplasmic reticulum544. Their redistribution occurs either in cells
with constitutively increased Src-activity or upon EGF or platelet derived growth
factor stimulation in a Src-dependent manner544. Since ADAM15 is a well known
binding partner of Src kinase, potential changes in aﬃnity of ADAM15 isoforms
towards Src could contribute to diﬀerences in β1 glycosylation.
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ADAM15 may modulate integrin function by its disintegrin-like domain which is
able to bind integrins. It may be possible that the ICD play an important role in
molecule shape by changing the ADAM structure. Some could make the disinte-
grin domain accessible for integrin binding which induces downstream signalling via
Rac or Serine/threonine-protein kinase (PAK) through FAK. Integrins can modu-
late cell adhesion, migration, actin polymerisation and mitogen-activated protein
(MAP) kinase signalling545. Src might be an important player in ADAM15 medi-
ated signalling, because its SH3 domain is required for binding β1 subunits546 and
to the proline rich regions in ADAM15.
Overall, here we identiﬁed that ADAM15 isoforms have distinct eﬀects on the dy-
namic turnover of FA, as well as cell adhesion on FN and VN. However, neither
cell spreading on the ECM substrates, nor subcellular localisation of these inte-
grins could explain altered FA turnover, and, consequently, the altered cell motility,
in our cell panel. Additionally, the subcellular fractionation approach provides a
more qualitative, rather than quantitative evaluation regarding the localisation of
a particular protein. This makes comparative analysis between the cell lines very
diﬃcult, if not impossible. An alternative approach would be FACS analysis that
could provide quantitative information and would allow a comprehensive compari-
son of the cell surface localised integrins between our cell panel. FACS analysis with
integrin conformation-speciﬁc antibodies would allow us to evaluate if the presence
of individual ADAM15 isoforms aﬀects the ECM ligand binding abilities of these
integrins. This in turn would enable us to evaluate if α5β1 and αvβ3 are involved in
altered FA dynamics in our cell panel. As integrin internalisation and recycling are
crucial factors in regulating FA turnover, it will be necessary to carry out detailed
comparative analysis of integrin traﬃcking in our cell panel.
One common link of how ADAM15 mediates changes in cell-cell junctions and cell-
adhesion could be provided by ILK. In chapter 4 we showed that overexpression of
ADAM15 isoforms lead to upregulation of claudin1 in ADAM15 A, C and E ex-
pressing cells, depending on their catalytic function. In this chapter we revealed
changes in FA turnover in ADAM15 C and D expressing cells. ILK functions as
scaﬀold protein promoting cell-cell contacts we as well as localisation to AJ and TJ
proteins547,548. ILK localised to ZO1548 which we identiﬁed as novel interaction
partner for ADAM15. ILK is recruited to β1- and β3-ICDs549 and part of FAs and
involved in several cellular mechanisms such as cell polarisation, spreading, prolifer-
ation, migration and survival550. ILK-phosphorylation is regulated by PI3K, since
inhibition of PI3K reduced ILK acitvity420. We found that claudin1 upregulation
is also mediated via PI3K pathway. In ruﬄes, ILK was found in a complex with
Nck and co-localised with α5β1-integrin415. Nck is an adaptor protein known to
interact with ADAM15179. It may be that ADAM15 could inﬂuences ILK activity
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via complex formation via its ICD domain, or indirect via direct binding to integrins
via its ECD. Or ECD cleaves an unknown substrate which activates RTKs.
We demonstrated that expression of β1 and β3 does not change. Diﬀerential ability
of ADAM15 isoform expressing cells to adhere to substrates was observed. This may
be due to higher aﬃnity of ADAM15 isoform binding to the integrins (extracellular
or intracellular via adaptor proteins) or due to changes in cell surface localisation of
integrins. The latter was observed for β3 integrin. IF analysis of integrins co-stained
with V5-ADAM15 would provide necessary information. To address whether the in-
teraction diﬀers between integrins and ADAM15 I would perform IP analysis with
corresponding antibodies. Additionally, using the ﬂow cytometre I could charac-
terise the integrin localisation on the cell surface of ADAM15 isoform expressing
cells. Using antibodies to active/inactive integrins could also provide information
about their activity in these cells. To address whether ADAM15-integrin interaction
occurs extra- or intracellularly, cells can be treated with various integrin-interacting
molecules such as osteopontin, RGD peptides or recombinant disintegrin domain of
ADAM15. The results of the FA disassembly assay indicate that endocytosis and
recycling are aﬀected by ADAM15 isoform expression. I would analyse the traﬃck-
ing of α5β1 and αvβ3-integrins by antibody- and biotin-IP/ELISA-based integrin
internalisation and recycling assays as described by Arjonen et al551. In antibody-
based internalisation and recycling assays cells are grown in dishes and labelled with
AlexaFluor-conjugated anti-integrin (e.g. β1) antibodies on ice. Incubation at 37◦C
stimulates integrin internalisation. Remaining ﬂuorescent signal on the surface is
quenched with antibodies against the primary antibody. The internalised integrins
are then measured with a plate reader. In order to determine the rate of recycling
the procedure is repeated, but with and additional incubation/quenching step prior
to measurement. During the additional step integrins are recycled and translocate
to the surface. However the second quenching step eliminates the signal again. The
higher the signal the slower the recycling would be, or the lower the signal the faster
the recycling.
An alternative approach is via biotin labelling. Cell surface proteins are labelled
with biotin at 4◦C and unbound biotin is washed oﬀ. Incubation at 37◦C allows
internalisation of the biotinylated integrins. For recycling measurements this a pro-
longed time point is necessary to ensure complete internalisation. On the cell surface
remaining biotin is removed by sodium 2-mercaptoethanesulfonate (MesNA) treat-
ment with consecutive quenching using iodoacetamide to block reactive sulfhydryl
groups. In case of recycling experiments the cells are incubated again at 37◦C to al-
low translocation to the cell membrane followed by MesNa treatment and quenching.
Cells are lysed and subjected to IP with antibodies against the integrin of interest
(e.g. β1). Western blot analysis using biotin targeting antibodies are used for detec-
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tion. Alternatively to the IP approach, lysed cells can also be transferred to micro
titre plates with immobilised anti-β1 antibodies. Streptavidin-conjugated HRP is
used to detect the internalised integrins552. I hypothesised that ADAM15 is in a
complex with SNX9/Aldolase in which ADAM15 recruits a kinase that phosphory-
lates SNX9 releasing aldolase. In order to conﬁrm this I would perform IF analysis
to our cell panel and co-staining of ADAM15-SNX9, ADAM15-Aldolase and SNX9-
Aldolase. This should provide information whether they remain in a complex and
where it is localised. Co-localisation is expected to be absent in ADAM15 D ex-
pressing cells. With IP analysis I would attempt to conﬁrm direct interaction of
ADAM15, SNX9 and aldolase within this complex.
A common problem with work on 2D substrates is that cells grow on a surface which
does not resemble the natural environment. Jayo and Parsons discussed diﬀerent
methods of imaging cell adhesion events in 3D matrix environments553. Most of the
knowledge about adhesive structures is derived from experiments on rigid 2D struc-
tures. The disadvantage is that ECM proteins face the cell only on one site, but in
vivo ECM proteins surround the cell that leads to diﬀerences in cellular behaviour
and migration. However, other technical issues occur within 3D matrices. For exam-
ple, cell protrusions can be thicker in 3D matrices which then needs to be examined
by microscopes with a larger ﬁeld of vision such as confocal or wideﬁeld microscopes.
Therefore, adhesion-speciﬁc ﬂuorescently labelled proteins may result in diﬀuse ﬂu-
orescent signal in the cytoplasm, masking neighbouring proteins554. Also matrix
stiﬀness could cause issues. The closer the cells grow to the border where the 3D
matrix is attached the greater the stiﬀness is. Also the size of structures such as
those for adhesion appear in generally smaller compared to 2D environments.
However, 3D models are likely to provide new insights in cellular behaviour which is
overseen when investigated in 2D environment. Thus it would be interesting to see
how ADAM15 isoform expressing cells behave in 3D. One of the most widely used
models depend on basement membrane-based gels or Matrigel
TM
. It is made of col-
lagen type IV, laminin and proteoglycans. It is commonly used for migration assays
and invadopodia research. Matrigel also demonstrates how a 3D matrix aﬀects the
morphology of a cell. While ﬁbroblasts are growing elongated on a 2D surface, do
they appear rounded in matrigel.
Another type of 3D matrix are type I collagen-based gels. They are commonly used
to study motility as an connective tissue model. However, depending on how it is
produced variations in collagen ﬁbre thickness and length as well as pore size and
rigidity.
Fibrin gels are another type of gels which are mainly composed of ﬁbrin. These
ﬁbres are thinner, shorter and straighter than collagen and engage with several in-
tegrins such as α5β1 and αvβ3. Based on the FA adhesion disassembly assay and
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ECM spreading experiments we have ﬁrst indications that ADAM15 isoforms have
an aﬀect on integrin dynamics it would be interesting to see how ADAM15 isoform
expressing cells behave in ﬁbrin gels.
Another type of matrices are the cell-based complex matrices which are rich in FN
and collagen. They provide high stiﬀness, are generally ordered and highly ﬁbrous.
It is widely used to study cell motility.
There are also artiﬁcial matrices which can be made of polyacrylamide. The ad-
vantage is that the stiﬀness can be precisely adjusted (similar to SDS-PAGE gels).
Together with collagen it was used to analyse eﬀects of matrix ﬂexibility and FA
formation.
Due to time constraints we only looked at these two integrins, as they are known to
interact with ADAM15. It is however possible that ADAM15 isoforms have other,
yet unknown, distinct integrins interaction partners. And it is possible that the
altered behaviour of these unknown integrins dictates the dynamics of FA turnover
in our cell panel. Future directions on continuing this work will be discussed in
chapter 7.
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In this project we observed many changes how ADAM15 isoforms aﬀected cell be-
haviour. A summary of all ﬁndings throughout the project are summarised in table
6.1.
In chapter 3 I described how we generated isogenic cells expressing each ADAM15
isoform in MDA-MB-231 cells. ADAM15 C and D are subjected to hypermethy-
lation in these cells to a varying degree. ADAM15 isoforms introduced morpho-
logical changes depending on catalytic function. Especially ADAM15 A expressing
cells showed tight cobblestone-like appearance. ADAM15 C and E expressing cells
were larger compared to the other isoforms or the parental cells. All cells express-
ing ADAM15 isoforms were rounder compared to parental cells. Introduction of
ADAM15 A, D and E reduced the growth rate independently of the catalytic func-
tion. ADAM15 B expression did not alter the proliferation while ADAM15 C re-
duced growth in WT, but not in cells expressing the catalytically inactive ADAM15.
We also found changes in the cytoskeletal rearrangement analysed by IF. ECM de-
grading, invadopodia-like structures, were found in all ADAM15 isoform expressing
cells, but to a greater degree in cell expressing ADAM15 D. ADAM15 A expressing
cells had more ruﬄes, while ADAM15 expressing cells showed more curved actin
bundles. ADAM15 E expressing cells showed more stress ﬁbres than the other cell
lines. We did not observe changes in total RhoA or Rac1 activity. Scratch wound
experiments revealed that introduction of ADAM15 reduced the migration rate of
ADAM15 A and B and to a greater degree also in ADAM15 C and D expressing
cells. Overexpression of ADAM15 E did not inﬂuence the migration rate.
In chapter 4 we showed that the morphological changes of ADAM15 isoform express-
ing cells are not due to mesenchymal-epithelial transition. Also changes of expression
in the tight junctions proteins ZO1, ZO2 and occludin were not observed. However,
upregulation of claudin1 in ADAM15 A, C and E expressing cells were observed
depending on their catalytic activity. With increasing cell density these cells ex-
pressed more claudin1. ZO1 and ZO2 were identiﬁed as potential novel interaction
partners of ADAM15. Claudin1 was found to co-localise with ADAM15 at cell-cell
junctions and along the cell periphery. Some claudin1 also localised in the nucleus of
ADAM15 A expressing cells. The upregulation of claudin1 in ADAM15 A, C and E
expressing cells is mediated by the PI3K/mTOR pathway. The reduction of migra-
tion in ADAM15 A expressing cells was not due to claudin1 which was investigated
by scratch wound asays with shClaudin1 knockdown cells.
In chapter 5 we attempted to investigate the reason for reduced migration. FA
disassembly assays demonstrated that ADAM15 D expressing cells have impaired
FA disassembly and enhanced reassembly. In contrast, ADAM15 C expressing cells
disassemble FA at the same rate as parental or the other ADAM15 isoform express-
ing cells, but fail to reassemble FA at the same rate. To get an indication whether
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ADAM15 aﬀects interaction of integrins with ECM substrates we performed exper-
iments on FN and VN, the major ligands for α5β1 as well as αvβ3 and α5β1, respec-
tively. We observed that by comparing the spreading of these substrates that most
cell lines preferred FN over VN. However, the expression of ADAM15 E reduced this
preference. ADAM15 A expressing cells even preferred VN over FN. Subcellular lo-
calisation showed that in all ADAM15 isoform expressing cells including the parental
cell line β1 integrin is exclusively localised in the membrane. However, in ADAM15
D expressing cells the molecular weight of the β1-subunit is smaller while it is larger
in ADAM15 E expressing cells. The localisation of β3-integrin was comparable in
MDA/FRT and ADAM15 B, C and D expressing cells. In these cells localisation
was observed in both, the cytoplasm and the membrane. Contrary, in ADAM15 A
and E expressing cells β3 exclusively localised in the membrane. Total expression of
both subunits did not change. Interestingly, we observed that the molecular weight
of β3 is slightly larger in the catalytically inactive ADAM15 isoform expressing cells,
compared to WT and parental cells.
We found that ADAM15 expression reduces cell migration in ADAM15 A-D, but
not in ADAM15 E expressing cells. Migration is decreased most in cells express-
ing ADAM15 C and D. To address weather claudin1 upregulation in ADAM15 A
expressing cells negatively inﬂuences the migration rate I performed wound heal-
ing experiments on MDA/ADAM15 A shClaudin1 knockdown cells. In many cell
lines claudin1 upregulation is known to cause reduced migration55,516. However, we
did not observe any diﬀerences in migration depending on claudin1 expression in
ADAM15 A expressing cells. Keeping in mind that ADAM15 D expression does not
upregulate claudin1, but decreases the migration most further suggests migration
rate is independent of claudin1 in MDA-MB-231 cells.
FA require to be assembled at the leading edge which indicates the direction a cell
moves to. The turnover of FA involves the disassembling at the rear tail. We found
that ADAM15 C and D expressing cells have impaired FA turnover. While all
ADAM15 isoform expressing cells disassemble FA quickly, it is signiﬁcantly reduced
in ADAM15 D expressing cells. This also leads to a quicker reassembly rate which
enhances the adherens to the substrate before the cell actually moved forward. In
contrast, ADAM15 C expressing cells cannot reassemble FA which may slow down
the formation of the leading edge indicated by slow migration.
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Table 6.1: Summary of findings of this project. The cell for MDA/FRT is kept empty if cells are compared to these cells. If information is available it will be
displayed. – = Strong reduction; - = Moderate reduction; 0 = no change; + = Moderate increase; ++ = Strong increase. N/A = no data available.
MDA/FRT ADAM15 A ADAM15 B ADAM15 C ADAM15 D ADAM15 E
Methylation of
ADAM15 gene
N/A N/A N/A yes yes (less than C) N/A
Morphology
(WT/E349A)
Spindle-like
Cobblestone-
like/Mixed
Spindle-like/
Spindle-like
Clustered/
Mixed
Clustered/
Clustered
Mixed/
Mixed
Cell size 0 0 ++ 0 +
Cell circularity + + + + +
Growth rate
WT/E349A
-/- 0/0 –/0 -/- –/–
Stress fibre
formation
present 0 0 0 0 ++
Curved actin
bundles
present 0 0 ++ 0 0
Invadopodia-like
structures
not present + + + ++ +
Ruﬄes not present 0 ++ 0 0 0
Total RhoA
activity
0 0 0 0 0
Total Rac1
activity
0 0 0 0 0
Migration - - – – 0
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Table 6.1 Continued: Summary of findings of this project. The cell for MDA/FRT is kept empty if cells are compared to these cells. If information is available
it will be displayed. – = Strong reduction; - = Moderate reduction; 0 = no change; + = Moderate increase; ++ = Strong increase. N/A = no data available.
MDA/FRT ADAM15 A ADAM15 B ADAM15 C ADAM15 D ADAM15 E
Claudin1
expression
WT/E349
no claudin1 yes/no no/no yes/no no/no yes/no
Claudin1
expression
increases with cell
density
no yes no yes no yes
Co-localisation of
ADAM15 with
claudin1
N/A
yes
(also in T47D)
N/A N/A N/A N/A
Complex
formation of
ADAM15 with
ZO1
N/A yes yes yes no yes
Complex
formation of
ADAM15 with
ZO2
N/A yes yes yes
yes
(indirectly)
yes
Nuclear claudin1 N/A yes N/A N/A N/A N/A
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Table 6.1 Continued: Summary of findings of this project. The cell for MDA/FRT is kept empty if cells are compared to these cells. If information is available
it will be displayed. – = Strong reduction; - = Moderate reduction; 0 = no change; + = Moderate increase; ++ = Strong increase. N/A = no data available.
MDA/FRT ADAM15 A ADAM15 B ADAM15 C ADAM15 D ADAM15 E
Claudin1 via
PI3K/mTOR
no claudin1 yes no claudin1 yes no claudin1 yes
FA disassembly
assay
no changes no changes
reduced
reassembly
impaired
disassembly,
enhanced
reassembly
no changes
ECM spreading FN>VN>Med VN>FN>Med FN>VN>Med FN>VN>Med FN>VN>Med FN=VN>Med
β1 localisation
Membrane
Membrane Membrane Membrane Membrane Membrane Membrane
β3 localisation
Cytoplasm &
Membrane
Membrane
Cytoplasm &
Membrane
Cytoplasm &
Membrane
Cytoplasm &
Membrane
(more in
cytoplasm)
Membrane
Molecular weight
of β1
(WT/E349A)
0/0 0/0 0/0 -/0 +/0
Molecular weight
of β3
(WT/E349A)
0/+ 0/+ 0/+ 0/+ 0/+
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Table 6.1 Continued: Summary of findings of this project. The cell for MDA/FRT is kept empty if cells are compared to these cells. If information is available
it will be displayed. – = Strong reduction; - = Moderate reduction; 0 = no change; + = Moderate increase; ++ = Strong increase. N/A = no data available.
MDA/FRT ADAM15 A ADAM15 B ADAM15 C ADAM15 D ADAM15 E
Total β1
expression
0 0 0 0 0
Total β3
expression
0 0 0 0 0
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Characterisation of MDA/ADAM15 isoform expressing cells opened up many av-
enues which can be followed leading to various exciting topics.
My work will have important implications for future ADAM15 research, as it high-
lighted major ADAM15 isoform-, as well as catalytic function dependent eﬀects on
various aspects of cell biology.
I showed that ADAM15 regulates cell proliferation (chapter 3), as well as gene
expression (chapter 4) in an isoform dependent and catalytic function dependent
manner, providing a strong evidence that ADAM15 isoforms are individually dis-
tinct proteases, that shed diﬀerent transmembrane proteins. Thus a major fol-
low on project will be identiﬁcation of ADAM15 isoform-speciﬁc substrates. This
can be achieved by a sophisticated Tandem-Mass-Tag R© (TMT) mass spectroscopic
(MS) terminal amino isotopic labelling of substrates (TAILS) approach. This ap-
proach, developed by Christopher Overall (Canada Research Chair in Proteinase
Proteomics and Systems Biology, University of British Columbia, Canada) is a pow-
erful proteomics method used to identify proteolytic events in mammalian cells.
TAILS identiﬁes both the identity of the substrate and the exact cleavage site and
can distinguish speciﬁc proteolytic events from background cleavages555. TMT-
MS-TAILS approach, combined with phosphoproteomic analysis using KINEXUS
phospho-antibody arrays, will allow identiﬁcation of the ADAM15 isoform-speciﬁc
substrates, as well as the major signalling pathways that are regulated by ADAM15
isoforms. Further RNA sequencing will allow identiﬁcation of ADAM15 isoform-
speciﬁc gene expression signatures.
I showed that ADAM15 isoforms regulate cell-cell junction formation in isoform-
dependent and catalytic function dependent manner. Key questions remain: Which
other TJ and AJ proteins are changed? Which cadherins localise to these junctions?
Detailed MS analysis of β-catenin immunoprecipitates will help to elucidate which
other junctional proteins are regulated by ADAM15.
I showed ADAM15 isoform-dependent eﬀects on cell migration and actin cytoskele-
ton structure (chapter 3), FA dynamic turnover and cell adhesion on diﬀerent ECM
components (chapter 5), providing strong evidence that ADAM15 isoforms regulate
integrin behaviour diﬀerently. Thus another major follow on project will be detailed
characterisation of how ADAM15 isoform regulate integrins, their activity, availabil-
ity for ECM adhesion, endocytosis and recycling. So far only three integrins have
been shown to interact with the disintegrin domain of ADAM15 (α5β1, αvβ3 and
α9β1). My data suggest that ADAM15 isoforms might have other integrin interac-
tion partners, which will be important to identify. Followed with 3D organotipic
invasion modelling, will allow us to understand how ADAM15 isoforms contribute
to tumour cell adhesion, migration, invasion, as well as interaction with the tumour
microenvironment.
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A common emerging theme eluded to throughout my work is the role of diﬀerential
protein-protein interactions with individual ADAM15 ICDs that regulate ADAM15
isoforms and dictate ADAM15 isoform speciﬁc eﬀects on cell behavior. ADAM15
isoforms have a vast number of common, as well as distinct interaction partners (de-
scribed in chapter 3). We could speculate that ADAM15 mediated shedding events
are likely to be controlled by speciﬁc ADAM15 ICD kinase interactions as shown
previously for ADAM15 B and Src207. To identify which interaction regulates a
speciﬁc shedding event, it would be necessary to identify the shed substrate(s) ﬁrst
as described earlier. We can then use an shRNA approach to deplete the candidate
intracellular interacting protein(s) and monitor if the shedding of that particular
substrate by ADAM15 is compromised. Similarly, we could speculate that ADAM15
mediated eﬀects on integrin traﬃcking are likely to be controlled by sorting nexins
or intersectins that interact with ADAM15 ICDs. These proteins have prominent
roles in regulating endocytic transport of various cargos. It is possible that integrin
endocytosis depends on ADAM15 integrin interaction via the disintegrin domain,
and the role of ADAM15 in that interaction is to provide an endocytosis route to the
integrins by bringing sorting nexins or itersectins into the complex. Again, to verify
that we would need detailed characterisation of integrin traﬃcking as a function
of ADAM15 splicing ﬁrst, followed by an shRNA approach to validate the role of
speciﬁed ADAM15 ICD interacting partners in that traﬃcking.
My work suggests that ADAM15 represents an important master switch in regulat-
ing the behaviour of tumour cells and potentially their ability to invade the body to
establish metastatic disease. Further work is necessary to investigate how ADAM15
is contributing to tumour invasion to understand in detail how this enzyme works.
This is a prerequisite of developing new therapies that will lead to new strategies to
suppress tumour cell invasion and block metastasis.
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9.1 Supplementary Data
9.1.1 Negative controls of claudin1 co-localisation experi-
ment
Figure 9.1: Control images of ADAM15 and claudin1 co-localisation in MDA/A15 A, MDA/A15
A non-target shRNA and MDA/A15 A shClaudin1 expressing cells. Columns from left to right:
DAPI, Ms-568 (goat), Rb-488 (goat) and merged image. Scale bar = 10 μm
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9.1.2 Negative controls of antibody validation experiment
Figure 9.2: Negative controls of claudin1 antibody validation in MDA/A15 A non-target shRNA
and shClaudin1 expressing cells. Left column: DAPI staining; Middle column: α-Ms- or Rb-488
(goat); Right column: Merged images. Scale bar = 10 μm
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9.1.3 Negative controls of the focal adhesion disassembly
assay
Figure 9.3: Negative controls of MDA/FRT and MDA/A15 A-E WT expressing cells for focal
adhesion disassembly assay. Slides were exactly treated as the analysed once but the primary
antibody incubation was done with 1% BSA. Left column: DAPI staining; Middle column: α –
mouse – 568 (goat); Right column: Merged images. Scale bar = 10 μm
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9.1.4 FAK and Src phosphorylation in MDA/FRT and
MDA/ADAM15 WT isoform expressing cells
Figure 9.4: Preliminary western blot analysis of FAK and Src phosphorylation in MDA/FRT and
MDA/ADAM15 WT isoform expressing cells. Exponential growing cells were lysed and subjected
to protein analysis. A summary of the used antibodies is shown in table 9.1. n=1
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Table 9.1: Detailed information about antibodies used to detect FAK and Src phosphorylation
Antibody Supplier
Catalogue
number
Source
Detected
band(s)
Primary
antibody
dilution
Secondary
antibody
dilution
Actin Sigma A2066 Rabbit 42 kDa 1:4,000 1:5,000
FAK1 SantaCruz sc-557 Rabbit 125 kDa 1:1,000 1:5,000
pFAK (Y397)1 Invitrogen 44-624G Rabbit 125 kDa 1:1,000 1:5,000
pFAK (Y576/577) CST #3281 Rabbit 125 kDa 1:1,000 1:5,000
pFAK (Y925) CST #3284 Rabbit 125 kDa 1:1,000 1:5,000
pSrc (Y416) CST #2101 Rabbit 60 kDa 1:1,000 1:5,000
1Blocking and primary antibody incubation in 3% BSA in TBST
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9.2 Software
Table 9.2: Detailed information about used software
Software Version Company
CFlow Plus
1.0.264.15
Build 20140714.264.15
BD
Oxford, Oxfordshire, UK
FlowJo 10.0.7
FlowJo, LLC
Ashland, OR, USA
Illustrator CC 2014
Adobe Systems, Inc.
San Jose´, CA, USA
ImageJ/Fiji 1.49m
National Institutes of Health
Bethesda, MD, USA
Leica LAS AF Lite
4.0.0
Build 11706
Leica Microsystems
Wetzler, Hessen, Germany
Mendeley Desktop 1.16
Mendeley Ltd.
London, UK
Oﬃce 365
Microsoft
Redmond, WA, USA
Photoshop CC 2014
Adobe Systems, Inc.
San Jose´, CA, USA
Prism 6.01
GraphPad Software, Inc.
La Jolla, CA, USA
TeXstudio 2.10.8 Free Software Foundation
9.3 Materials
9.3.1 Consumables
Table 9.3: Detailed information about used consumables
Product
Catalogue
number
Supplier
10 cm cell culture dish
(TC treated dish,
standard)
734-0006
VWR International
Lutterworth, Leicestershire, UK
150 mm cell culture dish
(TC treated dish, with 20
mm moulded grid)
734-0013
VWR International
Lutterworth, Leicestershire, UK
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Table 9.3 Continued: Detailed information about used consumables
Product
Catalogue
number
Supplier
35 mm cell culture dish
(TC treated dish,
Easy-Grip)
734-0005
VWR International
Lutterworth, Leicestershire, UK
6 cm cell culture dish
(TC treated dish,
Easy-Grip)
734-0007
VWR International
Lutterworth, Leicestershire, UK
96-well plate
(BD Falcon, ﬂat bottom
with lid)
734-0023
VWR International
Lutterworth, Leicestershire, UK
Annexin V-FITC
Apoptosis Detection Kit
BMS500FI
eBioscience, Ltd.
Hatﬁeld, Hertfordshire , UK
BCA Protein Assay Kit 23225
Fisher Scientiﬁc
Loughborough, Leicestershire,
UK
Dispenser tips 0.5 mL
(Classic, individual blister
pack)
613-1027
VWR International
Lutterworth, Leicestershire, UK
Dispenser tips 2.5 mL
(Classic, individual blister
pack)
613-1011
VWR International
Lutterworth, Leicestershire, UK
Dispenser tips 5 mL
(Classic, individual blister
pack)
613-1012
VWR International
Lutterworth, Leicestershire, UK
Falcon tube 15 mL
(ﬂat top)
11849650
Fisher Scientiﬁc
Loughborough, Leicestershire,
UK
Falcon tube 50 mL
(ﬂat top)
FB55958
Fisher Scientiﬁc
Loughborough, Leicestershire,
UK
Filter paper
(WYPALL X60, white, 420
x 310 mm)
115-2166
VWR International
Lutterworth, Leicestershire, UK
G-LISA RhoA Activation
Assay
BK124
Cytoskeleton Inc.
Denver, CO, USA
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Table 9.3 Continued: Detailed information about used consumables
Product
Catalogue
number
Supplier
G-LISA Rac1 Activation
Assay
BK128
Cytoskeleton Inc.
Denver, CO, USA
Gel loading tips
(1-200 μ/L)
732-3501
VWR International
Lutterworth, Leicestershire, UK
Gloves
(Nitrile, Semperguard
comfort, PPE category III)
11867192
Fisher Scientiﬁc
Loughborough, Leicestershire,
UK
Immobilon-P membrane,
PVDF 0.45 μm
IPVH00010
Millipore Ltd.
Watford, Hertfordshire, UK
KAPA 2G Robust Hot
Start Ready mix
KK5702
Kapa Biosystems Ltd.
London, UK
MTS assay solution
(CellTiter 96 R© AQueous
One Solution Cell
Proliferation Assay (MTS))
G3580
Promega UK
Southampton, Hampshire, UK
QIAshredder 79654
Qiagen
Manchester, UK
RNeasy Mini Kit 74104
Qiagen
Manchester, UK
Stripettes 5 mL
(Corning Costar, sterile)
10127400
Fisher Scientiﬁc
Loughborough, Leicestershire,
UK
Stripettes 10 mL
(Corning Costar, sterile)
10677341
Fisher Scientiﬁc
Loughborough, Leicestershire,
UK
Stripettes 25 mL
(Corning Costar, sterile)
TKV671070H
Fisher Scientiﬁc
Loughborough, Leicestershire,
UK
T25 cell culture ﬂask
(70 mL, vented, 25cm2,
canted)
734-0045
VWR International
Lutterworth, Leicestershire, UK
T75 cell culture ﬂask
(250 mL, vented, 75cm2,
canted )
734-0050
VWR International
Lutterworth, Leicestershire, UK
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9.3.2 Chemicals
In this subsection all used chemicals are listed in alphabetic order in table 9.4. Diﬀerent companies may helf the same distributor which
are indicated in the footnote. Antibodies and inhibitors are listed separately in their corresponding sections.
Table 9.4: Detailed information about used chemicals
Product Supplier
Catalogue
number
Solvent
Stock
concentration
Final
concentration
Function
α-V5 aﬃnity gel Sigma A7345 PBS - 10 μL/IP
Binds to V5 tag;
Used in IP
β-Mercaptoethanol Bio-Rad 161-0710 - - See methods Reducing agent
1,10-Phenanthroline
monohydrate
Sigma P9375 Methanol 200 mM 10 mM MMP inhibitor
5-Aza-2’-deoxycytidine
(Decitabine)
Sigma A3656
Growth
medium
50 mM 33.3 - 50 μM
Hypomethylation
agent
6-Aminohexanoic acid Sigma 07260
MilliQ
water
- 25 mM
Component of
Cathode buﬀer
Acrylamide/bis solution,
40%, 29:1
Bio-Rad 161-0146
MilliQ
water
40% 7-17%
Monomers for
PAA gels
Agarose Fisher BP160-500 1 x TAE - 1-2%
Component of
DNA gels
Ammonium persulfate Bio-Rad 161-0700
MilliQ
water
10% 0.1%
Oxidizing agent/
Provides free radicals
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Table 9.4 Continued: Detailed information about used chemicals
Product Supplier
Catalogue
number
Solvent
Stock
concentration
Final
concentration
Function
Beads (Protein G
Sepharose)
Sigma P3296 EtOH - -
Binds to Fc-region
of antibodies
BSA
Appli-
Chem
A1391
PBS or
TBST
0.1%
- 1-5 % Blocking reagent
Bromophenol blue Sigma B0126 Methanol 10 mg/mL 100 μg/mL Dye
cOmplete EDTA-free
protease inhibitor cocktail
Roche
11873580001
Lysis
buﬀer
20 x 1 x Proteinase inhibitor
DMEM Gibco 11960-085 - - - Cell culture medium
DMSO Sigma D2650 - - - Solvent
DNA Ladder (100 bp) NEB N3231
MilliQ
water
500 μg/mL 35 μg/mL Marker
dNTP mix Invitrogen 18427-013
Tris-HCl
(pH 7.5)
40 mM 400 μM
Nucleotide monomers
in RT-PCR
Dried skimmed milk
powder
Marvel -
0.1%
TBST
- 5% Membrane blocking
DTT Invitrogen
comes with
RT kit
- 0.1 M 400 μM
Reducing agent
in RT PCR
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Table 9.4 Continued: Detailed information about used chemicals
Product Supplier
Catalogue
number
Solvent
Stock
concentration
Final
concentration
Function
Ethanol Fisher 10437341 - - -
Solvent; Used in
RNAeasy Kit
Fibronectin Sigma F1411 PBS 1 mg/mL 10 μL/mL ECM substrate
FBS Sigma F7524 - 100% 10%
Growth media
supplement
Formaldehyde
(Pierce, Methanol-free)
Fisher 10751395 N/A 16% 4% Fixative
GelRed Biotium 41003 1 x TAE 10,000 x 1 x
DNA intercalating
agent
Glycine Fisher G/0800/60
MilliQ
water
- 1.92 M
Component of 10 x
SDS running buﬀer
HCl VWR 20252.335 - 37% - pH adjustment
Hygromycin B Invitrogen 10687010
Cell
culture
medium
50 mg/mL 450 μg/mL Selective antibiotic
Immersol 518 F Zeiss 630-0340 - - -
Oil for confocal
microscopy
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Table 9.4 Continued: Detailed information about used chemicals
Product Supplier
Catalogue
number
Solvent
Stock
concentration
Final
concentration
Function
L-Glutamine Sigma G7513
Cell
culture
grade
water
200 mM 2 mM
Growth media
supplement
Lipofectamine 2000 Invitrogen 11668019 OptiMEM - See manual Transfection reagent
Methanol Fisher M/4000/17 - - -
Used in SDS-Page
and WB
NaCl Fisher S/3160/65
MilliQ
water
- - Buﬀer ingredient
NaOH Fisher 10743591
MilliQ
water
- -
WB stripping and
pH adjustment
Nocodazole Sigma M1404 DMSO 25 mM 10 μM
Disrupt mitotic
spindle function
OptiMEM Gibco 31985062 - - -
Treatments and
transfections
PBS tablets Sigma P4417
MilliQ
water
- 1x Buﬀer
Penicillin/Streptomycin Sigma P0781 0.9% NaCl 100x 1x
Growth media
antibiotic
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Table 9.4 Continued: Detailed information about used chemicals
Product Supplier
Catalogue
number
Solvent
Stock
concentration
Final
concentration
Function
PhosSTOP Roche 4906845001
Lysis
buﬀer
20 x 1 x Phosphotase inhibitor
Polybrene Sigma 107689
MilliQ
water
800 μg/mL 8 μg/mL
Enhances viral
infection
Puromycin Thermo A1113803 - 10 mg/mL 1 μg/mL Selective antibiotic
Precision Plus Protein
Dual Colour Standards
Bio-Rad 161-0394 - -
5-7 μL per well
(15 well combs)
Protein marker
ProLong Gold Antifade
Mountant with DAPI
Invitrogen P-36931 - - Approx. 30 μL
Mounting and staining
of cover slips
Propidium iodide Sigma P4170
MilliQ
water
400 μg/mL 10 μg/mL Nucleic acid dye
Random hexamers Invitrogen N8080127 - 50 μM 500 nM
RNA primer for
RT-PCR
RIPA buﬀer Sigma R0278 - - - Lysis buﬀer
ScaI NEB R3122L
Neb buﬀer
3 in MilliQ
water
1,000 u 10 u Restriction enzyme
SDS solution
Appli-
Chem
MilliQ
water
A0675 20% various
Micelle
formation/negatively
charges proteins
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Table 9.4 Continued: Detailed information about used chemicals
Product Supplier
Catalogue
number
Solvent
Stock
concentration
Final
concentration
Function
Staurosporine solution Sigma S6942 DMSO 1 mM 1-10 μM
Apoptosis inducing
agent
Sulfuric acid Sigma 258105 - - -
Component of G-LISA
HRP stop solution
Superscript II RT Thermo 18064-071
Invitrogen
storage
buﬀer
10,000 u 200 u Reverse Transcriptase
TAE buﬀer
Appli-
chem
A4686 - 50 x 1 x Electrophoresis buﬀer
TEMED Bio-Rad 161-0800 N/A 100% 0.1% Catalyst for PAA gels
Trichostatin A Sigma T1952
Cell
culture
medium
5 mM 500 nM
Inhibits histone
deacetylase
Tris-Base Fisher BP152-1
MilliQ
water
- See methods pH buﬀer reagent
Trypsin-EDTA Sigma T4174 0.9% NaCl 10x 1x (in PBS)
Cell detachment
solution
Tween-20 Sigma P1379 - 100% 0.1% Soap in TBS buﬀer
Vitronectin Gibco PHE0011 PBS 0.5 mg/mL 10 μL/mL ECM substrate
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Table 9.4 Continued: Detailed information about used chemicals
Product Supplier
Catalogue
number
Solvent
Stock
concentration
Final
concentration
Function
Western Blot substrate
(Pierce ECL 2 WB
substrate)
Thermo 11517371 N/A - 40:1
Substrate for
chemiluminescence
reaction
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9.3.3 Laboratory Equipment
Table 9.5: Detailed information about used equipment
Item Manufacturer
-86◦C Freezer
(FormaScientiﬁc)
Thermo Fisher Scientiﬁc
Basingstoke, Hampshire, UK
Analytical balance
(MH 124)
Fisher Scientiﬁc
Loughborough, Leicestershire, UK
Aspirator
(Medical Suction Unit SAM12)
MG Electric Ltd.
Colchester, Essex, UK
Bright-ﬁeld microscope
(Olympus LH50A)
Olympus Scientiﬁc Solutions
Americas Inc.
Waltham, Massachusetts, USA
Casting stand for PAA gels
Mini-PROTEANR© Casting Stand
Bio-Rad Laboratories Ltd.
Hemel Hempstead, Hertfordshire, UK
Cell Imaging System
(EVOS R© XL Core)
Life Technologies Ltd.
Paisley, Renfrewshire, UK
Comb for PAA gels
Mini-PROTEANR© Comb, 10-well
Bio-Rad Laboratories Ltd.
Hemel Hempstead, Hertfordshire, UK
Comb for PAA gels
Mini-PROTEANR© Comb, 15-well
Bio-Rad Laboratories Ltd.
Hemel Hempstead, Hertfordshire, UK
Confocal microscope
(Leica SP5)
Leica Microsystems (UK) Ltd.
Milton Keynes, UK
Developer for Western Blot
Konica Minolta SRX-101A
Konica Minolta Medical & Graphic
Imaging Europe B.V.
Banbury, Oxfordshire, UK
Digital Graphic Printer for UV
Transilluminator (UP-D 897)
Sony Europe Ltd.
Weybridge, Surrey, UK
Electronic Pipette Controller
(peqMATE)
PEQLAB c/o VWR International
Lutterworth, Leicestershire, UK
Flake ice machine
Thermo Fisher Scientiﬁc
Basingstoke, Hampshire, UK
Flow Cytometer
(Accuri C6)
BD
Oxford, Oxfordshire, UK
Freezing Container
(Nalgene R© Cryo 1◦C “Mr. Frosty”)
Thermo Fisher Scientiﬁc
Basingstoke, Hampshire, UK
Freezer
(Labcold Borolabs)
Labcold Ltd.
Basingstoke, Hampshire, UK
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Table 9.5 Continued: Detailed information about used equipment
Item Manufacturer
Fridge
(Labcold Borolabs)
Labcold Ltd.
Basingstoke, Hampshire, UK
Gel electrophoresis tank for PCR
(Multi Sub Choice)
Geneﬂow Ltd.
Lichﬁeld, Staﬀordshire, UK
Gel electrophoresis tank for Western
Blot
(Mini-PROTEAN Tetra Cell)
Bio-Rad Laboratories Ltd.
Hemel Hempstead, Hertfordshire, UK
Heating Block
(Techne Dri-Block R© DB-2A)
Bibby Scientiﬁc Ltd.
Stone, Staﬀordshire, UK
Incubator
(HeraCell 240)
Thermo Fisher Scientiﬁc
Basingstoke, Hampshire, UK
Magnetic stirrer
(Stuart stir CB162)
Bibby Scientiﬁc Limited
Stone, Staﬀordshire, UK
Magnetic heatable stirrer
(Stuart stir SB161)
Bibby Scientiﬁc Limited
Stone, Staﬀordshire, UK
NanoDrop R© ND-1000
Thermo Fisher Scientiﬁc
Basingstoke, Hampshire, UK
Counting chamber
(Neubauer improved)
Hawksley
Lancing, Sussex, UK
Orbital platform shaker
(Stuart Mini Orbital Shaker SSM1)
Bibby Scientiﬁc Limited
Stone, Staﬀordshire, UK
pH-Meter
(S20 SevenEasy pH)
Mettler-Toledo Ltd.
Leicester, Leicestershire, UK
Pipettes (2 μL, 20 μL, 200 μL, 1000
μL,)
Gilson Scientiﬁc Ltd.,
Luton, Bedfordshire, UK
Pipettes for cell culture
(RAININ Pipet-like XLS)
Anachem Ltd.
Luton, Bedfordshire, UK
Plate Reader
(Fluostar Optima)
BMG Labtech
Ortenberg, Baden-
Wu¨rttemberg, Germany
Platform rocker
(STR)
Bibby Scientiﬁc Limited
Stone, Staﬀordshire, UK
Power supply for PCR
(Bio-Rad Model 200/2.0)
Bio-Rad Laboratories Ltd.
Hemel Hempstead, Hertfordshire, UK
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Table 9.5 Continued: Detailed information about used equipment
Item Manufacturer
Power supply for Western Blot
(GE electophoresis power supply
EPS30)
GE Healthcare
Little Chalfont, Buckinghamshire, UK
Precision balance
(GX-6100)
A&D Medical
San Jose, California, USA
Rotary wheel
(Stuart Rotary Drive STR4)
Bibby Scientiﬁc Limited
Stone, Staﬀordshire, UK
Safety Cabinet for cell culture
(HeraSafe KS)
Thermo Fisher Scientiﬁc
Basingstoke, Hampshire, UK
Scanner
(Canon CanoScan LiDE 210)
Canon UK Ltd.
Reigate, Surrey, UK
Sonicator
Diagenode
Seraing (Ougre´e), Belgium
Spectrophotometer
Ultrospec
TM
2100 Pro
GE Healthcare UK Limited
Little Chalfont, Buckinghamshire, UK
Stepper/Repetitive pipette
(peqSTEPPER)
PEQLAB c/o VWR International
Lutterworth, Leicestershire, UK
Table top autoclave
(Classic 2100 Portable)
Prestige Medical Ltd.
Blackburn, Lancashire , UK
Table top centrifuge for cell culture
(SANYO MSE Centaur2)
MSE (UK) Ltd
Lower Sydenham, London, UK
Table top centrifuge for cell culture
(SANYO MSE Micro Centaur)
MSE (UK) Ltd
Lower Sydenham, London, UK
Table top centrifuge
(Perfect 24 Plus)
PEQLAB c/o VWR International
Lutterworth, Leicestershire, UK
Table top centrifuge refrigerated
(Heraeus Fresco21)
Thermo Fisher Scientiﬁc
Basingstoke, Hampshire, UK
ThermoCycler
(MJ Research Peltier PTC-225)
Bio-Rad Laboratories Ltd.
Hemel Hempstead, Hertfordshire, UK
Trans-Blot R© Turbo Transfer System
Bio-Rad Laboratories Ltd.
Hemel Hempstead, Hertfordshire, UK
Vortexer
(Stuart SA7)
Bibby Scientiﬁc Limited
Stone, Staﬀordshire, UK
Water bath
(Grant SUB36)
Fisher Scientiﬁc
Loughborough, Leicestershire, UK
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Table 9.5 Continued: Detailed information about used equipment
Item Manufacturer
UV Transilluminator
(BioDoc-It R© Imaging Systems)
Ultra-Violet Products Ltd.
Cambridge, Cambridgeshire, UK
